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Abstract 
Pancreatic Ductal Adenocarcinoma (PDAC) is characterised by a dense desmoplastic 
reaction that is attributed to the activation of pancreatic stellate cells (PSCs) in the 
stroma. This alteration of the tumour microenvironment is thought to contribute to 
PDAC aggressiveness and resistance to therapy. Recent studies have shown that 
exosomes (a subgroup of secreted extracellular vesicles) secreted by cancer cells 
facilitate cross talk between tumour cells and the microenvironment. However, the 
mechanisms that lead to the secretion of these vesicles remains elusive.  
Here, we report for the first time, a novel role for centrosome amplification, a common 
feature of human tumours, in the secretion of small extracellular vesicles (sEVs). We 
show that centrosome amplification significantly correlates with and is sufficient to 
induce the elevated secretion of sEVs in PDAC cell lines. Furthermore, we demonstrate 
that oxidative stress in cells with supernumerary centrosomes is the driving force behind 
this altered sEV secretion. An analysis of centrosome amplification-associated increases 
in cellular reactive oxygen species (ROS) demonstrated an impaired lysosome function 
and the prevention of MVB/lysosome fusion events. The results indicate that 
centrosome amplification induced ROS induces sEV secretion by preventing MVB 
degradation by the lysosome, shifting their fate to fusion with the plasma membrane 
and subsequent secretion of their intraluminal vesicles (ILVs) as exosomes.  
To understand if exosomes secreted from cells with amplified centrosomes could impact 
the tumour microenvironment, we subsequently investigated the role of these sEVs on 
the activation of PSCs, as measured by the formation of fibres containing alpha-smooth 
muscle actin (α-SMA). We found that sEVs isolated from cells with supernumerary 
centrosomes elicit significantly stronger activation of PSCs compared to sEVs isolated 
from cells with a normal centrosome number, suggesting a difference in their biological 
cargo. SILAC based-proteomic analysis revealed the gain or loss of 6 EV protein in sEVs 
isolated from cells upon the induction of centrosome amplification, that may have a role 
in the activation of PSCs. We hypothesise, that further understanding the role of 
centrosome amplification in sEV-mediated PSC activation may help us to identify 
iv 
 
innovative ways to block PSC activation and prevent the progression of PDAC, which 
could have major clinical implications for patients with this devastating disease. 
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1.1 The centrosome  
The centrosome is a small cytoplasmic organelle that constitutes the main microtubule 
organising centre (MTOC) in eukaryotic cells. Centrosomes are comprised of a pair of 
orthogonally poisitioned barrel shaped centrioles embedded in a dense proteinaceous 
matrix called the pericentriolar material (PCM), which provides the site for microtubule 
nucleation (Figure 1.1). The centrioles are cylindrical structures, that range from 100-
400nm in length and 100-250nm in diameter (Carvalho-Santos et al., 2011) and are 
characterised by a highly conserved triplet of microtubules that  arrange in a nine-fold 
symmetry forming the centriole wall (Gönczy, 2012; Nigg and Holland, 2018). The two 
centrioles are structurally different with the older and more mature ‘mother’ centriole 
carrying subdistal and distal appendages that the younger ‘daughter’ centriole does not 
have (see Figure 1.1). These appendages are required for anchorage to microtubules and 
for membrane docking during ciliogenesis (Piel et al., 2000; Bettencourt-Dias and 
Glover, 2007; Gogendeau, Guichard and Tassin, 2015; Nigg and Holland, 2018). 
Together, the two centrioles are crucial for recruiting the PCM which consists of 
concentric protein layers that surround the centrioles (Fu and Glover, 2012; Lawo et al., 
2012; Mennella et al., 2012; Sonnen et al., 2012). The inner layer of the PCM contains 
gamma-tubulin ring complexes (- TuRCs) which are fundamental for microtubule 
nucleation. During mitosis, this inner layer expands and recruits additional components 
resulting in a mature centrosome with peak MTOC activity (Fu and Glover, 2012; 
Mennella et al., 2012).  
In cycling cells, owing to its role as an MTOC, the centrosome is vital for generating the 
mitotic spindle, regulating cell shape, cell polarity and cell motility (Nigg and Raff, 2009; 
Bornens, 2012; Conduit, Wainman and Raff, 2015; Fu, Hagan and Glover, 2015). In many 
differentiated cell types, however, the mother centriole acts as a basal body and 
provides a template for the formation of cilia and flagella (Kim and Dynlacht, 2013; Ito 
and Bettencourt-Dias, 2018). 
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Figure 1.1 Centrosome structure. Schematic diagram of the centrosome structure. The 
centrosome consists of two orthogonally positioned centrioles which are comprised of a nine-
fold symmetry of triplet microtubules. The older mother centriole carries distal and subdistal 
appendages that the younger daughter centriole lacks. The two centrioles are tethered together 
by a centriole linker and are surrounded by the pericentriolar material (PCM) which provides the 
site for microtubule nucleation. 
 
1.1.1 Centrosomes and cell division   
The centrosome, first described in 1887 by the German biologist Theodore Boveri as 
“the organ for cell division”, has been shown to play a vital role in nucleating and 
organising spindle microtubules (MT) during mitosis to ensure faithful segregation of 
chromosomes (Paintrand et al., 1992; Bignold, Coghlan and Jersmann, 2006; Boveri, 
2008). However, more recent studies have revealed that many cells which lack 
centrosomes, such as higher plant cells and oocytes, still have a robust ability to form 
bipolar mitotic/meiotic spindles (Dumont and Desai, 2012; Masoud et al., 2013). 
Additionally, it had been shown that in most cells, genetic or physical removal of the 
centrosome does not prevent the formation of a bipolar mitotic spindle and subsequent 
segregation of chromosomes (Lerit and Poulton, 2016). It is now understood that several 
non-centrosomal pathways exist which can nucleate MTs during mitosis in addition to 
or instead of centrosomal MT nucleation including: MT nucleation from mitotic 
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chromatin (Karsenti and Vernos, 2001; Gruss and Vernos, 2004; O’Connell and 
Khodjakov, 2007), the Augmin complex which nucleates MTs from existing MTs 
(Goshima et al., 2008; Lawo et al., 2009; Goshima and Kimura, 2010; Sánchez-Huertas 
and Lüders, 2015) and acentrosomal MTOCs (aMTOC) in which many components of the 
PCM self-organise in the absence of centrioles to nucleate MTs (Schuh and Ellenberg, 
2007; Moutinho-Pereira, Debec and Maiato, 2009; Kleylein-Sohn et al., 2012; Baumbach 
et al., 2015). The importance of bipolar mitotic spindle assembly and faithful segregation 
of the chromosomes to maintain genomic stability makes it unsurprising that cells have 
more than one method of forming the mitotic spindle. 
Interestingly, whilst it has been shown that the centrosome is not necessary for cell 
division to occur, the absence of functional centrosomes comes with a cost. In 
drosophila, research suggests that the centrosome is dispensable in most cells (Megraw, 
Kao and Kaufman, 2001; Basto et al., 2006; Blachon et al., 2008), however, as is seen 
with the developing fly wing disc, a significant fraction of cells without centrosomes 
develop increased rates of aneuploidy and DNA damage, often leading to apoptosis 
(Poulton, Cuningham and Peifer, 2014). Additionally, it has been demonstrated that the 
centrosome is required in early drosophila embryo development, specifically for the first 
division of a newly fertilised egg (Stevens et al., 2007; Rodrigues-Martins et al., 2008) 
and that embryos defective for key PCM proteins have aberrant mitotic spindles and 
damaged DNA (Megraw et al., 1999; Vaizel-Ohayon and Schejter, 1999; Varmark et al., 
2007; Lerit et al., 2015). Similar results have also been demonstrated in C. elegans where 
depletion of centrosome maturation factor Air-1 resulted in aberrant spindles, sever 
aneuploidy and embryonic lethality (Schumacher et al., 1998). Although the centrosome 
appears non-essential to invertebrate cell division, in vertebrates, the lack of functional 
centrosomes has been shown to induce chromosome segregation errors, leading to loss 
of cell viability (reviewed in Conduit, Wainman and Raff, 2015). Indeed, centrosome loss 
in cultured chicken cells has been shown to result in slower rates of mitosis, perturbed 
chromosome segregation, DNA damage, aneuploidy and often leads to cell death (Sir et 
al., 2013). Similarly, centrosome loss in mouse embryos and cultured mammalian cells 
has been shown to increase the rates of cell apoptosis (Bazzi and Anderson, 2014; 
Insolera et al., 2014; Wong et al., 2015). Furthermore, mouse embryonic tissues which 
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lack centrosomes have been shown to have significant mitotic delays which result in p53 
activation and subsequent p53-mediated cell apoptosis (Bazzi and Anderson, 2014; 
Insolera et al., 2014). Therefore, whilst cell division can occur in the absence of 
functional centrosomes, the centrosome facilitates the formation of the mitotic spindle 
and progression through mitosis in a timely manner preventing mitotic delays and 
maintaining cell viability. Moreover, centrosomes have been shown to play an important 
role in maintaining genomic stability and cell viability across many different species 
(Debec, 1978; Sir et al., 2013).  
 
1.1.2 The centrosome duplication cycle 
In dividing cells, centrosomes are duplicated in a semi-conservative manner ensuring 
that at mitotic onset only two centrosomes are present to facilitate bipolar spindle 
formation. Failure to properly regulate the centrosome duplication cycle has been linked 
to several human diseases including cancer and microcephaly. The centrosome 
duplication cycle occurs in a 5 step process: in late M phase/ G1 the centrioles disengage 
from one another, in S-phase the centrioles duplicate, in G2 the centrioles elongate and 
the centrosome matures and finally in late G2/M-phase the centrosomes segregate and 
move to the poles of the cell in preparation for bipolar spindle formation (Nigg and 
Stearns, 2011; Mardin, 2014; Fu, Hagan and Glover, 2015) (Figure 1.1.2). Recent 
advances in imaging, proteomics, structural biology and genome editing have provided 
key insights into the centrosome duplication cycle including  its regulation, centriole 
biogenesis and how alterations to the cycle can lead to human disease (reviewed by Nigg 
and Holland, 2018).  
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Figure 1.1.2 The centrosome duplication cycle. Schematic diagram of the centrosome 
duplication cycle. During the G1 phase of cell cycle the two centrioles disengage from one 
another but remain connected by a protein linker. At the transition from G1 to S phase, 
procentrioles form at the proximal end of each parent centriole. During S phase and G2, the 
procentrioles elongate into full sized centrioles and centrosome maturation takes place.  In G2 
the linker is removed and the two centrosomes segregate. Finally, during mitosis the newly 
formed mature centrosomes move to opposite poles and assemble the bipolar mitotic spindle.  
 
1.1.2.1 Centriole disengagement 
The centrosome duplication cycle begins at the end of mitosis when the two centrioles 
disengage from one another. Separation of the two centrioles is a crucial first step as 
the close proximity between the two centrioles is known to block duplication of the 
parent centriole (Tsou and Stearns, 2006; Loncarek et al., 2008; Tsou et al., 2009). 
Disengagement is controlled by the mitotic kinase Polo-like kinase 1 (PLK1) and the 
protein separase which likely cleaves the PCM component pericentrin (PCNT) promoting 
centriole separation (Tsou et al., 2009; Lee and Rhee, 2012; Matsuo et al., 2012). 
Importantly, PLK1-driven separase activity is required both for the separation of 
centrioles and the separation of sister chromatids during mitosis, linking the timing of 
these two events (Tsou et al., 2009). Additionally, the cell cycle kinase Cdk2 is also 
 Chapter 1. Introduction 
 
7 
 
required for both DNA replication and centriole duplication, where its presence is 
necessary for centriole disengagement and the initiation of centriole duplication 
(Hinchcliffe et al., 1999; Lacey, Jackson and Stearns, 1999).  Synchronising centriole 
disengagement and the DNA cycle ensures that centrosomes cannot duplicate before 
chromosome segregation has taken place, eliminating the possibility of multipolar 
spindles forming and subsequent chromosome missegregation. Upon separation of the 
centrioles, a proteinaceous tether forms between the two ensuring they remain 
localised near one another until the two newly formed centrosomes are finally 
separated in G2 (Mardin and Schiebel, 2012).  
 
1.1.2.2 Centriole duplication  
During G1/S transition, once the centrioles have successfully disengaged, centriole 
duplication begins with the assembly of a procentriole (which will form the new 
daughter centriole) perpendicular to the parent centriole. Centriole duplication is 
initiated by the centrosomal proteins CEP192 and CEP152 which recruit PLK4, the master 
regulator of centriole duplication, to the proximal end of the mother centriole 
(Bettencourt-Dias et al., 2005; Habedanck et al., 2005; Pelletier et al., 2006; Kim et al., 
2013; Sonnen et al., 2013; Park et al., 2014). PLK4 subsequently phosphorylates the 
conserved centriole duplication factor SCL/TAL-interrupting locus protein (STIL) which 
triggers the recruitment of the spindle assembly abnormal protein 6 homologue (SAS-6) 
to the centriole (Dzhindzhev et al., 2014; Ohta et al., 2014; Kratz et al., 2015; Moyer et 
al., 2015). Recruitment of SAS-6 results in the formation of the procentriole scaffold 
structure known as the cartwheel. The cartwheel consists of an internal ring composed 
of nine SAS-6 homodimers from which nine ‘spokes’ protrude to connect the nine 
triplets of microtubules that make up the centriole wall (Nakazawa et al., 2007; 
Gopalakrishnan et al., 2010; Kitagawa et al., 2011; van Breugel et al., 2011, 2014; 
Guichard et al., 2012; Arquint and Nigg, 2016; Marteil, Dias Louro and Bettencourt-Dias, 
2017). Thus PLK4, STIL and SAS-6 are crucial regulators of centriole duplication.  
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1.1.2.3 Centriole elongation  
During S-phase, following the formation of the procentriole cartwheel structure, the 
procentriole elongates to form a full-length centriole.  Elongation begins with the 
recruitment of centrosomal P4.1-associated protein (CPAP) to the cartwheel where it 
binds centrosome-associated protein 135 (CEP135) and stabilises the cartwheel 
structure (Lin et al., 2013).  CPAP, along with CEP135 and -tubulin, then regulate the 
deposition of centriolar microtubules around the cartwheel (Kleylein-Sohn et al., 2007). 
CEP135 connects SAS-6 to CPAP, bridging the gap between the SAS-6 homodimers and 
the microtubules (Lin et al., 2013).  Importantly, CP110 localises to the distal end of the 
elongating procentriole and acts as a cap to limit microtubule growth, thereby regulating 
centriole size (Tsang et al., 2008; Lee et al., 2017).  
 
1.1.2.4 Maturation of the centrosome 
Towards the end of G2, following centriole elongation, the PCM expands significantly in 
a process termed centrosome maturation. Maturation of the centrosomes is governed 
by PLK1 which localises Cep192, CDK5RAP2, pericentrin, Nedd1 and  -tubulin  to the 
centrosome (Haren, Stearns and Lüders, 2009; Zhang et al., 2009; Lee and Rhee, 2011; 
Fu and Glover, 2012). Furthermore, Aurora A has been shown to play a role in both the 
phosphorylation/activation of PLK1 and additionally in the enrichment of multiple 
centrosomal factors, including the transforming acidic coiled-coil protein 3 (TACC3) to 
the centrosome (Giet et al., 2002; Barros et al., 2005; Kinoshita et al., 2005; Macůrek et 
al., 2008). The recruited PCM proteins then activate the -TuRCs which are required for 
microtubule nucleation and mitotic spindle assembly (reviewed by Ito and Bettencourt-
Dias, 2018). Importantly, the PCM is only present around the mother centriole, however, 
during disengagement of the centrioles at G1 phase, PLK1 regulates the daughter 
centriole becoming competent and recruiting a PCM of its own (reviewed by Fu, Hagan 
and Glover, 2015). Additionally, in G2/M-phase the daughter centriole becomes fully 
mature by acquiring the appendages that are characteristic of a mother centriole in a 
process that is once again regulated by PLK1 (Kong et al., 2014).  
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1.1.2.5 Centrosome segregation 
At the end of G2, in preparation for mitosis, the two newly formed centrosomes 
separate and move to either pole of the cell to facilitate formation of the bipolar spindle. 
Centrosome segregation entails a two-step process, first the physical linker that binds 
the two centrosomes via their mother centrioles is severed and then force-dependent 
separation and movement of the two centrosomes occurs.  
The centrosomal linker is composed of several proteins including C-Nap1 (CEP250), 
rootletin, CEP68 and LLRC45 (Mayor et al., 2000; Bahe et al., 2005; Yang, Adamian and 
Li, 2006; Graser et al., 2007; He et al., 2013). At the proximal ends of the two mother 
centrioles is a CEP250 ring  which acts as an anchor for the filament-like proteins 
rootletin and LLRC45 which form the body of the linker (Yang, Adamian and Li, 2006; He 
et al., 2013; Panic et al., 2015; Vlijm et al., 2018). Specifically, a rootletin ring is organised 
at the CEP250 ring from which additional rootletin/Cep68 fibres and LLRC45 emanate 
and form a web like structure which provides flexibility to the linker (Vlijm et al., 2018). 
During the G2/M transition, the centrosomal linker is severed by the NIMA-related 
kinase 2A (Nek2A) which phosphorylates the linker proteins resulting in their 
disassociation from the centrosome and subsequent dissolution of the linker (Mayor et 
al., 2000; Bahe et al., 2005; Graser et al., 2007; Nigg and Stearns, 2011; Mardin and 
Schiebel, 2012; He et al., 2013). Following removal of the linker, force-dependent 
separation and movement of the centrosomes occurs under the control of motor 
proteins. The kinesin related plus-end-directed motor Eg5 is the main force generator 
responsible for centrosome separation, acting through anti-parallel microtubule sliding 
to physically push the centrosomes apart from one another (reviewed in Mardin and 
Schiebel, 2012). In fact, the strong force generated by Eg5 is sufficient to separate the 
two centrosomes even in the presence of an intact centrosomal linker (Mardin et al., 
2010). Inhibition of Eg5 results in prometaphase arrest and the formation of a 
monopolar spindle (Whitehead and Rattner, 1998; Kapoor et al., 2000). The activity of 
Eg5 is regulated by PLK1, which during prophase phosphorylates and activates the 
NIMA-related kinase Nek9, which in turn phosphorylates Nek6 and Nek7. Activated 
Nek6 then phosphorylates Eg5 targeting it to the centrosome resulting in Eg5 binding to 
MTs and enabling centrosome separation (Blangy et al., 1995; Roig et al., 2002, 2005; 
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Belham et al., 2003; Bertran et al., 2011; Mardin et al., 2011; Smith et al., 2011). In 
addition, nuclear envelope (NE)- associated dynein works in conjunction with Eg5 to 
separate centrosomes by pulling the centrosomes along the NE (Raaijmakers et al., 
2012; Raaijmakers and Medema, 2014). Following successful separation of the 
centrosomes and movement to opposite poles, each centrosome nucleates a 
microtubule array, forming a bipolar spindle which connects to and faithfully segregates 
the chromosomes into two daughter cells. 
 
1.2 Centrosome amplification and cancer 
A link between centrosome abnormalities and cancer was first proposed in the 19th 
century by Theodore Boveri who hypothesised that supernumerary centrosomes would 
lead to multipolar cell division resulting in malignant transformation due to genomic 
instability (Boveri, 1888, 2008). Using dispermic sea urchin eggs, which harbour extra 
centrosomes (as the sperm provides the centrosome during embryogenesis), Boveri 
observed the development of multipolar spindles and the subsequent asymmetric 
division of chromosomes into 3 or more highly aneuploid daughter cells (Figure 1.2).  
 
 
Figure 1.2 Theodor Boveri drawing of dispermic sea urchin eggs based on his microscopy 
observations. Theodor Boveri’s observation that amplified centrosomes (a-d) in a fertilised sea 
urchin egg resulted in uneven chromosome distribution (I-IV) and multipolar cell division, 
resulting in aneuploid daughter cells. He therefore hypothesised that supernumerary 
centrosomes could generate genetic instability and facilitate tumourigenesis (Boveri, 1888).  
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He found the resultant progeny to have different developmental characteristics which 
provided the first ever indication that chromosomes are important for cellular traits 
(Boveri, 1887, 1888). This finding, along with the contribution of his contemporaries 
Gino Galeotti and David von Hansemann who showed abnormal cell division to be a 
common feature of human tumours, led to Boveri’s later hypothesis that supernumerary 
centrosomes drive tumourigenesis by triggering aneuploidy (Hansemann, 1890; 
Galeotti, 1893; Boveri, 2008). However, whilst Hansemann’s work did show the frequent 
presence of asymmetric cell division and aneuploid progeny in tumours, he also 
observed faulty mitoses in benign lesions and therefore suggested they were not the 
cause of cancer (Hardy and Zacharias, 2005). Thus, whilst Boveri was in favour of 
chromosome segregation errors driving tumourigenesis, Hansemann was not. Indeed, 
many remained sceptical of the role of abnormal mitoses in the development of cancer 
and instead research remained focussed on the discovery of cancer-causing mutations. 
In the late 1990s, however, it was discovered that the loss of the key tumour suppressor 
p53 was associated with centrosome defects which led to renewed interest in the role 
of centrosome defects in tumourigenesis (Fukasawa et al., 1996). Following this 
discovery, extensive research has established centrosome abnormalities to be a 
common feature of both solid and haematological malignancies (reviewed in Chan, 
2011).  
 
1.2.1 Centrosome abnormalities in cancer 
Centrosome abnormalities can be classified as either structural or numerical aberrations 
where structural aberrations constitute defects in either centriole size/structure or 
alterations in the amount of PCM surrounding the centrosomes and numerical 
aberrations can include centrosome amplification or centrosome loss (reviewed by Nigg, 
2006). Currently numerical aberrations are far better characterised than structural ones 
owning to the difficulties in identifying structural abnormalities. As Centrioles are close 
to the limits of optical resolution of light microscopy at 0.2-0.5µM in length, specialised 
fluorescence microscopy is required to identify differences between structural and 
numerical anomalies. Historically, PCM markers have been used to analyse centrosomal 
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changes, however interpreting these changes as purely structural or numerical is 
difficult. For example, although increases in PCM is a characteristic of structural 
abnormalities, similarly increased PCM is observed when supernumerary centrosome 
cluster together in interphase constituting a numerical defect (D’Assoro et al., 2002a; 
Lingle et al., 2002; Nigg, 2006; Guo et al., 2007; Godinho et al., 2014). Thus, PCM markers 
alone cannot distinguish structural from numerical aberrations. As many studies 
analysing centrosome anomalies in tumour samples use PCM markers only, it is difficult 
to distinguish between the role of numerical and structural aberrations in cancer 
development and progression. To aid in the distinction between numerical and 
structural aberrations, it is now widely accepted that the use of bona fide centriole 
labelling is necessary. However, as structural abnormalities caused by increased 
centriole length can also result in centriole fragmentation, it is still possible to confuse 
the presence of fragmented centrioles with amplified centrioles (Kohlmaier et al., 2009). 
Therefore, more accurate methods to distinguish and classify centrosome abnormalities 
are required to gain further insight into how different centrosome aberrations affect the 
tumour landscape.  
Currently numerical aberrations, specifically centrosome amplification have been 
described as the most prevalent centrosomes defect in human cancers where the 
presence of extra centrosome has been identified in the majority of human tumour 
types including breast, prostate, colon, ovarian and pancreatic cancers (Lingle et al., 
1998; Pihan et al., 1998; Sato et al., 1999; Nigg, 2002; Giehl et al., 2005; Hsu et al., 2005; 
Krämer, Neben and Ho, 2005; Chan, 2011).  Furthermore, centrosome amplification has 
been shown to correlate with high-grade tumours and poor prognosis as well as tumour 
recurrence and metastasis (Pihan et al., 2001; D’Assoro et al., 2002a; Yamamoto et al., 
2004; Reiter et al., 2009; Chan, 2011). Currently the exact role of supernumerary 
centrosomes in tumour development and progression is unclear. However, amplified 
centrosomes have also been observed in early, low-grade lesions indicating that 
supernumerary centrosomes may play a driving role in tumourigenesis (Lingle et al., 
2002; Pihan et al., 2003; Segat et al., 2010; Lopes et al., 2018). Thus, understanding the 
link between centrosome amplification and disease progression may provide important 
new targets for therapy and biomarker development. 
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1.2.2 Causes of centrosome amplification 
Whilst it is still unclear how centrosome amplification arises in cancer; a few different 
methods have been shown to lead to its initiation. An important contributor to the 
overduplication of centrosomes is the dysregulation of the centrosome cycle, which can 
lead to centriole overduplication or overexpression of PCM proteins (reviewed in 
Godinho and Pellman, 2014). As previously described in this chapter, the centrosome 
duplication cycle is tightly regulated by crucial positive and negative regulators to ensure 
centrosomes are duplicated in a timely manner and only once per cell cycle (Nigg and 
Stearns, 2011; Brownlee and Rogers, 2013). Although these regulators are rarely 
mutated, centrosomal proteins are often found to be over or under expressed in cancer 
(Nigg and Raff, 2009; Chan, 2011; Gönczy, 2015). One major route to supernumerary 
centrosomes is dysregulation of centriole duplication through destabilisation of key 
centriolar proteins. For example, overexpression of PLK4, the master regulator of 
centriole duplication, leads to over duplication of centrioles and subsequent 
centrosome amplification (Habedanck et al., 2005; Kleylein-Sohn et al., 2007). 
Conversely, loss of PLk4 results in decreased centriole numbers (O’Connell et al., 2001; 
Bettencourt-Dias et al., 2005; Habedanck et al., 2005). Levels of PLK4 are tightly 
regulated throughout the cell cycle via its own autophosphorylation which leads to 
SCFβTrCP/ubiquitin-dependent proteolysis (Cunha-Ferreira et al., 2009; Rogers et al., 
2009; Guderian et al., 2010; Holland et al., 2010; Sillibourne et al., 2010; Brownlee et al., 
2011). In fact, it has been suggested that in some tumours, supernumerary centrosomes 
may arise from deregulation of ubiquitin regulators leading to over or under expression 
of centriolar components. For example, decreased expression of the ubiquitin ligase 
βTrCP has been shown to result in PLK4 stabilisation leading to amplified centrosomes 
(Wojcik, Glover and Hays, 2000; Guardavaccaro et al., 2003; Cunha-Ferreira et al., 2009; 
Rogers et al., 2009). Additionally, levels of the centriole capping protein CP110 are 
regulated by SCFcyclinF/ubiquitin-dependent proteolysis and the deubiquitinating enzyme 
USP33. Overexpression of USP33 has been shown to induce centrosome amplification 
through increased CP110 levels (Li et al., 2013). Supporting the notion that deregulation 
of ubiquitin regulators leads to amplified centrosomes through stabilisation of key 
centriolar proteins.  
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Another instance of centriole overduplication resulting in centrosome amplification is in 
High-risk human papillomavirus (HPV)-associated tumours. The HPV-16 E7 oncogene 
has been shown to induce centriole overduplication by increasing PLK4 mRNA levels 
(Korzeniewski, Treat and Duensing, 2011). Thus, regulation of centriole duplication can 
be affected at the transcriptional level. Importantly, the levels of PLK4 mRNA are 
negatively regulated through p53 which recruits histone deacetylases (HDAC) to the 
promoter of PLK4 repressing transcription (Li et al., 2005). Therefore, indicating that p53 
loss could lead to increased PLK4 levels, a view that has been supported by the 
observation that p53 loss in mouse fibroblasts is associated with centrosome 
amplification (Fukasawa et al., 1996). On the converse however, analysis of p53-/- 
mouse brains indicated no change in centrosome number  (Marthiens et al., 2013). 
Highlighting that whilst p53 loss may play a contributory role in the development of 
centrosome amplification, it is not sufficient to induce it alone.  
In addition to centriole overduplication, overexpression of key PCM components such 
as pericentrin and -tubulin can also induce centrosome amplification (Loncarek et al., 
2008). It has been demonstrated that upon loss of the tumour suppressor BRAC1, -
tubulin levels become elevated resulting in supernumerary centrosomes (Starita et al., 
2004). Disruption of cell cycle progression can lead to re-duplication of centrioles. 
Prolonged G2 arrest can lead to PLK1 activation which promotes premature centrosome 
maturation and disengagement prior to mitosis resulting in reduplication of centrioles 
(Lončarek, Hergert and Khodjakov, 2010). Therefore, DNA damage may induce 
centrosome amplification by elongating the time spent in G2 phase. Another mechanism 
of generating supernumerary centrosomes is through the formation of tetraploid cells, 
which can arise from cytokinesis failure, mitotic slippage or cell-cell fusion (Andreassen 
et al., 2001; Fujiwara et al., 2005) . Furthermore, over-elongation of the centrioles can 
result in their fragmentation which also promotes centrosome amplification (Marteil et 
al., 2018).  
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1.2.3 p53 activation  
Despite the maintained presence of centrosome amplification in cell lines and tumours, 
extra centrosomes have been shown to have a deleterious effect on cell proliferation 
and survival. This fitness disadvantage appears to arise from centrosome amplification-
associated p53 and subsequent p21 stabilisation resulting in G1 cell cycle arrest and 
decreased proliferation (reviewed in Rhys and Godinho, 2017; Nigg and Holland, 2018). 
In fact, it has been shown that supernumerary centrosomes arising from both centriole 
over-duplication and tetraploidisation trigger cell cycle arrest through p53 stabilisation 
(Holland et al., 2012; Ganem et al., 2014). Thus, highlighting that regardless of the 
method of amplification, extra centrosomes on their own confer a survival disadvantage 
to cells in culture. Interestingly, however, tetraploid cells have been shown to maintain 
a growth advantage and induce tumourigenesis, with strong evidence now indicating 
that a large proportion of human tumours may originate from tetraploid cells (Zack et 
al., 2013). Additionally, the established presence of supernumerary centrosomes in cell 
lines and human tumours indicates that cells must acquire further genetic alterations to 
enable them to overcome the fitness disadvantage associated with extra centrosomes. 
One important genetic alteration is loss of p53 which has been shown to rescue the 
detrimental effects of centrosome amplification enabling cells to not only survive and 
proliferate in the presence of but also maintain supernumerary centrosomes (Holland 
et al., 2012). Furthermore, work performed to identify modulators of p53-mediated 
arrest in tetraploid cells with amplified centrosomes revealed a role for the large tumour 
suppressor kinase 2 (LATS2) in arresting tetraploid cells in G1. LATS2 was found to be 
phosphorylated in cells with extra centrosomes which lead to activation of the Hippo 
pathway and subsequent proliferation defects (Ganem et al., 2014) (See Figure 1.2.3). 
Additionally, decreased RhoA activity has been observed in cells with extra centrosomes, 
which also leads to activation of the Hippo pathway (Ganem et al., 2014; Godinho et al., 
2014). Decreased RhoA activity is likely due to centrosome amplification-associated 
increases in microtubule nucleation which results in the hyperactivation of the RhoA 
antagonist Rac1 (Sander et al., 1999; Godinho et al., 2014). Similarly, amplified 
centrosomes have been found to activate PIDDosome components which leads to p53 
stabilisation through Caspase-2 mediated cleavage of the p53 regulator MDM2 (Fava et 
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al., 2017) (See Figure 1.2.3). Thus, it is possible that disruption of the Hippo pathway or 
PIDDosome activation may facilitate survival of cells with extra centrosomes.  
Although cancer cells can overcome the deleterious effects of amplified centrosomes 
through additional genetic alterations, it is still somewhat surprising that 
supernumerary centrosomes are such a common feature of human malignancies. 
Therefore, their maintained presence may suggest amplified centrosomes confer an 
advantage to tumourigenesis that outweighs their detrimental effects and warrants 
their preservation. 
 
Figure 1.2.3 Mechanisms of centrosome amplification-induced p53-mediated cell cycle arrest. 
Supernumerary centrosomes can result in Hippo pathway or PIDDosome activation leading to 
p53 stabilisation and cell cycle arrest.  
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1.2.4 Coping with extra centrosomes  
In the 18th century, Theodore Boveri hypothesized that supernumerary centrosomes 
would cause multipolar mitoses, inducing high levels of genetic instability and facilitating 
the formation of tumours (Boveri, 2008). It is unlikely, however, that this correlation is 
a result of centrosome amplification-induced multipolar cell division as recent studies 
have shown multipolar mitoses to result in catastrophic levels of aneuploidy and 
subsequent cell death (Ganem, Godinho and Pellman, 2009; Godinho and Pellman, 
2014) (Figure 1.2.4). In fact, it has been demonstrated that in mouse neuronal stem cell 
where centrosome amplification leads to multipolar mitosis’s, the resultant high levels 
of aneuploidy lead to developmental defects but not cancer (Marthiens et al., 2013). 
Therefore, multipolar cell division render a significant barrier to the survival of cells with 
supernumerary centrosomes and are thus detrimental to tumour formation. Instead, 
cells with extra centrosomes have been found to supress multipolar cell division 
thorough a process termed “centrosome clustering”, where centrosomes are coalesced 
into two poles. This phenomenon was first discovered through work performed in the 
N1E-115 mouse neuroblastoma cell line in which almost 100% of cells have extra 
centrosomes (Ring, Hubble and Kirschner, 1982). Amplified centrosomes were shown to 
cluster into two poles, enabling the formation of a bipolar spindle allowing chromosome 
segregation into two daughter cells (Ring, Hubble and Kirschner, 1982) (see Figure 
1.2.4). Following this finding, many cancer cell lines with high levels of centrosome 
amplification (>30% of cells with supernumerary centrosomes) have been shown to 
efficiently cluster centrosomes (Ring, Hubble and Kirschner, 1982; Brinkley, 2001; 
Quintyne et al., 2005; Kwon et al., 2008; Ganem, Godinho and Pellman, 2009). In fact, 
to date, centrosome clustering is the best characterised mechanism employed by cells 
with amplified centrosomes, to avoid the detrimental effects of multipolar mitoses.  
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Figure 1.2.4 Coping with supernumerary centrosomes. Supernumerary centrosomes can result 
in i) multipolar cell division, where chromosomes are separated into three or more daughter 
cells resulting in gross aneuploidy and poor survival or ii) pseudo-bipolar cell division, facilitated 
by centrosome clustering, where chromosomes are segregation into two daughter cells only 
resulting in little to no aneuploidy and cell survival.  
 
1.2.5 Centrosome amplification and tumourigenesis 
1.2.5.1 Chromosome instability (CIN)  
Since Boveri’s initial hypothesis, a strong correlation has been identified between 
centrosome amplification and chromosome instability (CIN) in human cancers and 
aneuploidy and CIN have been shown to facilitate the formation of tumours (Weaver et 
al., 2007; Zyss and Gergely, 2009; Chan, 2011). However, as centrosome amplification 
induced multipolar mitoses are detrimental to cell viability and proliferation, they do 
not explain the link between centrosome amplification and CIN, suggesting another 
mechanism is involved. In fact, centrosome clustering is now known to induce low levels 
of aneuploidy and CIN due to the increased formation of erroneous merotelic 
attachments, which can result in the formation of lagging chromosomes (Cimini, 2008; 
Ganem, Godinho and Pellman, 2009; Silkworth et al., 2009). If undetected by the spindle 
assembly checkpoint (SAC), lagging chromosomes can result in DNA damage, 
chromothripsis and the formation of micronuclei (Cimini, 2008; Janssen et al., 2011; 
Stephens et al., 2011; Crasta et al., 2012; Wang et al., 2014). Therefore, centrosome 
clustering enables cell survival, whilst also affording the cells losses or gains of genetic 
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material, which explains the observed correlation between centrosome amplification 
and CIN in tumours (Chan, 2011; Gönczy, 2015). Importantly, these centrosome 
amplification-associated chromosomal defects, both numerical and structural may 
facilitate tumourigenesis (Weaver et al., 2007; Holland and Cleveland, 2012). Whilst the 
exact mechanism behind this is unknown, it is believed that these defects drive genetic 
instability and heterogeneity which provides cancer cells with advantageous features 
that enable tumours to evolve and avoid cell death (reviewed in Nigg and Holland, 2018).  
 
1.2.5.2 Microtubule nucleation, cell polarity and motility 
In non-dividing cells, the centrosome plays an important role in organising microtubule 
(MT) arrays which affect cell polarity, cell motility and cell signalling (Bettencourt-Dias 
and Glover, 2007). During interphase, amplified centrosomes can be clustered into one 
“super centrosome” which recruits a large PCM affording these cells a heightened 
capacity for MT nucleation (D’Assoro et al., 2002b; Lingle et al., 2002). Therefore, 
amplified centrosomes may  also influence tumour biology by affecting MT nucleation 
and altering the subsequent associated cellular processes (Godinho and Pellman, 2014). 
Indeed, centrosome amplification-linked increases in MT nucleation have been 
correlated with high grade breast cancer independent of aneuploidy generation 
(Salisbury, D’Assoro and Lingle, 2004). Centrosome position and the direction of MT 
nucleation plays a major role in establishing cell polarity, determining cell shape and 
motility (Tang and Marshall, 2012). In fact in neurons, the direction of MT nucleation 
can determine the site of axon outgrowth and can affect the direction of migration by 
altering the positioning of the Golgi to the leading edge (Tang and Marshall, 2012). 
Additionally, increase MT nucleation can alter focal adhesion (FA) disassembly which is 
key for cell migration and regulated by MTs (Stephens et al., 2012). Therefore, whilst 
further study is necessary, in theory, super centrosomes have the potential to induce 
stronger polarisation and subsequently alter cell motility (Godinho and Pellman, 2014). 
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1.2.5.3 Cell Invasion 
The ability of a super centrosome to nucleate more MTs may also affect cell invasion 
through activation of the Rho GTPases (Lozano, Betson and Braga, 2003). For example, 
MT depolymerization induces RhoA activation and MT polymerisation activates Rac1 
resulting lamellipodia formation and cell migration by inducting Arp2/3-mediated actin 
polymerisation (Waterman-Storer et al., 1999; Yuan-Chen et al., 2008). Indeed using a 
3D culture model, Godinho et al have demonstrated that increased MT nucleation as a 
result of centrosome amplification leads to increased Rac1 activity, the formation of 
invadopodia, decreased cell-cell adhesion and subsequent cell invasion. Importantly, 
this result was shown to be independent of the degree of aneuploidy (Godinho et al., 
2014). Furthermore, recent work performed by Ganier et al has demonstrated that 
centrosome structural abnormalities also result in the formation of invasive protrusions. 
The authors show that the induction of centrosome structural aberrations trigger basal 
cell extrusion of damaged cells (Ganier, Schnerch and Nigg, 2018), suggesting that 
centrosome aberrations as a whole have the capacity to induce invadopodia formation 
and cell invasion.  
Importantly, a more recent study from our laboratory has shown centrosome 
amplification to drive non-cell-autonomous invasion in 3D mammary organoids and 
zebrafish models (Arnandis et al., 2018). Our work shows cells with extra centrosomes 
have an extra centrosomes-associated secretory phenotype (ECASP) which includes 
increased secretion of interleukin-8 (IL-8) and results in paracrine cell invasion through 
activation of human epidermal growth factor receptor 2  (HER-2) signalling. Moreover, 
we show that centrosome amplification induces oxidative stress in the human breast 
cell line MCF10A through increased levels of reactive oxygen species (ROS). These 
increases in ROS were shown to be responsible for the ECASP and subsequent paracrine-
mediated cell invasion (Arnandis et al., 2018). Crucially our work highlights that cells 
with supernumerary centrosomes have the capacity to alter the behaviours of 
surrounding cells, indicating that these cells may have further and more far-reaching 
impact on tumourigenesis.  
Therefore, the ability of cells with amplified centrosomes to increase cell invasion, 
whether it be autocrine or paracrine, may at least in part, explain the observed 
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association between centrosome amplification and advanced disease and metastasis 
(Godinho and Pellman, 2014).  
 
1.2.5.4 Cell signalling 
The centrosome has been established as a cellular signalling platform for many years, 
where it has been shown to concentrate signalling molecules and enhance signalling 
specificity (reviewed in Godinho and Pellman, 2014). One clear example, is the 
regulation of mitotic entry in fission yeast, where the centrosome/spindle body pole acts 
as a hub to regulate mitotic entry by amplifying cyclinB/cdk1 activity and circulating the 
signal throughout the cell (Hagan and Grallert, 2013). Centrosomal regulation of mitotic 
entry appears to be a widely conserved mechanism as it has been observed in C.elegans, 
Xenopus eggs and in human cells.  
The role of the centrosome as a signalling platform has been strengthened by proteomic 
analysis of purified centrosomes, which identified members of multiple signalling 
pathways as being associated with the centrosome (Andersen et al., 2003; Jakobsen et 
al., 2011). In fact, components of the Wnt, NF-κ B and integrin signalling pathways which 
can affect tumourigenesis, can associate with the centrosome (Fielding et al., 2008; 
Kfoury et al., 2008; Itoh et al., 2009). In addition, the centrosome is a known core for 
ubiquitin-mediated proteolysis (Wigley et al., 1999). For example, upon bone 
morphogenic protein (BMP) signalling, phosphorylated and polyubiquitinated Smad1 
becomes localized at the centrosome. In fact, following inhibition of the proteasome, 
the levels of phospho-Smad1 at the centrosomes greatly increases, therefore indicating 
that the centrosome may also act as a platform for proteasome-mediated degradation 
(Fuentealba et al., 2007). The centrosome, therefore, has been shown to act as a 
signalling hub, sequestering signalling proteins and promoting phosphorylation and 
degradation as necessary. Thus, it is likely, that centrosome aberrations would affect 
centrosome-mediated cellular signalling and contribute to the deregulated signalling 
often observed in cancer (Godinho and Pellman, 2014). 
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1.2.5.5 Transgenic mouse models 
Whilst a link between centrosome amplification and tumourigenesis has been 
postulated for many years, the role of extra centrosomes on tumour initiation and 
development remained largely untested in mammalian models until recently. However, 
the development of transgenic mouse models in which overexpression of PLK4 can be 
exploited to induce centrosome amplification has enabled further investigation into the 
role of supernumerary centrosomes in cancer development and progression. These 
models revealed that transient PLK4 overexpression leading to centrosome 
amplification in mice accelerates tumourigenesis in absence of the tumour suppressor 
p53 (Coelho et al., 2015; Serçin et al., 2015). Specifically, Serçin et al showed that in p53 
deficient mice, transient PLK4 overexpression in the mouse epidermis resulted in 
centrosome amplification and subsequent formation of tumours in the skin. 
Interestingly, prior to tumour formation, centrosome amplification in epidermal cells 
significantly decreased. The relatively short-lived presence of amplified centrosomes in 
the mouse epidermis, was sufficient to induce aneuploidy and resulted in spontaneous 
tumours in the absence of p53. Suggesting therefore that centrosome amplification may 
play a role in the development of these skin tumours (Serçin et al., 2015). Similarly, work 
performed by Coelho et al utilising inducible ubiquitous overexpression of PLK4 in p53 
knock out mice, revealed that centrosome amplification advanced the onset of tumours, 
primarily lymphomas and sarcomas (Coelho et al., 2015). In this study, hyperplasia of 
the pancreas and skin was also observed, although tumours did not develop in these 
areas. It is possible, however, that tumours did not form in these areas as the mice 
succumb early to lymphoma and sarcoma, preventing sufficient time for pancreatic 
cancer and/or skin cancer development (Coelho et al., 2015). Together these studies 
indicate that upon loss of p53, centrosome amplification accelerates tumourigenesis.  
Conversely, however, when an alternative mouse model was used to generate extra 
centrosomes, where PLK4 overexpression was ubiquitous, centrosome amplification did 
not induce or accelerate tumourigenesis even in the absence of p53 (Vitre et al., 2015). 
The exact reasons for these different observations are unknown, however, the different 
method for generating amplified centrosome may be accountable. It is possible that 
whilst transient overexpression of PLK4 is permissive to tumourigenesis, ubiquitous 
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overexpression is detrimental to the process. Furthermore, an additional study 
evaluating centrosome amplification on tumour formation in the mouse brain, found 
that extra centrosomes do not induce brain tumours but instead leads to microcephaly 
(Marthiens et al., 2013). Thus, indicating that centrosome amplification associated 
tumourigenesis is tissue dependent.  
Interestingly, a more recent study performed by (Levine et al., 2017) demonstrated that 
centrosome amplification was sufficient to promote tumourigenesis in mice with wild-
type (WT) p53. The authors showed that transient overexpression of PLK4 throughout 
the mice leads to centrosome amplification and subsequently results in the 
development of spontaneous tumours with high levels of genomic instability that have 
lost p53. These genomic effects strongly suggest that supernumerary centrosomes are 
not mere by-standers, but induce mitotic errors resulting in malignant karyotypes 
promoting tumourigenesis (Levine et al., 2017). These contradictory observations on the 
necessity of a p53 null background may be attributed to the use of different mouse 
models in the studies. Spontaneous tumour formation in the presence of WT p53 was 
induced by a single copy of the PLK4 transgene knocked into the COI1a1 locus resulting 
in a modest increase in PLK4 levels and relatively low levels of centrosome amplification 
(Levine et al., 2017). In the other models (described above), the PLK4 transgene is 
expressed at much higher levels leading to higher centrosome amplification. It is 
possible that small increases in centrosome number facilitate tumour development in a 
WT p53 background, whereas larger increases in centrosome number may be 
detrimental to cells (Levine et al., 2017). Furthermore, Lopes et al demonstrated the 
presence of amplified centrosomes in during Barrett’s esophagus tumourigenesis, 
where extra centrosomes were identified in the premalignant condition through to 
dysplasia and throughout malignant transformation and metastasis. This work showed, 
as has been previously described, that widespread centrosome amplification required 
p53 loss (Chan, 2011; Lopes et al., 2018), however, low incidence of centrosome 
amplification does arise in a p53 WT background (Lopes et al., 2018). Providing further 
evidence to suggest a role for centrosome amplification in the initiation and progression 
of tumourigenesis.  
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The work performed using mouse models of centrosome amplification highlights 
potential roles for supernumerary centrosomes in both initiating tumour formation and 
cancer progression. The presence of extra centrosomes in both early and late stages of 
disease indicate that centrosome amplification may be a promising marker for both 
early and late stage cancer development, highlighting the potential benefit of 
developing a biomarker for centrosome amplification.  
 
1.3 Pancreatic cancer 
1.3.1 Incidence and mortality rates 
Pancreatic cancer, one of the most aggressive solid malignancies, is the 5th leading cause 
of cancer related deaths in the UK (Cancer Research UK, 2019). This highly lethal cancer 
is associated with very poor prognosis, and mortality rates associated with the disease 
closely parallel incidence rates (Kamisawa et al., 2016). In fact, following diagnosis, 
patients suffering from pancreatic cancer have a median survival rate of 6 months and 
a 5-year survival rate of only 3% (Siegel, Miller and Jemal, 2019). This dismal prognosis 
is attributed to the absence of detectable symptoms during early stages of the disease, 
a lack of reliable biomarkers and aggressive metastasis which leads to poor response to 
treatment (Maitra and Hruban, 2008). As early stages of the disease are symptomless,  
at diagnosis, around 50% of patients present with late stage metastatic disease 
(Adamska, Domenichini and Falasca, 2017). Furthermore, autopsy reports have 
indicated that around 90% of pancreatic cancer related deaths are attributed to 
complications due to distant metastasis (Kamisawa et al., 1995). Shockingly, whilst 
significant strides have been made to improve the 5-year survival rates of patients 
suffering from other common cancers such as breast, prostate and bowel, survival rates 
for patients with pancreatic cancer have not improved (see Figure 1.3.1; Cancer 
Research UK, 2019). Moreover, incidences of pancreatic cancer have risen by 15% over 
the past 30 years (Rahib et al., 2014). With the current lack of significant advances in 
detection or treatment, pancreatic cancer is predicted to become the second leading 
cause of cancer related deaths, behind lung cancer, by 2030 (Rahib et al., 2014). Clearly, 
pancreatic cancer represents an area of unmet clinical need, where advancements in 
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early detection and novel therapeutics are desperately required to improve clinical 
outcome.  
 
 
Figure 1.3.1 Improvements in cancer 5-year survival rates.  Changes in 5-year survival rates for 
the 5 most common UK cancers from 1981-2010. Significant improvement is observed in the 5-
year survival of patients suffering prostate, breast and bowel cancer. Little improvement is 
observed in patients suffering lung or pancreatic cancer (data from Cancer Research UK, 2019). 
 
1.3.2 Risk factors for pancreatic cancer 
To date, the development of pancreatic cancer is largely unexplained by any known risk 
factors, and around 90% of cases arise from spontaneous somatic oncogenic mutations 
(Raimondi, Maisonneuve and Lowenfels, 2009; Kamisawa et al., 2016). Pancreatic 
cancer predominately affects the elderly, with the majority of diagnosis occurring in 
patients over 50 and over half of these patients being 70-80 years of age (Kleeff et al., 
2016). Thus, ageing is considered the greatest risk factor for pancreatic cancer. This is 
likely due to advanced age providing time for DNA damage to occur and facilitate 
oncogenic mutations (Raimondi, Maisonneuve and Lowenfels, 2009). Several other risk 
factors have been identified, however, including family history, personal history and 
underlying medical conditions. Around 5-10% of pancreatic cancer incidences are 
familial in origin, and several genetic syndromes are known to result in development of 
the disease (Klein et al., 2004; Hruban et al., 2010).  Such hereditary conditions include: 
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Peutz-Jeghers syndrome which is caused by germline alterations in STK11 (LBK1) 
(Giardiello et al., 1987), familial atypical mole-multiple melanoma (FAMMM) syndrome 
which arises as a result of CDKN2A (p16) mutation (A. M. Goldstein et al., 1995),  familial 
pancreatic cancer caused by PALB2 or ATM germline mutations (Jones et al., 2009; 
Roberts et al., 2012) and hereditary pancreatitis caused by germline mutations in PRSS1 
and SPINK1 (Lowenfels et al., 1997). Additionally, mutations in the BRCA1 gene have 
been shown to increase the risk of breast, ovarian and pancreatic cancer (Couch et al., 
2007; Kamisawa et al., 2016).  
Lifestyle risk factors are believed to be accountable for around 37% of pancreatic cancer 
incidences in the UK (Brown et al., 2018). Smoking tobacco increases the risk of 
developing pancreatic cancer by 75% and around 15-30% of pancreatic cancer cases are 
associated with smoking (Iodice et al., 2008; Parkin, 2011; Bosetti et al., 2012; Whiteman 
et al., 2015). Thus, smoking is the biggest avoidable cause of pancreatic cancer. Heavy 
alcohol consumption has also been shown to increase the risk of developing pancreatic 
cancer (Tramacere et al., 2010; Lucenteforte et al., 2012). This is believed to be due to 
the alcohol-associated development of chronic pancreatitis which is known to increase 
the risk of pancreatic cancer by more than 10-fold (Raimondi et al., 2010). Whilst 
pancreatitis can be hereditary, it accounts for only 1% of the disease, whereas 70% of 
chronic pancreatitis is caused by heavy alcohol consumption. Obesity, low physical 
activity and poor diet including high intake of saturated fats and red and processed meat 
have also been linked to an increased risk of pancreatic cancer (Larsson and Wolk, 2012; 
Bosetti et al., 2013; Rohrmann et al., 2013; Behrens et al., 2015; Genkinger et al., 2015). 
Furthermore, type 2 diabetes mellitus has been associated with an approximate 30% 
increase in the risk of pancreatic cancer (Sah et al., 2013; Bosetti et al., 2014). In fact, 
long term diabetes is believed to double the risk of pancreatic cancer (Bosetti et al., 
2014). However, diabetes, specifically type 3c diabetes, can also be caused by pancreatic 
cancer itself. Therefore, the development of diabetes in elderly patients can lead to a 
pancreatic cancer diagnosis (Chari et al., 2008; Bosetti et al., 2014). Thus, whilst most 
pancreatic cancer incidences are unexplained, a proportion of cases could be prevented 
by altering certain lifestyle choices.  
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1.3.3 Types of pancreatic cancer 
The pancreas is a highly specialised organ that carries out two key biological functions; 
the exocrine function and the endocrine function. The exocrine function, facilitated by 
the exocrine cells of the pancreas including acinar and ductal cells, involves the secretion 
of enzymes into the intestine to aid digestion (reviewed by Pandol, 2011). The endocrine 
function, facilitated by endocrine cells that are contained within the pancreatic islets of 
Langerhans, involves the secretion of pancreatic hormones such as insulin and glucagon 
into the bloodstream to regulate blood glucose levels ( reviewed by Nussey and 
Whitehead, 2001). The exocrine pancreas accounts for up to 98% of the pancreas 
volume, whereas the endocrine pancreas constitutes only 2-3% of the pancreas volume 
(Rahier, Wallon and Henquin, 1981).  
Pancreatic cancer consists of multiple different cancer subgroups that are classified 
based on the pancreatic cells from which they arise. The majority of pancreatic cancers 
are adenocarcinomas that originate from cells of the exocrine pancreas. In fact, 
pancreatic ductal adenocarcinoma (PDAC), which commonly arises from the ductal 
epithelium in the head of the pancreas, accounts for over 85% of all pancreatic cancer 
cases (Ryan, Hong and Bardeesy, 2014; Ilic and Ilic, 2016). Thus, when referring to 
pancreatic cancer, most studies focus on PDAC (reviewed by Kleeff et al., 2016). 
Less common exocrine tumours include acinar carcinomas (Chaudhary, 2015), 
pancreatoblastomas (Terino, Plotkin and Karagozian, 2018), colloid carcinomas (Liszka 
et al., 2008) and solid pseudopapillary neoplasms (Dinarvand and Lai, 2017).  Tumours 
arising from the endocrine pancreas, including pancreatic neuroendocrine tumours 
(PNETs), are rare in comparison and account for merely 5% of pancreatic cancer cases 
(Ilic and Ilic, 2016). These tumours arise from the islets of Langerhans and can result in 
the unregulated secretion of pancreatic hormones. Importantly, patients diagnosed 
with these tumours have significantly better prognosis with a 5-year survival rate of 59% 
compared to those diagnosed with PDAC who have a 3% 5-year survival rate (Bilimoria 
et al., 2008; Siegel, Miller and Jemal, 2019). Due to the high mortality rates and poor 5-
year survival rates, most pancreatic cancer research now focuses on gaining a better 
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understanding of PDAC and developing novel therapies to address the unmet clinical 
need this disease poses.  
 
1.4 Pancreatic ductal adenocarcinoma (PDAC) 
1.4.1 PDAC precursor lesions 
Histological studies have shown that PDAC evolves in a stepwise manner developing 
from non-malignant precursor lesions into an invasive cancer (Bardeesy and DePinho, 
2002; Maitra et al., 2005; Wood and Hruban, 2012). To date, 5 different precursor 
lesions have been identified in the development of  human PDAC: pancreatic 
intraepithelial neoplasias (PanINs), intraductal papillary mucinous neoplasms (IPMNs), 
intraductal tubular papillary neoplasms (ITPNs), intraductal oncocytic papillary 
neoplasms (IOPNs) and mucinous cystic neoplasms (MCNs) lesions (reviewed in by Kim 
and Hong, 2018). These lesions can be further categorised as low- or high-grade on the 
basis of atypia (Kamisawa et al., 2016). Typically, pancreatic cancer most frequently 
arises from PanIN precursor lesions. PanINs are small (< 0.5 cm), non-invasive lesions 
consisting of cuboidal or columnar epithelial cells confined within the pancreatic ducts 
(reviewed in Kim and Hong, 2018). Whilst PanINs are curable, the microscopic size of 
these lesions makes them difficult to detect by radiological modalities including 
magnetic resonance imaging (MRI) and computerized tomography (CT) scans (Canto et 
al., 2012). PanINs are stratified into low-grade and high-grade lesions based on the 
varying degrees of structural and cytological atypia and expression of mucin. Low-grade 
PanINs are flat or papillary lesions with mild to moderate atypia that typically have 
basally located nuclei (reviewed in Kim and Hong, 2018). High-grade PanINs, however, 
are categorized by the presence of papillary lesions, severe atypia, loss of polarity, 
tufting and in some cases the presence of intraluminal necrosis (reviewed in Kim and 
Hong, 2018). 
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1.4.2 Molecular pathology of PDAC 
The molecular pathology of PDAC is predominantly characterised by activating 
mutations in the KRAS GTPase, typically KRASG12D, KRASG12R, KRASG12Vor KRASG12C 
(Pellegata et al., 1994), which are observed in over 90% of tumours (Kleeff et al., 2016). 
Further genetic alterations associated with the development of PDAC include 
inactivating mutations in TP53, CDKN2A and SMAD which occur in 50-80% of cases 
(Kleeff et al., 2016). As the PanIN model of PDAC progression is the most frequently 
observed and studied, the molecular pathology of PDAC will be discussed in terms of 
this model. The PanIN model involves three PanIN stages which increase in degree of 
cellular atypia, from the low-grade PanIN-1A/B and PanIN-2 to the development of high-
grade PanIN-3 and invasive PDAC (reviewed in Hruban, Maitra and Goggins, 2008). Low-
grade PanIN-1A/B lesions are associated with oncogenic KRAS mutations, which occur 
in 36% of PanIN-1A lesions and 44% of PanIN-1B lesions (Pellegata et al., 1994; Löhr et 
al., 2005). KRAS mutations, causing constitutive activation of KRAS, results in 
constitutive signalling between KRAS and its multiple effector pathways resulting in 
dysregulated cell proliferation, differentiation and survival (reviewed in Liu, Wang and 
Li, 2019). HER-2 mutations are also observed in most of these early PanINs (Hruban et 
al., 2000) in addition to KRAS allele changes. Overexpression of HER-2 results in 
uncontrolled cell growth and tumourigenesis, also through activation of KRAS (Iqbal and 
Iqbal, 2014). Thus, KRAS and/or HER-2 mutation are the earliest genetic events 
associated with the development of PDAC and likely facilitate deregulated cell 
proliferation and survival. The second low-grade lesion, PanIN-2, is characterised by flat 
and papillary ducts with atypia (Hruban, Maitra and Goggins, 2008) and is associated 
with inactivation of CDKN2A (or loss of p16) in 55% of cases. The percentage of p16 loss 
increases during later stages of the disease with 71% loss in PanIN-3 and 85-98% loss in 
full-blown PDAC (Caldas et al., 1994; Schutte et al., 1997; Wilentz et al., 1998). Due to 
the apparent loss of p16 in later stages, CDKN2A inactivation is believed to occur after 
KRAS mutation. The p16 protein is important for cell cycle progression and its expression 
is enhanced in times of DNA damage, oxidative stress or oncogene activation and usually 
results in senescence (Rayess, Wang and Srivatsan, 2012). Loss of p16 therefore enables 
cancer (the transformed) cells to by-pass senescence. The development of the high-
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grade PanIN-3 lesions are characterised by significant cytological and architectural 
atypia including nuclear atypia and involves budding of cells into the ductal lumen 
(Hruban, Maitra and Goggins, 2008). In fact, PanIN-3 lesions are often considered 
carcinomas in situ. Since PanIN-3 lesions are usually observed in the presence of invasive 
PDAC, the progression from PanIN-3 to PDAC is unclear. As with PDAC,  PanIN-3 lesions 
are associated with mutation in the TP53  and BRCA2  genes (Hruban et al., 2000), but, 
interestingly, only 20% of PanIN-3 lesions have TP53 mutation (Yokode et al., 2018). 
Since TP53 mutation is observed in 50-70% of PDAC tumours, it is possible that TP53 
mutation may predominantly occur in PDAC and not PanIN-3 (Scarpa et al., 1993; 
Rozenblum et al., 1997). TP53 is arguably the most potent tumour suppressor gene and 
is involved in the regulation of numerous physiological processes including; cell cycle 
and senescence, survival/apoptosis, autophagy and responses to stress stimuli such as 
DNA damage, oxidative stress and oncogene activation (Zilfou and Lowe, 2009). Thus, 
regardless of when TP53 mutation occurs, loss of the functional p53 protein could 
advance tumourigenesis in many ways. Interestingly, whilst loss of BRCA2 is associated 
with PanIN-3, it has been shown that alone, it does not facilitate progression into PDAC. 
In fact, whilst deletion of this gene in developing mice did promote PanIN formation, 
only 15% of mice developed PDAC (Feldmann et al., 2011).  Crucially, however, when 
BRCA2 loss was analysed in combination with p53 mutation, most mice progressed to 
PDAC, indicating that loss of BRCA2 alone is not sufficient to induce PDAC progression 
(Feldmann et al., 2011). Finally, progression to full blown PDAC, which is characterised 
by invasive growth and marked desmoplasia, is associated with loss of SMAD4 (Hruban, 
Maitra and Goggins, 2008; Y. W. Chen et al., 2014; Wang et al., 2017). SMAD4 is 
commonly lost through homozygous deletion and is observed in 50% of PDAC tumours 
(Hahn et al., 1996; Kleeff et al., 2016). Since SMAD4 is required for TGF-β mediated PDAC 
cell cycle arrest and apoptosis, loss of this protein promotes many cellular processes 
including cell proliferation and differentiation (Kleeff et al., 2016; Ahmed et al., 2017). 
PDAC progression stages and associated mutations are summarised in table 1.4.2 
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Table 1.4.2 Stages of PDAC progression and associated mutations 
Stage Associated mutations 
PanIN-1A/B KRASG12D, KRASG12R, KRASG12V, KRASG12C and HER-2 
PanIN-2 CDKN2A (p16) 
PanIN-3 TP53  and BRCA2   
PDAC TP53 and SMAD4 
 
1.4.3 Clinical presentation and diagnosis 
The exceptionally poor prognosis associated with PDAC is due in part to late/advanced 
stage diagnosis, and the lack of effective therapeutic options for metastatic disease. To 
date, surgical resection remains the most successful treatment option for pancreatic 
cancer patients, however at diagnosis, only 8% of patients have stage I tumours and are 
suitable for this potentially curative surgery (Kimura et al., 2015). Whilst most patients 
present with metastatic disease, the time frame for the development of advanced stage 
pancreatic cancer is slow. In fact, it can take up to 10 years for the initiating oncogenic 
mutation to develop in the parental, non-metastatic founder cell (Yachida et al., 2010). 
From this founder cell, a further 5 years are required for the development of a 
metastatic phenotype (Yachida et al., 2010). Thus, there is a significant window for early 
detection of pancreatic cancer. Diagnosis during the localised stage of disease markedly 
increases patient 5-year survival rate to 34%, compared to 12% in patients diagnosed 
with locally advanced disease and 3% for those diagnosed with metastatic disease 
(Siegel, Miller and Jemal, 2019). Furthermore, it is estimated that patients diagnosed 
during stage I of the disease, where surgical resection is possible have a 5-year survival 
rate of between 37 and 59% (Tsuchiya et al., 1986; Shimizu et al., 2005). Whilst survival 
is still fairly low for these patients, diagnosis at an early stage may provide a window 
where therapeutic intervention could be potentially curative.  
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As the majority of PDAC patients do not present with symptoms until late stage disease, 
early diagnosis is difficult due to our current lack of sensitive and specific tumour 
markers, difficulties in imaging early tumour lesions and the absence of screening 
methods (Kleeff et al., 2016; Siegel, Miller and Jemal, 2019). To date, standard screening 
programmes are not possible for the detection of pancreatic cancer, even for those with 
higher risk of developing the disease. Mounting evidence, however, suggests that 
implementing screening regimes for individuals who are high-risk (with at least 2.5 times 
increased risk) could save lives (Pandharipande et al., 2015). Due to the small size of 
PanINs, however, detection by imaging is difficult and distinctions cannot be made 
between low and high-grade lesions (Kleeff et al., 2016). The development of a rapid 
process for monitoring specific biomarkers for pancreatic cancer is one possible route 
to improving early detection. Currently, specific biomarkers for the detection of 
pancreatic cancer do not exist.  Historically, serum carbohydrate antigen 19-9 (CA 19-9) 
has been used as a marker for pancreatic cancer, however, it is not specific to pancreatic 
cancer and lacks the sensitivity to be used for early diagnosis (Poruk et al., 2013). CA 19-
9 can, however, be used to monitor the progression of PDAC after diagnosis . Other 
promising biomarkers have emerged in recent years including (i) circulating tumour DNA 
encoding mutant KRAS which can be detected in 43% of patients with localised disease 
(Sausen et al., 2015), (ii) a highly specific protein signature of oestrogen receptor 1, HER-
2 and tenascin C (Mirus et al., 2015) and (iii) the presence of the heparin sulfate 
proteoglycan glypican 1 on the surface of exosomes (Melo et al., 2015)(discussed further 
in section 1.7). Despite initial success in both GEMM of pancreatic cancer and patient 
samples, these promising biomarkers are still in early stages of development and are not 
yet clinically available .  
 
1.4.4 Treatment of PDAC 
Where surgical resection is not possible, chemotherapy is the only remaining treatment 
option for PDAC patients but unfortunately it is not curative and offers only a modest 
survival increase. Currently, the most successful chemotherapeutic options available 
include gemcitabine (as a single agent), FOLFIRINOX (folinic acid, fluorouracil, irinotecan 
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and oxaliplatin) or gemcitabine nab-paclitaxel (Burris et al., 1997; Berlin et al., 2000; 
Conroy et al., 2011; Von Hoff et al., 2013; Goldstein et al., 2015). For roughly 20 years, 
5-fluorouracil (5-FU) was the only chemotherapeutic agent available for PDAC. In 1997 
however Gemcitabine was introduced after a significant increase in patient survival was 
demonstrated, where 1-year survival rose from 2% in 5-FU treated patients to 18% in 
gemcitabine treated patients (Burris et al., 1997; Berlin et al., 2000). To date, single 
agent gemcitabine is the gold standard chemotherapeutic treatment for PDAC, 
however, it is relatively ineffective and merely shrinks tumours, temporarily reducing 
the devastating symptoms of PDAC. The lack of any significant improvement in outcome 
is in part due to the rapid development of resistance to gemcitabine, which arises within 
weeks of administration (Binenbaum, Na’ara and Gil, 2015). 
More recently, treatment with the FOLFIRNOX regime was shown to offer the most 
significant survival benefit for PDAC patients, where median survival is 11.1 months 
compared to 6.8 months with gemcitabine (Conroy et al., 2011; Vaccaro, Sperduti and 
Milella, 2011). Furthermore, progression free survival rose from 3.3 month to 6.4 
months and 1-year survival rates rose from 21% to 48% for those treated with 
FOLFIRNOX compared to gemcitabine. Unfortunately, however, FOLFIRNOX is 
associated with high levels of toxicity and so is reserved for use in patients with good 
performance status only (Conroy et al., 2011; Vaccaro, Sperduti and Milella, 2011).  
More recently, combination treatment with gemcitabine and nab-paclitaxel has been 
shown to increase median survival from 6.8 months (gemcitabine alone) to 8.5 months 
(Goldstein et al., 2015). The use of combination therapy also resulted in adverse side 
effects. Thus, treatment with gemcitabine nab-paclitaxel is also limited to patients with 
good performance status (Von Hoff et al., 2013).  
The survival benefit associated with gemcitabine, FOLFIRINOX and gemcitabine plus 
nab-paclitaxel, is modest and only increases life expectancy by mere months. In 
addition, the toxicities associated with these treatments mean that patient quality of 
life is greatly decreased and may outweigh survival benefit and often palliative care is 
preferential. These poor patient outcomes highlight the inadequacies of current 
therapies targeting PDAC and emphasises the desperate need for new and more 
successful treatments.  
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1.4.5 Centrosome amplification and PDAC 
Centrosome amplification has been identified as a hallmark of most human cancers 
including pancreatic cancer. A study performed in 1999  examined surgically resected 
human pancreas tissues for the presence of centrosome abnormalities including 
amplification. Analysis of 13 pancreatic ductal adenocarcinoma identified the presence 
of supernumerary centrosomes in 85% of samples (see Figure 1.4.5.1) (Sato et al., 1999). 
Furthermore, no amplification was observed in any of the 12 normal duct and stromal 
tissues. Amplified centrosomes were observed in adenocarcinomas with varying 
degrees of atypia and so it has been suggested that centrosome amplification may occur 
early on in the multi-step progression of PDAC (Sato et al., 1999; Ansari et al., 2018). 
Interestingly, amplified centrosomes were not observed in pancreatic endocrine 
tumours. Endocrine tumours are often well differentiated and have few areas of atypia 
and mitotic activity in comparison to adenocarcinomas and are not associated with loss 
of cell polarity. It is therefore possible that the underlying drivers of endocrine tumours 
differ from those associated with adenocarcinomas (exocrine tumours) and are not 
associated with centrosome amplification (Sato et al., 1999; Ansari et al., 2018).  
 
Figure 1.4.5.1 Immunofluorescent staining of centrosomes in pancreatic tissues A) Centrosome 
staining (as defined by ϒ-tubulin staining) in normal pancreas duct, showing little to no 
centrosome amplification. B) Centrosome staining (as defined by ϒ-tubulin staining) in poorly 
differentiated pancreatic ductal adenocarcinoma, showing high centrosome amplification. 
Samples are formalin-fixed, paraffin embedded human pancreas tissue. ϒ-tubulin in green, 
propidium iodide in red. Scale bar represents 50 µm (taken from Sato et al., 1999). 
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More recent studies have linked centrosome amplification in pancreatic tumours to 
rapid disease progression, metastasis and worse clinical outcome (Sato et al., 2001; 
Shono et al., 2001; Mittal et al., 2015). Crucially, centrosome amplification was shown 
to enhance the motility and invasiveness of pancreatic cancer cells (Mittal et al., 2015). 
Whilst the exact mechanisms underlying the induction of centrosome amplification in 
pancreatic cancer remain elusive, the overexpression of PLK4 in mouse models has been 
shown to induce centrosome amplification and enhance tumour formation and 
progression (Coelho et al., 2015; Serçin et al., 2015; Levine et al., 2017). In fact using a 
transgenic mouse model,  Coelho et al. showed that in a p53 null background, transient 
PLK4 overexpression lead to the development of centrosome amplification in the 
pancreas, resulting in the hyperproliferation of cells in the pancreas and advancing the 
formation of pancreatic tumours. Furthermore, analysis of PLK4 expression in pancreatic 
cancer patients using the pancreatic expression database (PED) (Marzec et al., 2018) 
revealed patients with high PLK4 expression had a significantly lower survival probability 
(p=0.048) compared to patients with low expression (see Figure 1.4.5.2). Therefore, it is 
possible that centrosome amplification in PDAC is caused by PLK4 overexpression.  
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Figure 1.4.5.2 Survival probability of pancreatic cancer patients and PLK4 expression. Survival 
probability curves generated using the pancreatic expression data base, analysing relationship 
between PLK4 expression and predicted pancreatic cancer patient survival. Survival probability 
is significantly lower (p=0.048) for patients with high PLK4 expression compared to low PLK4 
expression (data from PED  http://www.pancreasexpression.org). 
 
In support of this hypothesis, a number of centrosome related proteins have been 
shown to be over-expressed in pancreatic cancer (Weng et al., 2012; Xie et al., 2016; 
Peng et al., 2017). For example, CEP70, a protein that induces centrosome amplification 
upon its overexpression (Xie et al., 2016), and the centrosome related protein 
phosphatase 4 (PP4) which plays a role in centrosome organisation and maturation 
(Weng et al., 2012) and is considered a prognostic factor for pancreatic cancer. 
Centrosomal protein 55 (CEP55), a microtubule bundling protein, is also over-expressed 
in pancreatic cancer (Peng et al., 2017) and has been shown to promote pancreatic 
cancer cell proliferation, migration and invasion in vitro and accelerated tumourigenicity 
in vivo through the activation of NF-κB signalling (Peng et al., 2017). CEP55 may be 
valuable as a prognostic marker for pancreatic cancer and may also represent a novel 
target for therapy.  
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The presence of amplified centrosomes in both early and late stage pancreatic cancer 
makes them intriguing targets for biomarker development and/or therapeutic 
intervention. Whilst detection of centrosomal abnormalities as a biomarker is a 
relatively unexplored area, the development of therapeutics targeting amplified 
centrosomes are in progress. Many of these therapeutics centre around centrosome de-
clustering, forcing cancer cells into multipolar mitoses, resulting in gross aneuploidy and 
cell death. The identification of the kinesin-14 family protein HSET as a key mediator of 
centrosome clustering has led to the development of a number of new therapeutics 
targeting HSET in cancer cells (Mountain et al., 1999; Cai et al., 2008; Kwon et al., 2008; 
Watts et al., 2013; Wu et al., 2013; Zhang et al., 2016). For example, the allosteric 
inhibitor CW069 gives rise to multipolar mitoses in cells with supernumerary 
centrosomes and shown promise as an HSET inhibitor in vitro (Watts et al., 2013). More 
recently, two more small molecule inhibitors, AZ82 and SR31527 have shown 
centrosome de-clustering and subsequent multipolar mitoses in cells with amplified 
centrosomes (Wu et al., 2013; Zhang et al., 2016). Further study into the biological 
efficacy and off target toxicity of these inhibitors however, revealed all three to have 
HSET-independent cytotoxicity (Yukawa et al., 2018). Despite the observed toxicities 
however, AZ82 was shown to have potent neutralising activity against HSET induced 
lethality in fission yeast (Yukawa et al., 2018). Thus, whilst further investigation and 
development is still required HSET inhibitors show promise as future centrosome 
amplification targeting therapeutics.    
 
1.5 The tumour microenvironment   
The current failures of pancreatic cancer therapeutics may be attributed to an important 
element of the tumour being largely ignored; the tumour stroma. Pancreatic cancer is 
characterised by a strong desmoplastic stromal reaction resulting in dense fibrosis 
around the tumour. The tumour stroma however is not accurately replicated in most of 
the experimental models used to develop new therapeutics for PDAC (Apte and Wilson, 
2012; Apte et al., 2013). Therefore, over the last decade researchers have directed their 
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attentions to understanding the pancreatic tumour stroma and its role in tumour 
progression and drug resistance.   
In normal tissues, the microenvironment is composed of numerous cellular and acellular 
components that form an organized niche to regulate homeostasis (Alderton, 2014; Hui 
and Chen, 2015). In a tumour setting, the stromal compartment consists of several 
extracellular matrix (ECM) proteins, signalling molecules, endothelial cells, immune 
cells, cancer associated fibroblasts (CAFs) and pancreatic stellate cells (PSCs) (Erkan, 
Hausmann, et al., 2012; Neesse et al., 2015) (see Figure 1.5). PDAC tumours have a 
significant, highly fibrotic, stromal compartment that can account for over 90% of the 
total tumour, making PDAC one of the most stroma-rich cancers (Neesse et al., 2011). 
Furthermore, the PDAC tumour microenvironment (TME) is known to facilitate cancer 
cell growth and survival, EMT, cell migration, metastasis and chemoresistance (Neesse 
et al., 2015; Nielsen, Mortensen and Detlefsen, 2016; Thomas and Radhakrishnan, 
2019). Thus, the TME plays a key role in the progression of pancreatic cancer .  
 
 
Figure 1.5 Pancreatic tumour microenvironment. Pancreatic cancer cells are surrounded by a 
dense stromal compartment consisting of ECM proteins, blood vessels, immune cells, activated 
PSCs and signalling molecules. ECM= extracellular matrix, PSC= pancreatic stellate cells.  
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1.5.1 Pancreatic stellate cells (PSCs) 
First identified in the liver in 1975, stellate cells have since been shown to frequent the 
pancreas of mice and humans. Stellate cells are star-shaped fibroblast like cells with long 
cytoplasmic projections that are woven into tissues.  In the normal healthy pancreas 
PSCs account for roughly 4-7% of parenchymal cells and exist in a quiescent state. PSC 
quiescence is characterised by their ability to store retinoids (vitamin A) in the form of 
droplets in the cytoplasm and little to no detectable α-smooth muscle actin (α-SMA) 
(Apte et al., 1998; Friedman, 2008). In their quiescent state, PSCs have a low mitotic 
index, have limited migratory capacity and function to synthesise and maintain the ECM 
(Apte et al., 1998; Phillips, McCarroll, et al., 2003). Upon injury or inflammation, PSCs 
become activated,  transitioning into myofibroblast-like cells which are characterised by 
loss of vitamin A droplets and increased expression of α-SMA stress fibres (Apte et al., 
1998; Erkan, Adler, et al., 2012). Once activated, PSCs adopt a spindle like shape and 
exhibit heightened migratory and proliferative capabilities (Bachem et al., 1998; 
Schneider et al., 2001; Mews et al., 2002; Phillips, Wu, et al., 2003; Omary et al., 2007; 
Keogh et al., 2011), increased contractility, excessive deposition of ECM proteins 
including collagens I, II and XI and fibronectin and remodelling of the ECM through 
secretion of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix 
metalloproteinases (TIMPs) (Apte et al., 1999, 2004; Schneider et al., 2001; Phillips, 
McCarroll, et al., 2003; Bachem et al., 2005). During injury, activated PSCs function to 
heal wounds in the tissue by substituting damaged cells with fibrotic tissue, thus 
generating a quick fix to maintain organ integrity (Ferdek and Jakubowska, 2017). The 
extended presence of activated PSCs, however, may become pathological with PSCs 
depositing excessive amounts of ECM proteins resulting in fibrosis. In fact, the 
desmoplastic stromal reaction/ fibrosis that is characteristic of PDAC has been 
attributed to chronic and sustained activation of PSCs during tumour progression (Erkan, 
et al., 2012). 
PSCs are activated in response to a number of different factors and stimuli including 
inflammatory cytokines such as TNF-α and IL-8, growth factors including platelet-derived 
growth factor (PDGF), the transforming growth factors TGF-α and TGF-β, and oxidative 
stress and alcohol metabolites (Apte et al., 1999, 2000; Andoh et al., 2000; Schneider et 
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al., 2001; Mews et al., 2002; Shek et al., 2002; Gao and Brigstock, 2005; Kordes et al., 
2005; Vonlaufen et al., 2010; Tahara et al., 2013). Many of these PSC activating factors 
are secreted by neighbouring cells including endothelial cells, acinar cells, infiltrating 
cells such as macrophages, platelets and pancreatic cancer cells (Masamune and 
Shimosegawa, 2009; Erkan, et al., 2012). In the normal pancreas, activation is transient, 
and PSCs will revert back to their quiescent state upon tissue restoration. In PDAC, 
however, once activated, PSCs remain in a chronic state of activation via both paracrine 
stimuli and autocrine signalling (Shek et al., 2002; Ohnishi et al., 2003; Aoki et al., 2005; 
Omary et al., 2007; Jiang et al., 2009). A summary of PSC activation is shown in figure 
1.5.1. 
 
 
Figure 1.5.1 Paracrine and autocrine-mediated activation of pancreatic stellate cells (PSCs). 
PSCs transition from a quiescent state (vitamin A storing) to an activated state (myofibroblast-
like phenotype) in response to paracrine signalling from neighbouring cells including pancreatic 
cancer cells. PSCs perpetuate their own activation through subsequent autocrine signalling. This 
PSC activation results in increased proliferation and migration and excessive ECM synthesis 
resulting in extensive fibrosis.  
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1.5.2  Activated PSCs and cancer 
Mounting evidence now suggests that the  increased presence of activated PSCs within 
a tumour correlates with poor clinical outcome. In fact, a study of 233 patients reported 
an association between the number of activated PSCs and poorest prognosis (Erkan et 
al., 2008). In addition, PSC activation has been observed during the PanIN stages, 
resulting in fibrosis surrounding these precursor lesions (Bynigeri et al., 2017). An 
additional study analysing prognosis of 145 patients in early stages of pancreatic cancer 
found that moderate-to-strong α-SMA expression in PSCs was associated with poorer 
progression-free survival (L. M. Wang et al., 2016). These findings indicate that the 
activation of PSCs may be an early event in the development of pancreatic cancer and 
chronic or sustained activation is associated with poorer clinical outcomes. 
Furthermore, two studies analysing orthotopic injection of human PDAC cells alone or 
in combination with PSCs into mouse pancreas demonstrated that the presence of PSCs 
induced fibrosis, increased tumour growth, and advanced invasion and metastasis. 
Therefore, PSC activation appears to have multiple roles in advancing PDAC.  
The strong desmoplastic reaction caused by activated PSCs results in the formation of a 
solid tumour with growth induced solid stress (GISS) which results in blood vessel 
compression and impairs the delivery of intravenous drugs to the tumour (Provenzano 
et al., 2012; Chauhan et al., 2013; DuFort, Christopher. C DelGiorno and Hingorani, 
2016). Furthermore, the presence of PSC deposited fibrillar collagen in the stroma 
inhibits concentration-driven delivery of cancer therapeutics to the cancer cells, by 
providing a physical barrier to drug diffusion (Provenzano et al., 2012; DuFort, 
Christopher. C DelGiorno and Hingorani, 2016). Thus, the extensive stroma associated 
with PSC activation creates a significant barrier to drug delivery.  
Importantly, GEMM of PDAC have demonstrated that stromal depletion can enhance 
drug delivery. In fact, in KPC mice with pancreatic tumours, treatment with the 
hyaluronidase PEGPH20, which degrades stromal components, was found to promote 
vascularisation of the tumours. This enhanced the intra-tumoural delivery of 
chemotherapeutic agents and improved overall survival of the mice (Provenzano et al., 
2012; Jacobetz et al., 2013). An additional study also demonstrated that stromal 
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depletion with the angiotensin inhibitor losartan resulted in reduced solid stress and 
increased vasculature of the tumour,  facilitating oxygen and drug delivery (Chauhan et 
al., 2013). Stromal depleting therapies have therefore been highlighted as strong 
candidates for the development of novel therapeutics. Unfortunately, despite numerous 
stromal depleting therapies reaching clinical trials, they have not translated well in the 
clinic, are often associated with toxicities and offer no survival benefit (reviewed in Kota 
et al., 2017). In fact, mounting evidence now indicates that the stroma has important 
anti-tumour properties, since its ablation has been shown to promote tumour 
progression and decrease survival (Özdemir et al., 2014; Rhim et al., 2014). For example, 
whilst the depletion of Shh in the dx1-Cre;KrasLSL-G12D/+;p53fl/+;Rosa26LSL-YFP/+ (PKCY) 
mouse model resulted in the depletion of stromal cells from PDAC tumours, this stromal 
depletion resulted in increased tumour vasculature, tumour cell proliferation and 
reduced survival (Rhim et al., 2014). Additionally, depletion of myofibroblasts in the 
Ptf1acre/+;LSL-KrasG12D/+;Tgfbr2flox/flox (PKT) mouse model of pancreatic cancer decreased 
fibrosis but enhanced cancer cell EMT leading to more invasive tumours (Özdemir et al., 
2014). The failure of stroma ablating therapies highlights the need to further understand 
the molecular mechanisms associated with PDAC stromal biology before stromal 
therapies can be implemented. Efforts are now focussed on the development of 
therapies that modulate the tumour stroma rather than fully ablating it. Indeed, recent 
studies are now analysing the potential therapeutic advantage of inducing stromal 
quiescence over stromal ablation. For example, treatment of PSCs with all-trans retinoic 
acid (ATRA) was shown to induce PSC quiescence which slowed tumour progression by 
reducing cancer cell proliferation and invasion in the LSL-KrasG12D/+; Trp53fl/+; Pdx1-Cre 
(KPC) mouse model (Froeling et al., 2011). Furthermore, combination therapy of 
gemcitabine and ATRA was shown to reduce cancer cell proliferation and invasion in KPC 
mice compared to those treated with gemcitabine alone (Carapuça et al., 2016). The 
success of ATRA/gemcitabine treatment in KPC mice lead to the development of the 
currently ongoing phase I STAR_PAC clinical trial in which patients with locally advanced 
or metastatic PDAC are treated with ATRA in combination with either gemcitabine or 
nab-paclitaxel (NCT03307148). 
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1.5.2.1 Activation of PSCs by PDAC cells 
Within the tumour setting, PDAC cells have been shown to activate PSCs and modulate 
their activity through a multitude of paracrine signals (Bachem et al., 2005). TGF- β is a 
key mediator of PSC activation and can be supplied to PSCs by the cancer cells. PSCs 
respond to TGF-β signalling in a SMAD-dependent manner resulting in the synthesis and 
deposition of excessive ECM components that can lead to fibrosis in the tumour (Apte 
et al., 1999; Löhr et al., 2001; Ohnishi et al., 2004). In addition, TGF-β signalling has been 
shown to enhance the proliferative capabilities of stellate cells (Pinzani et al., 1989). 
Interestingly, in addition to responding to PDAC-derived TGF-β1 signalling, PSCs 
themselves have been identified as a source of TFG-β1 (Ohnishi et al., 2004). Thus, PSCs 
can sustain their own activation through TGF-β1 autocrine signalling. Connective tissue 
growth factor (CTGF) has also been shown to induce stellate cell activation and was 
found to promote migration and extracellular matrix production through interaction 
with TGF-β 1 (Huang and Brigstock, 2012; Hao et al., 2014). PDAC cells can also induce 
accelerated ECM synthesis by PSCs via secretion of PDGF and/or, fibroblast growth 
factor 2 (FGF2) (Bachem et al., 2005). Additionally, PDAC cells secrete ECM 
metalloproteinase inducer (EMMPRIN) which induces PSCs to synthesise MMP-2, an 
important basement membrane degradation protein (Schneiderhan et al., 2007). As 
ECM re-modelling and basement membrane degradation are important steps in tumour 
progression, PDAC cells may be aiding their own metastasis through modulation of PSCs.  
 Another key factor secreted by PDAC cells that can activate PSCs is sonic hedgehog 
(shh). Whilst shh is not usually present in the healthy adult pancreas, it has been 
detected in up to 70% of patient tumours (Thayer et al., 2003). Secretion of shh by PDAC 
cells has been shown to mediate activation of the surrounding PSCs, enhancing PSC 
proliferation, differentiation and motility (Bailey et al., 2008; Fendrich et al., 2011). 
Moreover, shh has been shown to enhance ECM deposition by PSCs (Bailey et al., 2008; 
Fendrich et al., 2011; Rhim et al., 2014). Other PDAC secreted factors including PDGF, 
trefoil factor 1 (TFF1), insulin-like growth factor 1 (IGF1) and interleukin 6 (IL-6) have 
also been shown to enhance PSC proliferation and migration (Phillips, Wu, et al., 2003; 
Bachem et al., 2005; Arumugam et al., 2011; Rosendahl et al., 2015; Fu et al., 2018; 
Marzoq et al., 2019). Interestingly, whilst TFF1 is not expressed by normal pancreatic 
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cells, it is highly upregulated in pancreatic cancer cells. TFF1 is also significantly 
upregulated in PanINs (Arumugam et al., 2011) and so may play a role in the early stages 
of PDAC development.  
Pancreatic cancer cells are a significant source of reactive oxygen species (ROS). In fact, 
high levels of ROS, produced during oxidative stress, have been identified in many 
different cancers and are believed to promote tumour aggressiveness (Martinez-Useros 
et al., 2017). Interestingly, ROS and lipid peroxidation products have been shown to 
induce hepatic stellate cell (HSC) activation, promoting  HSC proliferation and deposition 
of ECM components (reviewed in Gandhi, 2012). Recently, exosomes have been shown 
to deliver ROS to injured neurons through transfer of NADPH2 oxidase, thereby 
promoting neuronal regeneration (Hervera et al., 2018). Thus, it is possible that 
pancreatic cancer cells may induce stellate cell activation through the transfer of 
secreted ROS.  
 
1.5.2.2 Effect of PSC activation on PDAC cells 
Current data suggests that PDAC cells and PSCs interact in a bidirectional manner, where 
PDAC cells recruit and activate PSCs, and in turn PSCs facilitate cancer cell growth, 
invasion and chemoradiation resistance (Bachem et al., 2005; Rosa F Hwang et al., 2008; 
Mantoni et al., 2011). In fact, the extensive bidirectional interplay between pancreatic 
cancer cells and PSCs has been shown to facilitate tumour progression (see Figure 
1.5.2.2) (Apte et al., 2004; Bachem et al., 2005; Rosa F Hwang et al., 2008; Vonlaufen et 
al., 2008; Xu et al., 2010).  
Studies have shown that paracrine signalling from PSCs stimulates PDAC proliferation 
and inhibits apoptosis (Bachem et al., 2005; Rosa F. Hwang et al., 2008; Vonlaufen et al., 
2008). Secretion of epidermal growth factor (EGF), connective tissue growth factor 
(CTGF), PDGF, Galectin-1 and adrenomedullin by PSCs have all been shown to enhance 
PDAC cell proliferation (Marzoq et al., 2019; Thomas and Radhakrishnan, 2019). 
Likewise, PSC secretion of C-X-C motif chemokine ligand 13 (CXCL13) recruits B cells to 
the TME, which in turn secrete IL-35 inhibiting PDAC cell apoptosis and stimulating 
proliferation (Nicholl et al., 2014; Pylayeva-Gupta et al., 2016). 
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PSCs have also been shown to induce EMT in PDAC cells, possibly facilitating PDAC cell 
invasion and metastasis. PDAC cells co-cultured with PSCs were reported to have 
decreased E-cadherin and beta-catenin expression, and increased vimentin and snail 
expression which is consistent with EMT (Kikuta et al., 2010). Interestingly, hypoxia has 
been shown to induce secretion of CTGF by PSCs which mediates PDAC cell EMT, 
facilitating cancer cell invasion (Eguchi et al., 2013). Additionally, the secretion of MMPs 
by PSCs has been shown to enhance the migration of PDAC cells and accelerate 
tumourigenesis (Schnelderhan et al., 2007; Tjomsland et al., 2016). Furthermore, 
Galectin-1 driven up-regulation of stromal cell-derived factor 1 (SDF-1) in PSCs has been 
shown to induce PDAC metastasis (Qian et al., 2017; Orozco et al., 2018).  
PSCs have been shown to mediate PDAC cell resistance to chemotherapy and 
radiotherapy for example by supporting PDAC cell resistance to gemcitabine, through 
the secretion of IGF1 and IGF2 which activate IGF receptors on the cancer cells (Ireland 
et al., 2016). Indeed, in vivo studies revealed that pharmacological blockage of IGF 
resulted in re-sensitisation to gemcitabine (Ireland et al., 2016). Secretion of fibronectin 
by PSCs  has also been shown to promote PDAC cell chemoresistance to gemcitabine 
(Amrutkar et al., 2019). Similarly, PSCs are thought to mediate chemoresistance in PDAC 
cells through nitric oxide (NO) and IL-1β secretion (Haqq et al., 2014). PSCs may also 
confer chemoresistance by increasing the expression of the stem cell related genes 
nestin, LIN28 and ABCG2 in PDAC cells, thereby inducing the establishment of stem cells 
within the tumour (Hamada et al., 2012; Lonardo et al., 2012). In conclusion, the 
significant bidirectional cross talk exhibited by PSCs and PDAC cells has a profound effect 
on PDAC cell proliferation, invasion, metastasis and chemoresistance (see Figure 
1.5.2.2).  
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Figure 1.5.2.2 Bidirectional cross talk between activated pancreatic stellate cells (PSCs) and 
pancreatic cancer cells. Pancreatic cancer cells stimulate PSC activation resulting in increased 
proliferation, migration, deposition of ECM, contractility and MMP secretion. In response, 
through paracrine signalling, activated PSCs stimulate proliferation, migration, EMT and 
chemoresistance in PDAC cells. Perpetual cross talk between PSCs and Pancreatic cancer cells 
results in tumour progression 
 
1.6 Extracellular vesicles 
1.6.1 Extracellular vesicles: classes and biogenesis 
Extracellular vesicles (EVs) are small, membrane-bound vesicles that are secreted by 
cells into the extracellular environment. Secretion of EVs appears to be conserved 
throughout evolution and all eukaryotic cell types demonstrate EV release (Raposo and 
Stoorvogel, 2013). EVs contain a biological cargo specific to their cell of origin that can 
influence the behaviours of surrounding cells upon interaction with neighbouring cells 
(Colombo, Raposo and Théry, 2014). Once released, EVs can enter the circulation and 
pass into most bodily fluids including blood, urine, saliva and breast milk (Crawford, 
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1971; Vlassov et al., 2012), thus EVs can communicate biological information with 
distant cells. 
Classically, the secretory pathway in eukaryotic cells involves packaging of cargo 
proteins into secretory vesicles via the endoplasmic reticulum (ER)-Golgi route 
(reviewed in Kim et al., 2018). Proteins targeted for secretion in this manner contain a 
recognition signal peptide at the N-terminus or transmembrane domain, which directs 
their translocation into the lumen of the ER (reviewed in Grieve and Rabouille, 2011). 
Secretory proteins are then transferred to the Golgi, where they are moved by cisternal 
migration to the trans-Golgi and into the trans-Golgi reticulum, where they are sorted 
into secretory vesicles (Grieve and Rabouille, 2011; Kim, Gee and Lee, 2018). Upon the 
recognition of a stimulus for exocytosis, these vesicles are trafficked to and fuse with 
the plasma membrane resulting in the release of their contents into the extracellular 
milieu (Bonifacino and Glick, 2004). EVs however, represent an unconventional 
secretory pathway that differs significantly from the ‘classical’ secretory pathway. These 
alternative pathways are detailed below.  
Eukaryotic cells secrete a range of different EV types which differ in their size, 
biogenesis, cargo and function. Whilst the nomenclature of these different vesicle types 
is in constant debate, broadly speaking, secreted vesicles can be separated into three 
main groups, i) the plasma membrane secreted apoptotic bodies and microvesicles and 
ii) the intracellularly generated exosomes. Apoptotic bodies, which are 1-5 µm in size,  
are released from dying cells through outward membrane blebbing and are thought to 
contain the potentially toxic debris of apoptotic cells preventing leakage of these factors 
into the extracellular milieu (Wickman, Julian and Olson, 2012). Microvesicles and 
exosomes, on the other hand, play critical roles in intercellular communication and have 
become the focus of many subsequent studies (Mathivanan, Ji and Simpson, 2010; 
György et al., 2011). 
Critically, the distinction between microvesicles and exosomes is dependent on which 
arm of the secretory pathway they originate from (György et al., 2011; Meckes and 
Raab-Traub, 2011). Microvesicles, generally considered the larger of the two EVs 
measuring between 100-1000 nm in diameter, are formed through outward budding or 
“shedding” of the plasma membrane into the extracellular space (Voichitoiu et al., 
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2019). Initially, it was assumed that all secreted EVs were generated in this manner, until 
the 1980s when a secondary more complex EV secretion pathway was described 
(Clifford Harding, Heuser and Stahl, 1983; Pan and Johnstone, 1983). It was discovered, 
that the smaller EVs, now termed exosomes, which range from 30-150 nm in diameter, 
form intracellularly within multivesicular bodies (MVBs) or early endosomes (Voichitoiu 
et al., 2019). In short, exosomes form as intraluminal vesicles (ILVs), through inward 
budding into MVBs, which can then fuse with the plasma membrane releasing the 
exosomes into the extracellular space. Conversely, these MVBs can fuse with lysosomes 
resulting in degradation and recycling of the vesicles and their contents (C Harding, 
Heuser and Stahl, 1983; Pan and Johnstone, 1983; Pan et al., 1985; Sun and Liu, 2014). 
A summary schematic of microvesicle and exosome biogenesis is shown in figure 1.6.1.  
 
Figure 1.6.1 Extracellular vesicle biogenesis and secretion. Exosomes: Early endosomes are 
formed through inward budding of the plasma membrane. Exosomes are synthesised by 
subsequent intraluminal budding inside early endosomes and multivesicular bodies (MVBs). 
Early endosomes mature into MVBs and late MVBs. MVB fate is either fusion with lysosomes 
and subsequent degradation of vesicle contents or fusion with the plasma membrane. Exosomes 
are secreted upon MVB or late MVB fusion with the plasma membrane. Microvesicles: 
microvesicles are formed through outward budding of the plasma membrane. 
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Microvesicles and other EV types that are similar in size to exosomes share similar 
characteristics, including density and membrane orientation. As a result of this, EV 
isolation methods struggle to efficiently separate the different types of vesicles and 
most protocols used to isolate exosomes also contain other EVs of non-endosomal origin 
and lipoproteins (lipid-based non-vesicular structures) (Kowal et al., 2016a; Karimi et al., 
2018). Recent investigation into the heterogeneity of exosome populations themselves 
revealed the existence of an additional non-membranous nano-particle termed 
‘exomeres’ (~ 35 nm in diameter) that may further contribute to the heterogeneity of 
EV samples (Zhang et al., 2018).  
To date, many studies have identified roles for exosomes in a multitude of 
pathophysiological situations, including cancer, cardiovascular diseases, immune 
responses, regeneration and stem cell-based therapies (Mathieu et al., 2019). The 
heterogeneity of isolated EV populations, however, means that we cannot specifically 
attribute these roles to specific vesicle types. To combat the issue of vesicle 
identification, many studies have been performed to identify markers specific for 
exosomes. However, Plasma membrane-derived and endosomal-derived EVs are both 
formed through membrane budding away from the cytosol, so they share the same 
membrane orientation, with similar membrane associated proteins and enclose 
cytosolic components. Identification of exosome specific markers has therefore proved 
a difficult task. More recently, however, it was demonstrated that the tetraspanins 
CD63, CD81 and CD9 are enriched on exosomes (Kowal et al., 2016a). Whilst further 
validation is required, these findings suggest that the presence of CD63, CD81 and CD9 
together on EVs within the correct size range (30-150 nm) could be indicative of 
exosomes (Mathieu et al., 2019).  
 
1.6.2 Exosomal cargo 
Exosomes contain a broad range of cargos that can be transferred to recipient cells 
though fusion with target cell plasma membranes (Montecalvo et al., 2012) or through 
exosome uptake into endocytic or phagocytic compartments (Morelli, 2006; Barrès et 
al., 2010; Tian et al., 2010). This cargo has been shown to be functional in target cells 
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and can regulate a number of cellular activities. Exosomal cargo is sequestered and 
packaged in the cells from which the exosomes originate, therefore, exosomes may in 
part, reflect the contents of the cells from which they are synthesised. Numerous 
different proteins have been identified in exosomes. These proteins can be ubiquitous 
and act as possible universal markers of exosomes, or they can be cell-specific and may 
prove useful in identifying characteristics of the cells that the exosomes originate from. 
Proteins that are ubiquitously expressed in all exosomes include the membrane-
associated tetraspansins CD9, CD63, CD81 and CD82, the cytoplasmic heat shock 
proteins Hsp70 and Hsp90, the endosomal sorting complex required for transport 
(ESCRT) associated proteins TSG101 and ALIX, and transport/fusion associated Annexins 
and the RAB small GTPases (Théry, Ostrowski and Segura, 2009; Mincheva-Nilsson and 
Baranov, 2010; Mathivanan et al., 2012; Vlassov et al., 2012). Examples of cell specific 
proteins sequestered into exosomes include the major histocompatibility complex 
(MHC) class-I and class-II secreted by MHC presenting cells (Denzer et al., 2000). 
Similarly, exosomes derived from tumour cells have been shown to contain many 
adhesion molecules, metalloproteinases and a number of oncogenic proteins that play 
a role in tumourigenesis and metastasis (Raimondo et al., 2011; Liang et al., 2013; Kruger 
et al., 2014). In addition to proteins, exosomes are rich in lipids and lipid-raft cholesterol 
(Théry, Ostrowski and Segura, 2009; Yuyama et al., 2012). 
Nucleic acids including DNA, long non-coding RNA (lncRNA), mRNA and microRNA 
(miRNA) are also present in exosomes. In general, RNA can be easily degraded by RNases 
present in the ECM, however RNA present in exosomes is significantly more stable (Ge 
et al., 2014) due to its compartmentalisation ‘stable’ exosomal mRNAs are functional 
and can be translated in recipient cells (Valadi et al., 2007). To date, thousands of 
different miRNAs have been identified within exosomes and the transfer of miRNAs has 
been shown to regulate gene expression and cellular activities in target cells(W. X. Chen 
et al., 2014).  It is reported that the majority of miRNA present in serum and saliva are 
contained within exosomes and evidence suggests that exosomal miRNA is more 
biologically active than others in circulation (Turchinovich et al., 2011; Gallo et al., 2012; 
Zhang and Grizzle, 2014). Recent work has shown an increase in exosomal miRNA in the 
sera of cancer patients, highlighting the potential for exosomal miRNAs as diagnostic 
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biomarkers for cancer (Rabinowits et al., 2009; Tanaka et al., 2013; Eichelser et al., 
2014). Similarly, evidence also supports the potential of exosomal lncRNA and double-
stranded DNA (dsDNA) as biomarkers for cancer (Kahlert et al., 2014; Takahashi et al., 
2014; Thakur et al., 2014; Q. Li et al., 2015). 
 
1.6.3 The formation and secretion of exosomes 
1.6.3.1 ILV formation inside MVBs 
Exosome biogenesis and secretion have been studied a great deal in recent years leading 
to significant advances in our understanding of the mechanisms involved. The best 
described method involves the ESCRT driven sorting and formation of ILVs (reviewed in 
Colombo, Raposo and Théry, 2014). The ESCRT machinery is composed of four 
complexes and associated proteins: ESCRT-0, ESCRT-I, ESCRT-II and ESCRT-III which 
associate at MVB membranes and regulate cargo targeting and the formation of ILVs in 
a successive manner (Hurley, 2015).  
The ESCRT-0 complex is involved in the identification and sequestering of ubiquitinated 
proteins into the endosomal membrane. This complex contains hepatocyte growth 
factor-regulated tyrosine kinase substrate (HRS) (encoded by HSG) which associates 
with other ESCRT-0 associated proteins including signal transducing adaptor molecule 1 
(STAM1) and the non ESCRT protein Eps15 and clathrin (Colombo, Raposo and Théry, 
2014). Components of the ESCRT-0 complex are generally not associated with vesicle 
budding from the plasma membrane and thus, their presence in EVs may indicate 
endosomal origin (Mathieu et al., 2019). HRS from ESCRT-0 then recruits the ESCRT-I 
complex protein TSG101, which subsequently recruits ESCRT-III through association with 
either ESCRT-II or the ESCRT associated protein ALIX (encoded by PDCD6IP). The ESCRT-
I and ESCRT-II complexes are then responsible for membrane deformation, inducing 
intraluminal budding and the ESCRT-III complex drives vesicle scission (Hanson and 
Cashikar, 2012; Henne, Stenmark and Emr, 2013). Furthermore, vesicle budding has 
been shown to involve a number of cone shaped lipids including ceramide which is 
generated by sphingomyelinases (Trajkovic et al., 2008; Bianco et al., 2009). Finally, 
vacuolar protein sorting associated protein 4 (VPS4) is required for the disassociation 
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and recycling of the ESCRT machinery (Colombo, Raposo and Théry, 2014; Jackson et al., 
2017).Interestingly, the ESCRT-associated protein ALIX has been shown to play a role in 
ILV formation by promoting intraluminal budding (Baietti et al., 2012; Romancino et al., 
2013).  
The mechanisms of cytosolic protein cargo sorting into ILVs are less well understood. 
However, a role for the ESCRT-0 associated protein HRS has been identified, whereby 
HRS recognises ubiquitin moieties on cargo proteins and sequesters ubiquitinated 
proteins into the ILVs (Colombo, Raposo and Théry, 2014). Additionally, a role for the 
heat shock protein HSC70 has been identified. HSC70 was shown to bind to 
phosphatidylserine on outer membranes of MVBs and to cytosolic proteins with a KFERQ 
sequence resulting in the inclusion of this protein and its binding partners in ILVs in a 
process that was found to be TSG101 and VPS4- dependent (Sahu et al., 2011). 
Furthermore, multiple roles have been identified for the ESCRT associated protein ALIX 
in cargo sorting. ALIX binding to the cytoplasmic domain of transferrin receptor (TfR) in 
reticulocytes was shown to induce the sorting of TfR into ILVs (Géminard et al., 2004) in 
what appears to be a competitive manner with HSC70 binding (Géminard et al., 2004). 
ALIX has also been shown to induce the sorting of syndecans via syntenin interaction 
into ILVs in an ESCRT-II, ESCRT-III and VPS4 dependent manner, resulting in the 
formation of syndecan, syntenin and ALIX containing exosomes (Baietti et al., 2012).   
Studies into the loading of miRNAs into exosomes have revealed a few different 
mechanisms by which miRNAs are sequestered into vesicles. One possible mechanism 
involves sphingomyelinase2 (nSMase2) which is believed to promote miRNA trapping in 
exosomes through the catalysation of ceramide (Kosaka et al., 2010). Additionally, 
miRNA packaging has been shown to be mediated through chaperone proteins such as 
hnRNPA2B1 (Batagov, Kuznetsov and Kurochkin, 2011; Villarroya-Beltri et al., 2013). 
Mechanistic studies have revealed that specific sequences at the 3’ end of miRNAs are 
recognised by effector proteins and thus determine which miRNAs are packaged into 
exosomes. For instance, the presence of 1,2, or 3 uridine or adenosine nucleotides at 
the 3’ end of miRNA specifically direct them to exosomes (Koppers-Lalic et al., 2014).    
 
 Chapter 1. Introduction 
 
53 
 
1.6.3.1 MVB trafficking and exosome secretion 
Mechanisms that drive exosome secretion have also been widely studied. The Rab 
family of small GTPases are known to play key roles in intracellular vesicle trafficking and 
so it is unsurprising that they have been implicated in various steps of MVB trafficking 
to the plasma membrane and subsequent exosome release  (Stenmark, 2009). 
Impairment of Rab27a or Rab27b has been shown to alter the ability of MVBs to dock to 
the plasma membrane resulting in decreased exosome secretion (Ostrowski et al., 
2010). Rab11, Rab35, Rab5a, Rab9a, Rab2b and Rab7 have also been identified as major 
players in exosome secretion, albeit in a cell line dependent manner(Savina et al., 2005; 
Hsu et al., 2010; Ostrowski et al., 2010; Baietti et al., 2012; Abrami et al., 2013; Frühbeis 
et al., 2013). 
In addition to the Rab GTPases, a number of ESCRT associated proteins have been shown 
to play a role in exosome secretion.  Depletion of the ESCRT-0 associated HRS and 
STAM1 have been implicated in exosome secretion, since their inhibition decreased 
exosome release (Tamai et al., 2010; Gross et al., 2012; Colombo et al., 2013; Hoshino 
et al., 2013). However, some evidence suggests that a confounding effect may also result 
in the decreased secretion of microvesicles. For instance, HRS depletion during HIV 
infection prevented viral release from the plasma membrane by inhibiting degradation 
of tetherin (Janvier et al., 2011). Tetherin, which holds viral particles at the membrane, 
is also found to be present on microvesicles and exosomes (Edgar et al., 2016). Thus, 
HRS depletion may lead to a decrease in both exosome and microvesicle secretion.  
Furthermore, the ESCRT-I associated protein TSG101 has also been implicated in 
exosome secretion, as evidenced by decreased exosome secretion upon its depletion 
(Baietti et al., 2012; Colombo et al., 2013). Whilst common mechanisms of exosome 
secretion have been demonstrated (including involvement of HRS and TSG101), many 
studies have revealed different secretion mechanisms that are dependent on cell type 
(Baietti et al., 2012; Abrami et al., 2013; Colombo et al., 2013; Romancino et al., 2013). 
For example, whilst Colombo et al., found silencing of VPS4B to induce the secretion of 
exosomes in HeLa cells,  Baietti et al., reported decreased exosome secretion in MCF7 
cells upon its depletion. Additionally, they showed that ALIX depletion in MCF7A 
decreased exosome secretion, however, no change in secretion was observed in HeLa 
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cells (Baietti et al., 2012; Colombo et al., 2013). Highlighting therefore, that some 
secretion mechanisms are cell dependent.  
Other important mediators of MVB-plasma membrane fusion are the soluble N-
ethylmaleimide-sensitive fusion attachment protein receptors (SNARES). SNAREs form 
complexes with the synaptosomal-associated proteins (SNAPs) on the membranes of 
different membrane bound organelles mediating the fusion of their membranes 
(Colombo, Raposo and Théry, 2014). SNAREs have since been shown to play a role in 
MVB fusion at the plasma membrane. For example, the Ykt6 SNARE has been shown to 
be required for the secretion of Wnt-containing exosomes (Gross et al., 2012), the syx-
5 (STX5 in humans) SNARE was shown to target MVBs to the plasma membrane via Ral-
1 small GTPase in C.elegans (Hyenne et al., 2015)  and the neurone specific snare 
Syntaxin 1a (STX1 in humans) alters exosome secretion in Drosophilla (Koles et al., 2012). 
Furthermore, the plasma membrane associated SNAP, SNAP23 was shown to be 
important for the fusion of both MVBs and secretory lysosomes with the plasma 
membrane (Puri and Roche, 2008; Tiwari et al., 2008; Verweij et al., 2018).  
Finally, the cytoskeleton is believed to play a role in the formation and secretion of 
extracellular vesicles. Actin has a well characterised role in clathrin-mediated 
endocytosis at the plasma membrane, where actin polymerisation stabilises and 
elongates the newly formed endosomal neck by exerting force against the membrane 
(Collins et al., 2011; Mooren, Galletta and Cooper, 2012). Additionally, depolymerisation 
of cortical actin at the plasma membrane is hypothesized to be required for MVB 
docking and subsequent exosome secretion (Antonyak, Wilson and Cerione, 2012; 
Sedgwick and D’Souza-Schorey, 2018). Furthermore, microtubule networks are required 
for the trafficking of MVBs and their transport to the plasma membrane, as 
pharmacological inhibition of microtubules results in decreased exosome secretion 
(Granger et al., 2014; Jackson et al., 2017). It is well established that endosomes are 
trafficked along microtubules by microtubule motors including dynein which directs 
minus-end directed transport (minus end is anchored to the MTOC) (Allan, 2011) and 
the kinesins which direct plus-end directed transport (plus ends emanate to the 
periphery of the cell) (Jon Kull and Endow, 2013). In fact, inhibition of dynein was shown 
to result in the scattering of early endosomes, late endosomes and lysosomes 
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throughout the cytosol, highlighting that dynein plays a key role in the inward trafficking 
of endosomes (reviewed in Granger et al., 2014). Interestingly, dynein is believed to be 
loaded onto endosomes by the Rab7 interacting lysosomal protein (RILP) which is known 
to bind to the HOPs complex (van der Kant et al., 2013). Crucially, the HOPs complex is 
known to play a key role in late endosome/lysosome fusion and so RILP and dynein may 
direct endosomes to lysosomes for cargo degradation (Balderhaar and Ungermann, 
2013). Thus, microtubule motors are key mediators of endosomal transport along 
microtubules and bidirectional movement of endosomes is facilitated by the presence 
of both plus-end and minus-end directed motors. Directional switching has been 
observed through a “tug of war”- like mechanism, where the endosome is subjected to 
opposing forces from microtubule motors until one prevails and trafficking resumes 
(reviewed in Granger et al., 2014). Whilst the exact mechanisms of directional switching 
are still under investigation, evidence suggests a potential role for posttranslational 
modification. For example, in neurons the regulatory factor for vesicular transport, 
huntingtin (htt) protein, was shown to favour retrograde movement until 
phosphorylation by the protein kinase Akt, which resulted in switching to plus-end 
directed movement (Colin et al., 2008). 
 
1.6.4 Targeting and uptake of extracellular vesicles by acceptor cells 
The ability of extracellular vesicles such as exosomes to trigger phenotypical changes in 
acceptor cells is well established and has resulted in numerous studies investigating 
their uptake by acceptor cells and the delivery of their cargo. Whilst EVs have been 
shown to influence recipient cells simply by acting at the surface without delivery of 
their contents (Raposo et al., 1996; Tkach et al., 2017), the majority of studies have 
revealed the full delivery of EV cargo. The exact mechanism behind EV uptake and cargo 
delivery, however, is still to be resolved. 
Recently, targeting of EVs to specific acceptor cells has been proposed in addition to 
non-specific uptake. For example, whilst Hela cells are able to internalise a wide variety 
of EVs from many different cell types (Svensson et al., 2013; Costa Verdera et al., 2017), 
EVs secreted by oligodendrocytes were found to be preferentially engulfed by microglia 
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compared to neurons (Fitzner et al., 2011). Likewise, EVs secreted by primary neurons 
were found to specifically target other neurons, whilst neuroblastoma-derived EVs were 
taken up by astrocytes (Chivet et al., 2014).  
A growing body of evidence now suggests that interplay between tetraspanins, integrins 
and other associated proteins within EV and cell membranes may regulate EV targeting 
and uptake. For instance, whilst EVs derived from the rat pancreatic adenocarcinoma 
cell line BSp73ASML were found to selectively target lung fibroblasts and lymph node 
stromal cells, upregulation of Tspan8 in these EVs resulted in preferential targeting to 
endothelial cells (Rana et al., 2012).  Upon transfection of Tspan8 and integrin β4, the 
selective targeting of the secreted EVs was altered again. This time, the EVs gained an 
increased metastatic capacity and were preferentially taken up by stromal cells in the 
liver and lung after intravenous injection (Yue et al., 2015). Evidence now suggests that 
tumours produce distinct EVs or subpopulations of EVs that facilitate metastasis to 
specific organs.  For instance, the presence of the integrins α6β1 and α6β4 on EVs was 
found to target them to lung fibroblasts and epithelial cells, thus facilitating lung 
metastasis (Hoshino et al., 2015). The presence of αvβ5, however, directs EV binding to 
Kupffer cells in the liver and therefore induces metastasis to the liver (Hoshino et al., 
2015). Similarly, the presence of CD47 on the surface of exosomes has been shown to 
prevent EV capture by immune cells, thereby increasing vesicle duration in circulation 
and enhances delivery of these EVs to pancreatic cells (Kamerkar et al., 2017) 
Furthermore, it has been demonstrated that neuroblastoma cells secrete two distinct 
subpopulations of EVs that selectively target different cell types depending on the 
expression of CD63 or amyloid precursor protein (APP) in the EV membrane (Laulagnier 
et al., 2018). The CD63+ subpopulation, generated via ESCRT-independent mechanisms, 
indifferently bound to neurons and glial cells, whereas the APP+ EVs, generated in an 
ESCRT-dependent manner, preferentially bound neurons (Laulagnier et al., 2018). Thus, 
an increasing body of evidence now suggests that tumour cells secrete different 
subpopulations of EVs that preferentially target acceptor cells through the altered 
expression of tetraspanins and integrins on the EV surface. 
Once EVs reach their target, they dock onto the surface of the cell through interaction 
with membrane-exposed proteins, lipids and/or sugars (Mathieu et al., 2019). Following 
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docking, the EV cargo can be transferred to the recipient cell. Whilst the mechanisms of 
EV cargo delivery are not fully characterised,  two distinct pathways have been described  
(see Figure 1.6.4). The first involves direct fusion of the EV with the plasma membrane 
of the recipient cell and the subsequent transfer of EV cargo into the cell cytosol (Parolini 
et al., 2009). This method of transfer is believed to be utilised by the larger, plasma-
membrane-derived EVs (Kanada et al., 2015). The second, more well characterised 
mechanism involves EV internalisation by the acceptor cell through endocytosis prior to 
cargo delivery. Following endocytosis, EVs can either i) fuse with the endosomal 
membranes releasing their contents into the cell cytosol ii) be targeted for degradation 
by the lysosome, or iii) be recycled and re-secreted (Svensson et al., 2013; Mulcahy, Pink 
and Carter, 2014; Costa Verdera et al., 2017; Horibe et al., 2018; Mathieu et al., 2019). 
 
 
Figure 1.6.4 Mechanisms of extracellular vesicle uptake by acceptor cells. 1) EVs are targeted 
to the acceptor cell and dock through interaction with membrane proteins, lipids or sugars. 2) 
EVs directly fuse with the plasma membrane releasing their cargo into the acceptor cell cytosol. 
3) EVs can be endocytosed by acceptor cells into endosomes. EVs can then either fuse with the 
endosomal membrane releasing their cargo into the acceptor cell cytosol (4), fuse with the 
lysosome resulting in degradation (5), or the EVs can be recycled and re-secreted (6).  
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1.7 Extracellular vesicles and cancer 
It is now widely accepted that cancer-derived EVs play key roles in the development and 
progression of cancer. In recent years, proteomic studies have revealed tumour-derived 
EVs to have significantly altered protein cargoes compared to EVs derived from non-
malignant cells (Hurwitz et al., 2016). Additionally, studies comparing the cargoes of EVs 
derived from different cancer types have identified a number of proteins that are 
common to all EVs (proteins involved in biogenesis) as well as a number of proteins that 
were uniquely packaged and representative of the cells from which they were derived 
(Hurwitz et al., 2016). Furthermore, analysis of pancreatic cancer-derived exosomes, 
revealed the presence of 362 cancer-related proteins that are known to have roles in 
tumour cell proliferation, invasion, metastasis and premetastatic niche formation 
(Emmanouilidi et al., 2019).  
 
1.7.1 The role of exosomes in tumourigenesis  
Many studies have analysed the effects of PDAC-derived exosomes on tumourigenesis, 
and recent evidence suggests that EVs can play a role in transforming normal cells into 
malignant cells through the transfer of oncogenic material (Al-Nedawi et al., 2008). For 
example, the transfer of mRNAs from metastatic cells have been shown to facilitate 
cancerous development in previously non-cancerous cells through modulation of target 
genes such as PTEN and HOXD10 (Melo et al., 2014; L. Zhang et al., 2015). Similarly, 
gastric cancer (GC)-derived exosomes have been shown to promote tumour growth 
through activation of PI3K/Akt and MAPK/ERK signalling pathways (Qu et al., 2009). 
Cancer-derived exosomes have also been shown to promote tumour growth through 
expression of TGF-β activated kinase 1 (TAK1) signalling which exerts anti-apoptotic 
effects on the cancer cells promoting their proliferation (Kogure et al., 2011). 
Cancer-derived exosomes have also been shown to play a role in ECM remodelling and 
local tumour invasion (Becker et al., 2016). For example, cancer-derived exosomes 
containing the ECM protein fibronectin were found to promote increased cancer cell 
motility (Sung et al., 2015) and secretion of tumour-derived exosomes enriched in 
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annexins, α3 integrins and ADAM10 all correlated with increased cell migration and local 
invasion (Keerthikumar et al., 2015). Furthermore, exosomes carrying Hsp90 released 
by metastatic cancer cells via Rab27b-mediated exocytosis have been shown to promote 
cancer cell invasion through activation of MMP2 resulting in ECM degradation (Hendrix 
et al., 2010).  
Tumour-derived exosomes have also been shown to play key roles in mediating 
angiogenesis. For instance, cancer-EVs enriched in Tspan8 have been shown to 
upregulate angiogenesis-related genes in endothelial cells, thereby inducing 
angiogenesis in tumours (Nazarenko et al., 2010). Similarly, cancer-exosomes containing 
miR-17-92 clusters have been shown to induce endothelial cell migration and tube 
formation (Umezu et al., 2013). Thus, cancer-exosomes have been shown to re-educate 
endothelial cells enhancing their motility and inducing formation of blood vessels to 
feed solid tumours.  
Significant evidence now also indicates a role for cancer-exosomes in communication 
with immune cells including macrophages, dendritic cells, neutrophils, natural killer cells 
and T cells. For example macrophage polarization towards tumour-promoting M2 
macrophages can be mediated through exosomal transfer of miR222-3p which activates 
SOCS3/STAT3 signalling (Ying et al., 2016). In addition, acute myelogenous leukaemia -
derived exosomes were found to decrease natural killer cell cytotoxicity through 
increased SMAD phosphorylation and decreased expression of the NKG2D receptor 
(Whiteside, 2013) indicating that cancer-derived exosomes can attenuate immune 
responses.  
 
1.7.2 Cancer-exosomes and metastasis 
Following secretion, tumour-derived exosomes may enter the circulation and 
transferred to distant sites throughout the body. In light of this, mounting evidence 
suggests a role for tumour-derived exosomes in the development of pre-metastatic 
niches and cancer cell metastasis. For example, PDAC-derived exosomes have been 
shown to initiate pre-metastatic niche formation in the liver in a stepwise manner  
(Costa-Silva et al., 2015). Kupffer cells, the resident macrophages of the liver, are 
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activated by PDAC exosomes containing elevated levels of macrophage migration 
inhibitory factor (MIF). Once activated, Kupffer cells secrete TGF-β causing hepatic 
stellate cells to secrete fibronectin and recruit bone marrow-derived cells to the site 
forming the pre-metastatic niche (Costa-Silva et al., 2015). Similarly, tumour-derived 
exosomes carrying the crucial ECM remodelling proteins MMP2 and MMP9 were found 
to degrade the ECM which subsequently enabled cancer cell invasion and metastasis (Ge 
et al., 2012). Furthermore, tumour-derived exosomal RNAs were found to promote 
metastatic niche formation in the lung by activating lung epithelial cells to recruit 
neutrophils, a critical first step in lung premetastatic niche formation (Liu et al., 2016).  
Interestingly, the enrichment of certain integrins on the surface of EVs has been shown 
to determine organotrophic metastasis. For instance, the presence of α6β1 and α6β4 
on breast cancer exosomes preferentially targets them to fibroblasts and epithelial cells 
in the lung, governing lung metastasis (Hoshino et al., 2015). Whereas αvβ5 on 
pancreatic cancer exosomes results in the preferential targeting of the Kupffer cells in 
the liver, facilitating metastasis to the liver (Hoshino et al., 2015). Likewise, PDAC 
tumour-derived exosomes positive for the cell surface adhesion receptor CD44 were 
found to aid the establishment of a premetastatic niche in the lung and lymph node 
(Jung et al., 2009). Thus, an increasing body of evidence now suggests that tumour-
derived EVs initiate premetastatic niche formation and facilitate cancer cell metastasis.  
 
1.7.3 Tumour-derived exosomes in stromal cell reprogramming 
During tumourigenesis, fibroblasts and stellate cells differentiate into an activated 
phenotype. Upon activation, these cells exhibit heightened migratory and invasive 
capacities and contribute to tumour growth and metastasis. Interestingly, cancer-
derived exosomes have been found to mediate the activation/differentiation of these 
stromal cells. For example, exosomal transfer of TGF-β  (a known fibroblast 
differentiation initiator) to fibroblasts was shown to promote conversion into 
myofibroblasts, resulting in tumour growth, local invasion and vascularization (De 
Wever et al., 2008; Webber et al., 2010a; Cho et al., 2012; Ringuette Goulet et al., 2018). 
Exosomal TGF-β was found to account for up to 86% of the TGF-β present in cancer cell 
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supernatants, thus exosomes may be a primary extracellular source of TGF-β. 
Additionally, it was demonstrated that exosomal TGF-β, as opposed to secreted TGF-β, 
was responsible for SMAD signalling in the target fibroblasts and subsequent fibroblast 
to cancer associated fibroblast transition (Ringuette Goulet et al., 2018).  
Recent studies have also revealed a role for tumour-derived exosomes in the activation 
of PSCs. For example, exosomes derived from PDAC cells were shown to activate PSCs, 
resulting in increased proliferation and migration, activation of ERK/Akt signalling, 
upregulation of fibrosis-related genes and enhanced production of procollagen type I C-
peptide (Masamune et al., 2018). Subsequent pathway analysis identified TGF-β1 and 
tumour necrosis factor (TNF) as the top upstream regulators commonly altered 
following treatment with PDAC-derived exosomes. During tumourigenesis, activated 
fibroblasts and PSCs are recruited to the premetastatic site to facilitate cancer cell 
metastasis. Interestingly, exosomes secreted by the pancreatic cancer cell lines PANC-1 
and MIA PaCa-2 have been shown to promote the recruitment of PSCs through the 
transfer of exosomal protein Lin28B (Zhang et al., 2019). Thus, cancer-derived exosomes 
have been shown to promote tumourigenesis by both activating stromal cells and 
promoting their recruitment.  
 
1.7.4 Exosomes as potential biomarkers for cancer.  
Due to their active role in tumour formation and abundance in biological fluids, 
circulating tumour exosomes have emerged as promising candidates for biomarker 
development.  In light of this, identifying proteins and RNAs that are unique to cancer-
derived exosomes has become a key focus of the exosome field. Many potential 
exosomal markers have already been identified and have promising clinical applications.  
For example, EpCAM positive exosomes are elevated in ovarian cancer and their 
abundance can distinguish cancer patients from those with benign conditions and 
healthy donors (Taylor and Gercel-Taylor, 2008). Similarly, plasma isolated exosomes 
from melanoma patients are enriched in caveolin-1 compared to healthy donors, 
highlighting the potential of caveolin-1 as a biomarker for melanoma (Logozzi et al., 
2009). Additionally, exosomal integrin combinations appear to dictate organ specific 
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metastasis and may mark for both the presence of cancer and the metastatic tendency 
(Hoshino et al., 2015b). Major advances have also been made in identifying potential 
biomarkers for pancreatic cancer with two studies in particular presenting promising 
candidates for PDAC. For example, Glypican-1 (GPC1) has been shown to be enriched in 
pancreatic cancer exosomes compared to exosomes secreted by the normal pancreas 
(Melo., et al., 2015a; Frampton et al., 2018). However, whether or not GPC1 can 
distinguish between cancer patients and sufferers of benign pancreatic disease is still in 
debate (Melo et al., 2015; Frampton et al., 2018). Additionally, Costa-Silva. et al. 
identified exosomal MIF as a potential prognostic biomarker for PDAC. They reported 
that stage I PDAC patients who go on to develop liver metastases have increased levels 
of exosomal MIF compared to patients who did not present with metastasis and normal 
healthy controls (Costa-Silva., et al., 2015).  
The genetic material contained within exosomes also shows promise as diagnostic 
biomarkers for cancer. dsDNA present in exosomes has been shown to reflect the 
oncogenic mutation status of the cells they originate from (Kahlert et al., 2014; Thakur 
et al., 2014; Melo et al., 2015). For example, the p53 and KRAS mutational states of PDAC 
cells has been observed in the dsDNA contained within the exosomes secreted by these 
cells (Melo et al., 2015). The presence of miRNA in cancer-derived exosomes may also 
serve as diagnostic and prognostic biomarkers. In colon cancer patients, the presence of 
exosomal miR-17-92a correlates with disease recurrence whereas miR-19a is associated 
with poor prognosis (Matsumura et al., 2015). In metastatic prostate cancer, the 
presence of exosomal miR-141 and miR-375 is observed (Bryant et al., 2012; Z. Li et al., 
2015) whereas low levels of miR125a are observed in advanced melanoma (Alegre et 
al., 2014). These observations highlight the potential of exosomal genetic material in the 
development of new biomarkers for cancer.  
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1.8 Project aims  
Human tumours are formed from a heterogenous population of cancer cells. Whilst 
being considered “less fit” cells and offering no proliferative advantage, cells with extra 
centrosomes are maintained in most human tumours. In recent years, cells with 
centrosome amplification have been shown to have an active role in the development 
and progression of cancer. Therefore, it is possible that these “less fit” cells are 
maintained because they offer a survival advantage to the tumour as a whole.  
Recent work from our laboratory has demonstrated that cells with extra centrosomes 
have an altered secretome which enhances tumour progression. Proteomic analysis of 
this altered secretome revealed that cells with extra centrosomes secrete several 
proteins associated with extracellular vesicles. Interestingly, whilst the roles of cancer 
exosomes, including PDAC-derived exosomes, on tumour progression and metastasis 
have been widely studied, it is not currently known if all cancer cells or a subtype of 
cancer cells are responsible for the secretion of cancer-promoting EVs. We therefore 
hypothesised that cancer cells with extra centrosomes may secrete more extracellular 
vesicles with the capacity to aid tumourigenesis. Identifying the role of vesicles secreted 
by specific cell subtypes may provide us with new targets for cancer therapeutics. The 
aims of this project were to: 
1. Determine if the presence of extra centrosomes is sufficient to increase 
extracellular vesicle secretion in PDAC cell lines. 
2. Identify key mechanisms involved in the increased secretion of extracellular 
vesicles by cells with extra centrosomes. 
3. Identify the role of extracellular vesicles secreted by cells with supernumerary 
centrosomes on tumour progression. 
4. Determine the exosomal cargo or cargos responsible for the cancer promoting 
activity of the vesicles.  
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2.1 Cell culture  
2.1.1 Cell culture reagents 
Dulbecco’s modified Eagle’s medium (DMEM): with 4.5 g/L glucose, 4mM L-glutamine 
and 110 mg/L sodium pyruvate. Sterile filtered. Stored at 4oC (Thermo Fisher Scientific, 
41966). 
Dulbecco’s modified Eagle’s medium/nutrient mixture F-12 Ham (DMEM F-12): with 3.15 
g/L glucose, 0.365 g/L L-glutamine, 15 mM HEPES, 14.2 mM sodium bicarbonate and 55 
mg/L sodium pyruvate. Sterile filtered.  Stored at 4oC. (Sigma Aldrich, D8437). 
RPMI-1640 medium (RPMI): with 2 g/L glucose, 2mM L-glutamine, 2 g/L sodium 
bicarbonate. Sterile filtered. Stored at 4oC (Thermo Fisher Scientific, 11875093). 
Keratinocyte serum free medium (1X): with L-Glutamine and supplemented with 0.2 
ng/ml human recombinant Epidermal Growth Factor (rEGF) 1- 53 and 30 µg/ml Bovine 
Pituitary Extract (BPE). Sterile filtered.  Stored at 4oC (Thermo Fisher Scientific, 
17005042). 
Opti-MEM® reduced serum medium: with L-glutamine and 2.4 g/L sodium bicarbonate. 
Stored at 4oC (Thermo Fisher Scientific, 31985070). 
Gibco ™ 0.05% Trypsin-ethylenediaminetetraacetic acid (Trypsin-EDTA) (1X): with phenol 
red. Stored at 4oC (Thermo Fisher Scientific, 25300-054).  
Gibco ™ Foetal Bovine Serum (FBS): Heat inactivated. 50 ml aliquots were stored at -
20oC. Prior to use aliquots were thawed at 37oC (Thermo Fisher Scientific, 10500064). 
HyClone ™ Foetal Bovine Serum, Tetracycline Screened (Tet-FBS): 50 ml aliquots were 
stored at -20oC. Prior to use aliquots were thawed at 37oC (GE Healthcare, 
SH30070.03T). 
Penicillin-Streptomycin (pen/strep): 100 U/ml was added to growth media. Stored at                
-20 oC long term and 4 oC for short term use, (Thermo Fisher Scientific, 15140122). 
EZSolution ™ Blasticidin S hydrochloride (Blasticidin): 10 mg/ml Blasticidin hydrochloride 
in 20 mM HEPES at pH 7.5. Sterile filtered. Blasticidin was used at a final concentration 
of 2.5-20 µg/ml. Stored at -20 oC (EZSolution ™, 2805). 
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Geneticin® (G418) Sulphate: A stock solution of 50 mg/ml was stored at -20 oC. G418 was 
used at a final concentration of 0.5-1 mg/ml (108321-42-2, Santa Cruz). 
Puromycin: A stock solution of 10 mg/ml was stored at -20 oC. Puromycin was used at a 
final concentration of 1-5 µg/ml (InvivoGen, ant-pr-1). 
 
2.1.2 Mainenance of a 2D cell monolayer 
The cell lines used in this thesis are detailed in Table 2.1.2. Adherent cell lines were 
cultured in the appropriate growth medium (supplemented with FBS and Pen/Strep as 
per Table 2.1.2) and incubated at 37oC and 5% humidified CO2. To maintain cells in a 2D 
monolayer, cells were passaged once they reached 70-80% confluency. To passage cells, 
the cell growth medium was aspirated, and cells were washed with 15ml of autoclaved 
phosphate-buffered saline (PBS). The PBS was then aspirated, and the cells were 
incubated with 0.05% Trypsin-EDTA at 37oC for approximately 5 minutes until the cells 
detached. The enzymatic activity of Trypsin-EDTA was then inhibited by adding the 
appropriate cell culture medium complete with FBS. The cell suspension was then 
centrifuged at 1200 rpm for 3 minutes to pellet the cells. The supernatant was then 
aspirated, and the cell pellet resuspended in fresh cell culture medium. Approximately 
0.5-1 ml of the cell suspension was then transferred into a fresh cell culture flask, or cells 
were counted using a haematocytometer and seeded accordingly depending on 
doubling times and experimental need. Growth medium was then added to the freshly 
seeded cells. The flasks were then gently agitated, to evenly distribute cells and 
incubated once again at 37oC, 5% CO2.  
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Table 2.1.2 Cell lines 
Cell line Growth medium Cell type Source 
PaTu-8988T DMEM + 10% FBS + 1 % Pen/Strep Pancreatic cancer 
(adenocarcinoma) 
Professor Hemant 
Kocher (BCI) 
PaTu-8988S DMEM + 10% FBS + 1 % Pen/Strep Pancreatic cancer 
(adenocarcinoma) 
Professor Yaohe 
Wang (BCI) 
Panc-1 DMEM + 10% FBS + 1 % Pen/Strep  Pancreatic cancer 
(adenocarcinoma) 
Professor Hemant 
Kocher (BCI) 
CFPAC-1 DMEM + 10% FBS + 1 % Pen/Strep Pancreatic cancer 
(adenocarcinoma) 
Professor David 
Pellman (Harvard) 
Hs766T DMEM + 10% FBS + 1 % Pen/Strep Pancreatic cancer 
(carcinoma) 
Professor Hemant 
Kocher (BCI) 
BxPC3 
 
DMEM + 10% FBS + 1 % Pen/Strep Pancreatic cancer 
(adenocarcinoma) 
Professor Hemant 
Kocher (BCI) 
Capan-1 RPMI + 10% FBS + 1 % Pen/Strep Pancreatic cancer 
(adenocarcinoma) 
Professor Hemant 
Kocher (BCI) 
Capan-2 DMEM + 10% FBS + 1 % Pen/Strep Pancreatic cancer 
(adenocarcinoma) 
Professor Hemant 
Kocher (BCI) 
Panc0403 DMEM + 10% FBS + 1 % Pen/Strep Pancreatic cancer 
(adenocarcinoma) 
Professor Hemant 
Kocher (BCI) 
HPAF-II DMEM + 10% FBS + 1 % Pen/Strep Pancreatic cancer 
(adenocarcinoma) 
Professor Hemant 
Kocher (BCI) 
MIA-PaCa-2 DMEM + 10% FBS + 1 % Pen/Strep Pancreatic cancer 
(carcinoma) 
Professor Hemant 
Kocher (BCI) 
AsPC-1 RPMI + 10% FBS + 1 % Pen/Strep Pancreatic cancer 
(adenocarcinoma) 
Professor Hemant 
Kocher (BCI) 
DEC-hTERT DMEM + 10% FBS + 1 % Pen/Strep  Normal pancreas Professor Hemant 
Kocher (BCI) 
HPDE keratinocyte-SFM (1X) serum free 
media +30ug/ml (BPE)+ 0.2ng/ml rEGF 
Normal pancreas Professor Yaohe 
Wang (BCI) 
PS1 DMEM: F12 + 10% FBS + 1 % Pen/Strep Normal pancreas Professor Hemant 
Kocher (BCI) 
HEK-293M DMEM + 10% FBS + 1 % Pen/Strep Embryonic kidney David Pellman 
(Harvard) 
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2.1.3 Drug treatments 
Doxycycline hyclate (Dox): Dox is a synthetic oxytetracycline derivative used to induce 
overexpression of PLK4 in the TetR.PLK4 cell lines. Stock solutions of 2 mg/ml were 
generated in autoclaved deionised water and aliquots stored at -20oC. To induce PLK4 
overexpression, 2 µg/ml of Dox was added to cell culture medium for 48 hours (Sigma-
Aldrich, D9891).  
Hydrogen peroxide (H2O2): H2O2 30%(w/w) in H2O was used to induce ROS production in 
our cells. The H2O2 stock was stored at 4oC. For use in cell culture, H2O2 was diluted in 
cell culture medium and sterile filtered before being used at a final concentration of 100 
µM (Sigma Aldrich, H1009). Cells were treated with H2O2 for a maximum of 48 hours.  
N-acetyl cysteine (NAC): NAC is a scavenger of ROS and so was used to quench ROS in 
our cells. NAC powder (stored at 4oC) was dissolved in autoclaved deionised water to 
generate a stock concentration of 613 mM. The NAC stock was aliquoted and stored at 
-20oC until needed. Prior to use in cell culture, the acidity of the NAC stock solution was 
neutralised to pH7 using sodium hydroxide (NaOH). The neutralised NAC was then 
sterile filtered, and used in cell culture at a final concentration of 5 mM (Sigma-Aldrich, 
A9165). Cells were treated with NAC for a maximum of 48 hours. 
Bafilomycin A1: Bafilomycin A1 (from Streptomyces griseus) is a vacuolar type H+-ATPase 
inhibitor and was used to prevent the acidification of lysosomes, diminishing their 
degradative capacity. Bafilomycin A1 was dissolved in DMSO to generate a stock solution 
of 0.1 mg/ml and aliquots were stored at -20oC. Bafilomycin A1 was used in cell culture 
at a final concentration of 20 nM (Sigma-Aldrich, B1793-10UG). Cells were treated with 
Bafilomycin A1 for a maximum of 24 hours. 
 
2.1.4 Small interfering RNA (siRNA) transfection 
PaTu-S.PLK4 and HPAF-II.PLK4 cells for siRNA transfection were seeded into 6 well tissue 
culture plates at a density of 2 x 105 and 5 x 105 cells per well respectively in antibiotic 
free growth medium. The following day, transfection was performed by diluting the 
appropriate siRNA and 10 µl of the transfection reagent Lipofectamine® RNAiMAX 
(Thermo Fisher Scientific, 13778030) in 500 µl of Opti-MEM® reduced serum medium. 
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The solution was incubated at room temperature for 20 minutes to enable to formation 
of liposomes before being added in a dropwise fashion onto the cells. For SAS-6 knock 
down experiments siNegative control (siNegative, Qiagen, 1027310) and siSAS-6 (siSAS6 
on-TARGET smart pool, Dharmacon, M-004158-02) were used. 20 nM of siRNA was used 
for PaTu-S.PLK4 cells and 50 nM for HPAF-II.PLK4 cells as PaTu-S.PLK4 cells were found 
to be more sensitive to SAS-6 depletion. siRNA stocks were diluted in RNase-free water 
to a concentration of 20 µM and stored at -20oC. 24 hours post transfection, the cells 
were trypsinised and seeded onto coverslips for analysis by immunofluorescence or into 
15 cm dishes for exosome harvest experiments.  
 
2.1.5 Measureing cellular reactive oxygen species (ROS) 
Cellular ROS levels were measured using the GSH/GSSG-Glo™ Assay (Promega, V6611). 
This Promega kit measures glutathione in its reduced (GSH) and oxidised (GSSG) forms. 
As glutathione is converted from its reduced from to its oxidised form upon oxidative 
stress, the ratio between the two forms of glutathione is a good read out  for ROS in cells 
and tissues (Carelli et al., 1997; Locigno and Castronovo, 2001; Noctor and Foyer, 2002; 
Townsend, Tew and Tapiero, 2003). The GSH/GSSG-Glo™ Assay is a luminescence-based 
assay, which relies on GSH-mediated conversion of the GSH probe Luciferin-NT to 
luciferin by a glutathione S-transferase enzyme. This reaction is coupled to a firefly 
luciferase reaction resulting in a luminescent signal that is proportional to the amount 
of GSH present in the sample. Parallel reactions are performed to determine total and 
oxidised levels of glutathione. The first utilises a reducing agent to convert all 
glutathione to the reduced form and gives a readout of total glutathione. The second 
reaction measures only the oxidised form by blocking the GSH present in the sample, a 
reducing step is then used to convert the GSSG to GSH for quantification. The ratio of 
GSH to GSSG can then be calculated to give a read out of oxidative stress in the cells, 
where a decrease in the ratio indicates an and increase in oxidative stress. All reactions 
and calculations were carried out as per the manufacturer’s instructions. Finally, the 
amount of protein present in each reaction was quantified using the Pierce™ BCA 
Protein Assay Kit (Thermo Fisher Scientific, 23227) as per the manufacturer’s 
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instructions. The final ratio of GSH/GSSG was then normalised to protein content to 
control for any changes in cell number.  
 
2.2 Lentivirus and Generation of PLK4 inducible cells 
As lentiviruses (a class of retrovirus) have the capacity to integrate viral DNA into the 
genome of both dividing and non-dividing cells, a lentiviral delivery system was used to 
generate genetically modified cell lines.  
 
2.2.1 Lentivirus production and infection 
To generate lentivirus, HEK-293M cells were seeded into a 6-well plate in growth 
medium without antibiotic supplementation. Once cells reached 50% confluency, 
transfection was performed. Cells were transfected with a transfection mixture 
consisting of 500 µl Opti-MEM, 10 µl lipofectamine® 2000 (Thermo Fisher Scientific, 
11668027), 2 µg of plasmid DNA, 1 µg of Gag-Pol DNA (Gag-Pol: psPAX2, Addgene, 
12260) and 0.5 µg VSV-G DNA (VSV-G: pMD2.G, Addgene, 12259). The transfection 
mixture was incubated at room temperature for 20 minutes to allow for the formation 
of liposomes before being added in a dropwise manner to the cells. 6 hours post 
transfection, the medium was replaced with 1.5 ml of fresh growth medium. Virus was 
collected 24- and 48-hours post-transfection, filtered using a 0.4 µM syringe filter and 
stored in cryovials at -80οC until needed.  
For lentiviral infection, PaTu-S or HPAF-II cells were plated in a 6-well plate. The 
following day, growth medium was replaced with 1 ml of medium without antibiotic 
supplementation. The appropriate lentivirus was then mixed with 8 μg/ml polybrene 
(Sigma-Aldrich, TR-1003-G) before being added to the cells in a dropwise fashion. An 8 
mg/ml stock solution of polybrene was generated in autoclaved deionised water and 
stored at -20οC. 6 hours post-infection, the virus was removed and replaced with normal 
growth medium. Infection was repeated the following day and antibiotic selection 
started 24 hours after final infection.  
 
 Chapter 2. Materials and Methods 
71 
 
2.2.2 Generation of cells with inducible PLK4 overexpression 
To generate PaTu-S and HPAF-II cell lines with an inducible PLK4-overexpression system, 
cells were initially infected with lentivirus containing a Tetracycline repressor (TetR), 
pLenti-CMV-TetR-Blast lentiviral vector (Addgene, 17492). Following viral infection, cells 
successful for transduction were selected for using Blasticidin (10 µg/ml). Post-selection, 
cells were then infected with a lentiviral vector containing PLK4 cDNA which had been 
previously cloned into the pLenti-CMV/TO-Neo-Dest vector using the gateway system 
by Susana Godinho (Godinho et al., 2014). Following infection with PLK4 lentivirus, cells 
were selected with Geneticin (200 µg/ml) for two weeks. The presence of the TetR 
ensures that PLK4 overexpression only occurs upon the addition of the tetracycline 
analogue doxycycline. This method allowed the generation of PaTu-S.PLK4 and HPAF-
II.PLK4 cell lines in which the PLK4 transgene is induced using 2 µg/ml of Doxycycline for 
48 hours.  
 
2.3 2D Immunofluorescent microscopy 
2.3.1 Reagents 
Methanol: ≥99.9% methanol was stored and used at -20οC (Sigma-Aldrich, 154903). 
Formaldehyde: Pierce™ 16% Formaldehyde (w/v), Methanol-free (Thermo Fisher 
Scientific, 28906). Stored at room temperature. 
Cell permeabilisation buffer: 0.02% v/v Triton X-100 diluted in PBS. Stored at room 
temperature. 
Blocking solution: 5% w/v Bovine Serum Albumin and 0.1% v/v Triton X-100 in PBS. Prior 
to use, blocking solution was filtered through a 0.2µM 500ml Rapid Flow Filter Unit 
(Thermo Fisher Scientific, 156-4020). Stored at 4οC. 
ProLong™ Gold Antifade Mountant: Ready to use and stored at room temperature 
(Thermo Fisher Scientific, P36934). 
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2.3.2 Cell fixation 
For immunofluorescent staining, cells were plated on 1.5 thickness, 18mm round glass 
coverslips (Warner Scientific, CS-18R15) at least 24 hours prior to fixation.  Cells were 
then treated for up to 48 hours with the appropriate drug treatments (controls left 
untreated). Post treatment, cells were washed twice in PBS and fixed in 4% 
Formaldehyde (diluted from 16% Formaldehyde stock in PBS) for 20 minutes at room 
temperature. Cells to be stained for the centrosomal protein centrin, however, were 
instead fixed in ice-cold methanol for 10 minutes at -20 ο C. Following fixation, cells were 
washed twice in PBS and stored at 4ο C until needed.  
 
2.3.3 Immunofluorescent staining 
Following fixation, cells were permeabilised for 5 minutes using our cell 
permeabilisation buffer and then blocked for 30 minutes in the previously generated 
blocking solution.  The cells were then incubated with primary antibody diluted in 
blocking solution (See Table 2.3.2 for primary antibodies and dilutions) for 1 hour at 
room temperature. Cells were then washed twice with PBS to remove any residual/non-
specifically bound primary antibody. Cells were then incubated with the appropriate 
secondary antibody conjugated to an Alexa Flour fluorophore diluted in blocking 
solution for 50 minutes at room temperature in the dark (see Table 2.3.2 for secondary 
antibodies and dilutions). Where phalloidin was used to stain for F-actin, cells were 
incubated with phalloidin in blocking solution for 1 hour only. To remove any non-
specifically bound secondary antibody, cells were then washed twice in PBS. DNA was 
then stained with Hoechst diluted in PBS for 5 minutes at room temperature. After a 
final PBS wash step, coverslips were mounted using ProLong™ Gold Antifade Mountant. 
Details of all antibodies and stains used for immunofluorescence staining can be found 
in table 2.3.2.  
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Table 2.3.2  Antibodies for immunofluorescence staining 
Primary Antibodies Product 
number 
Supplier Species raised Dilution 
Anti-centrin 2 (N-17-R) sc-27793-R 
 
Santa Cruz Rabbit 1:100 
Anti α-tubulin (DM1 α) T9026 
 
Sigma-Aldrich Mouse 1:1000 
Anti LBPA (6C4) MABT837 
 
Merck Millipore 
 
Mouse 1:100 
Anti LC3B (D11) XP ® 3868S 
 
Cell signalling 
 
Rabbit 1:200 
Anti α-SMA A2547 Sigma-Aldrich Mouse 1:300 
Secondary Antibodies Product 
number 
Supplier Species raised Dilution 
Anti-Rabbit Alexa Flour 488 A11008 Life Technologies Goat 1:1000 
Anti-Rabbit Alexa Fluor 568 A11011 Life Technologies Goat 1:1000 
Anti-Mouse Alexa Fluor 488 A11001 Life Technologies Goat 1:1000 
Other Product 
number 
Supplier Species raised Dilution 
Alexa Fluor 568 Phalloidin A12380 
 
Life Technologies - 1:250 
Hoechst 33342 H3570 ThermoFisher 
Scientific 
- 1:5000 
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2.3.4 Analysis 
Images were acquired using an inverted Nikon microscope coupled with a spinning disk 
confocal head (Andor). Unless otherwise stated, imaging of cancer cells was performed 
using a 100x objective and imaging of stellate cells with a 40x objective. 
Images/projection images (from z-stacks) were subsequently generated and analysed 
with Image J (please see each experiment for details). Where Z-stack images were 
required to analyse fluorescence intensity, Z-stack parameters were determined using 
the following equation: Zmin = 1.4λn/(NAobj)2. λ = the emission wavelength, n= 
refractive index of the immersion media,  NAobj = the numerical aperture of the 
objective. This equation calculates the ideal z stack step size to minimise overlap 
between each step of the stack. Sum intensity projection images were subsequently 
generated using Image J and fluorescence intensity was quantified using Image J.  
 
2.3.5 Magic Red ™ Cathepsin B analysis 
The Magic Red™ Cathepsin B kit (Bio-Rad, ICT937) was used to analyse the protease 
activity of Cathepsin B in lysosomes as a proxy to lysosome function. Cells were plated 
on coverslips and treated with Dox, Dox +NAC, H2O2, Bafilomycin A1 or left untreated as 
described previously. One hour prior to the end of the experiment, cells were given the 
Magic Red substrate and returned to the incubator. Magic Red is a cell-permeable and 
non-toxic reagent consisting of a cathepsin B target sequence peptide (RR)2 which has 
been linked to a Cresyl Violet fluorescent probe. In the presence of functional cathepsin 
B, Magic Red is cleaved allowing the Cresyl violet fluorophore to fluoresce red upon 
excitation at 550-590 nm. A stock solution of Magic Red was reconstituted in 50 µl of 
DMSO and stored thereafter at -20οC. Prior to use in cell culture, the reconstituted Magic 
Red was diluted 1 in 10 in deionised water and 20µl per 300µl of growth media was 
added to each coverslip as per the manufacturer’s instructions. One hour later, cells 
were fixed in 4% Formaldehyde as previously described. Cresyl Violet fluorescence was 
detected using an inverted Nikon microscope coupled with a spinning disk confocal head 
(Andor). Z-stack images were acquired, and sum intensity image projections were 
generated using Image J. Fluorescence intensity was then quantified per cell with 
ImageJ. 
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2.4. Extracellular vesicle (EV) isolation and quantification 
2.4.1 Materials and reagents 
Ultracentrifugation tubes: Tube, Thinwall, Ultra-Clear™, 38.5 mL, 25 x 89 mm 
(Beckman coulter, 344058). 
 Dulbecco’s Phosphate Buffered Saline (PBS): Sterile PBS (Sigma-Aldrich, D8537), filtered 
through two 0.22 µm filters before use.  
qEV original Size Exclusion Chromatography (SEC) columns: qEVoriginal/70 nm pore size 
SEC columns for exosomes separation and purification, 10ml volume. Stored at 4οC 
(izon, SP1). 
BODIPY® FL Maleimide (BODIPY® FL N-(2-Aminoethyl))Maleimide) (BODIPY): BODIPY was 
reconstituted in DMSO generating a stock solution of 5 mM (Thermo Fisher Scientific, 
B10250). Aliquots of the stock solution were stored at -20οC. BODIPY was used at a 
working dilution of 1/200.  
 
2.4.2 Extracellular vesicle harvest 
Prior to culturing cells for EV harvest, the FBS supplement added to the media first had 
to be depleted of naturally occurring EVs. Vesicle depletion in FBS was performed via 
ultracentrifugation at 100,000 x g at 4οC. As is described in Chapter 3 Results I section 
3.2.2, Gibco FBS required 2 hours of ultracentrifugation at 100,000 x g, whereas GE 
Healthcare FBS required 18 hours of ultracentrifugation at 100,000 x g to successfully 
deplete contaminating EVs.  
To harvest exosomes, cells were grown for 48 hours in vesicle depleted media. Where 
induction of centrosome amplification was necessary, cells were treated with Dox for 48 
hours, before cells were washed in PBS and subsequently cultured in EV depleted media. 
Where drug treatments were required, cells were treated for the duration of the 
exosome harvest (48 hours post addition of vesicle depleted media). After 48 hours, the 
conditioned medium was collected from the cells and a final cell count was performed 
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to ensure the final cell count always remained the same between cell types and 
experimental conditions. 
 
2.4.3 Extracellular vesicle isolation 
2.4.3.1 Serial ultracentrifugation (UC) 
Extracellular vesicles were isolated from the conditioned media via serial 
ultracentrifugation steps at 4οC (similar to Costa-Silva et al., 2015). Initially, the cell 
culture medium was subjected to a low speed centrifugation of 500 x g for 10 minutes 
to remove debris. The supernatant was then centrifuged at 12,000 x g for 20 minutes to 
pellet the large EVs (LEVs), after removal of the supernatant the LEVs were re-suspended 
in 500µl of PBS. The supernatant was then subjected to a high-speed ultracentrifugation 
at 100,000 x g for 70 minutes to pellet the smaller EVs (sEVs). The resultant pellet was 
washed in PBS and a second high-speed ultracentrifugation was performed at 100,000 
x g for 70 minutes to aid in removal of non-EV contaminants. The isolated sEV pellet was 
then re-suspended in 500 µl of PBS. Where necessary EV isolates were stored in PBS at 
-80οC and where possible isolates were used for further analysis or functional assays 
immediately.  
 
2.4.3.2 Size exclusion chromatography (SEC) 
To further purify EVs isolated by serial ultracentrifugation, size exclusion 
chromatography (SEC) was performed. Prior to use, size exclusion chromatography (SEC) 
columns were removed from 4οC and incubated at room temperature for 1 hour to 
equilibrate the column. The columns were then flushed with 5ml of buffer (PBS filtered 
twice through 0.22 µM filters). Once ready for use, any buffer present above the top 
filter was pipetted out and 500 µl of concentrated exosomes (isolated by serial 
ultracentrifugation) was added to the top of the column. The eluted fractions were 
immediately collected in 500 µl volumes. To prevent unintentional dilution of the 
samples, the sample was allowed to pass fully into the top filter before additional buffer 
was added. The column is then kept topped up with buffer (500 µl at a time) throughout 
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the experiment ensuring that the top filter never runs dry. The first six fractions collected 
contain the void volume which do not have EVs. The subsequent fractions, fraction 7-12 
contain the eluting EVs. Following collection of the EVs, the columns were flushed with 
10ml of buffer and stored at 4οC in storage buffer as per the manufacturer’s instructions. 
Columns were reused a maximum of 5 times before being discarded.  
 
2.4.4 Quantification of isolated vesicles 
2.4.4.1 Amins ImageStream® Mark II Imaging Flow Cytometer (ImageStream) 
Samples to be analysed by ImageStream were prepared in 50 µl volumes in Eppendorf 
tubes. Vesicles were labelled with the fluorescent lipid dye BODIPY (used at a 1/200 
dilution) and incubated at room temperature in the dark 10 minutes prior to analysis. In 
addition to vesicle samples, a control sample that had been processed and stained with 
BODIPY as if containing vesicles was also run to ensure that BODIPY alone did not 
contribute to the observed vesicle populations. Upon loading of the samples, the 
ImageStream uses syringe driven sample injection to accurately measure the volume of 
sample injected into the flow cell. This enables the software to accurately report the 
number of objects/ml that pass through the flow stream. Once loaded, vesicles were 
acquired at a slow flow rate with 60x magnification, a 488 nm excitation laser (BODIPY 
detection) and 765 nm laser (side scatter). The “remove bead” function was turned off 
and the flow rate allowed to stabilise before acquisitions began. For acquisition, the 
storage gate was set to collect all events and the stopping gate set to the vesicle 
population (low to mid BODIPY intensity and low side scatter). The stopping gate was 
set to ensure that at least 20,000 objects were analysed per acquisition. Three separate 
acquisitions were collected per sample. Analysis was then performed using the IDEAS 
software. To quantify objects/ml, a graph was generated plotting channel 02 
fluorescence intensity (BODIPY) against channel 12 scatter intensity (side scatter) and a 
vesicle gate was re-applied to select the population at the correct BODIPY and side 
scatter intensities to be EVs. Where necessary the gate was adjusted using the Image 
library to eliminate noise and artefacts from the vesicle population. The objects/ml 
statistic was then used to quantify the number of objects/ml in the gated region. The 
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average objects/ml was then calculated from the three separate acquisitions from each 
sample.  
 
2.4.4.2 Nanoparticle tracking anlaysis (NTA) 
Small particle analysis was also performed by NTA using a NanoSight NS300 with a high 
sensitivity camera and a syringe pump. As previously described, isolated EVs were 
resuspended (UC) or eluted (SEC) in Dulbecco’s PBS filtered twice through 0.22 µM 
filters. Prior to loading samples, the NS300 chamber was flushed first with 0.22 µM 
filtered deionised water and then again with 500 µl of PBS (Dulbecco’s PBS filtered twice 
through 0.22 µM filters) until the chamber is free of any particle matter. Using a 1 ml 
syringe 400 of EV samples was then flushed through the chamber until vesicles were 
visible on the camera to allow the focus and gain settings to be optimised. The sample 
was the injected into the flow cell at speed 50 and 3 recordings of 60 seconds each were 
acquired. Between samples filtered PBS was used again to flush the chamber ensuring 
no residual particles remained. The data was then analysed using the NTA 3.2 analysis 
software and averages of the three technical replicates were plotted per experiment. 
This analysis provides both a measure of vesicle concentration (objects/ml) and vesicle 
size.  
 
2.5 Western blotting 
2.5.1 Reagents 
Radioimmunoprecipitation assay (RIPA) lysis and extraction buffer:  Ready to use, stored 
at 4οC (Thermo Fisher Scientific , 89901). 
RIPA buffer with Protease Inhibitors: One cOmplete™ Mini Protease Inhibitor Cocktail 
tablet (Roche, 11836153001) was added to 10mls of RIPA buffer and vortexed until fully 
dissolved. Aliquots were stored at -20οC until required.  
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Bovine serum albumin (BSA): Protein Standards for Bradford assay were generated from 
a stock of 10 mg/ml BSA (Sigma-Aldrich, A2153) dissolved in deionised water. Standards 
ranged from 0-6 mg/ml BSA and were stored at 4οC. 
Bio-Rad Protein Assay Dye Reagent Concentrate: Bio-Rad Protein Assay Dye Reagent 
(Bio-Rad, 500-0006) was used to quantify protein using a colorimetric assay based on 
the Bradford method. Stored at 4οC. 
Laemmli SDS sample buffer, reducing 4x: Containing 250 mM Tris-HCL, 8% SDS, 40% 
glycerol, 8% beta-mercaptoethanol and 0.02% bromophenol blue. Used at 1x 
concentration. Stored at room temperature (Alfa Aesar, J60015). 
NuPAGE™ 10% Bis-Tris Protein Gels, 1.0 mm, 10-well: Precast polyacrylamide gels 
with a neutral pH. Stored at 4οC (Thermo Fisher Scientific, NP0301BOX). 
PageRuler™ Plus Prestained Protein Ladder: Ready to use ladder for use as size 
standards in SDS-Page, showing 10 to 250 kDa. Stored at -20οC (Thermo Fisher 
Scientific, 26619). 
Running buffer: NuPAGE™ MOPS SDS Running Buffer (20X) (Thermo Fisher Scientific, 
NP0001). Stored at room temperature. Diluted to 1X in deionised water.  
Transfer buffer: 10X Tris Glycine (Severn Biotech, 20630050) diluted to 1X in deionised 
water and 20% (final concentration) methanol. Stored at room temperature. 
Polyvinylidene fluoride (PVDF) western blotting membrane: PVDF western blotting 
membrane with 0.2 µm pore size (Merck, 3010040001). Activated with methanol 5 
minutes prior to use.  
TWEEN® 20: Stored at room temperature (Sigma- Aldrich). 
Tris buffered saline (TBS)- Tween (TBS-T):  TBS (Severn Biotech , 20730110) was diluted 
to 1X in deionised water and supplemented with 0.1% v/v Tween-20 to generate TBS-T. 
Blocking solution: Blocking solution was generated by dissolving 5% w/v skimmed milk 
powder (Sigma-Aldrich, 70166) in TBS-T. Blocking solution was made fresh prior to each 
use.  
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Pierce™ enhanced chemiluminescence reagent (ECL) Western Blotting Substrate: ECL 
Western Blotting Substrate was used to detect HRP on immunoblots (Thermo Fisher 
Scientific, 32106). Stored at 4οC. 
X-Ray Film: 18x24 cm X-ray film (Scientific Laboratory Supplies, MOL7016). 
 
2.5.2 Protein isolation and quantification 
Cells for protein extraction were placed on ice, washed twice in ice cold PBS and lysed 
in RIPA buffer with protease inhibitors. Lysis was further aided by scraping cells from the 
growth surface with a cell scraper. The lysed cells were then transferred into a 
microcentrifuge tube. Small extracellular vesicles harvested for protein extraction were 
isolated as described in section 2.4.3.1. Following the final wash step, PBS was removed 
from and the pelleted vesicles were lysed in RIPA buffer with protease inhibitors on ice. 
The subsequent lysate was then then transferred into a microcentrifuge tube. 
Henceforth all protein samples were processed in the same manner. To facilitate further 
lysis, samples were sonicated on ice. The resultant protein lysates were then centrifuged 
at 10,000 x g for 30 minutes at 4οC to pellet cell debris. The supernatant containing the 
soluble protein was collected and used for further analysis. Where necessary protein 
samples were stored at -80οC. 
The protein concentration of each sample was determined in a 96-well plate using the 
Bio-Rad Protein Assay, which is a colorimetric assay based on the Bradford protein 
analysis method. The concentrated Bio-Rad protein assay was diluted 1:4 in deionised 
water and 200 µl added per well to 2-4 µl of each sample. BSA standards ranging from 
0-6 µg/ml were used each time. Absorbance at 595 nm was measured using a plate 
reader. Readings from the BSA standards, enabled a standard curve to be plotted and 
the equation of the line generated. Using the equation of the line, the protein 
concentration for each sample was calculated. Western blot loading samples were then 
generated ensuring each sample had 1 µg/µl of protein, Laemmli Buffer diluted to a 1X 
concentration and the appropriate amount of RIPA buffer to make up the final volume. 
Prior to electrophoresis, the samples were boiled on a heat block at 98οC for 5 minutes 
to denature the proteins.  
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2.5.3 Western blotting 
Protein samples were resolved using the NuPAGE® Bis-Tris Electrophoresis System with 
NuPAGE™ 10% Bis-Tris Protein Gels (1.0 mm, 10-wells).  The protein gels were inserted 
into an electrophoresis tank before the tank was filled with running buffer. 5 µl of 
PageRuler™ Plus Prestained Protein Ladder was added to the first well and 15-20 µl of 
each protein loading samples was added to the subsequent wells. The gel was then run 
at 80 V for 20 minutes to allow time for the proteins to stack and then subsequently 
resolved at 150 V for the remaining run time (roughly 1 hour or until blue sample buffer 
reached the base of the gel).  
The resolved proteins were then transferred onto a PDVF membrane using the Mini 
Trans-Blot® wet transfer system. Prior to use, the PDVF membrane was equilibrated in 
methanol for 5 minutes. The gels and PDVF membrane were submerged in transfer 
buffer and tightly packaged into transfer cassettes, flanked either side with 
chromatography paper. These cassettes were then placed into the transfer tank and the 
tank was filled with transfer buffer. Additionally, to prevent over-heating, ice packs were 
added to the tank. The transfer was performed at 100 V for 1.25 hours.  
 
2.5.4 Immunoblot detection 
After transfer, the membranes were blocked in 10ml of blocking solution on a rocker at 
room temperature for 1 hour. Membranes were then incubated with primary antibody 
diluted in blocking buffer (See table 2.5.4 for primary antibodies and dilutions) on a 
gentle rocker at 4οC overnight. 12-18 hours later, membranes were washed in TBS-T 3 
times for 5 minutes each, on a rocker at room temperature. Membranes were then 
incubated with the appropriate secondary horseradish peroxidase (HRP)- conjugated 
antibody (See table 2.5.4 for secondary antibodies and dilutions) diluted in blocking 
buffer for 1 hour on a rocker at room temperature. Membranes were washed again with 
TBS-T 3 times for 5 minutes each, on a rocker at room temperature. Protein bands were 
the visualised by adding the Pierce™ enhanced chemiluminescence reagent (ECL) 
Western Blotting Substrate which acts as a substrate for HRP resulting in the emission 
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of low-intensity light. In a dark room, X-ray film is placed over the membranes for various 
exposure times and films were developed using a SRX-101A table top film processor.  
 
Table 2.5.4 Antibodies for western blotting 
Primary Antibodies Product 
number 
Supplier Species 
raised 
Dilution 
Anti TSG101 (EPR7130(b)) ab125011 
 
Abcam Rabbit 1:1000 
 Anti CD63 ab68418 
 
Abcam 
 
Rabbit 1:1000 
Anti CD81 (B-11) sc-166029 
 
Santa Cruz 
Biotechnology 
 
Mouse 1:500 
Anti  ALIX (3A9) 2171 Cell signalling 
 
Mouse 1:1000 
Anti Flotillin-1 (18) 610821 
 
Biosciences 
 
Mouse 1:1000 
Secondary Antibodies Product 
number 
Supplier Species Dilution 
HRP- anti rabbit secondary  NA934V GE Healthcare Donkey 1:5000 
HRP- anti mouse secondary NA931V GE Healthcare Sheep 1:5000 
 
2.6 sEV uptake by recipient cells 
To visualise sEVs uptake by recipient cells, initially fluorescently labelled sEVs were 
generated. To do this, sEVs were harvested from PaTu-S cells using the 
ultracentrifugation protocol described in section 2.4.3.1 with the following alteration. 
Prior to the final PBS wash step, sEVs were resuspended in 200 µl of PBS and 
fluorescently labelled with a 1/200 dilution of BODIPY. sEVs were then incubated at room 
temperature for 5 minutes before being diluted in 31.5 ml of PBS to dilute out any 
unbound dye. The final 100,000 x g ultracentrifugation step was then performed and the 
subsequent sEV pellet resuspended in 200 µl of PBS. The isolated sEVs were then added 
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to the desired recipient cells (either PaTu-T or PS1 cells) that had been plated on glass 
coverslips 24 hours prior. 3 hours post addition of exosomes coverslips were fixed in 4% 
formaldehyde and stained with phalloidin and DAPI as described in section 2.3. 
Representative z-stack images were taken using a spinning disk confocal microscope as 
described in section 2.3.4. 
 
2.7 sEV-mediated PSC activation 
PaTu-S.PLK4 cells were untreated or treated with 2 µg/ml doxycycline for 24 hours to 
induce over expression of the PLK4 transgene leading to centrosome amplification. The 
following day cells were plated into 14 T175 flasks at a density of 1x106 cells per flask. 
Doxycycline (2 µg/ml) was again added to the cells being induced for centrosome 
amplification. 24 hours later, the cells were washed twice with PBS and 15 ml of fresh, 
vesicle depleted media (see section 2.4.2) was added to the cells. 48 hours later, sEVs 
were harvested from the cells by ultracentrifugation alone, or in combination with SEC 
as described in section 2.4.3. The number of sEVs present in each isolate was then 
quantified by ImageStream as described in section 2.4.4.1. PS1 cells were plated on glass 
coverslips at a density of 1x104 cells 24 hours prior to sEVs harvest. 24 hours after plating, 
PS1 cells were then left untreated (negative control), or treated with i) 5 ng/ml TGF-β 
(positive control), ii) 20 million sEVs from cells without the induction of centrosome 
amplification, iii) 20 million sEVs from cells with the induction of centrosome 
amplification. 48 hours later, a second dose of 20 million sEVs was administered per 
condition. 24 hours post the final addition of sEVs (72 hours post the initial addition of 
sEVs), cells were fixed and stained for α-SMA and DAPI (as described in section 2.3). 
Representative images of the cells were taken using a spinning disk confocal microscope 
as described in section 2.3.4. PS1 activation was quantified based on α-SMA 
organisation, where the formation of α-SMA fibres was used as a measure of activation. 
Roughly 150 cells were quantified by eye per condition. All conditions were quantified 
blind.  
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2.8 SILAC based Proteomic Analysis 
SILAC based proteomic analysis of exosomes was performed in collaboration with Dr 
Faraz Mardakheh. All amino acids (heavy and medium) and buffers were provided by 
our collaborator. 
 
2.8.1 Reagents 
Gibco ™ Foetal Bovine Serum, Dialyzed (FBS for SILAC): 50 ml aliquots were stored at -
20oC. Prior to use aliquots were thawed at 37oC (Thermo Fisher Scientific, 26400044). 
Dulbecco’s modified Eagle’s medium for SILAC (DMEM for SILAC): with L-glutamine, 
deficient in L-lysine and L-arginine. 0.2 µm Sterile filtered.  Stored at 4oC (Thermo Fisher 
Scientific, 88364). 
Buffer A*: 2 ml acetonitrile, 0.1 ml trifluoroacetic acid, 0.5 ml acetic acid in 97.4 ml of H2O. 
Buffer A: 0.5 ml acetic acid in 99.5 ml H2O. 
Buffer B: 80 ml acetonitrile, 0.5 ml acetic acid in 19.5 ml H2O. 
STOP 5 Buffer: 4% acetonitrile, 1% trifluoroacetic acid in H2O. 
 
2.8.2 Generation of SILAC media 
SILAC DMEM was supplemented with 10% dialyzed FBS that had been ultracentrifuged 
for 18 hours at 100,000 x g to removed naturally occurring EVs. Additionally, the media 
was supplemented with 600 mg/L Proline and 100 mg/L of heavy or medium Lysine and 
Arginine depending on the condition. Amino acids were dissolved in deionised and 
sterile filtered prior to media supplementation.  
 
2.8.3 SILAC label incorporation tests 
PaTu-S.PLK4 cells were grown in SILAC DMEM supplement with heavy or medium 
labelled amino acids,  for 2 weeks before label incorporation tests were performed. Cells 
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were trypsinised and pelleted as previously described before being washed twice in PBS.  
Following the final PBS wash, residual PBS was removed from the cell pellet. Samples 
were then processed as described in section 2.8.5. For label incorporation tests, 3 μg of 
each sample was injected into the mass spectrometer for analysis. Upon confirmation 
that the PaTu-S.PLK4 cells had successfully incorporated the SILAC labels, these cells 
were used for further analysis.  
 
2.8.4 Exosome harvest for SILAC based proteomic analysis 
PaTu-S.PLK4 cells were grown in either heavy or medium SILAC in T175 flask. Cells grown 
in heavy growth medium were then induced to overexpress PLK4 with 2 µg/ml 
doxycycline and the cells grown in medium growth medium were left untreated. 24 
hours later, cells were plated into 40 T175 flasks at a density of 1x106 cells per flask, per 
condition. Doxycycline (2 µg/ml) was again added to each flask grown in heavy growth 
medium. The following day, media was removed from the flask, cells were washed twice 
with PBS and then 15 ml of fresh EV depleted medium supplemented with the correct 
amino acids (heavy or medium) was added to the cells. 48 hours later, the conditioned 
medium was harvested from the cells and pooled together.  Additionally, a final cell 
count was performed to ensure that the same number of cells was present per 
condition. EVs were then isolated from the harvested cell culture medium using the 
ultracentrifugation protocol described in section 2.4.3.1. To further purify and separate 
the isolated sEVs, SEC was then performed as described in section 2.4.3.2. Vesicles per 
ml were then quantified in each SEC fraction using ImageStream as described in section 
2.4.4.1. Samples were then frozen at -80οC prior to processing for mass spectrometry 
analysis. The whole experiment was then repeated using the reverse labelling, where 
cells grown in the medium labelled medium were induced with doxycycline and the 
heavy left untreated to replicate the experiment and account for any potential effects 
of the different labels.  
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2.8.5 Sample processing for mass spectrometry 
Cells or extracellular vesicles were lysed in 8 M Urea dissolved on a rocker in 50 mM 
Ammonium bi-carbonate (ABC) (made up in deionised water, pH 8).  Samples were then 
sonicated using a Diagenode Bioruptor sonicator at 4οC. Samples were sonicated at high 
power for 15 cycles of 30 seconds on and 30 seconds off. A reducing step was then 
performed by adding 1 M DTT to a final concentration of 10 mM for 20 minutes at room 
temperature. Next an alkylating step was performed by adding 550 mM Iodoacetamide 
to a final concentration of 55 mM incubated for 30 minutes in the dark. Samples were 
then centrifuged using a tabletop centrifuge at full speed to remove debris. Protein 
quantification was then performed as previously described. 15 µg of protein was then 
selected per sample for the label incorporation tests. Urea was then diluted out of the 
sample from 8 M to 2 M final concentration using 50 mM ABC. Digestion of the sample 
was then performed by incubating the sample with 0.1 µg of trypsin per µg of protein 
for 16-18 hours at room temperature. Digestion was then stopped by acidifying the 
sample using equal amounts of the STOP 5 buffer and sample. Additionally, 2% 
Acetonitrile (ACN) was added to the sample to enable sample binding to the filter for 
stagetipping. It was then ensured that the sample has a pH of less than 2. The sample is 
then cleaned up and desalted using a stagetipping approach. Stage tips were generated 
using 200 μl pipette tips (no filter) as the column. Then 3 layers of C18 were cut out using 
a plunger and then plunged into the bottom of the 200 μl tip. The filter was plunged 
gently and as far as possible to pack the filter down. Stagetips were then added to 2 ml 
collection tubes with a custom-made black holder added to the opening to hold 
stagetips in place. Optimally packed tips elute 200 μl in 3 minutes at 2000 x g and so 
stagetips were tested for this capability prior to use. To activate the filter, 100 μl of 
methanol was added to each stagetip. The stagetips were then centrifuged at 2000 x g 
for 3 minutes at room temperature to pass the methanol through the filter. Next 200 μl 
of buffer A* was added and the stage tips centrifuged as before. Once the flow through 
had been discarded the last step was repeated. The sample was then loaded onto the 
stage tip and centrifuged at 500 x g for 3 minutes at room temperature. 200 μl of buffer 
A was then added to the stage tip and centrifuged at 2000 x g for 3 minutes at room 
temperature. Stage tips were then transferred into RNase free micro-centrifuge 
collection tubes with Mass spectrometry (Mass spec) collection tubes placed inside, 
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ensuring that the stagetip tip was placed inside the Mass spec tube. 20 μl of the elution 
buffer, buffer B was then added to each stage tip. The stagetips were then centrifuged 
at 500 x g for 3 minutes. This step was then repeated resulting in the eluted peptides 
being present in 40 μl of buffer B. Peptides were then dried using a speed vac. Finally, 
the peptides were resuspended in 10 μl of buffer A*. Mass spec and subsequent analysis 
was performed by our collaborator Dr Faraz Mardakheh. 
 
2.9 Statistical analysis  
Graphs and statistics were generated using Prism 8 (GraphPad Software) where results 
are presented as mean ± standard deviation (SD) unless otherwise stated. Statistical 
analysis was performed using one-way ANOVA with Tukey’s post hoc test unless 
otherwise stated. Significance is equal to *p<0.1, **p<0.01, ***p<0.001  and 
***P<0.0001.  
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3.1 Centrosome amplification in pancreatic cancer cell lines 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a 
less than 2% 5 year survival rate (Siegel, Miller and Jemal, 2019). Currently surgical 
resection is the most successful treatment option, however upon diagnosis only 15-20% 
of patients are suitable for this potentially curative surgery (Kim, Ahmed and Hsueh, 
2011). For patients where surgical resection is not an option, chemotherapy can be 
administered. However, current chemotherapeutics for PDAC patients offer limited 
responses and life expectancy in these patients is extended by mere months (Burris et 
al., 1997; Berlin et al., 2000; Conroy et al., 2011; Vaccaro, Sperduti and Milella, 2011). 
Thus, there is an urgent need for further research into the development and progression 
of pancreatic cancer in the hopes of developing novel and more successful treatment 
options.  
A study performed by Sato and colleagues  (Sato et al., 1999)  identified centrosome 
amplification in ~85% of analysed pancreatic tumours. Therefore, understanding the 
role of centrosome amplification in the development of pancreatic cancer could lead to 
the identification of novel targets for new cancer therapeutics. Interestingly in our most 
recent publication (Arnandis et al., 2018) we showed that cells with supernumerary 
centrosomes secrete an increased number of proteins associated with the extracellular 
compartment. In particular these proteins were found to be associated with 
extracellular vesicles (EVs), and more specifically, exosomes. Thus, we hypothesised that 
pancreatic cancer cells with extra centrosomes may secrete more EVs. Additionally, as 
exosomes have been shown to play roles in tumourigenesis (reviewed in Wortzel et al., 
2019), we speculated that an increase in EV secretion may contribute to the progression 
and spread of pancreatic cancer.   
To investigate if pancreatic cancer cells with amplified centrosomes secrete more EVs, 
we first assessed centrosome amplification in a panel of 12 PDAC cell lines: PaTu-T, 
Capan-1, PANC-1, CFPAC-1, Hs766T, BxCP3, AsPC-1, Capan-2, Panc 04.03, PaTu-S, HPAF-
II and MIA PaCa-2, and two immortalised cell lines generated from normal pancreas: 
HPDE and DEC hTERT. Cells were grown on glass coverslips for 48 hours before being 
fixed and labelled with antibodies directed against microtubules (α-tubulin) and 
centrioles (centrin). DNA was stained with Hoechst dye.  
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Using 2D immunofluorescence microscopy the percentage of cells with either normal or 
amplified centrosome number was quantified. Since centrosome number changes 
throughout the cell cycle, centrosome amplification was quantified specifically during 
metaphase (as evidenced by the presence of the mitotic spindle). During normal cell 
division, cells in metaphase have one centrosome (2 centrioles) present at each pole of 
the bipolar mitotic spindle (Figure 3.1.1 left panel). Cells with more than two 
centrosomes either in a pseudo-bipolar or multipolar spindle formation are considered 
to have amplified centrosomes (Figure 3.1.1 middle and right panels respectively).  
 
 
Figure 3.1.1 Representative images of cells in metaphase with normal or amplified 
centrosomes. Immunofluorescent staining of microtubules and centrioles in metaphase cells. 
Representative images of cells undergoing bipolar cell division (left), clustered pseudo bipolar 
division (middle) and multipolar cell division (right). Cells stained with centrin (green), α-tubulin 
(red) and DNA in Hoechst (blue). Cells are HPAF-II, scale bar represents 5µm. 
 
Centrosome amplification levels are stratified in the current literature, where > 30% 
centrosome amplification is considered high and < 10% is considered low (Lopes et al., 
2018; Rhys et al., 2018) . As expected, centrosome amplification was found to be low 
(<3%) in the pancreatic control cell lines HPDE and DEC-hTERT. The levels of centrosome 
amplification varied across the panel of PDAC cell lines (Figure 3.1.2), however, with 4 
cell lines exhibiting particularly high levels of centrosome amplification (>30% of cells): 
PaTu-T, Capan-1, Panc-1 and CFPAC-1. In contrast, 3 cell lines emerged as having 
particularly low centrosome amplification (<7% of cells): PaTu-S, HPAF-II and MIA-PaCa-
2. These 9 cell lines harbouring particularly high or low percentages of cells containing 
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centrosome amplification were selected to investigate the secretion of vesicles from 
pancreatic cells in relation to centrosome amplification.  
 
 
Figure 3.1.2 Quantification of centrosome amplification in PDAC cell lines. Average percentage 
of cells with amplified centrosomes in a panel of pancreatic cell lines.  Total centrosome 
amplification (clustered and multipolar) was assessed in 12 pancreatic cancer cell lines (Black 
text) and 2 pancreatic control cell lines (Blue text). The dashed line represents 30% centrosome 
amplification. Centrosome amplification above this threshold is considered high. Error bars 
represent mean ± standard deviation (n=3).   
 
3.2 Extraction of extracellular vesicles. 
3.2.1 Isolation and quantification of extracellular vesicles from cell culture 
medium 
Extracellular vesicles (EVs) including larger microvesicles (100-1000nm) and smaller 
exosomes (30-150nm) are secreted by cells into the extracellular space. In cultured cells, 
the secreted EVs can be isolated from the cell culture medium. As these two types of 
EVs somewhat differ in size/buoyant density (size of particle and density of cargo), we 
can crudely isolate the two populations based on their sedimentation rate using a serial 
ultracentrifugation protocol similar to that used by Costa-Silva et al., 2015 (Figure 
3.2.1.1 A). Initially, the cell culture medium is removed from cells and subjected to a low 
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speed centrifugation (500 x g for 10 minutes) to remove cell debris and apoptotic bodies 
from the supernatant. The supernatant is then centrifuged at 12,000 x g for 20 minutes 
to pellet the large EVs (LEVs) which in theory should be >200nm in size (Théry et al., 
2018) and therefore likely to be microvesicles. The subsequent supernatant is then 
subjected to high speed ultracentrifugation (100,000 x g for 70 mins) to pellet the 
smaller EVs (sEVs), which should be <200nm in size (Théry et al., 2018) and thus enriched 
in exosomes. Non-EV contaminants are removed with a wash step and subsequent high 
speed ultracentrifugation (Théry et al., 2006). Although this wash step is known to 
decrease EV yield it is important for increasing the purity of the EV pellet (Webber and 
Clayton, 2013). Finally, the isolated EV pellet is re-suspended in PBS for further analysis. 
Two parameters for ultracentrifugation are particularly important to ensure good 
separation of the vesicles. Duration of the ultracentrifugation is vital, as increasing the 
time of the spin will increase the presence of impurities in the pellet (Van Deun et al., 
2014). Ultracentrifugation speed is also critical as increasing the speed will elevate the 
formation of EV aggregates. Although re-suspension in PBS can separate most of the 
aggregates, the presence of residual EV aggregates may interfere with downstream 
analysis (Théry et al., 2006).  
To validate the serial ultracentrifugation protocol for isolation of EVs, we isolated LEVs 
and sEVs from the PDAC cell line PaTu-T. Cells were grown in vesicle-depleted media (see 
section 3.2.2) before the culture medium was removed and EVs were isolated. The size 
distribution of vesicles in each pellet was quantified by nanoparticle tracking analysis 
(NTA) using the NanoSight NS300. Analysis using the NTA 3.2 analysis software 
demonstrated that the LEVs population had a mean size of 290.9 nm and a mode size of 
158.7 nm, whereas the sEV population had a mean size of 141.6 nm and a mode size of 
113.3 nm (Figure.3.2.1.1 B). This analysis confirmed that the two populations were 
within the correct average size range to be considered large and small EVs respectively. 
As there is an overlap in the size of microvesicles (100-1000 nm) and exosomes (30-150 
nm), size alone cannot distinguish the two vesicle types. However, the observed size 
ranges suggest an enrichment of microvesicles in the LEV pellet and enrichment of 
exosomes in the sEV pellet.   
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Figure 3.2.1.1 Extracellular vesicle isolation by ultracentrifugation and particle size 
distribution quantification by Nanosight NS300. A) Schematic of the serial ultracentrifugation 
protocol for isolation of Large EVs and Small EVs. B) Size distribution curves determined by 
Nanosight NS300 (Nano-particle tracking analysis) of LEVs and sEV isolates. LEV isolates have a 
mean size of 290.9nm and a mode size of 158.7nm (grey distribution) whereas sEV isolates have 
a mean size of 141.6nm and a mode size of 113.3nm (red distribution). Dotted line indicates the 
mode size of each EV population. Error bars (shown in red for sEVs and grey for LEVs) indicate 
standard error of the mean. 
 
An Amnis ImageStream® Mark II Imaging Flow Cytometer (ImageStream) was used to 
quantify the number of EVs present in each pellet.  Traditionally, NTA  has been 
considered the gold standard for quantification of EV number and EV size. However, 
whilst the ImageStream does not have the capacity to quantify EV size, it offers certain 
advantages for the quantification of EV number. Unlike ImageStream, classical NTA is 
likely to over-estimate EV counts as the technique is not specific to EVs and analyses all 
particles regardless of their composition (reviewed in Théry et al., 2018). The 
ImageStream, however, enables quantification of particles specifically containing lipids 
by virtue of fluorescent labelling, in this case using the lipid dye BODIPY-Maleimide. It 
should be noted that the ImageStream may underestimate vesicle numbers as vesicles 
smaller than 20nm may be below the fluorescence threshold (Headland et al., 2014). 
The ImageStream calculates a BODIPY intensity value and side scatter value for each 
particle, and a graph of BODIPY intensity against side scatter intensity can be plotted. 
Extracellular vesicles are predicted to have low side scatter and mid to low BODIPY 
fluorescence distinguishing them from other particles and thus can be gated as shown 
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in Figure 3.2.1.2 A. Speed beads are used to internally calibrate the machine but can be 
excluded from the gating region as they have high side scatter and low BODIPY intensity. 
Contaminating cells and cell debris can also be removed from the gating region as they 
have high side scatter and high BODIPY intensities (See Figure 3.2.1.2 A)(Headland et al., 
2014). The ImageStream also provides an image gallery of all objects that pass through 
the stream permitting confirmation that the particles within the gated region are small 
and spherical, indicative of vesicles (representative images shown in Figure 3.2.1.2 B). 
We have therefore opted to use ImageStream to quantify vesicle number and NTA to 
quantify vesicle size.  
 
Figure 3.2.1.2 Extracellular vesicle quantification by Nanosight NS300 and Amnis 
ImageStream® Mark II Imaging Flow Cytometer. A) Example graph from the Amnis 
ImageStream, displaying side scatter plotted against BODIPY intensity. Representative gating 
regions are shown. Gating region for extracellular vesicles (in blue) at low side scatter and mid 
to low BODIPY intensity. Gating region for contaminating cells and cell debris (yellow) at high 
side scatter and high BODIPY. Gating region for speed beads (green) used to internally calibrate 
the ImageStream at high side scatter and low BODIPY. Gating region for lysed vesicles (purple) 
at low side scatter and low BODIPY B) Representative images of particles taken from the 
ImageStream image gallery that are present in the extracellular vesicles gating region, showing 
small spherical vesicles. Vesicles are labelled with BODIPY-Maleimide (green).  
 
3.2.2 Depletion of extracellular vesicles from foetal bovine serum 
Foetal bovine serum (FBS) which is used to supplement cell growth media contains a 
large number of bovine extracellular vesicles that may affect the quantitative and 
qualitative analyses of EVs secreted by cultured cells. Therefore, depletion of 
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contaminating EVs from the FBS prior to use in cell culture is crucial. Ultracentrifugation 
is used to remove bovine EVs from the FBS. During this process, the duration of the 
ultracentrifugation was found to be critical and had to be optimised for FBS from 
different providers. We tested vesicle depletion in both Gibco FBS (non-tetracycline 
screened) and GE Healthcare (tetracycline Screened) FBS which are used throughout this 
thesis. Post ultracentrifugation, the FBS was added to DMEM to a final concentration of 
10% and the residual bovine vesicles present in this media were quantified (Figure 
3.2.2). Two hours of ultracentrifugation was sufficient to deplete Gibco FBS of 
contaminating EVs (from a mean of ~1.3 x108 to ~3.8 x107 objects/ml), however, GE 
Healthcare FBS required ultracentrifugation for 18 hours to deplete EVs to acceptable 
levels (from a mean of ~7.1 x108 to ~2.8 x107 objects/ml).  
 
Figure 3.2.2 Optimisation of vesicle depletion in foetal bovine serum (FBS). Gibco  
(non-tetracycline screened) or GE Healthcare (tetracycline screened) FBS was ultracentrifuged 
at 100,000 x g for 0, 2, 6 or 18 hours to deplete bovine EVs. Following the addition of vesicle-
depleted FBS to DMEM, residual vesicles (LEVs and sEVs) present in the media were isolated by 
ultracentrifugation and quantified by ImageStream. Error bars represent mean ± standard 
deviation (n=3). 
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3.3 Extracellular vesicle secretion in pancreatic cancer and 
pancreatic control cell lines 
3.3.1 Pancreatic cancer cells with supernumerary centrosomes secrete more 
small extracellular vesicles 
As previously shown in Figure 3.1 B, centrosome amplification levels vary between 
pancreatic cell lines. To investigate if pancreatic cell lines with amplified centrosomes 
secrete more EVs, LEVs and sEVs were isolated from the following pancreatic cell lines:  
i) PaTu-T, Capan-1, Panc-1 and CFPAC-1 (PDAC cell lines with high centrosome 
amplification), 
ii) PaTu-S, HPAF-II, MIA-PaCa-2 (PDAC cell lines with low centrosome 
amplification), 
iii)  HPDE, DEC-hTERT (pancreatic control cell lines which harbour low  levels of 
centrosome amplification). 
 
Cells were grown in vesicle-depleted media for 48 hours ensuring that at the 48-hour 
time point all cell lines had the same final cell count of ~6x106 cells/ml. The conditioned 
media was then harvested and EVs were isolated using serial ultracentrifugation.  
Quantification of the isolated vesicles showed an increased presence of sEVs and LEVs in 
the media of cells with extra centrosomes compared to cells with little or no centrosome 
amplification (Figure 3.3.1 A). Further analysis of these results revealed a strong 
significant correlation between sEVs secretion and centrosome amplification where 
rSpearman=0.6863,  compared to LEV secretion and centrosome amplification where 
rSpearman = 0.2971 (Figure 3.3.1 B). These results demonstrate a robust correlation 
between centrosome amplification and the secretion of sEVs, potentially indicating 
increased exosome secretion in cells with extra centrosomes. This result, however, is 
purely correlative and does not in itself indicate causation, prompting further analysis 
into whether centrosome amplification is sufficient to induce EV secretion in pancreatic 
cancer cell lines. 
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Figure 3.3.1 Extracellular vesicle secretion in pancreatic cells.  A) Quantification of LEVs and 
sEVs secreted by pancreatic cancer cells (black text) and immortalised pancreatic cells (blue text) 
with high and low centrosome amplification. Error bars represent mean ± standard deviation 
(n=6). B) Linear regression graph of the data present in A and Spearman correlation coefficients 
(rSpearman) showing a correlation between LEVs (blue) or sEV (grey) secretion in relation to 
centrosome amplification. Significant correlation is observed between both LEVs and sEV 
secretion and increased centrosome amplification (LEVs rSpearman =  0.2971, sEV rSpearman 
=0.6863 and p< 0.0001). Dashed lines = confidence intervals. 
 
 Chapter 3. Results I 
98 
 
3.3.2 Small extracellular vesicle isolates contain canonical extracellular 
vesicle protein markers    
To further validate the presence of EVs in our sEV preparations we analysed the sEV 
isolates for the presence of the canonical EV protein markers CD63, CD81 and flotillin. 
As expected, western blot analysis showed the sEV pellet to be enriched in these EV 
protein markers compared to the cell lysate (Figure 3.3.2). To date, it is not possible to 
conclusively distinguish different types of extracellular vesicles by the presence of 
specific protein markers (Théry et al., 2018). However, the presence of certain protein 
markers may indicate which biogenesis pathway the majority of the EVs in the sample 
originate from. Vesicles in the sEV pellet were enriched in the endosomal sorting 
complex responsible for transport (ESCRT) machinery component TSG101 and ESCRT 
associated protein ALIX (Figure 3.3.2). The presence of these proteins may indicate that 
the vesicles originate from the endocytic compartment and are therefore likely to be 
exosomes. It should be noted however, that to date the only way to specifically 
determine the origin of an EV is through live cell imaging and tracking of the vesicles 
(Théry et al., 2018).  
 
Figure 3.3.2 Western blot analysis of sEVs lysates and total cell lysates from PaTu-T cells. The 
preparations were probed for EV/Exosomal protein markers using antibodies directed against 
CD63, CD81, TSG101 and ALIX and flotillin.  
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3.4 Transient overexpression of PLK4 results in centrosome 
amplification in PaTu-S and HPAF-II cell lines 
Our data thus far suggest that cells with supernumerary centrosomes secrete more sEVs, 
however, it is unclear whether centrosome amplification itself is sufficient to induce sEV 
secretion, or if increased sEV secretion is simply a result of other undefined cellular 
changes. To further explore this,  we investigated whether the induction of centrosome 
amplification in cell lines that naturally harbour low levels of centrosome amplification 
would lead to increased sEV secretion.  
To generate supernumerary centrosomes, a previously established method was used 
whereby centrosome amplification can be achieved through transient overexpression of 
PLK4 (Godinho et al., 2014), the master regulator of centriole duplication (Bettencourt-
Dias et al., 2005; Habedanck et al., 2005; Kleylein-Sohn et al., 2007; Basto et al., 2008). 
PLK4 overexpression is controlled by the presence of a tetracycline repressor (TetR) 
which binds to the CMV/TO promoter inhibiting the expression of PLK4. The addition of 
doxycycline hyclate (DOX) supresses the tetracycline repressor allowing PLK4 
overexpression and the subsequent induction of centrosome amplification.  
We selected two PDAC cell lines which naturally harbour low levels of centrosome 
amplification (<7% of cells), PaTu-S and HPAF-II and transduced them with a tetracycline 
repressor using lentivirus. These cells were then subsequently transduced with lentivirus 
harbouring inducible PLK4, generating two cell lines, PaTu-S TetR PLK4 (henceforth 
referred to as PaTu-S.PLK4) and HPAF-II TetR PLK4 (hence forth referred to as HPAF-
II.PLK4)  in which centrosome amplification can be induced upon the addition of DOX. 
To generate extra centrosomes, DOX was added to the newly generated cell lines for 48 
hours to ensure that sufficient time had passed for centrosome over duplication and 
subsequent maturation to occur (Godinho et al., 2014) (Figure 3.4 A). 
PLK4 overexpression for 48 hours in PaTu-S.PLK4 and HPAF-II.PLK4 cells upon the 
addition of DOX led to significantly increased centrosome amplification in both cell lines 
(Figure 3.4 B/C). With centrosome amplification increasing from average 26% to 92% in 
PaTu-S.PLK4 and from average 18% to 81% in HPAF-II.PLK4. It should be noted that even 
in the absence of DOX, both PLK4 inducible cell lines have higher centrosome 
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amplification than their parental cell lines (PaTu-S and HPAF-II). We attribute this 
observation to the TetR PLK4 system being “leaky” and resulting in low levels of 
recombinant PLK4 expression. However, the increase in centrosome amplification upon 
the induction of DOX is highly significant making these cell lines suitable for further 
study. 
 
 
Figure 3.4 Centrosome amplification upon PLK4 overexpression in PaTu-S and HPAF-II cells. A) 
Schematic diagram illustrating method for inducing extra centrosomes via transient 
overexpression of PLK4. PLK4 overexpression is induced for 48 hours following the addition of 
DOX, resulting in cells with extra centrosomes. B) Centrosome amplification in PaTu-S.PLK4 cells 
treated with (+) and without (-) DOX and the parental PaTu-S cell line (no treatment). C) 
Centrosome amplification in HPAF-II.PLK4 cells treated with (+) and without (-) DOX and the 
parental HPAF-II cell line (no treatment). Error bars represent mean ± standard deviation (n=3, 
300 cells). Data analysed using one-way ANOVA with Tukey’s post hoc test ( **** p<0.0001 *** 
p<0.001 ,** p<0.01). DOX=doxycycline hyclate.   
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3.5 Small extracellular vesicle secretion is elevated upon induction 
of centrosome amplification 
To investigate whether centrosome amplification induces EV secretion in pancreatic 
cancer cell lines, we analysed EV secretion in the newly generated PaTu-S.PLK4 and 
HPAF-II.PLK4 cells with and without the induction of extra centrosomes. PaTu-S.PLK4 
and HPAF-II.PLK4 cells were induced with DOX for 48 hours before the conditioned 
media was removed, the cells were washed and fresh vesicle-depleted media (see Figure 
3.2.2) was added. Cells were subsequently cultured for 48 hours before the conditioned 
media was collected and secreted EVs were isolated and quantified.  
A significant increase in the secretion of sEVs was observed following induction of 
centrosome amplification in both PaTu-S.PLK4 (from a mean of ~2.8 x108 to ~5.6 x108 
objects/ml) and HPAF-II.PLK4 cells (from a mean of ~8 x108 to ~1.9 x109 objects/ml) 
(Figure 3.5). However, no significant difference was observed in LEVs secretion upon 
induction of centrosome amplification in either cell line. This result reflects the data 
shown in Figure 3.3 where a strong correlation was only observed between centrosome 
amplification and sEV secretion in the panel of pancreatic cell lines. Thus, it appears that 
the induction of centrosome amplification preferentially increases the secretion of sEVs.  
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Figure 3.5 Extracellular vesicle secretion upon induction of centrosome amplification in PaTu-
S.PLK4 and HPAF-II.PLK4 cells. A)  Secretion of LEVs and sEVs from PaTu-S.PLK4 with (+DOX) and 
without (-DOX) the induction of centrosome amplification. B) Secretion of LEVs and sEVs from 
HPAF-II.PLK4 with (+DOX) and without (-DOX) the induction of centrosome amplification. Levels 
of centrosome amplification (%CA) are indicated in red. Error bars represent mean ± standard 
deviation (n=6). Data analysed using two-way ANOVA with Tukey’s post hoc test (**** 
p<0.0001). Significance relates to sEVs secretion only. No significant difference was observed in 
LEVs secretion between conditions (DOX=doxycycline hyclate, %CA = % cells with centrosome 
amplification). 
 
3.6 In the absence of centrosome amplification, PLK4 
overexpression is not sufficient to induce extracellular vesicle 
secretion 
To ensure that the increase in sEV secretion observed upon induction of centrosome 
amplification in PaTu-S.PLK4 and HPAF-II.PLK4 is attributed to centrosome amplification 
alone and is not an artefact of the induction method, we controlled for unspecific affects 
caused by the addition of DOX and the overexpression of PLK4.  
Previous studies have shown the centrosomal protein SAS-6 to be necessary for 
centriole duplication, and so depletion of SAS-6 has been shown to hamper the 
amplification of centrosomes induced by PLK4 overexpression (Arnandis et al., 2018). 
Therefore, in order to analyse the effect of PLK4 overexpression on EV secretion in the 
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absence of centrosome amplification we performed siRNA mediated SAS-6 knockdown 
whilst inducing PLK4 overexpression with DOX.  
As expected, quantification of centrosome amplification following siRNA knockdown of 
SAS-6 (siSAS-6) in PaTu-S.PLK4 and HPAF-II.PLK4 treated with DOX, resulted in 
significantly lower centrosome amplification levels compared to cells treated with the 
siRNA control (siCntrl) and DOX (Figure 3.6.1 A/B). SAS-6 depletion in HPAF-II.PLK4 cells 
+DOX resulted in levels of centrosome amplification that were similar to the untreated 
control cells, however, SAS-6 depletion in PaTu-S.PLK4 cells +DOX resulted in 
centrosome amplification levels that were significantly lower than the untreated control 
cells. Centriole number was therefore quantified to ensure that SAS-6 depletion did not 
cause high levels of centrosome loss in cells overexpressing PLK4. Quantification of 
centriole number revealed that SAS-6 depletion in PLK4 overexpressing cells leads to a 
relatively small percentage of metaphase cells containing less than three centrioles 
(Figure 3.6.1 C/D), 35% in PaTu-S.PLK4 cells and 28% in HPAF-II.PLK4 cells. As SAS-6 is 
important for centriole duplication, it is possible that these results arise as a 
consequence of SAS-6 depletion in cells that do not have amplified centrosomes, thus 
preventing centriole duplication in these cells and leading to the observed centriole 
losses. Despite these low levels of centrosome loss, most cells in both cell lines 
contained normal centriole numbers and were able to form a bipolar metaphase plate 
with either 3 or 4 centrioles present at each pole. These conditions were therefore used 
for further analysis. 
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Figure 3.6.1 Centrosome amplification upon siRNA depletion of centrosomal protein SAS-6 in 
the presence of PLK4 overexpression. A) Quantification of the percentage of cells with 
centrosome amplification in PaTu-S.PLK4 cells untreated, or treated with DOX and siCntrl or DOX 
and siSAS-6. B) Quantification of the percentage of cells with centrosome amplification in HPAF-
II.PLK4 cells untreated, or treated with DOX and siCntrl or DOX and siSAS-6. C) Quantification of 
the percentage cells with >4, 3-4 or <3 centrioles in PaTu-S.PLK4 cells untreated, or treated with 
DOX and siCntrl or DOX and siSAS-6. D)  Quantification of the percentage cells with >4, 3-4 or <3 
centrioles in HPAF-II.PLK4 cells untreated, or treated with DOX and siCntrl or DOX and siSAS-6. 
Error bars represent mean ± standard deviation (n=3, 300 cells). Data analysed using one-way 
ANOVA with Tukey’s post hoc test ( **** p<0.0001, ** p<0.01).  DOX=doxycycline hyclate.  
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Extracellular vesicles were then harvested from the conditioned medium of cells treated 
in the same manner as above. It was found that, following SAS-6 depletion, sEVs 
secretion is greatly decreased compared to the siCntrl treated cells, despite DOX 
treatment and over expression of PLK4 in both PaTu-S.PLK4 and HPAF-II.PLK4 cells 
(Figure 3.6.2). No significant difference was observed in LEV secretion between 
conditions. These results indicate that the increased sEV secretion observed upon the 
induction of centrosome amplification is not an artefact of PLK4 overexpression or DOX 
treatment but is instead due to the increased presence of extra centrosomes. 
Taken together, these results indicate that centrosome amplification is sufficient to 
induce sEV secretion in pancreatic cancer cells. In contrast, LEV secretion remains largely 
unchanged following induction of supernumerary centrosomes.  
 
 
Figure 3.6.2 Extracellular vesicle secretion upon siRNA depletion of SAS-6 in the presence of 
PLK4 overexpression. A) Quantification of LEVs and sEVs secreted by PaTu-S.PLK4 cells 
untreated, or treated with DOX and siCntrl or DOX and siSAS-6. B) Quantification of LEVs and 
sEVs secreted by HPAF-II.PLK4 cells untreated or treated with DOX and siCntrl or DOX and siSAS-
6. Levels of centrosome amplification denoted in red. Error bars represent mean ± standard 
deviation (n=3). Data analysed using two-way ANOVA with Tukey’s post hoc test (**** 
p<0.0001). Significance relates to sEV secretion only. No significant difference was observed in 
LEVs secretion between conditions. DOX=doxycycline hyclate, % CA= % cells with centrosome 
amplification. 
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3.7 Discussion 
In recent years centrosome amplification has been shown to play an active role in 
tumourigenesis in vivo (Coelho et al., 2015; Serçin et al., 2015; Levine et al., 2017). Since 
pancreatic tumours have been shown to harbour up to 85% of cells with centrosome 
amplification (Sato et al., 1999), further research into the role of centrosome 
amplification in the initiation and progression of pancreatic cancer may reveal new  
targets for the development of novel therapeutic strategies.  
Recent work from our laboratory (Arnandis et al., 2018), demonstrated that cells with 
extra centrosomes secrete an increased number of proteins associated with EVs. We 
therefore hypothesised, that cells with amplified centrosomes secrete more EVs than 
cells that do not contain supernumerary centrosomes.   
Here we show that centrosome amplification positively correlates with the secretion of 
LEVs and sEVs in pancreatic cancer cell lines. Moreover, using two different cell lines in 
which we can induce centrosome amplification through transient overexpression of 
PLK4, we have demonstrated that centrosome amplification induces the secretion of 
sEVs in PDAC cells. However, no change was observed in the ability of either cell line to 
secrete LEVs upon induction of centrosome amplification. Furthermore, we have shown 
that in the absence of centrosome amplification, DOX treatment and PLK4 
overexpression do not result in increased EV secretion. Taken together these results 
suggest that centrosome amplification itself is sufficient to induce sEV secretion in PDAC 
cell lines. 
Throughout this chapter, vesicle isolation was performed using a serial 
ultracentrifugation protocol which separated EVs into LEVs and sEVs based on 
differences in buoyant densities (particle size and density of cargo). Although the 
classical ultracentrifugation protocol is still widely used, it is not without its drawbacks 
and the purity of the isolated vesicles has been questioned, leading to the development 
of new methods for EV isolation.  In recent years, a modification to the 
ultracentrifugation protocol utilising a density gradient has emerged as a better method 
of EV isolation from cell culture medium (Abramowicz, Widlak and Pietrowska, 2016). 
The presence of a density gradient results in further separation of the EVs due to their 
specific buoyant densities. This method is now believed to yield EVs with a higher purity 
 Chapter 3. Results I 
107 
 
compared to the classical ultracentrifugation protocol (Théry et al., 2006; Webber and 
Clayton, 2013; Abramowicz, Widlak and Pietrowska, 2016). Size exclusion 
chromatography (SEC), where samples are  passed through a column containing porous 
resin particles, has also emerged as an effective method of EV isolation and purification. 
Vesicles pass through the SEC column largely unimpeded due to their size, whereas 
impurities including small molecules and contaminating proteins enter the pores and 
elute much later. As such,  SEC has been shown to yield high purity EVs (Böing et al., 
2014; Muller et al., 2014; Welton et al., 2015; Benedikter et al., 2017). Although the 
work described in this chapter was carried out using the classical serial 
ultracentrifugation approach for EV isolation, an additional SEC purification step was 
included in subsequent work to improve EV purity where necessary (see chapter 5). 
Although it is not possible to definitively identify the type of EV present in the sEV pellet, 
our work provides evidence to suggest that the pellet may be enriched in exosomes. 
Nano-particle tracking analysis showed that the sEV pellets have a size distribution curve 
with a mode particle size  of 113.3nm. This particle size is within the accepted size range 
for exosomes ie 30-150nm.  Furthermore, the presence of the protein markers TSG101 
and ALIX in the sEV pellet may give insight into the biogenesis pathway from which these 
vesicles originate. Since both TSG101 and ALIX are associated with the ESCRT machinery 
and thus the endocytic pathway, it is likely that the sEV pellet is enriched in exosomes.  
In addition, proteomic analysis recently published by our laboratory (Arnandis et al., 
2018) revealed that cells with extra centrosomes secrete a number of proteins 
specifically associated with exosomes. Taken together these results suggest that the 
vesicles isolated in the sEV pellet are likely to be enriched exosomes, thus indicating that 
centrosome amplification likely results in the increased secretion of exosomes. Further 
evidence  corroborating the identification of these vesicles is detailed in Chapter 5.  
Interestingly, current literature in the extracellular vesicle field has indicated that EV 
secretion is increased in cancer cells and that EV proteins are elevated in the sera of 
cancer patients (Szczepanski et al., 2011; Huang and Deng, 2019). However, it is not 
known if all cancer cells or a subset of cancer cells are responsible for this increased 
secretion. Our results suggest that, a subset of cancer cells, those harbouring amplified 
centrosomes, may contribute to the increase in EV protein secretion that has been 
observed in cancer patients. Since cancer-associated EVs, including exosomes, are 
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known to contribute to the progression and spread of cancers (reviewed in Wortzel et 
al., 2019) our findings may have much wider implications and raise the following 
questions (i) why do cells with extra centrosomes secrete high levels of sEVs and (ii) do 
these vesicles contribute to tumourigenesis? 
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Chapter 4 
 
Results II: 
Centrosome amplification-induced oxidative stress 
impairs lysosome function, preventing lysosomal 
degradation of multivesicular bodies and resulting in 
increased small extracellular vesicle secretion 
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4.1 Cells with Centrosome amplification have increased levels of 
reactive oxygen species  
To better understand the role of centrosome amplification in tumourigenesis we first 
investigated why cells with extra centrosomes secrete high levels of sEVs. Recent work 
published by our laboratory demonstrated that centrosome amplification induces an 
early oxidative stress response through increased generation of reactive oxygen species 
(ROS) (Arnandis et al., 2018). Interestingly, the increase in cellular ROS associated with 
centrosome amplification resulted in an altered secretory phenotype, an extra 
centrosome-associated secretory phenotype (ECASP), that lead to paracrine cell 
invasion. As this work also showed the ECASP included the increased secretion of 
exosomal proteins, we hypothesised that centrosome amplification-associated ROS may 
be responsible for the increased secretion of sEVs. To investigate this, we first quantified 
ROS levels in our PaTu-S.PLK4 and HPAF-II.PLK4 cell lines following the induction of 
centrosome amplification. ROS levels were determined using the Promega GSH/GSSG-
Glo™ Assay. Glutathione (GSH) is an important antioxidant/ ROS scavenger which exists 
mostly in its reduced form, however, following oxidative stress, GSH is converted into 
its oxidized form Glutathione disulfide (GSSG), which consists of two GSH molecules 
linked by a disulphide bond. Briefly, the Promega GSH/GSSG-Glo™ Assay is a linked assay 
utilising glutathione S-transferase and Luciferin-NT that generates a luminescent signal 
in response to levels of GSH present in the sample. The ratio of GSH to GSSG can then 
be calculated to give a read out of oxidative stress in the cells, where a decrease in the 
ratio indicates an increase in oxidative stress. 
As expected, the induction of centrosome amplification (+DOX) in PaTu-S.PLK4 and 
HPAF-II.PLK4 cells results in a decreased ratio of GSH/GSSG indicating an increase in 
cellular oxidative stress/ROS (Figure 4.1.1 A/B). PaTu-S.PLK4 cells were found to exhibit 
~1 fold increase in cellular ROS, whereas HPAF-II.PLK4 exhibited ~2 fold increase. 
Furthermore, it is possible to manipulate levels of cellular ROS using the ROS scavenger 
N-acetyl cysteine (NAC) and the ROS inducing reagent, hydrogen peroxide (H2O2). The 
addition of NAC to samples where centrosome amplification has been induced (+DOX 
+NAC) reverted the ratio of GSH/GSSG back to that of the control cells (no treatment) in 
both cell lines. Moreover, the addition H2O2 at low concentration was sufficient to 
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induce ROS independently of centrosome amplification in both cell lines and results in a 
ratio of GSH/GSSG similar to that observed upon the induction of centrosome 
amplification. Interestingly, PaTu-S.PLK4 cells were found to have higher basal levels of 
ROS compared to HPAF-II.PLK4 cells. Whilst HPAF-II.PLK4 cells exhibited the largest fold 
increase in ROS upon the induction of centrosome amplification, HPAF-II.PLK4 ROS levels 
were still lower than even the basal ROS levels observed in the PaTu-S.PLK4 cells 
(discussed in more detail later in this chapter). 
 
 
Figure 4.1.1 Levels of intracellular reactive oxygen species as measured by the ratio of 
GSH/GSSG. A) Ratio of GSH/GSSG in PaTu-S.PLK4 cells untreated or treated with +DOX, +DOX 
+NAC or + H2O2. B) Ratio of GSH/GSSG in HPAF-II.PLK4 cells untreated or treated with +DOX, 
+DOX +NAC or + H2O2. Error bars represent mean ± standard deviation (n=3). Data analysed 
using one-way ANOVA with Tukey’s post hoc test (**** p<0.0001 , ** p<0.01, * p<0.05). 
DOX=doxycycline hyclate, NAC = N-acetyl cysteine, H2O2= hydrogen peroxide. 
 
It has been previously demonstrated that changes in cellular ROS do not affect 
centrosome amplification (Arnandis et al., 2018). To confirm this finding in our cell lines, 
we quantified centrosome amplification in each of the four conditions: i) no treatment, 
ii) +DOX, iii) +DOX +NAC and iv) +H2O2 (Figure 4.1.2 A/B). Centrosome amplification in 
cells treated with DOX and NAC yield similar levels of centrosome amplification (%) to 
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the cells treated with DOX alone. Thus, the reduction of cellular ROS does not prevent 
centrosome amplification in PaTu-S.PLK4 or HPAF-II.PLK4 cells treated with DOX. 
Moreover, centrosome amplification levels in cells treated with H2O2 remain similar to 
those of the untreated control cells, indicating that oxidative stress does not induce 
supernumerary centrosomes.  
 
 
Figure 4.1.2 Intracellular reactive oxygen species do not affect centrosome amplification in 
PaTu-S.PLK4 or HPAF-II.PLK4 cells. A) Centrosome amplification in PaTu-S.PLK4 cells untreated 
or treated with +DOX, +DOX +NAC or + H2O2. B) Centrosome amplification in HPAF-II.PLK4 cells 
untreated or treated with +DOX, +DOX +NAC or + H2O2. Error bars represent mean ± standard 
deviation (n=3). Data analysed using one-way ANOVA with Tukey’s post hoc test ( **** 
p<0.0001). Significance stars shown where conditions are significantly different from the 
untreated control cells.  DOX=doxycycline hyclate, NAC = N-acetyl cysteine, H2O2= hydrogen 
peroxide. 
 
Taken together these results demonstrate that centrosome amplification leads to 
increased cellular ROS in PDAC cell lines. Importantly, however,  changing ROS levels 
does not affect the percentage of cells with extra centrosomes.  
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4.2 Enhanced reactive oxygen species in cells with extra 
centrosomes drives small extracellular vesicle secretion 
Thus far, our results have demonstrated that cells with extra centrosomes secrete 
significantly more sEVs and have increased levels of cellular ROS. We therefore 
investigated whether centrosome amplification-induced changes in cellular ROS were 
responsible for the altered sEV secretion observed. To test this, we harvested LEV and 
sEVs from PaTu-S.PLK4 and HPAF-II.PLK4 cells under the following conditions: i) no 
treatment, ii) +DOX, iii) +DOX +NAC and iv) +H2O2 (see Figure 4.2). Interestingly, whilst 
centrosome amplification induced sEV secretion as expected, quenching ROS with NAC 
in these cells prevented this increase in sEV secretion. This suggests that the increase in 
sEV secretion observed from cells with extra centrosomes is caused by centrosome 
amplification-induced cellular ROS. Additionally, it was found that the induction of ROS 
with H2O2 resulted in a significant increase in sEV secretion compared to the untreated 
control cells. This indicates that increased cellular ROS can induce sEV secretion 
independently of centrosome amplification. No changes were observed in the secretion 
of LEVs under any experimental condition, suggesting that changes in cellular ROS are 
only responsible for the secretion of sEVs. Interestingly, whilst HPAF-II.PLK4 cells were 
found to have relatively less ROS than PaTu-S.PLK4 cells before and after the induction 
of centrosome amplification, these cells always exhibited higher sEV secretion. As basal 
ROS levels do not appear to correlate to sEV secretion, it is possible that centrosome 
amplification induces the production of a specific form of ROS that is capable of 
increasing the secretion of sEV. Importantly, ROS can be produced in different sub-
cellular compartments including the mitochondria, where the majority of cellular ROS is 
produced, and the cytosol (reviewed in Klionsky et al., 2016). Our previous work 
demonstrated centrosome amplification to induce cytoplasmic ROS, where ROS was 
generated by the NADPH oxidases (NOXs) in the cytoplasm (Arnandis et al., 2018). It is 
therefore possible that the generation of cytoplasmic ROS, induced by centrosome 
amplification, is required to induce sEV secretion in PDAC cells.  
 
Taken together, these results indicate that centrosome amplification-induced cellular 
ROS are responsible for the increase in sEV secretion observed in cells with extra 
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centrosomes. Furthermore, the effect of increased ROS is specific to the secretion of 
sEVs only, indicating that centrosome amplification-associated increases in ROS affects 
the biogenesis and/or the trafficking of sEVs. 
 
 
Figure 4.2 Extracellular vesicle secretion is affected by cellular reactive oxygen species in PaTu-
S.PLK4 and HPAF-II.PLK4. A) Secretion of LEVs and sEVs from PaTu-S.PLK4 cells untreated or 
treated with +DOX, +DOX +NAC or + H2O2. B) Secretion of LEVs and sEVs from HPAF-II.PLK4 cells 
untreated or treated with +DOX, +DOX +NAC or + H2O2.  Error bars represent mean ± standard 
deviation (n=3). Data analysed using two-way ANOVA with Tukey’s post hoc test (**** p<0.0001, 
*** p<0.001). Significance relates to sEVs secretion only. No significant difference was observed 
in LEVs secretion between conditions. DOX=doxycycline hyclate, NAC = N-acetyl cysteine, H2O2= 
hydrogen peroxide.  
 
4.3 Lysosomal deacidification by bafilomycin A1 leads to increased 
small extracellular vesicle secretion 
To further investigate how centrosome amplification-induced ROS contributes to 
increased sEV secretion in pancreatic cancer cells we looked into the likely origins of the 
secreted sEVs. Previous analysis of the isolated sEV by nanoparticle tracking analysis 
(NTA) (Chapter 3) indicated that these vesicles are within the size range associated with 
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exosomes. Moreover, western blot analysis revealed the presence of the ESCRT 
associated proteins TSG101 and ALIX in the sEV isolates, indicating a possible endosomal 
origin for these vesicles. Furthermore, proteomic analysis of sEVs isolated from PaTu-
S.PLK4 cells revealed them to be significantly enriched in proteins associated with 
exosomes (see Chapter 5). This analysis also revealed a significant enrichment in 
proteins associated with recycling endosomes, the ESCRT, late endosomes and the 
endocytic vesicle, further supporting the notion that these vesicles are of endosomal 
origin and therefore likely to be exosomes. We therefore investigated the effects of ROS 
on exosome biogenesis and trafficking. 
Exosomes form within the cell by inward budding into early and late endosomes, which 
are generally referred to as multivesicular endosomes, or multivesicular bodies (MVBs). 
These MVBs are usually destined for fusion with lysosomes, resulting in degradation of 
their contents. Alternatively, MVBs can be trafficked to the extremities of the cell, where 
fusion with the plasma membrane results in exosome secretion (C Harding, Heuser and 
Stahl, 1983; Pan and Johnstone, 1983; Johnstone et al., 1987). Interestingly, it has 
recently been shown that lysosome dysfunction can shift the fate of MVBs targeted for 
degradation to fusion with the plasma membrane and exocytosis, leading to increased 
exosome secretion (Alvarez-Erviti et al., 2011; Miao et al., 2015; Latifkar et al., 2019). 
Since the functional capacity of lysosomes is dependent on an acidic luminal pH, 
lysosomes are particularly sensitive to membrane permeabilization and loss of acidity. 
Interestingly, cellular ROS has been shown to contribute to lysosome membrane 
permeabilization (LMP) through the generation of highly reactive hydroxyl radicals 
which compromise the integrity of lysosomal membranes by causing lipid peroxidation 
and damaging lysosomal membrane proteins (Nilsson, Ghassemifar and Brunk, 1997; 
Kurz, Terman, Gustafsson and Ulf T Brunk, 2008; Kurz, Terman, Gustafsson and Ulf T. 
Brunk, 2008; Johansson et al., 2010; Aits and Jaattela, 2013). Other methods of ROS-
mediated lysosome dysfunction have also been suggested, including constitute 
activation of lysosomal Ca2+ channels leading to LMP (Sumoza-Toledo and Penner, 2011) 
and ROS -linked changes in lysosomal enzyme activity (Aits and Jaattela, 2013). We 
therefore hypothesised that increased ROS in cells with centrosome amplification 
impairs lysosome function, preventing lysosomal degradation of MVBs and resulting in 
increased exosome secretion (Figure 4.3.1). 
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Figure 4.3.1 Hypothesis schematic: Increased intracellular reactive oxygen species blocks 
lysosomal/multivesicular body fusion, resulting in increased exosome secretion. ROS = 
reactive oxygen species, MVBs = multivesicular bodies, ILVs = intraluminal vesicles. 
 
Initially, to confirm whether lysosome dysfunction induces the secretion of sEV in our 
cells, we treated cells with low levels (20nM final concentration) of the macrolide 
antibiotic bafilomycin A1. Bafilomycin A1 is potent vacuolar proton pump inhibitor that 
prevents the acidification of lysosomes, thereby hampering their degradative capacity 
(Yoshimori et al., 1991) and results in the increased release of exosomes (Savina et al., 
2003). Bafilomycin A1 has also been shown to inhibit autophagy by preventing 
autophagosome-lysosome fusion (Müller et al., 2015). To confirm bafilomycin A1 
activity in the PaTu-S.PLK4 cells, we immunofluorescently stained for autophagy marker 
light chain 3-II (LC3-II). LC3-II can be used as a quantitative marker for the presence of 
autophagosomes since it is recruited to the autophagosome membranes and degraded 
following fusion with lysosomes (Kabeya, 2000; Mizushima and Yoshimori, 2007; Tanida, 
Ueno and Kominami, 2008; Klionsky et al., 2016; Redmann et al., 2017). As expected, 
LC3-II accumulates following bafilomycin A1 treatment in PaTu-S.PLK4 cells (Figure 4.3.2 
A), indicating an increase in autophagosomes at low antibiotic concentration. Large and 
small EVs were then harvested from the PaTu-S.PLK4 cell line treated with and without 
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bafilomycin A1 and quantified (Figure 4.3.2 B). As expected, Bafilomycin A1 treatment 
significantly increased the secretion of sEVs in PaTu-S.PLK4 cells, from a mean of ~ 1.9 
x108 to ~ 6.75 x108. No significant difference was observed in the levels of LEVs secretion.  
These results confirm that deacidification of lysosomes induces secretion of sEVs in 
pancreatic cancer cells.  
 
 
Figure 4.3.2 Extracellular vesicle secretion post treatment with Bafilomycin A1 in PaTu-S.PLK4 
cells. A) Immunofluorescent staining of LC3-II in PaTu-S.PLK4 cells, showing an increase in LC3-
II puncta upon treatment with 20nM Bafilomycin A1. LC3-II (LC3B (D11) XP) shown in green, DNA 
(Hoechst) in blue. Scale bar represents 10 µm. B) Secretion of LEVs and sEVs from PaTu-S.PLK4 
cells treated without (-) and with (+) bafilomycin A1 (20nM final concentration). Error bars 
represent mean ± standard deviation (n=3). Data analysed using two-way ANOVA with Tukey’s 
post hoc test (** p<0.01 ). Significance relates to sEV secretion only. No significant difference 
was observed in LEVs secretion between conditions. Baf.A1 = bafilomycin A1, LC3-II = Autophagy 
marker light chain 3-II. 
 
4.4 Centrosome amplification-associated ROS compromises 
lysosomal protease activity 
Our results thus far have demonstrated that centrosome amplification-associated ROS 
is responsible for the increased secretion of sEVs in cells with extra centrosomes. 
Furthermore, we have demonstrated that lysosome dysfunction induces sEVs secretion 
in PDAC cell lines. We therefore analysed whether centrosome amplification increased 
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in ROS may impair lysosome function, preventing MVB-lysosome fusion and shifting the 
fate of MVBs from degradation by the lysosome to secretion at the plasma membrane. 
To test our hypothesis, we first analysed the activity of the lysosomal hydrolase 
cathepsin B as a proxy to lysosome function in PaTu-S.PLK4 cells under the following 
conditions: i) untreated, ii) + DOX (to induce centrosome amplification), iii) +DOX +NAC 
(to quench the induction of ROS in cells with extra centrosomes), iv) + H2O2 (to induce 
ROS independently of centrosome amplification) and v) + bafilomycin A1 (to induce 
lysosome dysfunction through alkalinisation of the lysosomal lumen). Cathepsin B is a 
cysteine protease responsible for driving proteolytic degradation in the lysosome 
(Leung-Toung et al., 2002). Initially synthesised as an inactive zymogen, cathepsin B 
becomes activated upon entry into the acidic environment of the lysosome (reviewed 
by Stoka, Turk and Turk, 2016), making it a good measure of lysosome function. To 
detect cathepsin B protease activity in live cells we used a Cathepsin B Magic Red ™ kit. 
Magic Red™ is a non-toxic and freely permeable substrate that is cleaved in the presence 
of active cathepsin B to produce a red (Cresyl Violet) fluorescent product. Thus, a strong 
Magic Red™ fluorescence intensity is indicative of functional lysosomes. 
Spinning disk confocal microscopy was used to visualise changes in Magic Red™ 
fluorescence intensity between conditions (Figure 4.4 A). Using Image J the mean Magic 
Red™ fluorescence intensity per cell was quantified and normalised to cell area (Figure 
4.4 B). To ensure that total Magic Red™ fluorescence intensity was analysed per cell, z-
stack sum intensity projection images were used for quantification. Analysis revealed 
that Magic Red™ fluorescence intensity significantly decreased in cells with extra 
centrosomes (+DOX) compared to the untreated control cells (represented in grey). This 
demonstrates that cells with extra centrosomes have decreased lysosomal protease 
activity. Interestingly, quenching ROS accumulation in cells with extra centrosomes 
(+DOX +NAC) prevented this decrease in Magic Red™ fluorescence. Furthermore, when 
ROS was induced in the absence of centrosome amplification (+H2O2), Magic Red™ 
fluorescence intensity also significantly decreased. Together, these results indicate that 
lysosome dysfunction in cells with extra centrosomes is caused by increased cellular 
ROS. Moreover, preventing  lysosome acidification with bafilomycin A1 also lead to a 
marked decrease in Magic Red™ fluorescence intensity (see Figure 4.4).  We therefore 
asked the question, does centrosome amplification-induced ROS causes lysosome 
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dysfunction through the deacidification of the lysosomes or through another, as yet, 
unidentified mechanism? 
 
Figure 4.4 Cathepsin B activity as measured by Magic Red™ fluorescence intensity in PaTu-
S.PLK4. A) Representative confocal z-stack projection images of Magic Red™ fluorescence (red) 
in PaTu-S.PLK4 cells, untreated or treated with DOX, DOX and NAC, H2O2, or Baf.A1. DNA was 
stained with Hoechst. Scale bar represents 10µm. B) Quantification of total Magic Red™ 
fluorescence intensity per cell in PaTu-S.PLK4 cells treated as described in A. Control represented 
in grey, treatment conditions in red. Error bars represent mean ± standard deviation (n=60 ± 5 
cells). Data analysed using one-way ANOVA with Tukey’s post hoc test (**** p<0.0001). 
DOX=doxycycline hyclate, NAC = N-acetyl cysteine, H2O2= hydrogen peroxide, Baf.A1 = 
bafilomycin. A1. 
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4.5 Oxidative stress in cells with centrosome amplification impairs 
lysosome and multivesicular body fusion  
Since centrosome amplification-induced ROS was found to compromise lysosome 
function in pancreatic cancer cells (see Figure 4.4) and compromising lysosome function 
with bafilomycin A1 leads to increased sEV secretion we postulated that lysosome 
impairment may prevent lysosomal degradation of MVBs leading to the increased sEV 
secretion observed in cells with supernumerary centrosomes. Furthermore, we 
hypothesised that centrosome amplification-associated ROS may lead to lysosome 
dysfunction through deacidification of lysosomes. To investigate this, we analysed 
changes in lysosome number, MVB number and lysosome/MVB co-localisation in PaTu-
S.PLK4 cells treated as detailed in Figure 4.4 above.  
Lysosome number was quantified using the red fluorescent dye LysoTracker® Red DND-
99 (LysoTracker). LysoTracker contains a fluorophore linked to a weak base which is 
partially protonated at neutral pH and can freely permeate cell and organelle 
membranes in live cells. Upon entry to the acidic environment of the lysosome, the 
lysotracker red probe becomes protonated and is sequestered in the lumen of the 
lysosome (Zhitomirsky, Farber and Assaraf, 2018). Thus, LysoTracker is highly selective 
for acidic organelles, and a strong LysoTracker fluorescent signal is indicative of 
lysosomes with a functional low pH. PaTu-S.PLK4 cells were incubated with LysoTracker 
Red for 1 hour before being fixed and subsequently stained for the presence of MVBs. 
To analyse MVBs, cells were labelled with an antibody directed against the MVB marker 
lyso-bisphosphatidic acid (LBPA). LBPA plays a role in the formation of intraluminal 
vesicles (Kobayashi et al., 1998). Confocal fluorescence microscopy revealed the 
presence of  red (LysoTracker) and green (LBPA) puncta as shown in Figure 4.5.1.  
To ensure all endosomes were quantified, z-stack projection images were used for 
analysis. Lysosome number was analysed in Image J using the point maxima function to 
quantify LysoTracker positive puncta per cell (Figure 4.5.2 A). This analysis revealed a 
significant decrease in LysoTracker puncta in PaTu-S.PLK4 cells where centrosome 
amplification had been induced (+DOX) compared to the untreated control cells 
(represented in grey). This result suggests that cells with supernumerary centrosomes 
have significantly fewer acidic lysosomes. Furthermore, this result is consistent with our 
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magic red data, in demonstrating the reduced presence of functional lysosomes in cells 
with amplified centrosomes. Interestingly when ROS was quenched with NAC in cells 
with extra centrosomes, the number of LysoTracker positive puncta reverted back to 
that of the untreated control. Additionally, induction of ROS with H2O2 in control cells 
was sufficient to significantly decrease LysoTracker puncta independently of 
centrosome amplification. Together, these results indicate that centrosome 
amplification-associated increases in cellular ROS are responsible for the significant 
decrease in acidic lysosomes observed in cells with supernumerary centrosomes. As 
expected, treatment of PaTu-S.PLK4 cells with the lysosome alkalising agent bafilomycin 
A1 resulted in significantly fewer acidic lysosomes. 
The number of LBPA positive MVBs was also quantified in ImageJ using the point maxima 
function (figure 4.5.2 B). Interestingly, no changes were observed in the number of LBPA 
puncta following the induction of centrosome amplification (+DOX) in PaTu-S.PLK4 
compared to the untreated control (represented in grey). In addition, no changes  in the 
number of LBPA puncta were observed following ROS quenching in cells with extra 
centrosomes (+DOX +NAC), or the induction of ROS in the absence of centrosome 
amplification (H2O2). These results indicate, that the number of LBPA+ve MVBs is 
unaffected by centrosome amplification or ROS. Interestingly, LBPA+ve MVBs were more 
disperse throughout the cytoplasm in cells with centrosome amplification and those 
treated with H2O2 compared to untreated control cells (-DOX). This result may indicate 
enhanced trafficking of MVBs in cells with centrosome amplification and treated with 
H2O2. A significant increase in LBPA positive puncta (MVBs) was observed, however, 
upon treatment with bafilomycin A1, indicating a different mechanism of action from 
increased ROS.  Importantly, bafilomycin A1 has been shown to result in the 
accumulation and expansion of autophagic structures in addition to preventing 
lysosome acidification. It is therefore possible that in bafilomycin A1 treated cells, 
increased LBPA puncta are representative of an increased number of autophagosomes 
(Mauvezin and Neufeld, 2015). 
Next, we investigated whether lysosome dysfunction caused by centrosome 
amplification-induced ROS could also prevent lysosome-MVB fusion in PDAC cells. Using 
the Image J threshold function, fluorescence intensity masks were generated for the 
LysoTracker channel (red) and LBPA channel (green) and overlaid to generate a co-
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localisation mask (co-localisation observed in yellow) (representative images shown in 
Figure 4.5 A). Co-localisation events between LysoTracker and LBPA puncta were then 
quantified as a proxy to lysosome-MVB fusion. Points of co-localisation were manually 
analysed per cell and the percentage of LBPA co-localised with LysoTracker was 
calculated (Figure 4.5.2 C). Induced lysosome dysfunction with bafilomycin A1, resulted 
in a significant decrease in LysoTracker/LBPA co-localisation in PaTu-S.PLK4 cells 
compared to the control cells (represented in grey), confirming that lysosome 
dysfunction impairs lysosome-MVB fusion in PDAC cells. We then went on to analyse the 
effects of centrosome amplification on lysosome-MVB fusion in PaTu-S.PLK4 cells. This 
analysis revealed that cells with extra centrosomes (+DOX) have significantly fewer 
LysoTracker/LBPA co-localisation events compared to control cells indicating that 
centrosome amplification does in fact impair lysosome-MVB fusion. Interestingly, the 
decrease in LysoTracker/LBPA co-localisation in cells with extra centrosomes was 
reverted when centrosome amplification-associated ROS were prevented with NAC 
(+DOX +NAC). This effect of ROS was confirmed using H2O2 treatment in control cells (no 
centrosome amplification), where a significant decrease in LysoTracker/LBPA co-
localisation was also observed (see Figure 4.5.1/4.5.2 C). Taken together, these results 
demonstrate that centrosome amplification-induced increases in cellular ROS are 
responsible for impairing lysosome-MVB fusion in PaTu-S.PLK4 cells.  
In conclusion, these results demonstrate that centrosome amplification-associated 
increases in cellular ROS lead to a significant decrease in the levels of acidic functional 
lysosome and significantly fewer lysosome-MVB co-localisation events in PDAC cells. 
Thus, our results support our hypothesis that centrosome amplification-induced ROS 
impairs lysosome function, reducing MVB degradation by lysosomes and leading to 
increased sEV secretion in pancreatic cancer cells. 
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Figure 4.5.1 Representative images of LysoTracker and LBPA co-localisation events in PaTu-
S.PLK4 cells. Representative confocal z-stack projection images of LysoTracker (red), LBPA 
(green), merged images and co-localization masks (col-localisation in yellow) in PaTu-S.PLK4 
cells, untreated or treated with i)DOX, ii)DOX and NAC, iii)+ H2O2, iv) bafilomycin A1. DNA was 
stained with Hoechst. Scale bar represents 10 µm. DOX=doxycycline hyclate, NAC = N-acetyl 
cysteine, H2O2= hydrogen peroxide, Baf.A1 = bafilomycin. A1. 
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Figure 4.5.2 Quantification of LysoTracker and LBPA co-localisation events in PaTu-S.PLK4 
cells. A) Quantification of LysoTracker puncta per cell in PaTu-S.PLK4 cells, untreated or treated 
with i)DOX, ii)DOX and NAC, iii)+ H2O2, iv) bafilomycin A1. Control cells (-DOX) are represented 
in grey, treatment conditions are shown in red. B) Quantification of LBPA puncta per cell in PaTu-
S.PLK4 cells treated as described in A. Control cells (-DOX) are represented in grey, treatment 
conditions are shown in green. C) Quantification of LBPA puncta co-localised with LysoTracker 
per cell in PaTu-S.PLK4 cells treated as described in A. Control cells (-DOX) are represented in 
grey, treatment conditions are shown in purple. Error bars represent mean ± standard deviation 
(n= 45 ± 6 cells). Data analysed using one-way ANOVA with Tukey’s post hoc test (**** p<0.0001, 
** p<0.01). DOX=doxycycline hyclate, NAC = N-acetyl cysteine, H2O2= hydrogen peroxide, Baf.A1 
= bafilomycin. A1. 
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4.6 Discussion  
Our initial findings demonstrate that pancreatic cancer cells with extra centrosomes 
secrete an increased number of sEVs (see Chapter 3). Since EVs secreted by cancer cells 
have been shown to play important roles in the development and spread of cancer 
(reviewed in Wortzel et al., 2019), we asked two important questions, (i) why do cells 
with extra centrosomes secrete more sEVs?  and (ii) do sEVs secreted by cells with 
supernumerary centrosomes contribute to tumourigenesis? We address the first of 
these questions in this chapter.   
Previous work from our laboratory (Arnandis et al., 2018) indicated that centrosome 
amplification-associated increases in cellular ROS were responsible for the altered 
secretory phenotype observed in cells with supernumerary centrosomes. We therefore 
hypothesised that centrosome amplification-associated changes in cellular ROS may 
lead to the increased sEV secretion observed by cells with extra centrosomes. Here we 
show that the induction of centrosome amplification in PaTu-S.PLK4 and HPAF-II.PLK4 
cells leads to an increase in cellular ROS in PDAC cells, confirming the findings of 
Arnandis et al in mammary cells and establishing that this effect is not tissue specific. 
Importantly, whilst centrosome amplification is sufficient to induce ROS in PDAC cells, 
changing ROS levels do not affect the levels of centrosome amplification. Furthermore, 
we demonstrate that centrosome amplification-associated increases in cellular ROS are 
in fact responsible for the increased sEV secretion observed in cells with extra 
centrosomes, confirming our hypothesis.  
To further elucidate the mechanisms behind ROS-mediated increases in sEV secretion 
we first investigated the origin of these sEVs. Within this study we have demonstrated 
that the secreted sEVs harbour many characteristics of exosomes, we therefore 
investigated the possible effects of ROS on exosome biogenesis and trafficking. 
Exosomes are generated intracellularly through intraluminal budding into MVBs and are 
released upon MVB fusion with the plasma membrane (C Harding, Heuser and Stahl, 
1983). However, a second fate exists for MVBs, whereby upon fusion with the lysosome 
the MVB contents are degraded and recycled, thus preventing exosome secretion 
(reviewed in Piper and Katzmann, 2007). Interestingly, lysosome dysfunction has been 
shown to prevent MVB-lysosome fusion (Alvarez-Erviti et al., 2011; Miao et al., 2015; 
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Latifkar et al., 2019) and high cellular ROS has been shown to elicit LMP, which leads to 
lysosome dysfunction (reviewed by Aits and Jaattela, 2013). We therefore hypothesised 
that centrosome amplification-associated ROS mediate lysosome dysfunction, 
ultimately reducing MVB degradation by lysosomes and shifting the fate of the MVBs to 
secretion at the plasma membrane. Our results demonstrate that centrosome 
amplification-associated increases in cellular ROS do in fact lead to decreased lysosomal 
activity (as measured by cathepsin B activity) in pancreatic cancer cells. In addition, we 
found that supernumerary centrosome-associated increases in ROS lead to a significant 
decrease in the number of acidic lysosomes. Taken together, these results indicate that 
high levels of cellular ROS, induced by cells with extra centrosomes, results in lysosome 
dysfunction in PDAC cells. Interestingly, centrosome amplification did not induce 
changes in MVB number in pancreatic cancer cells. This indicates that the increase in sEV 
secretion observed from cells with extra centrosomes is not caused by increased MVB 
biogenesis but is a result of altered MVB trafficking.  Furthermore, analysis of lysosome-
MVB fusion events through co-localisation of lysosome (LysoTracker) and MVB (LBPA) 
markers demonstrate that centrosome amplification leads to significantly reduced 
lysosome-MVB fusion in the cells. Additionally, it was shown that quenching ROS (+NAC) 
in cells with extra centrosomes prevented this decrease in lysosome-MVB fusion. Taken 
together, our results suggest that oxidative stress in cells with supernumerary 
centrosomes mediates lysosome dysfunction, subsequently impairing MVB-lysosome 
fusion and resulting in the increased secretion of  sEVs.  
The exact mechanisms behind centrosome amplification-associated ROS-induced 
lysosome dysfunction remain elusive. Currently, our results cannot distinguish whether 
increases in cellular ROS affect lysosome biogenesis, or lysosomes functionality. Current 
literature indicates that high cellular ROS can lead to LMP, resulting in lysosome 
dysfunction (reviewed by Aits and Jaattela, 2013). Our results demonstrate that 
increased cellular ROS depletes lysosomal protease activity and decreases the number 
of acidic, and therefore, functional lysosomes. Thus, centrosome amplification-induced 
increases in ROS may cause lysosome dysfunction through deacidification of the 
lysosomal lumen. To confirm this, we plan to quantify total lysosome number in each 
cell using additional markers for lysosomes that are not dependent on an acidic pH, such 
as LAMP1. Comparison between total lysosome number and acidic lysosome number 
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should give an indication of whether centrosome amplification-associated increases in 
cellular ROS cause lysosome dysfunction/deacidification or if lysosome biogenesis is 
affected.  
It is important to note that the complexity of the endocytic pathways within a cell make 
the identification of specific endosomes very difficult and most markers will identify 
multiple endosomes. For example,  whilst LysoTracker has a high affinity for lysosomes, 
due to their acidic nature, it is also possible that other acidic organelles will be identified 
using this fluorescent probe. Therefore, it is possible that some lysosomes and lysosome 
co-localisation events have been over-estimated. Moreover, the MVB marker LBPA has 
been shown to be present in late endosomes as well as multivesicular bodies, thus it is 
not possible to distinguish which endosomal type is being identified in our cells. It is also 
possible that LBPA+ve MVBs only account for only a subset of the total MVBs present 
within a cell, which may also account for the differences in MVB number we observed 
upon Bafilomycin A1 treatment. It is possible that whilst Bafilomycin A1 results in the 
increased presence of LBPA+ve MVBs, centrosome amplification may affect other subsets 
of MVBs. Thus, analysis with additional MVB markers may reveal previously undetected 
changes in MVB number or size. Additionally, to overcome the limitations of endosomal 
markers, we plan to analyse changes in lysosomes, MVBs and lysosome-MVB fusion 
events in PDAC cells using electron microscopy to visually identify the different 
endosomal types. Furthermore, as analysis of lysosomes, MVBs and lysosome-MVB co-
localisation was performed on z-stack projection images, it is possible that endosomes 
from different plans will project together. Thus, it is possible that the number of 
lysosomes and MVBs have been underestimated and co-localisation events have been 
over estimated. However, these inaccuracies are predicted to be infrequent and 
consistent between treatments. 
Whilst our results to date provide evidence to support our hypothesis, it is possible that  
this mechanism only accounts in part for the increase in sEV secretion observed in cells 
with extra centrosomes. Endosomes, including MVBs are trafficked along microtubules 
within the cell to reach their destination. Interestingly, increased microtubule 
nucleation has been observed in cells with supernumerary centrosomes (Godinho et al., 
2014). It is therefore possible that cells with extra centrosome do have elevated 
numbers of MVBs but they are trafficked for secretion faster than in cells with normal 
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centrosome number and so numerical differences are not observed. We therefore plan 
to investigate the effect of centrosome amplification-induced microtubule nucleation 
on exosome secretion in PDAC cells. To do this, PaTu-S.PLK4 cells induced to have 
centrosome amplification will be treated with siRNA targeted against the centrosomal 
protein CEP192. Depletion of this centrosomal protein has previously been shown to 
revert the level of microtubule nucleation back to that of normal cells without extra 
centrosomes (Godinho et al., 2014). Extracellular vesicles will be harvested from cells 
with extra centrosomes following treatment with siRNA (siCEP192) and the number of 
secreted EVs will be quantified to determine if increased microtubule nucleation 
promotes increased sEV secretion. If microtubule nucleation is found to affect sEV 
secretion, we will analyse the effects of ROS on microtubule nucleation in cells with extra 
centrosomes. Recent literature has shown that high cellular ROS can lead to changes in 
the post-translational modification (PTM) of microtubules including detyrosination (Kerr 
et al., 2015). Interestingly, detyrosination of microtubules has been shown to favour 
microtubule plus end directed transport via kinesin-1 (Janke and Chloë Bulinski, 2011). 
Thus, ROS-linked changes in microtubule PTMs may facilitate MVB trafficking to the 
plasma membrane, potentially resulting in increased sEV secretion. To test this, we plan 
to quantify the levels of microtubule detyrosination via immunofluorescence staining 
and microscopy in PaTu-S.PLK4 cells under the following conditions: i) untreated, ii) + 
DOX, iii) +DOX +NAC and iv) + H2O2. If detyrosination is observed in cells with extra 
centrosomes, it may be possible to analyse the effects on sEV secretion. To do this, levels 
of detyrosination may be reduced in cells with extra centrosomes using Parthenolide, 
an inhibitor of the tubulin carboxypeptidase (Chen et al., 2018), and sEV secretion 
quantified.   
In conclusion, whilst further work is necessary to determine the exact mechanism of 
action, our results suggest that centrosome amplification-induced changes in cellular 
ROS causes reduced lysosome functionality and results in increased sEVs secretion.  
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5.1 Extracellular vesicles secreted by PDAC cells are naturally taken 
up by recipient cells  
Our results thus far have demonstrated that cells with supernumerary centrosomes 
secrete more sEVs. Since cancer-derived sEVs are known to contribute to tumour 
progression and metastasis (Tai et al., 2018; Tung et al., 2019; Wortzel et al., 2019), and 
centrosome amplification has recently been shown to play an active role in 
tumourigenesis (Coelho et al., 2015; Serçin et al., 2015; Levine et al., 2017), we 
hypothesised that sEVs secreted by cells with extra centrosomes may have pro-
tumourigenic properties. We therefore decided to investigate functional roles for these 
vesicles in tumourigenesis. In order to do this, we analysed cellular changes in response 
to treatment with sEVs from cells with and without the induction of centrosome 
amplification. 
Importantly, to elicit biological changes in recipient cells, sEV cargo must be transferred 
to the target cell. Therefore, we first had to determine if sEVs secreted by PDAC cells 
could be naturally taken up by recipient cells to facilitate transfer of their biological 
cargo. As cancer- sEVs have been shown to affect the behaviour of both cancer cells and 
fibroblast/stellate cells, we initially investigated the ability of both the PDAC cell line 
PaTu-T and the pancreatic stellate cell (PSC) line PS1 to engulf sEVs secreted by cancer 
cells. To do this we isolated pancreatic cancer sEVs from the conditioned  media of  PaTu-
S cells using the previously described ultracentrifugation method (Section 2.4) with one 
modification: prior to the final PBS wash step, the isolated sEVs were fluorescently 
labelled by incubation with the lipid dye BODIPY for 5 minutes. The sEVs were then re-
suspended in 31.5 mls of PBS to dilute out any unbound dye and the final 100,000 x g 
ultracentrifugation step was performed. The isolated fluorescent vesicles were then 
added to the growth media of the recipient cells. Cells were incubated with fluorescent 
sEVs over a time course (data not shown) and it was determined that 3 hours of 
incubation with BODPIY labelled sEVs was optimal to visualise uptake. The cells were 
then fixed and stained with phalloidin (F-actin) and Hoescht. Spinning disk confocal z-
stack images were taken of the cells and maximum intensity projection images 
generated using image J. This revealed the presence of BODPIY labelled sEVs (green) 
inside both the cancer cells (PaTu-T) and the PSCs (PS1) as shown in Figure 5.1. The 
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presence of the BODPIY labelled sEVs inside both cell types demonstrates that sEVs from 
PaTu-S cells are naturally taken up by recipient cells. 
 
 
 
 (Figure 5.1 Cancer sEVs uptake in PaTu-T and PS1 cells. Top row, PaTu-T cells untreated (left) 
and treated with BODIPY labelled sEVs (middle = merge, right = sEVs only). Bottom row, PS1 cells 
untreated (left) and treated with BODIPY labelled sEVs (middle = merge, right = sEVs only). Cells 
stained with Phalloidin (F-actin) in red, BODIPY (sEVs) in green and Hoechst (DNA) in blue. Cells 
were fixed for 3 hours  after the addition of sEVs. Scale bar represents 10 µm.  
 
5.2. sEVs secreted by PDAC cells with supernumerary centrosomes 
significantly enhance PSC activation 
Having confirmed that PaTu-S sEVs can be transferred to recipient cells and thus have 
the potential to transfer their biological cargo to target cells, we investigated whether 
sEVs secreted by cells with and without extra centrosomes are functionally different 
from one another. Initially, we decided to investigate possible tumourigenic roles for 
these EVs in the cells of the tumour microenvironment. 
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Pancreatic cancer is characterised by the presence of a dense desmoplastic stroma that 
consists of numerous extracellular matrix (ECM) proteins, and stromal cells including 
cancer associated fibroblasts (CAFs) and pancreatic stellate cells (PSCs) (Erkan, 
Hausmann, et al., 2012). In recent years, the desmoplastic stromal reaction/ fibrosis that 
is characteristic of PDAC has been attributed to chronic and sustained activation of PSCs 
during tumour progression (Erkan, Adler, et al., 2012). Additionally, once activated, the 
PSCs promote fibrosis and facilitate tumour growth progression through extensive 
bidirectional interplay between the PSCs and PDAC cells (Apte et al., 2004; Bachem et 
al., 2005; Rosa F Hwang et al., 2008; Vonlaufen et al., 2008; Xu et al., 2010). Notably, it 
has been demonstrated, that during tumourigenesis, PSCs can become activated in 
response to paracrine signalling from neighbouring cancer cells (Apte et al., 1999; Mews 
et al., 2002; Gao and Brigstock, 2005; Kordes et al., 2005; Vonlaufen et al., 2010). 
Furthermore, recent studies have identified a role for cancer-derived sEVs (e.g. 
exosomes) in the activation of fibroblasts and pancreatic stellate cells (Webber et al., 
2010a; Masamune et al., 2018).  We therefore, decided to investigate changes in PSC 
activation in response to treatment with sEVs derived from cells with and without the 
induction of centrosome amplification. 
 
5.2.1. Design of EV-mediated PSC activation experiments 
To analyse differences in the activating capacity of EVs from cells with and without extra 
centrosomes the following experimental procedure was used: PaTu-S.PLK4 cells were 
plated in T175 cell culture flasks and either left untreated or treated with DOX (to induce 
centrosome amplification) for 48 hours. Cells were then washed in PBS before EV-
depleted growth medium was added to each flask. 48 hours later, the conditioned 
medium was harvested and EVs were isolated by serial ultracentrifugation as previously 
described (section 2.4). As we have previously shown that cells with extra centrosomes 
secrete more EVs, EV quantities were normalised between conditions, either by EV 
protein or EV number. Equal amounts (protein or number) of EVs from cells with (+ DOX) 
and without (- DOX) induction of centrosome amplification were then added to PS1 cells. 
If required, a second dose of the EVs was added 48 hours after the first. A schematic of 
the experimental procedure is detailed in Figure 5.2.1 A. In addition to EV treatments, 
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two control conditions were also included with each experiment:  a negative control in 
which no treatment was issued to the PS1 cells to ensure basal activation levels 
remained low and a positive control in which TGF-β was used to strongly activate the 
PS1 cells to ensure the stellate cells were sensitive to activation stimuli.  
Activated PSCs are characterised by an increase in expression and change in the 
organisation of the cytoskeletal protein α-SMA. Upon activation α-SMA shifts from 
diffuse throughout the cell to organised stress fibres, therefore, to analyse PSC 
activation, we performed immunofluorescent staining of α-SMA on PSCs 72 hours after 
the addition of EVs and quantified stress fibre formation per cell. Activation was 
stratified into three categories; i) basal activation, where α-SMA is predominantly 
diffuse throughout the cell ii) activation, where thin α-SMA stress fibres have formed 
but some α-SMA still remains diffuse throughout the cell and iii) strong activation, where 
α-SMA is no longer diffuse and full α-SMA fibres have formed throughout the cell. 
Representative images of these three activation categories are shown in Figure 5.2.1 B.  
Activation was quantified per cell, based on α-SMA fibre formation in roughly 150 cells 
per condition. 
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Figure 5.2.1 Experimental design for analysing EV-mediated PSC activation. A) Schematic of 
the experimental procedure. EVs were harvested from donor cells (PaTu-S.PLK4) with (+ DOX) 
or without (- DOX) centrosome amplification. EVs were normalised either to EV protein or EV 
number. Equal amounts of the isolated EVs was added to the growth media of PS1 cells. 72 hours 
later PS1 activation was quantified based on α-SMA fibre formation. D= donor cells B) 
Representative confocal images of PS1 activation levels based on α-SMA organisation showing 
low activation, activation and strong activation. α-SMA is depicted in green, DNA in blue. Scale 
bar represents 20 µm. 
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5.2.2. Optimising experimental conditions for analysing EV-mediated PSC 
activation 
Whilst EVs have been used in functional assays for the past few decades, no standard 
protocols are currently in place specifically for sEVs. Initial experiments were therefore 
performed using different quantities and doses of sEV exosomes to optimise the 
experimental conditions. EV quantities were used at 5-30 µg, similar to that used in a 
selection of recent publications (Costa-Silva et al., 2015; Wei et al., 2017).  
Prior to the addition of EVs to PS1 cells, a number of important controls were performed 
and used throughout subsequent experiments (see Figure 5.2.2.1 A). Here we show that 
basal levels of PS1 activation remain consistently at around 5% (ctr; see Figure 5.2.2.1) 
and we demonstrate that the PS1 cells have a high capacity for activation in response to 
recombinant TGF-β, our positive control, which resulted in activation in ~98-99% of cells. 
Furthermore, we tested the activating capacity of the conditioned media harvested from 
PaTu-S.PLK4 cells with (+) and without (-) DOX both before and after EV removal by 
ultracentrifugation (After UC; see Figure 5.2.2.1). To do this, conditioned medium was 
added directly onto PS1 cells for 72 hours and PS1 activation was quantified (see Figure 
5.2.2.1). This analysis showed that conditioned media alone was not sufficient to induce 
PS1 activation above basal levels.  
 To analyse the effect of concentrated EVs on PS1 activation, LEVs and SEVs were 
harvested from PaTu-S.PLK4 cells as described in section 5.2.1 and the protein content 
of each sample quantified using the BioRad protein assay. EV protein concentration was 
then normalised between conditions and incremental concentrations of EVs were added 
to the stellate cells, ranging from 5 µg -30 µg (see Figure 5.2.2.1 A). As LEV harvests 
always resulted in a much lower yield than sEVs harvests, LEVs were used at 20 µg only. 
From these initial experiments, it was found that in all cases, stellate cells incubated with 
EVs from + DOX cells always resulted in increased total PS1 activation (strong activation 
and activation combined) as determined by α-SMA fibre formation, indicating for the 
first time that EVs from cells with supernumerary centrosomes can enhance PSC 
activation. Furthermore, in most cases, a clear increase was also observed in % strong 
activation after treatment with EVs from + DOX cells. As conditioned media alone is not 
sufficient to elicit PS1 activation, this result indicates that a higher concentration of EVs 
 Chapter 5. Results III 
136 
 
is necessary to induce PSC activation and indicates that it is the EVs and not other 
secreted factors that are causing PSC activation. These initial experiments also 
demonstrate that increasing the sEV protein concentration from 5 µg to 10 µg more than 
doubled the % total PS1 activation, where activation with SEVs from - DOX cells rose 
from 9.7 - 21.1% and activation with SEVs from +DOX cells rose from 16.2 - 38.3%. 
Interestingly, the % of PS1 activation after treatment with 20 µg and 30 µg of sEVs, 
resulted in only modest increases in activation (~5-6%) compared to those achieved with 
10 µg for both types of sEV. As TGF- β has the capacity to strongly activate almost all the 
PS1 cells present in the sample (~95%), this result may indicate that a threshold exists 
for PS1 activation by sEVs. Whether increased incubation time or further increases in sEV 
protein could overcome this remains to be tested. These experiments also revealed that 
treatment of PS1 cells with 20 µg of LEVs resulted in very minor levels of PS1 activation, 
<9% with LEVs from + DOX cells and < 5% with LEVs from - DOX cells. Thus, as sEVs are 
secreted more and LEVs do not activate PSCs, sEVs became the focus of the subsequent 
work.  
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Figure 5.2.2.1 Initial PS1 activation tests. A) Quantification of % PS1 activation as determined 
by α-SMA fibre formation in control conditions. PS1 cells were treated as follows for 72 hours: 
i) untreated (ctr), ii) TGF-β, iii) CM  from donor cells - DOX, iv) CM  from donor cells + DOX, v) CM 
from donor cells – DOX after UC, vi) CM from donor cells + DOX after UC. Error bars represent 
mean ± standard deviation, N=3. Data analysed using one-way ANOVA with Tukey’s post hoc 
test (**** p<0.0001). Significant difference to the control is highlighted with ****. B) 
Quantification of % PS1 activation as determined by α-SMA fibre formation after 72 hour 
treatment with 5- 30 µg of sEVs and 20 µg of LEVs from donor cells – or + DOX. N=1. 
Activation levels stratified into two categories: strong activation and activation.  Ctr=control, 
CM= conditioned media, UC = ultracentrifugation, DOX=doxycycline hyclate. D = donor cells. 
Donor cells were PaTu-S.PLK4.  
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To determine if the % PS1 activation achieved with 10 µg of sEV protein could be 
improved, similar experiments were set up with an additional sEV dosing step. Here, two 
doses of sEVs at either 10 µg or 20 µg were added to the PS1 cells, the first at 0 hours 
and the second at 48 hours. As can be seen in Figure 5.2.2.2 A, a clear increase in PS1 
activation can be seen upon treatment with 2 doses of sEVs from + DOX cells compared 
to 2 doses of sEVs from – DOX cells both at 10 µg and 20 µg of sEV protein. The addition 
of a second dose of sEVs resulted in around 10% higher PS1 activation in cells treated 
with  sEVs from +DOX cells compared to an increase of merely 4% in sEVs from – DOX 
cells. All subsequent experiments were therefore performed using a double dose of sEVs. 
Whilst two doses of sEVs at 20 µg resulted in visibly higher levels of PSC activation, sEV 
preparation is a limiting step. Consequently, for practical reasons, two doses of sEVs at 
10 µg were used for future experiments.  
While normalising sEVs to protein content has long been the norm for functional assays, 
it is conceivable that the induction of centrosome amplification may alter the protein 
content of the sEVs. As our initial results, (outlined in Chapter 3), show that centrosome 
amplification induces sEV secretion, it was decided that normalising to sEV number may 
be more prudent. Using ImageStream to analyse EV number and BioRad protein assay 
to quantify protein, it was determined that there were roughly 20 million sEVs present 
in 10 µg of the PaTu-S.PLK4 – DOX sEVs. We therefore investigated whether two doses 
of 20 million sEVs would elicit similar results to those observed with 10 µg of sEVs 
protein. As can be seen in Figure 5.2.2.2 B, when sEVs were normalised to number, a 
clear increase in % total PS1 activation (similar to when normalising to EV protein) could 
still be observed in PS1 cells treated with sEVs from + DOX cells compared to sEVs from - 
DOX cells. Notably, however, PSC activation post treatment with 20 million sEVs resulted 
in lower levels of PSC activation compared to treatment with 10 µg of EV protein. It is 
therefore likely that 20 million sEVs does not equate exactly to 10 µg of EV protein. 
However, as 20 million sEVs still resulted in a clear increase in PSC activation, henceforth, 
all further PS1 activation experiments were performed using two doses of 20 million 
sEVs.  
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Figure 5.2.2.2 PS1 activation following 2 doses of sEVs normalised to protein or sEVs number. 
A) Quantification of % PS1 activation as determined by α-SMA fibre formation after 72 hour 
treatment with 2 doses of sEVs from donor cells – /+ DOX normalised to sEV protein (10 µg or 20 
µg) N=2. B) Quantification of % PS1 activation as determined by α-SMA fibre formation after 72 
hour treatment with 2 doses of sEVs from donor cells – /+ DOX normalised to sEV number (20 
million sEVs). N=1.  
Activation levels stratified into two categories: strong activation and activation. Error bars 
represent mean ± standard deviation. DOX=doxycycline hyclate. D = donor cells. Donor cells 
were PaTu-S.PLK4.  
 
5.2.3. sEVs secreted by cells with supernumerary centrosomes significantly 
enhance PS1 cell activation  
Using the experimental conditions outlined in section 5.2.2, we investigated the ability 
of sEVs secreted by PATu-S.PLK4 cells with (+DOX) and without (-DOX) the induction of 
centrosome amplification to activate PS1 cells. Analysis revealed that sEVs secreted  by 
cells with supernumerary centrosomes significantly enhanced PS1 activation (Figure 
5.2.3). An average of 30% total PS1 activation (strong activation and activation) was 
observed in samples treated with sEVs from + DOX donor cells compared to 6.8% total 
PS1 activation in samples treated  with sEVs from - DOX donor cells. In fact, significant 
increases could be observed in strong activation alone, where strong activation reached 
~ 13.9% in PS1 cells treated with sEVs from + DOX donor cells compared to 1.6% in PS1 
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cells treated with sEVs from - DOX donor cells, indicating that sEVs secreted  by cells with 
extra centrosomes have a much stronger effect on the activation of PSCs.  
Taken together, the work presented here demonstrates for the first time that sEVs 
derived from cells with amplified centrosomes elicit a stronger activation of PSCs 
compared to sEVs from cells with normal centrosome number. As sEV number was 
normalised between conditions, our results suggest that sEVs secreted by cells with extra 
centrosomes may have an altered biological cargo. This in turn suggests that centrosome 
amplification may not only induce overall secretion of sEVs but also induce secretion of 
a specific subset of sEVs which have enhanced PSC activating potential. Furthermore, 
these results have since been replicated by another member of the Godihno laboratory  
using sEVs secreted by the HPAF-II.PLK4 cell line, providing further evidence to support 
the findings presented here.  
 
Figure 5.2.3 sEVs from PDAC cells with supernumerary centrosomes significantly enhance PS1 
cell activation. A) Representative confocal images of α-SMA organisation in PS1 cells 72 hours 
post treatment with i) untreated control (ctr)  ii) 20 million sEVs (2 doses) from – DOX donor cells 
iii) 20 million sEVs (2 doses) from + DOX donor cells. α-SMA is depicted in green, DNA in blue. 
Scale bar represents 20 µm. B) Quantification of % PS1 activation as determined by α-SMA fibre 
formation in PS1 cells treated as described in (A). Activation levels stratified into two categories: 
strong activation and activation. Error bars represent mean ± standard deviation, N=3. Data 
analysed using one-way ANOVA with Tukey’s post hoc test (*** p<0.001).  
DOX=doxycycline hyclate. D = donor cells. Donor cells were PaTu-S.PLK4. 
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5.2.4. Centrosome amplification-associated ROS is required for PSC 
activation by sEVs from cells with amplified centrosomes  
Our results demonstrate that sEVs secreted by cells with supernumerary centrosomes 
have enhanced PSC activating capabilities, suggesting that centrosome amplification 
induces not only an increase in total sEV secretion but also in the secretion of a subset 
of sEVs. Since our previous work (Chapter 4) found centrosome amplification-linked ROS 
to be responsible for the increased secretion of sEVs by cells with extra centrosomes, we 
hypothesised that these changes in cellular ROS may also play a role in the secretion of 
sEVs that harbour the heightened PSC activation capacity. To test this, we analysed the 
PS1 activating capacity of sEVs secreted by PaTu-S.PLK4 donor cells that had been 
treated as follows: i) – DOX, ii) + DOX and iii) +DOX +NAC. Interestingly, whilst sEVs 
derived from + DOX cells increased PS1 activation as expected, quenching centrosome 
amplification–associated ROS with NAC in these cells prevented the secreted sEVs from 
eliciting the same increase in PS1 activation. Whilst a third replicate is still required for 
this experiment, these results indicate that centrosome amplification-associated ROS is 
likely responsible for the increased secretion of a subset of sEVs which contain an altered 
biological cargo that confers a heightened capacity for sEV-mediated PSC activation. The 
experiments performed here, however, cannot determine whether the observed effect 
is specific to increased cellular ROS alone, or specific to centrosome amplification- 
associated ROS. It would therefore be interesting to perform the same analysis using 
sEVs  harvested from cells where ROS is induced independently of centrosome 
amplification with H2O2. These additional experiments would provide a clearer view on 
whether this result is specific to centrosome amplification-associated ROS or if it is a 
more global mechanism relating to generalised increases in cellular ROS.  
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Figure 5.2.4 Centrosome amplification-associated ROS is required for PSC activation by sEVs 
from cells with amplified centrosomes. A) Representative confocal images of α-SMA 
organisation in PS1 cells 72 hours post treatment with: i) 20 million sEVs (2 doses) from – DOX 
donor cells ii) 20 million sEVs (2 doses) from + DOX donor cells, iii) 20 million sEVs (2 doses) from 
donor cells treated with DOX and NAC. α-SMA is depicted in green, DNA in blue. Scale bar 
represents 20 µm. B) Quantification of % PS1 activation as determined by α-SMA fibre formation 
in PS1 cells treated as described in A. Activation levels stratified into two categories: strong 
activation and activation. Error bars represent mean ± standard deviation,  N=2.  
DOX=doxycycline hyclate, NAC = N-acetyl cysteine, D = donor cells. Donor cells were PaTu-
S.PLK4. 
 
5.3 sEVs capable of activating PSCs elute specifically in Size 
Exclusion Chromatography fraction 8.  
Whilst classical ultracentrifugation (UC) is still one of the most widely used methods for 
EV isolation it has a number of drawbacks. Crucially, the purity of the isolated vesicles 
has been questioned and a number of studies have revealed EVs isolated by UC to co-
pellet with larger contaminating proteins. Thus, we cannot be certain if the PSC 
activation we observed with sEVs pelleted by UC is truly due to the EVs themselves or 
contaminating proteins/ other aggregates. To address this, the PSC experiments were 
performed using vesicles prepared with an additional EV purification step, whereby EVs 
isolated by UC were then subjected to size exclusion chromatography (SEC). This process 
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involves passing the UC sample through a column containing porous resin particles. Due 
to their size, EVs themselves pass through the column largely unimpeded, however, 
impurities including proteins, protein complexes and other small molecules enter the 
pores of the resin particles. This impedes their passing through the column and results 
in them eluting in much later fractions (see schematic in Figure 5.3.1 A). SEC columns 
such as the qEV original izon science SEC columns used for these experiments, have 
previously been shown to yield high purity EVs (Böing et al., 2014; Muller et al., 2014; 
Welton et al., 2015; Benedikter et al., 2017). To perform SEC, 500 µl of sEVs isolated by 
UC were applied to the column. Once the sample had passed into the top filter, the 
column was topped up with PBS buffer that had been twice filtered using 0.22 µm 
syringe filters. Immediately after the sample had passed into the column, 500 µl 
fractions were taken. Fractions 1-12 were collected, (EVs are expected to elute in 
fractions 7-10 using this column), with contaminating proteins eluting in fractions 11 
onwards (as described in izon science technical note). The number of sEVs present in 
each fraction was then quantified using ImageStream (Figure 5.3.1 B). As expected, sEVs 
were found to elute in fractions 7-10, with the majority eluting in fractions 8 and 9. 
Whilst some vesicles were observed in fraction 7 and 10, the yield is very low. The 
primary eluting fractions (8 and 9) did not change with sample type i.e sEVs isolated from 
donor cells treated with and without DOX eluted in similar fractions. It is important to 
note that whilst purity of these sEVs is improved, the yield is clearly decreased. It was 
found that only around 55-60% of the sEVs present in the UC samples were recovered in 
the SEC fractions (sum fractions 7-10). Additionally, these fractions are significantly 
diluted as they are split over 4 x 500 µl fractions. Therefore, to obtain vesicles after SEC 
at a high enough concentration to perform PSC activation experiments, a much larger 
initial UC harvest of EVs is required. To perform these experiments, we therefore harvest 
EVs from the conditioned media of at least 12 x T175 flasks per condition.  
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Figure 5.3.1 sEV purification and separation by size exclusion chromatography. A) Schematic 
diagram depicting size exclusion chromatography. Larger particles including EVs pass largely 
unimpeded through the column, whereas small molecules including contaminating proteins 
enter the pores of the resin beads, impeding their progress and resulting in their elution in much 
later fractions. B) Quantification of sEVs isolated from donor cells  treated without (-) and with 
(+) DOX, after UC and then subsequently after SEC as measured by ImageStream® Mark II 
Imaging Flow Cytometer. Error bars represent mean ± standard deviation, N=3. 
DOX=doxycycline hyclate, UC=ultracentrifugation, SEC=size exclusion chromatography. Donor 
cells were PaTu-S.PLK4. 
 
In addition to vesicle concentration, the size distribution of sEVs present in each sample 
was also quantified (Figure 5.3.2). As before, size was measured using NanoSight particle 
tracking analysis (NTA) with a NanoSight NS300. Analysis revealed that sEVs isolated by 
UC only, from PaTu-S.PLK4 cells without centrosome amplification had a mean particle 
size of 96 nm. Interestingly, upon induction of centrosome amplification in these cells, 
the mean particle sEV size increased slightly to 101 nm. Furthermore, NTA analysis 
revealed slight differences in the mean sEVs populations in the two main SEC fractions 
(fraction 8 and fraction 9). It was found that sEVs from – DOX cells that eluted in SEC 
fraction 8 had a mean size of 97 nm whereas those that eluted in fraction 9 had a mean 
size of 95 nm. Similarly, sEVs isolated from + DOX cells, that eluted in SEC fraction 8 had 
a mean size of 104 nm compared to a mean size of 101 nm in SEC fraction 9. Therefore, 
in addition to suggesting that sEVs secreted by cells with extra centrosomes may be 
slightly larger than those secreted by cells with normal centrosome number, this result 
also indicates that the vesicles present in each SEC fraction may differ in size. 
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Importantly, the observed particle sizes all fall within the correct size range to be 
considered exosomes. However, whilst size alone is not sufficient to distinguish 
exosomes from MVs or other EV types, this result indicates that there is likely an 
enrichment of exosomes in the isolated sEV pellets. Due to the small volume of vesicles 
collected in Fraction 7, the size of these vesicles could not be analysed. 
 
 
Figure 5.3.2 Particle size distribution quantification of UC and SEC samples. A) Size distribution 
curves determined by Nanosight NS300 (Nano-particle tracking analysis) of sEVs isolated from 
donor cells  treated without (-) DOX after UC alone and post SEC. The primary EV elution 
fractions, SEC fraction 8 and SEC fraction 9 were analysed.  Mean particle size was determined 
as 96 nm for UC isolates (red distribution), 97 nm for SEC 8 isolates (green distribution) and 95 
nm for SEC 9 isolates (blue distribution). B) Size distribution curves determined by Nanosight 
NS300 (Nano-particle tracking analysis) of sEVs isolated from donor cells  treated with (+) DOX 
after UC alone and post SEC. The primary EV elution fractions, SEC fraction 8 and SEC fraction 9 
were analysed.  Mean particle size was determined as 101 nm for UC isolates (red distribution), 
104 nm for SEC 8 isolates (green distribution) and 101 nm for SEC 9 isolates (blue distribution). 
Error bars (shown in red for UC isolates, green for SEC 8 isolates and blue for SEC 9 isolates) 
indicate standard error of the mean. DOX=doxycycline hyclate, UC=ultracentrifugation, SEC=size 
exclusion chromatography. Donor cells were PaTu-S.PLK4. 
 
The sEVs isolated by SEC were then used for subsequent PS1 activation experiments 
(Figure 5.3.3). Additionally, where possible sEVs that eluted in SEC fraction 7 were also 
used, however low yields resulted in only one replicate to be generated with these sEVs.  
Analysis revealed that sEVs derived from cells without the induction of centrosome 
amplification (- DOX) induced only low levels of total activation ( <10%) regardless of SEC 
fraction. As expected sEVs isolated from cells with extra centrosomes (+ DOX) were 
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found to activate PS1 cells as previously demonstrated. Interestingly however, the sEVs 
that retain these activating capabilities were found to elute specifically in SEC fraction 
8, where these vesicles resulted in an average of ~36% PS1 activation. Furthermore, sEVs 
from + DOX donor cells that eluted in this fraction were also found to significantly induce 
strong activation of PSCs compared to controls and all other SEC fractions. 
In conclusion, after the removal of contaminating small molecules by SEC, these results 
provide strong evidence to support the hypothesis that the sEVs in the samples are 
responsible for the observed increases in PS1 activation. Moreover, these experiments 
revealed that the sEVs from + DOX cells that confer PS1 activating capabilities specifically 
elute in one SEC fraction (fraction 8). This result  suggests that cells with centrosome 
amplification may secrete a specific subset of sEVs that have heightened PSC activating 
abilities.  
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Figure 5.3.3 sEVs from PDAC cells with supernumerary centrosomes that elute in SEC fraction 
8 significantly enhance PS1 cell activation. A) Representative confocal images of α-SMA 
organisation in PS1 cells 72 hours post treatment with sEVs derived from – DOX or + DOX donor 
cells that have eluted in SEC fractions 7-9. PS1 cells were treated with 2 doses of 20 million sEVs 
per condition. α-SMA is depicted in green, DNA in blue. Scale bar represents 20 µm. B) 
Quantification of % PS1 activation as determined by α-SMA fibre formation in PS1 cells treated 
as described in A. Activation levels stratified into two categories: strong activation and 
activation. For SEC fraction 8 and 9 N=3, for SEC fraction 7 N=1. Error bars represent mean ± 
standard deviation. Data analysed using one-way ANOVA with Tukey’s post hoc test (**** 
p<0.0001).  
DOX=doxycycline hyclate, SEC=size exclusion chromatography, D = donor cells. Donor cells were 
PaTu-S.PLK4. 
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5.4. Proteomic analysis of sEVs with stable isotope labelling of 
amino acids in culture 
5.4.1 sEVs sample preparation for SILAC-based proteomic analysis 
The difference in PSC activating potential between exosomes from cells with and 
without supernumerary centrosomes suggests that they harbour a different  biological 
cargo. We therefore planned to analyse changes in the cargoes of these vesicles, in the 
hopes of identifying the factor/s contributing to PSC activation. Whilst EVs contain a 
number of different biological cargos, including proteins, RNA, DNA and lipid rafts, a 
number of studies looking at the EV-mediated activation of PSCs had previously 
identified EV proteins  such as TGF-β  to have key roles in this process (Webber et al., 
2010b; Charrier et al., 2014; Masamune et al., 2018). We therefore began our analysis 
on the biological cargo of the isolated sEVs by performing proteomic analysis. To analyse 
protein changes in sEVs upon the induction of centrosome amplification, we used a 
stable isotope labelling by amino acids in cell culture (SILAC) based proteomic technique 
in collaboration with Faraz Mardakheh at the BCI. SILAC is a powerful method of 
quantitative proteomics that involves metabolic labelling of the samples with normal, 
medium and heavy labelled amino acids prior to mass spectrometry (MS). Typically, 
SILAC labelling involves labelling of lysine and arginine residues with normal/light, heavy 
[15N213C6-lysine (Lys8) and 15N413C6-arginine (Arg10)] or medium [2H4-lysine (Lys4) 
and 13C6-arginine (Arg6)] labels, which in combination with trypsin digest, ensures that 
all peptides in the sample will retain a label. Label incorporation followed by Liquid 
Chromatography with tandem mass spectrometry (LC-MS-MS) enables the 
identification and quantitation of the proteins present in each sample. As this method 
relies on efficient incorporation of the labels, cells are grown in media supplement with 
dialysed serum. This ensures that the amino acids added to the cell culture are the 
exclusive source of amino acids. Proline is also added to the medium to prevent 
metabolic conversion of the labelled arginine to proline. Whilst other proteomic 
methods require labelling post processing, SILAC-based differential labelling of cells 
allows samples to be combined early on during sample preparation. Thus, SILAC samples 
can be processed together, eliminating variability that could result from separate 
sample preparations. Additionally, the samples can be analysed together by LC-MS/MS, 
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enabling the relative peaks of the differentially labelled proteins to be accurately 
quantified in relation to each other and a ratio of the two labels to be generated.  
 SILAC based proteomic analysis of cells is fairly straightforward, light and heavy labels 
are usually sufficient. SILAC proteomic analysis of EVs however proved more complex. 
As EVs contain a relatively small number of proteins compared to total cell lysates, 
contaminating proteins can become an issue. Therefore, as EVs are isolated from the 
conditioned growth medium, it is possible that media proteins will be present in the 
samples and may cloud the analysis. As naturally occurring amino acids, such as those 
present in the  media are labelled light, proteomic analysis of exosomes was performed 
using medium and heavy amino acid labels. This enabled any light labelled amino acids 
present in the samples to be disregarded as media/ other contaminants. 
Prior to vesicle harvest for SILAC based proteomic analysis, PaTu-S.PLK4 cells were 
grown in SILAC DMEM supplemented with 10% dialysed FBS (that had been 
ultracentrifuged at 100,000 x g for 18 hours to deplete EVs), 1% penicillin/streptomycin 
and heavy or medium labelled amino acids for 2 weeks. The efficiency of heavy and 
medium label incorporation into cells was then analysed. To do this, a small aliquot of 
cells was lysed and digested as described in section 2.8 and analysed by Mass spec. 
MaxQuant analysis performed by our collaborator Faraz Mardakheh identified over 99% 
label incorporation in both cell lines. Once label incorporation had been confirmed, cells 
were plated for sEV harvest. 40 x T175 flask containing heavy labelled cells were induced 
to amplify centrosomes (+DOX) and 40 x T175 flasks containing medium labelled cells 
were left untreated (-DOX). A schematic representation of the experimental workflow is 
depicted in Figure 5.4.1.1. Importantly, the experiment was replicated twice, the second 
time with reverse labelling i.e where medium labelled cells were induced with DOX and 
the heavy labelled cells left untreated. Reverse labelling was used to eliminate potential 
protein changes that result from the differentially labelled amino acids.  
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Figure 5.4.1.1 Schematic representation of SILAC proteomic analysis protocol. PaTu-S.PLK4 
cells were grown in SILAC DMEM supplemented with heavy or medium labelled amino acids. 
Conditioned medium was harvested from untreated (- DOX) medium labelled cells and 
centrosome amplification induced (+DOX) heavy labelled cells. CM was harvested from all cells 
and pooled prior to sEV isolation by UC and purification by SEC. SEC fractions 7, 8 and 9 were 
then prepared from mass spec analysis and mass spec was performed by our collaborator Faraz 
Mardakheh. 
DOX=doxycycline hyclate, UC=ultracentrifugation, SEC=size exclusion chromatography, CM = 
conditioned media. 
 
To ensure that the vesicles harvested were suitable for MS analysis, the conditioned 
media from two flasks per condition were collected and the sEVs were isolated by 
ultracentrifugation for use in PS1 activation experiments. Analysis revealed that sEVs 
secreted by + DOX cells for both the forward and reverse experiments were able to 
activate PS1 cells as expected (see Figure 5.4.1.2). Therefore, the sEVs were deemed 
suitable for mass spec analysis. The conditioned media from the remaining flasks was 
then harvested to be processed for MS. Henceforth the conditioned media from the 
heavy labelled and medium labelled cells was pooled together and the samples were 
processed as one, eliminating potential variations associated with separate sample 
preparation. sEVs were then isolated from the pooled conditioned media by 
ultracentrifugation and then purified further by SEC.  
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Figure 5.4.1.2 sEVs isolated for SILAC based proteomic analysis activate PS1 cells. A) PS1 
activation after the addition of sEVs from the SILAC forward labelling experiment.  
Representative confocal images of α-SMA organisation and quantification of activation as 
determined by α-SMA fibre formation in PS1 cells 72 hours post treatment with i) 20 million sEVs 
(2 doses) from – DOX medium labelled donor cells iii) 20 million sEVs (2 doses) from + DOX heavy 
labelled donor cells. α-SMA is depicted in green, DNA in blue. Scale bar represents 20 µm. B) PS1 
activation post the addition of sEVs from the SILAC reverse labelling experiment.  Representative 
confocal images of α-SMA organisation and quantification of activation as determined by α-SMA 
fibre formation in PS1 cells 72 hours post treatment with i) 20 million sEVs (2 doses) from – DOX 
heavy labelled donor cells iii) 20 million sEVs (2 doses) from + DOX medium labelled donor cells. 
α-SMA is depicted in green, DNA in blue. Scale bar represents 20 µm. 
Activation levels stratified into two categories: strong activation and activation. N=1. 
DOX=doxycycline hyclate. D = donor cells. Donor cells were PaTu-S.PLK4. 
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The number of sEVs present in each SEC fraction for both the forward and reverse 
experiments was quantified by ImageStream (see Figure 5.4.1.3). Analysis revealed 
similar distributions of sEVs post SEC as had been previously observed. A slightly higher 
yield of sEVs was recovered, however, in the reverse labelled experiment. SEC fractions 
7, 8 and 9 were then prepared for MS analysis as described in section 2.8. MS and 
MaxQuant analysis was performed by our collaborator Faraz Mardakheh. 
 
 
Figure 5.4.1.3 Purification and separation of sEVs for proteomic analysis by size exclusion 
chromatography. A) Quantification of sEVs isolated from the SILAC forward labelling experiment 
after UC and then subsequently after SEC, as measured by ImageStream® Mark II Imaging Flow 
Cytometer N=1. B) Quantification of sEVs isolated from the SILAC reverse labelling experiment 
after UC and then subsequently after SEC, as measured by ImageStream® Mark II Imaging Flow 
Cytometer. N=1. 
UC=ultracentrifugation, SEC=size exclusion chromatography. Donor cells were PaTu-S.PLK4. 
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5.4.2 SILAC-based proteomic analysis of sEVs derived from cells with and 
without the induction of centrosome amplification 
MaxQuant analysis of the proteomic data provided a comprehensive list of all the 
proteins (heavy and medium labelled) detected in each SEC fraction. A total of 486 
proteins were detected in SEC fraction 7, 825 in SEC fraction 8 and 836 in SEC fraction 9 
(Figure 5.4.2.1 A). Of the proteins identified, 464 were found to be common to all 
fractions, including the key exosomal markers including CD81, CD9, TSG101 and ALIX,  
providing further evidence to suggest that analysed vesicles are likely to be enriched in 
exosomes. CD63, however, could not be detected in any of the 3 fractions. Interestingly, 
other  EV studies have found CD63 expression to be low or restricted in comparison to 
the other tetraspanins including CD81 and CD9 (Kowal et al., 2016b; Barranco et al., 
2019). Therefore, levels of CD63 in our samples may simply be too low for detection. 
Comparison of our sEV proteomics data with the extracellular vesicle database 
Vesiclepedia (Kalra et al., 2012) revealed that the majority of the proteins observed in 
our screen have previously been identified in other EV proteomic studies, with only 14 
emerging as specific to our data set (Figure 5.4.2.1 B). The significant overlap between 
our data set and the Vesiclepedia data set provides further evidence that our samples 
are enriched in extracellular vesicles.  
Initial analysis our SILAC screen also revealed that TGF-β was not present in any of the 
samples. Exosomal TGF-β has previously been shown to trigger fibroblast to 
myofibroblast differentiation (Webber et al., 2010b). The absence of TGF-β in our 
samples therefore indicates that PSC activation is likely achieved through an ulterior 
mechanism. Furthermore, proteins that have previously been linked to oncogenic 
transformation and tumourigenesis were also identified within the samples, including 
CEP55 and CTGF. 
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Figure 5.4.2.1 Venn diagrams comparing extracellular vesicle proteomes. A) Venn diagram 
comparing the sEV proteomes of SEC fractions 7,8 and 9. B) Venn diagram comparing the EV 
proteomes of SEC fractions 7, 8 and 9 with the Vesiclepedia database (Kalra et al., 2012).  
SEC=size exclusion chromatography.  
 
 
 
To identify the most commonly upregulated protein pathways in each fraction, 
enrichment analysis was performed by our collaborator Faraz Mardakheh using a Fishers 
exact test (see Figure 5.4.2.2). This analysis calculates an enrichment score which 
reflects the degree to which proteins associated with a specific category are 
overrepresented in the sample compared to proteins outside of the pathway. We found 
that in all three SEC fractions, the top 3 most significantly enriched categories consisted 
of vesicles, membrane-bound vesicles and exosomes. Furthermore, all three fractions 
were found to also be significantly enriched in pathways unique to exosome biogenesis 
including; ESCRT I, Recycling endosomes, endocytic vesicles and late endosomes. The 
results of this analysis therefore highlight that our samples are significantly enriched in 
protein associated with exosomes.  
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Figure 5.4.2.2 Pathway enrichment analysis of sEV proteins identified using SILAC-based 
proteomics. Bubble graphs depicting pathway enrichment per SEC fraction (7, 8 &9), where 
bubble size is indicative of the number of enriched proteins per pathway. Enrichment analysis 
was performed using a Fishers exact test. Results for SEC fraction 7 shown in green, SEC fraction 
8 in pink and SEC fraction 9 in blue. Left graphs show the top 3 most significantly enriched 
categories per fraction. Right graphs show other highly significantly enriched categories per 
fraction. SEC=size exclusion chromatography.  
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To analyse changes in the ratio of proteins present in the heavy labelled and medium 
labelled sEVs, normalisation was first performed. As samples were mixed at an early 
stage, results were auto normalised to ensure that heavy and medium intensities in each 
sample were equivalent. Subsequently, SILAC ratios of the proteins present in each 
sample were calculated. A fold change of 1.5 or above, that could be replicated in the 
forward and reverse experiments, were considered significant hits . Log2 fold change of 
heavy to medium labels, for the forward and reverse experiments were plotted on 
correlation graphs for each SEC fraction (figure 5.4.2.3). The dashed diagonal line 
indicates where identical M and H values would be plotted. The closer the proteins are 
plotted to this line, the more consistent the values are for the forward and reverse 
experiment.  Interestingly, SILAC ratios did not significantly change in any fraction and 
the fold change per protein largely remained below 1. Where fold changes above 1.5 
were observed, they were only present in one repeat and so not deemed reliable. The 
analysis of these results indicates that the induction of centrosome amplification in 
PDAC cells does not change the relative ratios of the proteins identified inside the 
secreted sEVs. Crucially however, alteration in the protein content of sEVs may not be 
restricted to changes in the ratios of proteins but also total changes in the presence or 
absence of specific protein which SILAC ratios do not reflect. Therefore, whilst analysis 
of SILAC ratios is prudent for whole cell lysates, it may miss key protein changes in EV 
proteins. We therefore also analysed the original intensity files provided by MaxQuant 
analysis to determine if total changes in protein were observed between the SILAC 
labelled samples in each condition per SEC fraction. Interestingly, this new analysis 
revealed total loss/gain of 8 new proteins in Fraction 7 (see Table 5.4.2.1) and 6 proteins 
in fraction 8 (see Table 5.4.2.2). No differences were observed in fraction 9. As fraction 
8 contains the sEVs that activate PSCs, protein changes in this fraction were considered 
our hits.  These hits were the tetraspanin CD81 which was lost in sEVs from + DOX cells 
and phosphoglucomutase 3 (PGM3), carbamoyl-phosphate synthetase 2 aspartate 
transcarbamylase and dihydroorotase (CAD), mitochondrially encoded cytochrome C 
oxidase II (MT-CO2), FAM129A (NIBAN) and coiled-coil domain containing 124 
(CCDC214) which were all gained in sEVs from + DOX cells. These findings confirmed that 
sEVs secreted by cells with extra centrosomes, do have an altered protein cargo and it is 
therefore possible that one or more of these 6 proteins may be responsible for the 
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heightened capacity of sEVs from cells with extra centrosomes to activate pancreatic 
stellate cells.  
 
Figure 5.4.2.3 Correlation graphs of sEV protein expression ratios in forward and reverse SILAC 
experiments. A) Correlation graphs plotting Log2 fold change in the ratio of heavy and medium 
labelled proteins of the forward and reverse experiments from SEC fraction 7 (green). B) 
Correlation graphs plotting Log2 fold change in the ratio of heavy and medium labelled proteins 
of the forward and reverse experiments from SEC fraction 8 (pink). C) Correlation graphs plotting 
Log2 fold change in the ratio of heavy and medium labelled proteins of the forward and reverse 
experiments from SEC fraction 9 (blue). 
Dashed diagonal line characterises where identical M and H values would lie. SEC= size exclusion 
chromatography. 
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Table 5.4.2.1 SILAC protein hits SEC fraction 7 
Gene name - DOX sEVs + DOX sEVs Peptide 
number 
KIF5B  ✓ 42 
B2M  ✓ 3 
CYBRD1  ✓ 1 
ERLIN2  ✓ 13 
SLC25A3  ✓ 14 
OCLN  ✓ 5 
ANXA3  ✓ 19 
MAPK1IP1L ✓  1 
 
Table 5.4.2.2 SILAC protein hits SEC fraction 8 
Gene name - DOX sEVs + DOX sEVs Peptide 
number 
CD81 ✓  3 
PGM3  ✓ 8 
CAD  ✓ 48 
MT-CO2  ✓ 3 
NIBAN  ✓ 9 
CCDC124 
 
 ✓ 8 
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To help narrow down which proteins may be playing a role in PSC activation we checked 
whether or not the proteins identified in SEC fraction 8 were also present in the sEVs 
isolated in fraction 7 and 9 which did not activate PSCs (see Table 5.4.2.3). Importantly, 
whilst the same protein hits were found in both the forward and reverse experiment in 
SEC fraction 8, the presence or absence of these proteins was not robustly established 
across replicates in the other two fractions, making interpretation difficult.  CD81 was 
found to be present in at least one replicate of sEVs isolated from donor cells with (+ 
DOX) and without (-DOX) the induction of centrosome amplification that eluted in both 
SEC fractions 7 and 9. This result may indicate that CD81 is only completely lost in sEVs 
isolated from + DOX cells that elute in fraction 8, making it a strong candidate for further 
investigation (see Table5.4.2.3). Interestingly, CAD was only identified in sEVs isolated 
from + DOX cells that eluted in fraction 8, thus CAD is also a strong candidate for further 
investigation. CCDC124 and MT-CO2, which were identified in SEC fraction 8 +DOX sEVs 
only, were also both identified in SEC fraction 9. However, these proteins were only 
found in one replicate of SEC fraction 9 (CCDC124 in one -DOX replicate and MT-CO2 in 
one +DOX replicate of SEC fraction 9) (see Table 5.4.2.3). It is therefore possible that 
these are false positives and so further validation is required to confirm the 
presence/absence of these proteins under these conditions. Furthermore, NIBAN1 and 
PGM3 were also identified in SEC fraction 9. These proteins were identified in two 
replicates , one +DOX and one – DOX, making interpretation difficult (see Table 5.4.2.3). 
Therefore, until these results are validated, it is unclear what, if any, potential role these 
proteins may play in PSC activation.  
In conclusion, SILAC-based proteomic analysis demonstrated that upon the induction of 
centrosome amplification, cells secrete sEVs with an altered protein cargo. In particular, 
sEVs that retain the PSC activating potential were found to have alterations in the loss 
or gain of 6 proteins. Of these 6 proteins, CD81 and CAD appear to be strong candidates 
for further analysis due to their pattern of presence/absence in various protein fractions 
from treated and untreated cells. Furthermore, enrichment analysis revealed all 
samples to be significantly enriched in proteins associated with exosomes and exosome 
biogenesis, providing further evidence that our sEVs preparations are enriched in 
exosomes.  
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Table 5.4.2.3 Presence of SEC fraction 8 SILAC sEV protein hits (from cells in the 
presence of DOX) in SEC fraction 7, 8 and 9 
 SEC Fraction 7 SEC Fraction 8 SEC Fraction 9 
 - DOX  + DOX  - DOX  + DOX  - DOX  + DOX 
Gene 
name 
Rep 
1 
Rep
2 
Rep 
1 
Rep
2 
Rep 
1 
Rep
2 
Rep 
1 
Rep
2 
Rep 
1 
Rep
2 
Rep 
1 
Rep
2 
CD81 ✓  ✓  ✓ ✓   ✓  ✓ ✓ 
PGM3   ✓    ✓ ✓ ✓   ✓ 
CAD       ✓ ✓     
MT-CO2       ✓ ✓   ✓  
NIBAN   ✓    ✓ ✓ ✓  ✓  
CCDC124 
 
  ✓    ✓ ✓ ✓    
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5.5 Discussion 
Our previous results had demonstrated that PDAC cells with amplified centrosomes 
secrete an increased number of sEVs (Chapter 3). Since sEVs are known to contribute to 
tumourigenesis, we hypothesised that sEVs from cells with extra centrosomes may have 
pro-tumourigenic properties. As sEVs have been shown to promote tumour growth and 
metastasis through activation of cancer-associated fibroblasts and stellate cells we 
decided to investigate the PSC activating capabilities of sEVs derived from cells with and 
without the induction of centrosome amplification.  
Here we report for the first time that sEVs from PDAC cells with supernumerary 
centrosomes significantly enhance PSC activation compared to sEVs from cells with 
normal centrosome number. We also demonstrate that sEVs from cells with amplified 
centrosomes have an altered biological cargo. Interestingly, conditioned medium from 
these cells was not sufficient to induce PSC activation, and we found it necessary to 
concentrate the sEVs to elicit an effect. Importantly, the design of these experiments 
dictated that PS1 cells be treated with equal numbers of sEVs from cells with and without 
the induction of centrosome amplification (to exclude any differential vesicle 
concentration effects). Despite normalisation, sEVs from cells with extra centrosomes 
significantly activated the PSCs whereas those from cells without centrosome 
amplification did not. As our previous work has shown that cells with extra centrosomes 
secrete more sEVs than normal cells, normalisation of the sEV numbers may in fact be 
minimising the true effects of centrosome amplification derived sEVs on PSC activation. 
Additionally, in a tumour setting where cells with extra centrosomes are present, the 
PSCs would likely be in proximity to a more concentrated population of sEVs with 
heightened capacity for PSC activation. Whilst the concentration of EVs present in the 
conditioned media was not sufficient to induce PSC activation over 3 days, it would be 
interesting to analyse activation over a longer time period to determine if an extended 
exposure would be sufficient to elicit a response. Additionally, it would be interesting to 
analyse PSC activation upon co-culture with cells with and without the induction of 
centrosome amplification. This would determine if proximity to a constant supply of sEVs 
would increase PSC activation without the need to concentrate the vesicles. Although 
the results we present here are robust, it will be important to analyse PSC activation 
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using a second PSC cell line to confirm the theory. To rule out experimental artefacts, 
alternative methods of measuring PSC activation may be employed. For example, PSC 
cells become highly contractile once they are activated. It would therefore be interesting 
to analyse the contractility of the PSCs after treatment with sEVs using gel contraction 
assays similar to those performed by Calvo et al., 2013.  
Interestingly, sEVs that conferred heightened PSC activating capabilities were shown to 
elute in one specific fraction following SEC. NanoSight analysis revealed that the sEVs 
present in SEC fraction 8 were slightly larger than those present in SEC fraction 9. 
Together these results indicate that the sEVs that harbour enhanced PSC activating 
capabilities may be a specific subset of sEVs. SILAC-based proteomic analysis of sEVs 
isolated from cells with and without centrosome amplification revealed 6 proteins 
changes in SEC fraction 8, confirming that sEVs from cells with supernumerary 
centrosomes have an altered protein cargo compared to those secreted by cells with a 
normal centrosome number. Importantly, TGF-β was not detected in the any of the 
samples, indicating that the mechanism of PSC activation is TGF-β independent and is 
therefore due to some other factor(s)/mechanism yet to be identified. Candidate 
proteins involved in a TGF-β independent mechanism of activation have been identified 
(CD81, CAD, MT-CO2, NIBAN1, CCDC124 and PGM3), but confirmation of their identities 
is required before further experimentation is carried out. To achieve this, the presence 
or absence of the identified proteins will be analysed in sEVs from PaTu-S.PLK4 and 
HPAF-II.PLK4 cells with and without the induction of centrosome amplification by dot 
blot. Once the protein identities have been confirmed, siRNA knock down of the SILAC 
hits may be performed and the ability of the secreted vesicles to activate PSCs analysed.  
These experiments should confirm whether or not the targeted proteins play a role in 
this TGF-β independent mechanism of activation. 
Thus far, our work has demonstrated that cells with amplified centrosomes not only 
induce sEV secretion (Chapter 3) but also induce secretion of sEVs with an altered 
biological cargo. Importantly, we have previously demonstrated that this increased sEV 
secretion is associated with centrosome amplification-induced ROS (Chapter 4). We 
therefore hypothesised that centrosome amplification-associated ROS may also be 
responsible for secretion of sEVs containing a cargo that confers heightened PSC 
activation capabilities. ROS was therefore quenched in cells with extra centrosomes and 
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the ability of the secreted sEVs to activate PSCs quantified. Analysis revealed that when 
centrosome amplification- associated ROS was diminished, the sEVs no longer retained 
enhanced PSC activating capabilities, indicating that centrosome amplification-
associated ROS is responsible for the secretion of sEVs with an altered biological cargo. 
As our SILAC screen identified a number of EV proteins that change in response to 
centrosome amplification it would be interesting to see if depletion of ROS in cells with 
centrosome amplification reverts the cargo of these EVs back to those of – DOX cells or 
results in a completely different protein cargo. Our initial experiments indicate that 
centrosome amplification-associated ROS is responsible for the secretion of sEVs which 
contain factors that activate PSCs. Whether this ROS related change in secretion is 
specific to centrosome amplification or a more global mechanism remains to be seen. It 
would be interesting to test the ability of sEVs  harvested from cells where ROS is induced 
independently of centrosome amplification with H2O2 to activate PSC. Subsequent 
analysis of protein changes in these sEVs may provide insight into whether centrosome 
amplification-associated ROS or ROS in general is responsible for the changes in EV 
protein cargoes.   
In conclusion, the work presented here demonstrates for the first time that sEVs 
secreted by cells with extra centrosomes have an altered biological cargo that enhances 
PSC activation compared to sEVs from cells with normal centrosome number. SILAC-
based proteomic analysis identified 6 factors present in the sEVs secreted by cells with 
amplified centrosomes that may be involved in PSC activation. Furthermore, our results 
indicate that the changes in  sEV protein cargo observed in cells with extra centrosomes 
may be influenced by centrosome amplification-associated increases in cellular ROS 
levels.  
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6.1 Overview 
In recent years, centrosome amplification has emerged as a hallmark of human 
malignancies including pancreatic cancer (Chan, 2011), with up to 85% of PDAC tumours 
harbouring amplified centrosomes (Sato et al., 1999). In fact, despite offering no 
proliferative advantage to the cancer cells in which the supernumerary centrosomes 
reside, centrosome amplification has been shown to play a role in both the development 
and progression of cancer. Indeed, amplified centrosomes have now been associated 
with tumourigenic properties such as elevated CIN, altered signalling, changes in cell 
polarity and heightened invasive capabilities (reviewed in Godinho and Pellman, 2014). 
For example, a recent study from our laboratory demonstrated that amplified 
centrosomes drive non-cell-autonomous invasion in 3D mammary organoids through 
the secretion of the ECASP (Arnandis et al., 2018). This altered secretion was attributed 
to centrosome amplification-driven changes in cellular ROS (Arnandis et al., 2018). 
Proteomic analysis of the altered secretome revealed that cells with extra centrosomes 
also secrete a number of proteins associated with EVs. As numerous studies have now 
identified clear roles for cancer-derived EVs in the development and progression of 
cancer (reviewed in Xu et al., 2018), we hypothesised that cells with supernumerary 
centrosomes may contribute to cancer progression through the secretion of tumour 
promoting EVs. Here, we show for the first time, that cells harbouring supernumerary 
centrosomes secrete an increased number of sEVs. We identify a role for centrosome 
amplification-associated ROS in the induction of this increased EV release and reveal 
that sEVs secreted by cells with extra centrosomes have an altered protein cargo. We 
also demonstrate that sEVs from cells with amplified centrosomes have heightened PSC 
activating capabilities and are therefore likely to contribute to PSC-mediated fibrosis and 
PDAC progression (see Figure 6.1).  
 
 Chapter 6. Discussion 
166 
 
 
Figure 6.1 Working model of tumour progression driven by sEV secretion. Tumour cells 
harbouring extra centrosomes have increased cellular ROS which leads to the elevated secretion 
of sEVs with an altered protein cargo. These secreted sEVs enhance activation of pancreatic 
stellate cells, which may in theory lead to increased ECM deposition/fibrosis and promote 
tumour progression. 
 
6.2 The secretion and packaging of sEVs in cells with extra centrosomes 
The work presented here demonstrates a positive correlation between centrosome 
amplification and EV secretion in pancreatic cancer cell lines. In fact, using two cell lines 
in which centrosome amplification can be induced through overexpression of PLK4, we 
reveal that centrosome amplification is sufficient to drive the secretion of elevated 
levels of sEVs in PDAC cells, but not LEVs. Interestingly, increased EV secretion has 
already been observed in a number of tumour-derived cell lines compared to non-
transformed cells, and exosomes are often elevated in the plasma and bodily fluids of 
cancer patients  (Dabitao et al., 2011; Szczepanski et al., 2011; Keustermans et al., 2013). 
It is not currently known, however, if all tumour cells or a subset of tumour cells are 
responsible for the increased EV secretion. Our results suggest that a subset of tumour 
cells harbouring extra centrosomes secrete more EVs than other tumour cells and non-
malignant cells and may be responsible for the elevated presence of EVs in patient fluids.  
Whilst our results provide strong evidence to suggest centrosome amplification induces 
sEV secretion in pancreatic cancer cells, the driving mechanism behind increased vesicle 
release has been elusive. Recent work from our laboratory, however, has revealed that 
centrosome amplification induces an early stress response though increased generation 
of ROS. Moreover, this centrosome amplification linked increase in cellular ROS was 
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found to result in an altered secretion profile, the ECASP (Arnandis et al., 2018). We 
therefore hypothesised that centrosome-amplification induced ROS may also be the 
driving force behind increased sEV secretion in cells with supernumerary centrosomes. 
Here, we confirm the findings of Arnandis et al., that cells with supernumerary 
centrosomes have increased cellular ROS. Furthermore, we demonstrate that this 
increase in ROS is required for the elevated sEV release observed by cells with extra 
centrosomes. Interestingly, however, despite having higher basal levels of ROS, PaTu-
S.PLK4 cells were found to secrete less sEVs than HPAF-II.PLK4 cells. ROS can be 
produced in different sub-cellular compartments including the mitochondria, where the 
majority of cellular ROS is produced, and the cytosol, where ROS is largely produced by 
NADPH-oxidases (NOXs) (reviewed in Klionsky et al., 2016). Recent work from our 
laboratory demonstrated that centrosome amplification-associated ROS is cytoplasmic 
in origin and generated by NOXs (Arnandis et al., 2018). It is therefore possible that the 
relatively high basal levels of ROS in PaTu-S.PLK4 cells are the result of increased 
production of a different type of ROS (ROS from a different subcellular compartment) 
that does not induce sEV secretion.  
In support of our findings, similar mechanisms of stress driven EV secretion have been 
described in the literature. For example, heat stress and ER stress have been shown to 
induce EV release (Kanemoto et al., 2016; Bewicke-Copley et al., 2017). In other work, 
metabolic stress in pancreatic cancer cells was shown to induce autophagy and increase 
EV secretion (Bhattacharya et al., 2014) and a number of studies have now revealed 
increases in EV secretion in response to chemotherapy and radiation-induced cell stress 
(reviewed in O’Neill, Gilligan and Dwyer, 2019). Furthermore, hypoxia has been shown 
to lead to the release of EVs in multiple different cancer types (reviewed in O’Neill, 
Gilligan and Dwyer, 2019). Hypoxia, or low oxygen tension, is a common feature of 
tumours and is caused by the high oxygen demand of proliferating cancer cells coupled 
with the low supply of oxygen due to irregular vascularisation and distance from the 
supporting blood supply (reviewed in Eales, Hollinshead and Tennant, 2016; Ayob and 
Ramasamy, 2018). Hypoxia has been shown to alter the expression of numerous plasma 
membrane receptors including  EGFR and GLUT-1 which can result in increased 
internalisation of these receptors via endocytosis and result in the increased production 
of MVBs and exosomes (Huber, Kraut and Beug, 2005). Moreover, hypoxia is known to 
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induce production of cellular ROS in the cytosol through NOX activation (Jiang, Zhang 
and Dusting, 2011), thus, it is possible that cytoplasmic ROS is also the driving force 
behind EV secretion in hypoxic cells. It is conceivable that cellular stress-induced ROS 
generation may alter the expression of plasma membrane proteins influencing the 
exosome biogenesis pathway, leading to increases in exosome secretion.  
To further understand how centrosome amplification-associated ROS contributes to 
increased sEV secretion in pancreatic cancer cells, we first identified the likely origins of 
these vesicles. Here we demonstrate that the vesicles in our sEV isolates exhibit many 
characteristics of exosomes. Initially, we performed nanoparticle tracking analysis on 
the isolated vesicles which confirmed that these sEVs were within the correct size range 
for exosomes (30-150 nm). Furthermore, subsequent full proteomic profiling of the 
vesicles using a SILAC-based proteomic method revealed the sEVs to be significantly 
enriched in proteins associated with exosomes, and exosome biogenesis. Whilst it is not 
possible to definitively define the vesicles based on these characteristics, our analysis 
provides significant evidence to suggest that our sEV isolates are heavily enriched in 
exosomes. We therefore decided to analyse the effects of centrosome-amplification 
associated ROS on exosome biogenesis and trafficking.  
Using a SILAC-based proteomic approach, our analysis revealed that sEVs secreted by 
cells with and without the induction of centrosome amplification have different protein 
cargos. Interestingly, a number of these differentially expressed proteins, CD81, CAD, 
NIBAN and CCDC124 have been shown to localise, at least in part, to  cellular membranes 
(Sigoillot et al., 2005; Sato et al., 2015; Thul et al., 2017). Changes in the presence or 
absence of these proteins at the plasma membrane may therefore influence MVB and 
ILV formation. As the enhanced sEV secretion observed in cells with supernumerary 
centrosomes is driven by centrosome-associated ROS, it will be important to determine 
if the changes in sEV protein cargo associated with centrosome amplification, can be 
reverted back to those observed in the control conditions upon treatment with the ROS 
quenching agent NAC. 
Whilst the results reported here do not indicate changes in MVB formation upon 
centrosome amplification or ROS induction, only LBPA+ve MVBs were analysed due to 
time constraints. It is possible that LBPA+ve MVBs only account for a subset of the total 
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MVBs present within a cell, therefore analysis with additional MVB markers may reveal 
previously undetected changes in MVB number or size. Our analysis did reveal however, 
that in cells with centrosome amplification, the cellular localisation of LBPA+ve MVBs is 
more disperse throughout the cytoplasm compared to cells with normal centrosome 
number where LBPA+ve MVBs are localised closer to the perinuclear region. These 
observations may indicate that more MVBs are trafficked to the plasma membrane of 
cells harbouring supernumerary centrosomes, enabling the expulsion of more 
exosomes. In our current work we were not able to analyse cellular MVBs in real time, 
so we cannot discount the possibility that cells with extra centrosomes generate 
elevated levels of LBPA+ve MVBs but they are trafficked for secretion faster than in cells 
with normal centrosome number and so numerical differences are not observed.  
MVBs are believed to be trafficked along microtubules and it is now well established 
that centrosome amplification induces increased microtubule nucleation resulting in 
larger microtubule networks (Godinho et al 2014; Monteiro and Godinho, unpublished). 
Interestingly, current work being performed in our laboratory suggests that centrosome 
amplification induces a change in the balance of microtubule motors that favour the + 
end directed motor kinesin-1 (Monteiro and Godinho, unpublished). It is therefore 
possible that centrosome amplification  may result in increased trafficking of MVBs to 
the plasma membrane through the induction of larger microtubule networks and the 
increased activity of kinesin-1. Furthermore, recent studies have shown increased 
cellular ROS to lead to post-translational modifications (PTM) of microtubules, including 
detyrosination which has been shown to favour microtubule + end directed transport 
by kinesin-1 (Janke and Chloë Bulinski, 2011; Kerr et al., 2015). It is therefore also 
possible that centrosome amplification-linked changes in ROS alter microtubule PTMs 
and facilitate increased MVB trafficking to the plasma membrane, resulting in increased 
sEV secretion. In order to provide a comprehensive view of MVB formation and 
trafficking upon the induction of centrosome amplification and ROS treatments, a live 
cell imaging approach should be used. 
The MVBs formed within a cell have two fates, either they are trafficked to the plasma 
membrane, where fusion results in release of their ILVs as exosomes, or they are 
targeted to the lysosome for degradation. Recent work has shown that lysosome 
dysfunction shifts the fate of MVBs targeted for degradation, to instead fuse with the 
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plasma membrane (Alvarez-Erviti et al., 2011; Miao et al., 2015; Latifkar et al., 2019). 
The degradative activities of lysosomes are dependent on the presence of an acidic 
intraluminal pH and so it has been suggested that preventing the acidification of 
exosomes would result in increased sEV secretion (Yoshimori et al., 1991; Savina et al., 
2003). We therefore quantified sEV secretion in our cells following treatment with the 
vacuolar proton pump inhibitor bafilomycin A1 which prevents the acidification of 
lysosomes (Yoshimori et al., 1991). As expected, bafilomycin A1 treatment significantly 
increased the secretion of sEVs in PaTu-S.PLK4 cells confirming what has previously been 
described in the literature. We therefore hypothesised that lysosome function may be 
compromised in cells with amplified centrosomes leading to the observed increase in 
sEV secretion.  
Lipids are one of the most significant targets of cellular ROS. These free radicals steal 
electrons from lipids in cell membranes in a process termed lipid peroxidation which 
substantially impacts the structure and permeability of the targeted membranes 
(reviewed in Tafani et al., 2016). As lysosomal function is dependent on an acidic 
intraluminal pH, lysosomes are particularly sensitive to lipid peroxidation and 
subsequent membrane permeabilisation. We therefore hypothesised that centrosome 
amplification-associated ROS may induce lysosome peroxidation, raising the 
intraluminal pH and impairing lysosome function. Using LysoTracker as a marker for 
lysosomes with a functional low pH and Magic Red as a readout of lysosome activity, we 
showed that cells with centrosome amplification have significantly fewer acidic 
lysosomes and lower lysosomal activity compared to cells with normal centrosome 
number. Taken together, these results indicate that centrosome amplification initiates 
lysosome dysfunction in PDAC cells. Furthermore, we demonstrated that centrosome 
amplification-associated changes in cellular ROS are responsible for this observed 
lysosome dysfunction. Whilst the exact mechanisms leading to this dysfunction remain 
elusive we hypothesis that lysosomal lipid peroxidation may be involved.  Analysing 
lysosomal lipid peroxidation could be achieved using a newly generated Foam-LPO 
fluorescent probe, which specifically targets lysosomes and contains a fluorophore that 
degrades in response to lipid peroxidation, resulting in a fluorescence shift (X. Zhang et 
al., 2015; Ahmad and Leake, 2019). Using this technique, lysosomal lipid peroxidation 
could be monitored over time, in response to centrosome amplification. To analyse the 
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effects of centrosome amplification induced lysosome dysfunction on MVBs and their 
degradation, we analysed co-localisation events between the lysosome marker 
LysoTracker and the MVB marker LBPA as a proxy for lysosome/MVB fusion.  Here we 
demonstrate that centrosome amplification, and more specifically, centrosome 
amplification- associated ROS, significantly reduces the incidence of lysosome/MVB co-
localisation in PDAC cells. These observations indicate that centrosome amplification 
linked ROS may prevent lysosomal degradation of MVBs, shifting the fate of these MVBs 
to fusion with the plasma membrane and resulting in increased sEV secretion. These 
results again highlight the need to analyse MVB trafficking in cells with and without the 
induction of centrosome amplification by live cell imaging. Additionally, it is important 
to note, that the induction of ROS with H2O2 in the absence of centrosome amplification, 
recapitulated the effects of centrosome amplification on lysosomal function and 
lysosome/MVB co-localisation. These findings indicate that the effects are not specific 
to centrosome amplification-associated ROS and may represent a more globalised 
response to certain types of ROS.  
Our results to date indicate that centrosome amplification-associated ROS may change 
the fate of MVBs, directing them away from lysosomal degradation and instead to the 
cell surface where they fuse with the plasma membrane and expel their ILVs as 
exosomes. Since some MVBs within a cell are targeted for degradation and others for 
transport to the plasma membrane, trafficking regulators must be in place to direct MVB 
fate. Evidence now suggests a role for ubiquitination, a reversible PTM, in the sorting of 
protein cargo into ILVs and the targeting of MVBs to the lysosome (reviewed in Davies 
et al., 2009). Similarly, ISGylation, a ubiquitin-like PTM, was also recently shown to 
trigger MVB co-localisation with lysosomes, promoting degradation of the MVBs and 
impairing exosome secretion (Villarroya-Beltri et al., 2016). Moreover, a recent study 
performed by Latifkar et al., revealed that upon the SIRT1-mediated induction of 
lysosome dysfunction, cells secrete an increased numbers of exosomes with significantly 
higher levels of protein ubiquitination (Latifkar et al., 2019), providing further evidence 
to suggest a role for PTMs in directing MVB trafficking. It is therefore possible that 
currently unknown centrosome amplification associated PTMs could influence the 
packaging and trafficking of ILVs and MVBs. Crucially, an increasing number of studies 
suggest that ubiquitination and other PTMs including SUMOylation can be regulated by 
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ROS during oxidative stress (reviewed in Stankovic-Valentin and Melchior, 2018). It is 
therefore possible that centrosome amplification-associated ROS plays a role in both the 
packaging and trafficking of ILVs and MVBs through regulation of PTMs. It would 
therefore be interesting to analyse changes in EV protein cargo PTMs, particularly 
ubiquitination, in response to centrosome amplification and ROS treatments.  
Whilst the PTM status of the protein cargos in sEV secreted by cells with supernumerary 
centrosome is currently unknown, SILAC-based proteomic analysis revealed changes in 
the protein cargo. Six proteins were identified as being differentially present or absent 
upon the induction of centrosome amplification, these were CD81, PGM3, CAD, MT-
CO2, NIBAN and CCDC214. Importantly, CD81, a key membrane tetraspanin, was the 
only protein found to be lost in sEVs secreted by cells with extra centrosomes. 
Interestingly, Latifkar et al., reported similar loses of CD81 in exosomes upon the 
induction of lysosome dysfunction by SIRT1 down regulation (Latifkar et al., 2019). As 
we have shown that centrosome amplification also leads to lysosomal dysfunction, it is 
possible that similar mechanisms of CD81 loss are present in both systems. It has been 
previously demonstrated that ubiquitination of tetraspanins, including CD81 and CD151, 
downregulate their expression at the cell surface (Lineberry et al., 2008). Thus, cellular 
stresses (such as ROS) leading to, or resulting from lysosome dysfunction, may result in 
the PTM of CD81, thereby signalling for its downregulation or preventing its 
incorporation into ILVS.  To gain further understanding as to why CD81 is lost in sEVs 
secreted by cells with supernumerary centrosomes, it will be important to analyse the 
PTM status of CD81 following the induction of centrosome amplification, or H2O2 
treatment. A similar investigation into the PTMs on the other 5 proteins identified in the 
SILAC-based proteomic analysis may provide insight into the mechanisms behind their 
packaging into ILVs and their trafficking to the plasma membrane. 
 
6.3 The activation of PSC by sEVs derived from cells with amplified 
centrosomes 
Since our results show that cells with supernumerary centrosomes secrete more  sEVs 
and amplified centrosomes have been associated with tumourigenesis, we hypothesised 
 Chapter 6. Discussion 
173 
 
that sEVs secreted by cells with extra centrosomes may have pro-tumourigenic 
properties in PDAC. In recent years it has been established that activated pancreatic 
stellate cells have key roles in PDAC tumourigenesis, including facilitating fibrosis, 
tumour growth and metastasis. Since PSCs can be activated through paracrine signalling 
from cancer cells, including through transfer of cancer-derived exosomes, we decided 
to investigate changes in PSC activation in response to treatment with sEVs derived from 
cells with and without the induction of centrosome amplification. Here we report for 
the first time that sEVs  derived from PDAC cells with supernumerary centrosomes 
significantly enhance PSC activation compared to sEVs from cells with normal 
centrosome number. PSCs were treated with equal numbers of sEVs or equal sEVs 
protein from cells with and without the induction of centrosome amplification. In all 
cases, sEVs from cells with extra centrosomes significantly activated the PSCs whereas 
those from cells without centrosome amplification did not. Interestingly, we found that 
the conditioned media generated by cells with extra centrosomes, was not sufficient to 
significantly induce PSC activation, and that concentration of the sEVs was required to 
elicit an effect. Since these experiments were only performed over 72 hours, it would 
be interesting to determine if long term exposure to the conditioned media (where sEV 
concentration is low) would result in enhanced PSC activation, or if sEV concentration is 
absolute required to elicit the effect. In a tumour setting, PSCs are in close proximity to 
large numbers of tumour cells, which could harbour extra centrosomes. Since we have 
already demonstrated that cells with amplified centrosomes secrete significantly more 
sEVs, PSCs may therefore, be in close proximity to a constant supply of elevated levels 
of sEVs from these cells. Therefore, it is conceivable that the close proximity and 
prolonged exposure to these sEVs in tumours tissues would elicit PSC activation. It would 
therefore be interesting to analyse PSC activation following co-culture with PDAC cells 
with and without the induction of centrosome amplification.  
Interestingly, the sEVs harbouring a heightened capacity for PSC activation were found 
to elute in one specific fraction, SEC fraction 8, following size exclusion chromatography. 
Whilst large numbers of sEVs were also present in SEC fraction 9, these vesicles did not 
significantly activate PSCs, indicating that the sEVs conferring heightened PSC activating 
capabilities may be a specific subset of vesicles.  
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The work presented here demonstrates that lysosome function becomes impaired 
following the induction of centrosome amplification due to the presence of centrosome 
amplification associated ROS. Furthermore, we have shown that this lysosome 
dysfunction results in decreased MVB/lysosome fusion and increased sEV secretion. It is 
therefore possible that the MVBs carrying the sEVs capable of inducing PSC activation 
are normally targeted for degradation within the cell by lysosomes. However, upon the 
induction of lysosome dysfunction by centrosome amplification associated ROS, these 
MVBs are instead targeted for secretion resulting in the secretion of sEVs that can 
activate PSCs. Thus, centrosome amplification may play a role in PDAC tumourigenesis, 
by inducing the secretion of a subset of sEVs that contain pro-tumourigenic factors. 
 Our results demonstrate that sEVs secreted by cells with supernumerary centrosomes 
have an altered biological cargo and that the changes to the protein complement are 
dependent on centrosome amplification-associated ROS. In fact, sEVs secreted by cells 
with supernumerary centrosomes where ROS has been depleted through treatment 
with NAC, were found to no longer retain enhanced PSC activating capabilities. A 
number of studies have also identified exosomal cargo changes in response to 
insult/cellular stress that confer pro-tumourigenic properties (reviewed in O’Neill, 
Gilligan and Dwyer, 2019). For example, hypoxia in glioblastoma multiforme (GBM) cells 
results in the secretion of exosomes elevated in protein-lysine 6-oxidase (LOX), 
thrombospondin 1 (TSP1) and VEGF which were shown to enhance tumour progression, 
metastasis and angiogenesis in recipient cells (Kore et al., 2018). Similarly, 
chemotherapeutic stresses have been shown to induce the increased secretion of 
exosomes with an altered cargo that confer drug resistance upon uptake by recipient 
cells (reviewed in O’Neill, Gilligan and Dwyer, 2019). For instance, breast cancer cells 
have been shown to secrete exosomes containing the multi drug resistance related gene 
MDR-1 and P-glycoprotein upon chemotherapeutic insult, that induce a drug resistant 
phenotype in recipient cells (X. Wang et al., 2016). Additionally, upon exposure to the 
microtubule stabilising agent paclitaxel, breast cancer cells were shown to secrete 
exosomes enriched in survivin, which promotes drug resistance and cell survival in 
recipient cells (Kreger et al., 2016).  Furthermore, oxidative stress itself has been shown 
to induce changes in the exosomal cargoes of mouse mast cells which can communicate 
a protective message to surrounding cells upon their uptake, conferring resistance to 
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subsequent oxidative insult (Eldh et al., 2010). Thus, cellular stress induced changes in 
exosomal cargoes are a well-established means of communicating important 
information to surrounding cells to increase cell survival under otherwise detrimental 
stimuli.  
 
6.3.1 Proteomic analysis of sEVs derived from cells with extra centrosomes 
To determine the factors influencing PSC activation, we first analysed changes in the sEV 
protein cargo upon the induction of centrosome amplification. SILAC-based proteomic 
analysis was performed on sEVs from cells with (+DOX) and without (-DOX) the induction 
of centrosome amplification that had been separated into three SEC fraction, fractions, 
7,8 and 9. Crucially, sEVs that contained the enhanced PSC activating potential were 
found to elute specifically in SEC fraction 8. Analysis revealed differential gains or losses 
of six proteins in the sEVs isolated from +DOX compared to – DOX cells that eluted in SEC 
fraction 8. These consisted of gains in CAD, MT-CO2, NIBAN1, CCDC124 and PGM3 and 
loss of CD81. Interestingly, CD81 was identified in at least one replicate of all fractions 
except sEVs from + DOX cells that eluted in SEC fraction 8 (see Table 5.4.2.3). Thus, CD81 
was identified as a strong candidate for further analysis. Additionally, CAD was only 
observed in sEVs from + DOX cells that eluted in SEC fraction 8 and so was also selected 
as a strong candidate for further analysis. Whilst CCDC124 and MT-CO2 were identified 
in sEVs isolated from +DOX cells and not – DOX cells that eluted in SEC fraction 8, these 
proteins were also identified in sEVs that eluted in fraction 9 (see Table 5.4.2.3). Crucially 
however, these proteins were each present in only one sample replicate (CCDC124 in 
one -DOX replicate and MT-CO2 in one +DOX replicate of SEC fraction 9) leading to the 
possibility that these are false positives. Validation of these hits by Western blot should 
determine whether or not these are true findings. NIBAN1 and PGM3 were also 
identified in SEC fraction 9(see Table 5.4.2.3). Both proteins were identified in two 
replicates, one +DOX and one – DOX, making interpretation difficult. Until this result is 
confirmed (for example by validation by Western blot) it is unclear what, if any, potential 
role these proteins may play in PSC activation.  
As discussed above, CD81 and CAD were selected as strong candidates for further 
analysis due to their presence/absence in specific sEV samples and the effects of these 
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samples on PSC activation. CD81 is a cell surface glycoprotein that is a member of the 
transmembrane 4 superfamily known as the tetraspanins. Interestingly, the tetraspanins 
have been shown to influence cell proliferation and migration and tumour cell invasion 
(Hemler, Mannion and Berditchevski, 1996; Raimondo et al., 2011). In addition to 
appearing on cell surface membranes, the tetraspanins have been identified on the 
surface of EVs including exosomes (Berditchevski and Odintsova, 1999; Sincock et al., 
1999; Witwer et al., 2018). A mounting body of evidence now suggests that interplay 
between tetraspanins, integrins and other adhesion molecules on the surface of EVs are 
crucial for regulating targeting and uptake of EVs (reviewed in Willms et al., 2018). In 
fact, a recent publication has demonstrated that neuroblastoma cells secrete different 
subsets of exosomes which have altered protein cargoes, where one subset was CD63 
positive and the other negative for CD63 but positive for amyloid precursor protein 
(APP) (Laulagnier et al., 2018). Crucially, whilst the CD63 positive exosomes were able 
to bind to multiple target cells, the APP positive subset were found to be specifically 
endocytosed by neurons (Laulagnier et al., 2018). It is therefore possible that changes 
in the expression of CD81 on  the surface of the sEVs could alter targeting and uptake of 
the vesicles. Thus, loss of CD81 in  sEVs secreted by cells with extra centrosomes may 
facilitate increased EV uptake. Proteomic analysis identified the presence of numerous 
proteins inside the isolated sEVs that have previously been associated with 
tumourigenesis. Increased delivery of these EVs would therefore potentially result in the 
increased transfer of a number of oncogenic proteins. 
The second protein identified as a strong candidate for PSC activation, CAD, is a 
multifunctional protein that catalyses the first three steps of de novo pyrimidine 
biosynthesis. Pyrimidine nucleotide biosynthesis is essential for DNA synthesis and so 
upon phosphorylation by its activator mitogen-activated protein (MAP) kinase, CAD  
plays an important role in regulating the cell cycle and proliferation (Sigoillot et al., 
2005). CAD has also been shown to regulate notch signalling (Coxam et al., 2015) which 
is known to mediate cell proliferation and differentiation as well as cell fate. 
Furthermore, Notch signalling has been shown to play a role in the activation of hepatic 
stellate cells (HSCs) (Bansal et al., 2015). Therefore, delivery of CAD to PSCs by sEVs may 
initiate PSC activation by inducing Notch. Additionally, whilst CAD is usually located in 
the cytoplasm, it has also been shown to accumulate at the membranes of LAMP2 
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positive late endosomes (Sigoillot et al., 2005; Sato et al., 2015), thus CAD may be 
present on the surface of sEVs. Similar to CD81, it is therefore possible that CAD could 
affect the behaviours of PSCs by facilitating increased delivery of the sEVs. 
Proteomic analysis also revealed MT-CO2 to be gained in sEVs derived from cells with 
extra centrosomes. MT-CO2 is the second subunit of the mitochondrially encoded 
cytochrome C oxidase (COX) enzyme. COX is a large transmembrane protein that plays 
a key role in the final stages of the respiratory electron transport chain by catalysing the 
reduction of oxygen to water. Importantly , the biogenesis and activities of COX appear 
to prevent oxidative stress (Bourens et al., 2013). Down regulation of MT-CO2 has been 
shown to decrease the activity of COX and initiate the differential expression of genes 
involved in cell cycle, signalling, apoptosis and angiogenesis (Nuha M, Hiba S and 
Christina Wasunna, 2015). Additionally, MT-CO2 is highly prevalent in the plasma of 
cancer patients, including sufferers of breast cancer, ovarian cancer and melanoma 
(Jang et al., 2019). Thus, it is hypothesised that MT-CO2 may play a role in 
tumourigenesis. Therefore, whilst a link between MT-CO2 and PSC activation is not 
immediately apparent, it is possible that exosomal delivery of MT-CO2 to PSCs may 
induce pro-tumourigenic changes in these cells resulting in their activation. 
Furthermore, Jang et al., described MT-CO2 as being present within the membranes of 
cancer-derived EVs (Jang et al., 2019). As EV membrane proteins can affect the uptake 
of sEVs by their target cells, this protein could also play a role in delivery of sEVs to PSCs. 
CCDC124 was also found to be gained in sEVs secreted upon the induction of centrosome 
amplification. CCDC124 is a novel centrosomal protein that co-localises with ϒ-tubulin 
at the centrosome until telophase where it relocates to the midbody, where it is 
required for the progression of the late cytokinesis stage (Telkoparan et al., 2013). 
Whilst little is known about this protein, it has been identified as an unfavourable 
prognostic marker in liver cancer (Uhlen et al., 2017) and its presence in EVs has been 
confirmed in Vesiclepedia data sets (Kalra et al., 2012). Additionally, CCDC124 has been 
identified as enriched in both the cytoplasm and in the plasma membrane (Thul et al., 
2017). It is therefore possible that CCDC124 could affect PSC activation itself, or by 
mediating delivery of the sEVs to PSCs. As the activity and function of this protein remain 
relatively unstudied, it is not clear exactly how transfer of CCDC124 would mediate PSC 
activation. 
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Although not considered a strong hit, PGM3 was also identified as gained in sEVs 
secreted by cells with amplified centrosomes. Whilst this protein is not one of the 
strongest candidates for inducing tumourigenesis due to its presence in multiple SEC 
fractions, a role for this protein in PSC activation cannot be ruled out. PGM3 plays an 
important role in carbohydrate metabolism by mediating glycogen formation and 
utilization. Interestingly, inhibition of PGM3 by the inhibitor FR054 has been shown to 
decrease the proliferation, survival, adhesion and migration of breast cancer cells, 
highlighting a potential role for PGM3 in promoting cancer growth and spread 
(Ricciardiello et al., 2018). Additionally, the presence of PGM3 has been identified as an 
unfavourable marker for breast cancer and prostate cancer (Munkley et al., 2016; Uhlen 
et al., 2017). Whilst studies describing the presence of PGM3 in EVs are currently lacking, 
its appearance in the Vesiclepedia database indicates its presence in vesicles (Kalra et 
al., 2012). Furthermore, PGM3 is a cytoplasmic protein that has not been identified in 
cell membranes  (Thul et al., 2017) and is therefore not likely to be involved in the 
delivery of EVs to target cells. Therefore, any PGM3 mediated PSC activation is likely to 
de due to the transfer of PGM3 itself.  Exactly how PGM3 could activate PSCs, however, 
is unclear and would require further experimental investigation. 
The last protein that we identified as potentially  gained in our sEVs  is NIBAN1, although 
further validation is required to confirm this finding. NIBAN1, also known as FAM129A, 
is believed to have a role in the endoplasmic reticulum stress response and modulates 
apoptosis by regulating translation (Sun et al., 2007). NIBAN1 has also been shown to 
promote prostate cancer cell growth and survival through regulation of ATF4 (Pällmann 
et al., 2019). In fact, NIBAN1 is highly expressed in a number of cancers including 
prostate, thyroid, renal and head and neck cancers (Adachi et al., 2004; Matsumoto et 
al., 2006; Ito et al., 2010; Pällmann et al., 2019). Crucially, NIBAN1 was found to be 
overexpressed in HSCs upon activation (Kannangai et al., 2005). Moreover, NIBAN1 has 
been identified in EVs as reported by Vesiclepedia  (Kalra et al., 2012). It is therefore 
possible that sEV directed transfer of NIBAN1 to pancreatic stellate cells may induce their 
activation, making NIBAN1 a promising candidate for future analysis if presence in the 
activating fraction alone is confirmed. Furthermore, NIBAN1 has also been shown to 
localise to the plasma membrane. Thus, as with CD81, CAD, MT-CO2 and CCDC124, 
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NIBAN1 may play a role in enhancing the delivery of sEVs to target PSCs, thereby 
promoting PSC activation.  
To investigate roles for these proteins in sEV-mediated PCS activation, a small siRNA 
screen will be performed to deplete each protein from sEVs secreted by cells with 
amplified centrosomes and the PSC activating potential of the vesicles will be quantified. 
If proteins involved in the activation are identified, these will be selected for further 
analysis. It is possible, however, that the PSC activation observed is not mediated by sEV 
protein but by other sEV cargoes, such as RNA. In fact, a number of studies have now 
identified specific miRNAs as having a role in PSC activation and inducing PSC-mediated 
fibrosis. For example, exosomal transfer of miRNA from hepatitis C virus replicating cells 
has been shown to induce HSC differentiation (Kim, Lee and Lee, 2019), whilst cancer-
derived exosomes harbouring miR-214 promoted HSC activation and liver fibrosis (Ma 
et al., 2018). Additionally, exosomes derived from pancreatic cancer cells that were 
enriched in mir-1246 and mir-1290 were shown to upregulate fibrosis related genes in 
PSC (Masamune et al., 2018). Therefore, if sEV protein proves not to be responsible for 
the observed PSC activation, additional sEV cargos should be analysed. Furthermore, it 
has recently been demonstrated that ROS can be transferred to recipient cells via 
exosomes or other EVs (reviewed in Tafani et al., 2016). As cells with extra centrosomes 
have increased cytoplasmic ROS, it is possible that the sEVs secreted by these cells 
harbour ROS that can be transferred to target cells upon uptake by the recipient cells. 
Importantly, ROS has been shown to activate stellate cells by elevating  NF-κB activation 
(reviewed in Gandhi, 2012), therefore direct transfer of ROS via sEVs may induce PSC 
activation.  
 
6.3.2 Delivery of sEVs derived from cells with supernumerary centrosomes to PSCs 
As the proteins identified in our SILAC screen may be affecting sEV delivery, it will be 
necessary to quantify the uptake of sEVs from cells with and without centrosome 
amplification in PS1 cells. To analyse vesicle uptake, PS1 cells are currently generating a  
Cre-LoxP reporter system which will result in a cell colour change  due to a switch from 
dsRed to EGFP expression upon Cre-mediated recombinase incorporation. In parallel we 
are generating PaTu-S.PLK4 cells to overexpress (OE) Cre, leading to Cre incorporation 
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into secreted EVs. As demonstrated by Zomer et al., 2015, encapsulation of Cre inside 
EVs is sufficient to drive the dsRed- EGFP switch (see Figure 6.3.2). Once the system is 
generated, sEVs secreted by Cre OE in PaTu-S.PLK4 cells with and without the induction 
of centrosome amplification will be isolated and added to the conditioned media of PS1 
dsRed-EGFP cells. sEV uptake will then be quantified based on the number of GFP 
positive cells. If uptake of sEV differs between sEVs secreted by cells with amplified and 
normal centrosome number, we will analyse the ability of sEVs secreted by cells with 
extra centrosomes to enter PSCs following depletion of each of the previously identified 
candidate proteins in an attempt to identify factor(s) responsible for increased sEV 
uptake. Should sEV uptake be found to be affected, sEV cargos that do not change 
between the activating and non-activating sEVs could be influencing the activation of 
PSC. 
 
 
Figure 6.3.2 Schematic diagram of Cre-loxP reporter system for dsRed to EGFP switch upon 
delivery of Cre enriched exosomes. Cre-LoxP reporter system results in a cell colour change 
from dsRed to EGFP expression upon Cre-mediated recombinase. sEVs secreted by PaTu-S.PLK4 
cells over-expressing Cre will be enriched in Cre and drive a dsRed- EGFP switch following their 
incorporation. 
 
Our SILAC-based proteomic analysis revealed a large number of additional proteins 
present in the isolated sEVs, however, a few are particularly noteworthy including 
connecting tissue growth factor (CTGF/CCN2) and Cep55.  CTGF is known to be a central 
mediator of tissue remodelling through the activation of HSCs resulting in increased ECM 
deposition and liver fibrosis (Huang and Brigstock, 2012; Lipson et al., 2012; Hao et al., 
2014). Furthermore, it is has been demonstrated that CTGF can be transferred between 
HSCs in exosomes  (Charrier et al., 2014). Thus, it is possible that sEVs derived from PDAC 
cells with centrosome amplification activate PSCs due to increased uptake and 
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subsequent heightened transfer of the pro-fibrotic CTGF. Additionally, whilst not yet 
shown to play a role in stellate cell activation directly, the centrosomal protein CEP55 
has been shown to promote pancreatic cancer progression and aggressiveness (Peng et 
al., 2017). CEP55 promotes progression through the activation of NF-κB signalling (Peng 
et al., 2017) and since activated PSCs are known to have elevated NF-κB activation 
(Masamune et al., 2002; Masamune and Shimosegawa, 2009), it is possible that CEP55 
could induce PSC activation through activation of NF-κB (Peng et al., 2017). Hence, the 
increased delivery of sEVs derived from cells with extra centrosomes could result in PSC 
activation through CEP55 mediated NF-κB activation. 
Therefore, although the identity of sEVs factor(s) mediating PSC activation remains to be 
confirmed, a number of candidate factors have been identified for further analysis. 
 
6.4 Future directions 
Here we report the increased secretion of sEVs from cells harbouring supernumerary 
centrosomes. We also demonstrate that these sEVs have an altered protein cargo 
compared to sEVs secreted from cells with a normal centrosome number. Furthermore, 
we have shown that sEVs secreted specifically by cells with extra centrosomes are able 
to activate the main fibrosis promoting cells of the pancreas, the pancreatic stellate 
cells. The mechanisms leading to this PSC activation however remain elusive. Initially, 
we plan to perform a small siRNA screen based on our SILAC proteomic analysis, to 
deplete the identified protein in sEVs. The PSC activating potential of the sEVs will then 
be analysed to determine if these proteins play a role in sEV-mediated PSC activation. 
Additionally, as ROS can be transferred to recipient cells directly through exosomes 
(reviewed in Tafani et al., 2016), we plan to assess the potential role of ROS transfer. To 
do this we will quantify PSC activation upon treatment with sEVs in the presence of the 
ROS scavenger NAC. Furthermore, whilst our proteomics data rule out TGF-β as the 
direct activator of the PSCs (since TGF-β was not identified in the sEVs), a role for the 
TGF-β pathway could initially not be ruled out. Recent work performed in our laboratory 
however found that sEV-mediated PSC activation did not result in the accumulation of 
nuclear SMAD4 (Csere and Godinho, unpublished) which is a hallmark of TGF-β  
activation (Dennler et al., 1998). Thus, indicating that sEVs from cells with extra 
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centrosomes activate PSCs in a TGF- β independent manner. We therefore plan to 
perform RNA-seq and phosphoproteomics analysis to determine the signalling pathways 
activated upon sEV-mediated PSC activation. 
Although we have identified a role for sEVs in the activation of PSCs, the direct cellular 
consequences of this activation remain to be analysed. Future work will therefore focus 
on determining the physiological effects of PSC activation by sEVs from cells with extra 
centrosomes, looking in particular at ECM deposition/fibrosis and PSC mediated PDAC 
cell invasion. Initially, centrosome amplification-induced fibrosis will be analysed in vitro 
by performing matrisome proteomic analysis of PSC derived ECM upon treatment with 
sEVs from cells with and without the induction of centrosome amplification. If a 
centrosome amplification-associated fibrotic signature is identified, this signature will 
be subsequently analysed in 3-D using a recently establish 3-D spheroid model (in 
collaboration with Richard Grose and Ed Carter at the BCI). Prior to co-culture, PSCs will 
be pre-educated with sEVs derived from PaTu-S.PLK4 and HPAF-II.PLK4 cells with and 
without the induction of centrosome amplification. The resultant PSCs will then be co-
cultured with PaTu-S or HPAF-II cells and the presence or absence of a centrosome 
amplification-associated fibrotic signature will be analysed. As activated pancreatic cells 
have been shown to induce PDAC cell invasion, we will also utilise this model to analyse 
the role of centrosome amplification associated PSC activation on PDAC cell invasion. 
Again, PSCs will be pre-educated by sEVs derived by PDAC cells with and without 
centrosome amplification before being co-cultured with PDAC cells. PSC led PDAC 
invasion out from the 3D sphere will then be analysed by quantifying the total 
percentage invasive area after 2-5 days.  
If centrosome amplification associated activation of PSCs results in fibrosis, the role of 
PSC activation will be analysed in vivo. In collaboration with Professor Hemant Kocher 
at the BCI we plan to use orthotopic xenograft models to assess the role of cells with 
centrosome amplification in the recruitment and activation of PSCs, development of 
fibrosis and metastasis. PDAC cells with and without the induction of centrosome 
amplification will be injected orthotopically into the pancreases of 
immunocompromised mice (Hotz et al., 2003) and 10 weeks later, the mice will be 
sacrificed and the tumours analysed. Paraffin embedded tumour sections will be used 
to perform immunofluorescence staining of α-SMA to enable PSC 
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recruitment/activation to be quantified. Frozen tumour sections will be analysed for the 
fibrotic signature developed in vitro, and mRNA and protein analysis will be performed 
(see Figure 6.1.4). MRI will be used throughout the experiment to monitor tumour 
burden and metastasis to the liver (the main metastasis site for pancreatic cancer). 
Furthermore, to analyse the effects of sEVs secreted by cells with supernumerary 
centrosomes in PDAC fibrosis, we are currently developing a synergistic mouse model 
to enable us to track cells that incorporate sEVs.  To do this we will use the mT/mG 
mouse model which constitutively expresses membrane targeted tdTomato until Cre 
recombination switches expression to membrane targeted GFP (Muzumdar et al., 2007) 
and the mouse KPC-derived cell line TB32048, that we are currently generating to 
express our PLK4 inducible construct (enabling the induction of centrosome 
amplification) and constitutive Cre. As has been previously described by Zomer et al., 
2015, overexpression of Cre results in its incorporation into exosomes/ sEVs (Zomer et 
al., 2015). Therefore, mT/mG mouse cells that incorporate sEVs from TB32048.PLK4.CRE 
cells will result in a cre recombination mediated switch from membrane targeted 
tdTomato to membrane targeted GFP, permitting us to determine which of the 
surrounding tumour cells incorporate sEVs from the tumour. The mT/mG mouse will be 
injected with TB32048.PLK4.CRE cells with and without the induction of centrosome 
amplification. After 4 weeks, mice will be sacrificed and tumours will be analysed.  
Analysis of the GFP+ve cells will enable us to determine differences in the uptake of sEVs 
from cells with and without centrosome amplification. Furthermore, we will quantify 
the percentage of activated fibroblasts using an α-SMA+ve GFP+ve cell analysis, to 
determine if cells with extra centrosomes enhance PSC activation via exosomal cargo 
transfer in vivo compared to cells with normal centrosome number. Subsequently, 
fibrosis and metastasis will be analysed again as previously described. If changes in PSC 
activation and fibrosis are observed upon injection of TB32048.PLK4.CRE cells induced 
for centrosome amplification, we will analyse the response of these tumours to the 
PDAC chemotherapeutic agent gemcitabine. As fibrosis is known to provide a barrier to 
therapeutic intervention, we hypothesise that increased fibrosis induced by cells with 
centrosome amplification will hamper treatment. 
In addition to analysing the effects of centrosome amplification derived sEVs on 
tumourigenesis, we also aim to determine whether or not these sEVs may be used as a 
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centrosome amplification associated prognostic biomarker for PDAC. As our proteomic 
analysis revealed gains and losses in 6 key proteins, we plan to determine if these 
changes in sEV protein can be used as a signature for centrosome amplification. We 
therefore plan to isolate sEVs from the blood of mice taken at multiple time points 
following injection with PDAC cells with and without the induction of centrosome 
amplification. sEVs in the blood will be harvested and analysed for our centrosome 
amplification signature (see Figure 6.4). This mouse model will enable us to quantify 
centrosome amplification at various stages of PDAC progression and blood biopsies 
taken from the same mice will enable us to identify the stage of PDAC progression in 
which our marker presents.  Furthermore, in collaboration with Professor Hemant 
Kocher at the BCI we also plan to analyse matching blood and tumour samples from 
PDAC patients to determine whether or not centrosome amplification in human 
tumours correlates with our centrosome amplification signature in liquid biopsies (see 
Figure 6.4). 
The dense fibrosis associated with PDAC is now understood to be a significant barrier to 
therapeutic intervention. Thus, therapeutics were designed to ablate the tumour stroma 
in the hopes of improving drug delivery and reducing metastasis (Provenzano et al., 
2012; Chauhan et al., 2013; Jacobetz et al., 2013). Mounting evidence now indicates, 
however, that ablating the tumour stroma is actually detrimental to survival and 
promotes tumour cell proliferation and invasion (Özdemir et al., 2014; Rhim et al., 
2014). Subsequent efforts have therefore been focused on modulating the tumour 
microenvironment rather than completely ablating it. Clearly it is necessary to increase 
our understanding of stroma dynamics in PDAC. The future work presented here aims 
to identify a centrosome amplification associated stromal signature that could help us 
identify novel targets to modulate the PDAC stroma. Furthermore, we aim to identify a 
centrosome amplification associated sEV signature that could potentially be used as a 
biomarker for PDAC patients with tumours harbouring extra centrosomes. In this way, 
we hope to be able to identify patients who may benefit from centrosome amplification 
targeting or associated therapies.  
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Figure 6.4 Schematic diagrams of future in vivo work. A) Mouse xenograft model. 
Immunocompromised mice will be injected with cells harbouring supernumerary or normal 
centrosomes. Tumours will be analysed for PSC activation and fibrosis. sEVs from the blood of 
the mice will be isolated and analysed for the presence of the centrosome amplification-
associated sEV signature. B) Human validation model. Matching human tumour and blood 
biopsies will be used to determine whether a centrosome amplification marker can be detected 
in sEVs isolated from the blood of patients with tumours harbouring supernumerary 
centrosomes. 
 
 186 
 
Bibliography  
Abrami, L., Brandi, L., Moayeri, M., Brown, M. J., Krantz, B. A., Leppla, S. H. and 
VanderGoot, F. G. (2013) ‘Hijacking Multivesicular Bodies Enables Long-Term and 
Exosome-Mediated Long-Distance Action of Anthrax Toxin’, Cell Rep., 5(4), pp. 
986–996. 
Abramowicz, A., Widlak, P. and Pietrowska, M. (2016) ‘Proteomic analysis of exosomal 
cargo: The challenge of high purity vesicle isolation’, Mol. Biosyst., 12(5), pp. 
1407–1419. 
Adachi, H., Majima, S., Kon, S., Kobayashi, T., Kajino, K., Mitani, H., Hirayama, Y., et al. 
(2004) ‘Niban gene is commonly expressed in the renal tumors: A new candidate 
marker for renal carcinogenesis’, Oncogene, 23(19), pp. 3495–3500. 
Adamska, A., Domenichini, A. and Falasca, M. (2017) ‘Pancreatic ductal 
adenocarcinoma: Current and evolving therapies’, Int. J. Mol. Sci. MDPI AG. 
Ahmad, F. and Leake, D. S. (2019) ‘Lysosomal oxidation of LDL alters lysosomal pH, 
induces senescence, and increases secretion of pro-inflammatory cytokines in 
human macrophages’, J. Lipid Res., 60(1), pp. 98–110. 
Ahmed, S., Bradshaw, A.-D., Gera, S., Dewan, M. and Xu, R. (2017) ‘The TGF-β/Smad4 
Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance’, J. 
Clin. Med., 6(1), p. 5. 
Aits, S. and Jaattela, M. (2013) ‘Lysosomal cell death at a glance’, J. Cell Sci., 126(9), pp. 
1905–1912. 
Al-Nedawi, K., Meehan, B., Micallef, J., Lhotak, V., May, L., Guha, A. and Rak, J. (2008) 
‘Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived 
from tumour cells’, Nat. Cell Biol., 10(5), pp. 619–624. 
Alderton, G. K. (2014) ‘Microenvironment: An exercise in restraint.’, Nat. Rev. Cancer, 
14(7), p. 449. 
Alegre, E., Sanmamed, M. F., Rodriguez, C., Carranza, O., Martín-Algarra, S. and 
González, Á. (2014) ‘Study of circulating MicroRNA-125b levels in serum exosomes 
 187 
 
in advanced melanoma’, Arch. Pathol. Lab. Med., 138(6), pp. 828–832. 
Allan, V. J. (2011) ‘Cytoplasmic dynein.’, Biochem. Soc. Trans., 39(5), pp. 1169–78. 
Alvarez-Erviti, L., Seow, Y., Schapira, A. H., Gardiner, C., Sargent, I. L., Wood, M. J. A. 
and Cooper, J. M. (2011) ‘Lysosomal dysfunction increases exosome-mediated 
alpha-synuclein release and transmission’, Neurobiol. Dis., 42(3), pp. 360–367. 
Amrutkar, M., Aasrum, M., Verbeke, C. S. and Gladhaug, I. P. (2019) ‘Secretion of 
fibronectin by human pancreatic stellate cells promotes chemoresistance to 
gemcitabine in pancreatic cancer cells’, BMC Cancer, 19(1). 
Andersen, J. S., Wilkinson, C. J., Mayor, T., Mortensen, P., Nigg, E. A. and Mann, M. 
(2003) ‘Proteomic characterization of the human centrosome by protein 
correlation profiling’, Nature. 
Andoh, A., Takaya, H., Saotome, T., Shimada, M., Hata, K., Araki, Y., Nakamura, F., et al. 
(2000) ‘Cytokine regulation of chemokine (IL-8, MCP-1, and RANTES) gene 
expression in human pancreatic periacinar myofibroblasts.’, Gastroenterology, 
119(1), pp. 211–9. 
Andreassen, P. R., Lohez, O. D., Lacroix, F. B. and Margolis, R. L. (2001) ‘Tetraploid State 
Induces p53-dependent Arrest of Nontransformed Mammalian Cells in G1’, Mol. 
Biol. Cell. 
Ansari, D., Del Pino Bellido, C., Bauden, M. and Andersson, R. (2018) ‘Centrosomal 
Abnormalities in Pancreatic Cancer: Molecular Mechanisms and Clinical 
Implications’, Anticancer Res., 38(3), pp. 1241–1245. 
Antonyak, M. A., Wilson, K. F. and Cerione, R. A. (2012) ‘R(h)oads to microvesicles’, 
Small GTPases. Taylor and Francis Inc. 
Aoki, H., Ohnishi, H., Hama, K., Ishijima, T., Satoh, Y., Hanatsuka, K., Ohashi, A., et al. 
(2005) ‘Autocrine loop between TGF-β 1 and IL-1β through Smad3- and ERK-
dependent pathways in rat pancreatic stellate cells’, Am. J. Physiol. Physiol., 
290(4), pp. C1100–C1108. 
Apte, M. V., Wilson, J. S., Lugea, A. and Pandol, S. J. (2013) ‘A starring role for stellate 
cells in the pancreatic cancer microenvironment’, Gastroenterology, 144(6), pp. 
 188 
 
1210–1219. 
Apte, M. V, Haber, P. S., Applegate, T. L., Norton, I. D., McCaughan, G. W., Korsten, M. 
A., Pirola, R. C., et al. (1998) ‘Periacinar stellate shaped cells in rat pancreas: 
identification, isolation, and culture.’, Gut, 43(1), pp. 128–33. 
Apte, M. V, Haber, P. S., Darby, S. J., Rodgers, S. C., McCaughan, G. W., Korsten, M. A., 
Pirola, R. C., et al. (1999) ‘Pancreatic stellate cells are activated by 
proinflammatory cytokines: implications for pancreatic fibrogenesis.’, Gut, 44(4), 
pp. 534–41. 
Apte, M. V, Phillips, P. A., Fahmy, R. G., Darby, S. J., Rodgers, S. C., McCaughan, G. W., 
Korsten, M. A., et al. (2000) ‘Does alcohol directly stimulate pancreatic 
fibrogenesis? Studies with rat pancreatic stellate cells.’, Gastroenterology, 118(4), 
pp. 780–94. 
Apte, M. V, Park, S., Phillips, P. A., Santucci, N., Goldstein, D., Kumar, R. K., Ramm, G. 
A., et al. (2004) ‘Desmoplastic reaction in pancreatic cancer: role of pancreatic 
stellate cells.’, Pancreas, 29(3), pp. 179–87. 
Apte, M. V and Wilson, J. S. (2012) ‘Dangerous liaisons: Pancreatic stellate cells and 
pancreatic cancer cells’, J. Gastroenterol. Hepatol., 27(SUPPL.2), pp. 69–74. 
Arnandis, T., Monteiro, P., Adams, S. D., Bridgeman, V. L., Rajeeve, V., Gadaleta, E., 
Marzec, J., et al. (2018) ‘Oxidative Stress in Cells with Extra Centrosomes Drives 
Non-Cell-Autonomous Invasion’, Dev. Cell, 47(4), pp. 409-424.e9. 
Arquint, C. and Nigg, E. A. (2016) ‘The PLK4-STIL-SAS-6 module at the core of centriole 
duplication’, Biochem. Soc. Trans. Portland Press Ltd, pp. 1253–1263. 
Arumugam, T., Brandt, W., Ramachandran, V., Moore, T. T., Wang, H., May, F. E., 
Westley, B. R., et al. (2011) ‘Trefoil factor 1 stimulates both pancreatic cancer and 
stellate cells and increases metastasis’, Pancreas, 40(6), pp. 815–822. 
Ayob, A. Z. and Ramasamy, T. S. (2018) ‘Cancer stem cells as key drivers of tumour 
progression.’, J. Biomed. Sci., 25(1), p. 20. 
Bachem, M. G., Schneider, E., Gross, H., Weidenbach, H., Schmid, R. M., Menke, A., 
Siech, M., et al. (1998) ‘Identification, culture, and characterization of pancreatic 
 189 
 
stellate cells in rats and humans.’, Gastroenterology, 115(2), pp. 421–32. 
Bachem, M. G., Schünemann, M., Ramadani, M., Siech, M., Beger, H., Buck, A., Zhou, 
S., et al. (2005) ‘Pancreatic carcinoma cells induce fibrosis by stimulating 
proliferation and matrix synthesis of stellate cells.’, Gastroenterology, 128(4), pp. 
907–21. 
Bahe, S., Stierhof, Y.-D., Wilkinson, C. J., Leiss, F. and Nigg, E. A. (2005) ‘Rootletin forms 
centriole-associated filaments and functions in centrosome cohesion.’, J. Cell Biol., 
171(1), pp. 27–33. 
Baietti, M. F., Zhang, Z., Mortier, E., Melchior, A., Degeest, G., Geeraerts, A., Ivarsson, 
Y., et al. (2012) ‘Syndecan-syntenin-ALIX regulates the biogenesis of exosomes’, 
Nat. Cell Biol., 14(7), pp. 677–685. 
Bailey, J. M., Swanson, B. J., Hamada, T., Eggers, J. P., Singh, P. K., Caffery, T., Ouellette, 
M. M., et al. (2008) ‘Sonic hedgehog promotes desmoplasia in pancreatic cancer’, 
Clin. Cancer Res., 14(19), pp. 5995–6004. 
Balderhaar, H. J. kleine and Ungermann, C. (2013) ‘CORVET and HOPS tethering 
complexes - coordinators of endosome and lysosome fusion.’, J. Cell Sci., 126(Pt 
6), pp. 1307–16. 
Bansal, R., Van Baarlen, J., Storm, G. and Prakash, J. (2015) ‘The interplay of the Notch 
signaling in hepatic stellate cells and macrophages determines the fate of liver 
fibrogenesis’, Sci. Rep., 5. 
Bardeesy, N. and DePinho, R. A. (2002) ‘Pancreatic cancer biology and genetics’, Nat. 
Rev. Cancer, pp. 897–909. 
Barranco, I., Padilla, L., Parrilla, I., Álvarez-Barrientos, A., Pérez-Patiño, C., Peña, F. J., 
Martínez, E. A., et al. (2019) ‘Extracellular vesicles isolated from porcine seminal 
plasma exhibit different tetraspanin expression profiles’, Sci. Rep., 9(1), p. 11584. 
Barrès, C., Blanc, L., Bette-Bobillo, P., André, S., Mamoun, R., Gabius, H. J. and Vidal, M. 
(2010) ‘Galectin-5 is bound onto the surface of rat reticulocyte exosomes and 
modulates vesicle uptake by macrophages’, Blood, 115(3), pp. 696–705. 
Barros, T. P., Kinoshita, K., Hyman, A. A. and Raff, J. W. (2005) ‘Aurora A activates D-
 190 
 
TACC-Msps complexes exclusively at centrosomes to stabilize centrosomal 
microtubules.’, J. Cell Biol., 170(7), pp. 1039–46. 
Basto, R., Lau, J., Vinogradova, T., Gardiol, A., Woods, C. G., Khodjakov, A. and Raff, J. 
W. (2006) ‘Flies without Centrioles’, Cell, 125(7), pp. 1375–1386. 
Basto, R., Brunk, K., Vinadogrova, T., Peel, N., Franz, A., Khodjakov, A. and Raff, J. W. 
(2008) ‘Centrosome Amplification Can Initiate Tumorigenesis in Flies’, Cell, 133(6), 
pp. 1032–1042. 
Batagov, A. O., Kuznetsov, V. A. and Kurochkin, I. V. (2011) ‘Identification of nucleotide 
patterns enriched in secreted RNAs as putative cis-acting elements targeting them 
to exosome nano-vesicles’, in 10th Int. Conf. Bioinforma. - 1st ISCB Asia Jt. Conf. 
2011, InCoB 2011/ISCB-Asia 2011 Comput. Biol. - Proc. from Asia Pacific 
Bioinforma. Netw. 
Baumbach, J., Novak, Z. A., Raff, J. W. and Wainman, A. (2015) ‘Dissecting the function 
and assembly of acentriolar microtubule organizing centers in Drosophila cells in 
vivo.’, PLoS Genet., 11(5), p. e1005261. 
Bazzi, H. and Anderson, K. V (2014) ‘Acentriolar mitosis activates a p53-dependent 
apoptosis pathway in the mouse embryo.’, Proc. Natl. Acad. Sci. U. S. A., 111(15), 
pp. E1491-500. 
Becker, A., Thakur, B. K., Weiss, J. M., Kim, H. S., Peinado, H. and Lyden, D. (2016) 
‘Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis’, Cancer Cell, 
pp. 836–848. 
Behrens, G., Jochem, C., Schmid, D., Keimling, M., Ricci, C. and Leitzmann, M. F. (2015) 
‘Physical activity and risk of pancreatic cancer: a systematic review and meta-
analysis.’, Eur. J. Epidemiol., 30(4), pp. 279–98. 
Belham, C., Roig, J., Caldwell, J. A., Aoyama, Y., Kemp, B. E., Comb, M. and Avruch, J. 
(2003) ‘A Mitotic Cascade of NIMA Family Kinases’, J. Biol. Chem., 278(37), pp. 
34897–34909. 
Benedikter, B. J., Bouwman, F. G., Vajen, T., Heinzmann, A. C. A., Grauls, G., Mariman, 
E. C., Wouters, E. F. M., et al. (2017) ‘Ultrafiltration combined with size exclusion 
 191 
 
chromatography efficiently isolates extracellular vesicles from cell culture media 
for compositional and functional studies’, Sci. Rep., 7(1). 
Berditchevski, F. and Odintsova, E. (1999) ‘Characterization of Integrin–Tetraspanin 
Adhesion Complexes: Role of Tetraspanins in Integrin Signaling’, J. Cell Biol., 
146(2), p. 477. 
Berlin, J. D., Adak, S., Vaughn, D. J., Flinker, D., Blaszkowsky, L., Harris, J. E. and Benson 
IIIAB, A. B. A. B. B. (2000) ‘A phase II study of gemcitabine and 5-fluorouracil in 
metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study 
(E3296).’, Oncology, 58(3), pp. 215–8. 
Bertran, M. T., Sdelci, S., Regué, L., Avruch, J., Caelles, C. and Roig, J. (2011) ‘Nek9 is a 
Plk1-activated kinase that controls early centrosome separation through Nek6/7 
and Eg5.’, EMBO J., 30(13), pp. 2634–47. 
Bettencourt-Dias, M., Rodrigues-Martins, A., Carpenter, L., Riparbelli, M., Lehmann, L., 
Gatt, M. K., Carmo, N., et al. (2005) ‘SAK/PLK4 is required for centriole duplication 
and flagella development’, Curr. Biol., 15(24), pp. 2199–2207. 
Bettencourt-Dias, M. and Glover, D. M. (2007) ‘Centrosome biogenesis and function: 
centrosomics brings new understanding.’, Nat. Rev. Mol. Cell Biol., 8(6), pp. 451–
63. 
Bewicke-Copley, F., Mulcahy, L. A., Jacobs, L. A., Samuel, P., Akbar, N., Pink, R. C. and 
Carter, D. R. F. (2017) ‘Extracellular vesicles released following heat stress induce 
bystander effect in unstressed populations.’, J. Extracell. vesicles, 6(1), p. 
1340746. 
Bhattacharya, S., Pal, K., Sharma, A. K., Dutta, S. K., Lau, J. S., Yan, I. K., Wang, E., et al. 
(2014) ‘GAIP interacting protein C-Terminus regulates autophagy and exosome 
biogenesis of pancreatic cancer through metabolic pathways’, PLoS One, 9(12). 
Bianco, F, Perrotta, C, Novellino, L, Francolini, M, Riganti, L, Menna, E, Saglietti, L, et al. 
(2009) ‘Acid sphingomyelinase activity triggers microparticle release from glial 
cells.[Erratum appears in EMBO J. 2009 May 6;28(9):1374]’, EMBO J., 28(8), pp. 
1043–1054. 
 192 
 
Bignold, L. P., Coghlan, B. L. D. and Jersmann, H. P. A. (2006) ‘Hansemann, Boveri, 
chromosomes and the gametogenesis-related theories of tumours’, Cell Biol. Int., 
30(7), pp. 640–644. 
Bilimoria, K. Y., Talamonti, M. S., Tomlinson, J. S., Stewart, A. K., Winchester, D. P., Ko, 
C. Y. and Bentrem, D. J. (2008) ‘Prognostic score predicting survival after resection 
of pancreatic neuroendocrine tumors: analysis of 3851 patients.’, Ann. Surg., 
247(3), pp. 490–500. 
Binenbaum, Y., Na’ara, S. and Gil, Z. (2015) ‘Gemcitabine resistance in pancreatic 
ductal adenocarcinoma.’, Drug Resist. Updat., 23, pp. 55–68. 
Blachon, S., Gopalakrishnan, J., Omori, Y., Polyanovsky, A., Church, A., Nicastro, D., 
Malicki, J., et al. (2008) ‘Drosophila asterless and vertebrate Cep152 Are orthologs 
essential for centriole duplication.’, Genetics, 180(4), pp. 2081–94. 
Blangy, A., Lane, H. A., d’Hérin, P., Harper, M., Kress, M. and Nigg, E. A. (1995) 
‘Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a 
kinesin-related motor essential for bipolar spindle formation in vivo.’, Cell, 83(7), 
pp. 1159–69. 
Böing, A., van der Pol, E., Grootemaat, A., Coumans, F., Sturk, A. and Nieuwland, R. 
(2014) ‘Single-step isolation of extracellular vesicles by size-exclusion 
chromatography’, J. Extracell. Vesicles, 3(1). 
Bonifacino, J. S. and Glick, B. S. (2004) ‘The Mechanisms of Vesicle Budding and 
Fusion’, Cell. Cell Press, pp. 153–166. 
Bornens, M. (2012) ‘The centrosome in cells and organisms’, Science (80-. )., 
335(6067), pp. 422–426. 
Bosetti, C., Lucenteforte, E., Silverman, D. T., Petersen, G., Bracci, P. M., Ji, B. T., Negri, 
E., et al. (2012) ‘Cigarette smoking and pancreatic cancer: An analysis from the 
International Pancreatic Cancer Case-Control Consortium (PANC4)’, Ann. Oncol., 
23(7), pp. 1880–1888. 
Bosetti, C., Bravi, F., Turati, F., Edefonti, V., Polesel, J., Decarli, A., Negri, E., et al. (2013) 
‘Nutrient-based dietary patterns and pancreatic cancer risk.’, Ann. Epidemiol., 
 193 
 
23(3), pp. 124–8. 
Bosetti, C., Rosato, V., Li, D., Silverman, D., Petersen, G. M., Bracci, P. M., Neale, R. E., 
et al. (2014) ‘Diabetes, antidiabetic medications, and pancreatic cancer risk: an 
analysis from the International Pancreatic Cancer Case-Control Consortium.’, Ann. 
Oncol.  Off. J. Eur. Soc. Med. Oncol., 25(10), pp. 2065–72. 
Bourens, M., Fontanesi, F., Soto, I. C., Liu, J. and Barrientos, A. (2013) ‘Redox and 
reactive oxygen species regulation of mitochondrial cytochrome C oxidase 
biogenesis’, Antioxidants Redox Signal., pp. 1940–1952. 
Boveri, T. (1887) ‘Uber Die Befunchtung Der Eier von Ascaris Megalocephala.tle’, 
SitzBer. Ges. Morph. Phys. Munchen, 3, pp. 71–80. 
Boveri, T. (1888) ‘Zellen-Studien 2: Die Befrunchtung Und Telung Des Eies von Ascaris 
Megalocephala’, Jenaische Zeitschr. Med. Naturw, 22, pp. 685–882. 
Boveri, T. (2008) ‘Concerning the Origin of Malignant Tumours by Theodor Boveri. 
Translated and annotated by Henry Harris’, J. Cell Sci., 121(Supplement 1), pp. 1–
84. 
van Breugel, M., Hirono, M., Andreeva, A., Yanagisawa, H. -a., Yamaguchi, S., 
Nakazawa, Y., Morgner, N., et al. (2011) ‘Structures of SAS-6 Suggest Its 
Organization in Centrioles’, Science (80-. )., 331(6021), pp. 1196–1199. 
van Breugel, M., Wilcken, R., McLaughlin, S. H., Rutherford, T. J. and Johnson, C. M. 
(2014) ‘Structure of the SAS-6 cartwheel hub from Leishmania major’, Elife, 3, p. 
e01812. 
Brinkley, B. R. (2001) ‘Managing the centrosome numbers game: from chaos to 
stability in cancer cell division.’, Trends Cell Biol., 11(1), pp. 18–21. 
Brown, K. F., Rumgay, H., Dunlop, C., Ryan, M., Quartly, F., Cox, A., Deas, A., et al. 
(2018) ‘The fraction of cancer attributable to modifiable risk factors in England, 
Wales, Scotland, Northern Ireland, and the United Kingdom in 2015.’, Br. J. 
Cancer, 118(8), pp. 1130–1141. 
Brownlee, C. W., Klebba, J. E., Buster, D. W. and Rogers, G. C. (2011) ‘The Protein 
Phosphatase 2A regulatory subunit Twins stabilizes Plk4 to induce centriole 
 194 
 
amplification’, J. Cell Biol., 195(2), p. 231. 
Brownlee, C. W. and Rogers, G. C. (2013) ‘Show me your license, please: deregulation 
of centriole duplication mechanisms that promote amplification’, Cell. Mol. Life 
Sci., 70(6), pp. 1021–1034. 
Bryant, R. J., Pawlowski, T., Catto, J. W. F., Marsden, G., Vessella, R. L., Rhees, B., 
Kuslich, C., et al. (2012) ‘Changes in circulating microRNA levels associated with 
prostate cancer’, Br. J. Cancer, 106(4), pp. 768–774. 
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. 
R., Cripps, M. C., et al. (1997) ‘Improvements in survival and clinical benefit with 
gemcitabine as first- line therapy for patients with advanced pancreas cancer: A 
randomized trial’, J. Clin. Oncol., 15(6), pp. 2403–2413. 
Bynigeri, R. R., Jakkampudi, A., Jangala, R., Subramanyam, C., Sasikala, M., Rao, G. V., 
Reddy, D. N., et al. (2017) ‘Pancreatic stellate cell: Pandora’s box for pancreatic 
disease biology’, World J. Gastroenterol., 23(3), p. 382. 
Cai, S., Weaver, L. N., Ems-McClung, S. C. and Walczak, C. E. (2008) ‘Kinesin-14 Family 
Proteins HSET/XCTK2 Control Spindle Length by Cross-Linking and Sliding 
Microtubules’, Mol. Biol. Cell, 20(5), pp. 1348–1359. 
Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., 
Weinstein, C. L., et al. (1994) ‘Frequent somatic mutations and homozygous 
deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.’, Nat. Genet., 
8(1), pp. 27–32. 
Calvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., 
Harrington, K., et al. (2013) ‘Mechanotransduction and YAP-dependent matrix 
remodelling is required for the generation and maintenance of cancer-associated 
fibroblasts’, Nat. Cell Biol., 15(6), pp. 637–646. 
Cancer Research UK (2019) Cancer Statistics for the UK. Available at: 
https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-
uk. 
Canto, M. I., Hruban, R. H., Fishman, E. K., Kamel, I. R., Zhang, Z., Topazian, M., 
 195 
 
Takahashi, N., et al. (2012) ‘Frequent detection of pancreatic lesions in 
asymptomatic high-risk individuals: screening for early pancreatic neoplasia (CAPS 
3 Study)’, Gastroenterology, 142(4), pp. 796–804. 
Carapuça, E. F., Gemenetzidis, E., Feig, C., Bapiro, T. E., Williams, M. D., Wilson, A. S., 
Delvecchio, F. R., et al. (2016) ‘Anti-stromal treatment together with 
chemotherapy targets multiple signalling pathways in pancreatic 
adenocarcinoma.’, J. Pathol., 239(3), pp. 286–96. 
Carelli, S., Ceriotti, A., Cabibbo, A., Fassina, G., Ruvo, M. and Sitia, R. (1997) ‘Cysteine 
and glutathione secretion in response to protein disulfide bond formation in the 
ER.’, Science, 277(5332), pp. 1681–4. 
Carvalho-Santos, Z., Azimzadeh, J., Pereira-Leal, J. B. and Bettencourt-Dias, M. (2011) 
‘Evolution: Tracing the origins of centrioles, cilia, and flagella.’, J. Cell Biol., 194(2), 
pp. 165–75. 
Chan, J. Y. (2011) ‘A clinical overview of centrosome amplification in human cancers’, 
Int. J. Biol. Sci., 7(8), pp. 1122–1144. 
Chari, S. T., Leibson, C. L., Rabe, K. G., Timmons, L. J., Ransom, J., de Andrade, M. and 
Petersen, G. M. (2008) ‘Pancreatic cancer-associated diabetes mellitus: 
prevalence and temporal association with diagnosis of cancer.’, Gastroenterology, 
134(1), pp. 95–101. 
Charrier, A., Chen, R., Chen, L., Kemper, S., Hattori, T., Takigawa, M. and Brigstock, D. 
R. (2014) ‘Exosomes mediate intercellular transfer of pro-fibrogenic connective 
tissue growth factor (CCN2) between hepatic stellate cells, the principal fibrotic 
cells in the liver’, Surg. (United States), 156(3), pp. 548–555. 
Chaudhary, P. (2015) ‘Acinar Cell Carcinoma of the Pancreas: A Literature Review and 
Update’, Indian J. Surg. Springer India, pp. 226–231. 
Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V, 
Stylianopoulos, T., et al. (2013) ‘Angiotensin inhibition enhances drug delivery and 
potentiates chemotherapy by decompressing tumour blood vessels.’, Nat. 
Commun., 4, p. 2516. 
 196 
 
Chen, C. Y., Caporizzo, M. A., Bedi, K., Vite, A., Bogush, A. I., Robison, P., Heffler, J. G., 
et al. (2018) ‘Suppression of detyrosinated microtubules improves cardiomyocyte 
function in human heart failure’, Nat. Med., 24(8), pp. 1225–1233. 
Chen, W. X., Liu, X. M., Lv, M. M., Chen, L., Zhao, J. H., Zhong, S. L., Ji, M. H., et al. 
(2014) ‘Exosomes from drug-resistant breast cancer cells transmit 
chemoresistance by a horizontal transfer of micrornas’, PLoS One. Edited by M. 
Tan, 9(4), p. e95240. 
Chen, Y. W., Hsiao, P. J., Weng, C. C., Kuo, K. K., Kuo, T. L., Wu, D. C., Hung, W. C., et al. 
(2014) ‘SMAD4 Loss triggers the phenotypic changes of pancreatic ductal 
adenocarcinoma cells’, BMC Cancer, 14(1). 
Chivet, M., Javalet, C., Laulagnier, K., Blot, B., Hemming, F. J. and Sadoul, R. (2014) 
‘Exosomes secreted by cortical neurons upon glutamatergic synapse activation 
specifically interact with neurons.’, J. Extracell. vesicles, 3, p. 24722. 
Cho, J. A., Park, H., Lim, E. H. and Lee, K. W. (2012) ‘Exosomes from breast cancer cells 
can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-
like cells’, Int. J. Oncol., 40(1), pp. 130–138. 
Cimini, D. (2008) ‘Merotelic kinetochore orientation, aneuploidy, and cancer’, Biochim. 
Biophys. Acta - Rev. Cancer. 
Coelho, P. A., Bury, L., Shahbazi, M. N., Liakath-Ali, K., Tate, P. H., Wormald, S., Hindley, 
C. J., et al. (2015) ‘Over-expression of Plk4 induces centrosome amplification, loss 
of primary cilia and associated tissue hyperplasia in the mouse.’, Open Biol., 5(12), 
pp. 150209-. 
Colin, E., Zala, D., Liot, G., Rangone, H., Borrell-Pagès, M., Li, X. J., Saudou, F., et al. 
(2008) ‘Huntingtin phosphorylation acts as a molecular switch for 
anterograde/retrograde transport in neurons’, EMBO J., 27(15), pp. 2124–2134. 
Collins, A., Warrington, A., Taylor, K. A. and Svitkina, T. (2011) ‘Structural organization 
of the actin cytoskeleton at sites of clathrin-mediated endocytosis.’, Curr. Biol., 
21(14), pp. 1167–75. 
Colombo, M., Moita, C., van Niel, G., Kowal, J., Vigneron, J., Benaroch, P., Manel, N., et 
 197 
 
al. (2013) ‘Analysis of ESCRT functions in exosome biogenesis, composition and 
secretion highlights the heterogeneity of extracellular vesicles.’, J. Cell Sci., 126(Pt 
24), pp. 5553–65. 
Colombo, M., Raposo, G. and Théry, C. (2014) ‘Biogenesis, Secretion, and Intercellular 
Interactions of Exosomes and Other Extracellular Vesicles’, Annu. Rev. Cell Dev. 
Biol., 30(1), pp. 255–289. 
Conduit, P. T., Wainman, A. and Raff, J. W. (2015) ‘Centrosome function and assembly 
in animal cells’, Nat. Rev. Mol. Cell Biol., 16(10), pp. 611–624. 
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, 
A., et al. (2011) ‘FOLFIRINOX versus gemcitabine for metastatic pancreatic 
cancer.’, N. Engl. J. Med., 364(19), pp. 1817–25. 
Costa-Silva, B., Aiello, N. M., Ocean, A. J., Singh, S., Zhang, H., Thakur, B. K., Becker, A., 
et al. (2015) ‘Pancreatic cancer exosomes initiate pre-metastatic niche formation 
in the liver.’, Nat. Cell Biol., 17(6), pp. 1–7. 
Costa Verdera, H., Gitz-Francois, J. J., Schiffelers, R. M. and Vader, P. (2017) ‘Cellular 
uptake of extracellular vesicles is mediated by clathrin-independent endocytosis 
and macropinocytosis.’, J. Control. Release, 266, pp. 100–108. 
Couch, F. J., Johnson, M. R., Rabe, K. G., Brune, K., de Andrade, M., Goggins, M., 
Rothenmund, H., et al. (2007) ‘The prevalence of BRCA2 mutations in familial 
pancreatic cancer.’, Cancer Epidemiol. Biomarkers Prev., 16(2), pp. 342–6. 
Coxam, B., Neyt, C., Grassini, D. R., Le Guen, L., Smith, K. A., Schulte-Merker, S. and 
Hogan, B. M. (2015) ‘carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase (cad) regulates Notch signaling and 
vascular development in zebrafish’, Dev. Dyn., 244(1), pp. 1–9. 
Crasta, K., Ganem, N. J., Dagher, R., Lantermann, A. B., Ivanova, E. V., Pan, Y., Nezi, L., 
et al. (2012) ‘DNA breaks and chromosome pulverization from errors in mitosis’, 
Nature. 
Crawford, N. (1971) ‘The presence of contractile proteins in platelet microparticles 
isolated from human and animal platelet-free plasma.’, Br. J. Haematol., 21(1), 
 198 
 
pp. 53–69. 
Cunha-Ferreira, I., Rodrigues-Martins, A., Bento, I., Riparbelli, M., Zhang, W., Laue, E., 
Callaini, G., et al. (2009) ‘The SCF/Slimb Ubiquitin Ligase Limits Centrosome 
Amplification through Degradation of SAK/PLK4’, Curr. Biol., 19(1), pp. 43–49. 
D’Assoro, A. B., Barrett, S. L., Folk, C., Negron, V. C., Boeneman, K., Busby, R., 
Whitehead, C., et al. (2002a) ‘Amplified centrosomes in breast cancer: a potential 
indicator of tumor aggressiveness.’, Breast Cancer Res. Treat., 75(1), pp. 25–34. 
D’Assoro, A. B., Barrett, S. L., Folk, C., Negron, V. C., Boeneman, K., Busby, R., 
Whitehead, C., et al. (2002b) ‘Amplified centrosomes in breast cancer: a potential 
indicator of tumor aggressiveness.’, Breast Cancer Res. Treat., 75(1), pp. 25–34. 
Dabitao, D., Margolick, J. B., Lopez, J. and Bream, J. H. (2011) ‘Multiplex measurement 
of proinflammatory cytokines in human serum: comparison of the Meso Scale 
Discovery electrochemiluminescence assay and the Cytometric Bead Array.’, J. 
Immunol. Methods, 372(1–2), pp. 71–7. 
Davies, B. A., Lee, J. R. E., Oestreich, A. J. and Katzmann, D. J. (2009) ‘Membrane 
protein targeting to the MVB/lysosome’, Chem. Rev., pp. 1575–1586. 
Debec, A. (1978) ‘Haploid cell cultures of Drosophila melanogaster [19]’, Nature, pp. 
255–256. 
Dennler, S., Itoh, S., Vivien, D., Dijke, P. Ten, Huet, S. and Gauthier, J. M. (1998) ‘Direct 
binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter 
of human plasminogen activator inhibitor-type 1 gene’, EMBO J., 17(11), pp. 
3091–3100. 
Denzer, K., Kleijmeer, M. J., Heijnen, H. F., Stoorvogel, W. and Geuze, H. J. (2000) 
‘Exosome: from internal vesicle of the multivesicular body to intercellular 
signaling device.’, J. Cell Sci., 113 Pt 19, pp. 3365–74. 
Van Deun, J., Mestdagh, P., Sormunen, R., Cocquyt, V., Vermaelen, K., Vandesompele, 
J., Bracke, M., et al. (2014) ‘The impact of disparate isolation methods for 
extracellular vesicles on downstream RNA profiling’, J. Extracell. Vesicles, 3(1), p. 
24858. 
 199 
 
Dinarvand, P. and Lai, J. (2017) ‘Solid pseudopapillary neoplasm of the pancreas a rare 
entity with unique features’, Arch. Pathol. Lab. Med. College of American 
Pathologists, pp. 990–995. 
DuFort, Christopher. C DelGiorno, K. E. and Hingorani, S. R. (2016) ‘Mounting Pressure 
in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal 
Adenocarcinoma’, Rev. BASIC Clin. Gastroenterol. Hepatol., 150, pp. 1545–1557. 
Dumont, J. and Desai, A. (2012) ‘Acentrosomal spindle assembly and chromosome 
segregation during oocyte meiosis.’, Trends Cell Biol., 22(5), pp. 241–9. 
Dzhindzhev, N. S., Tzolovsky, G., Lipinszki, Z., Schneider, S., Lattao, R., Fu, J., Debski, J., 
et al. (2014) ‘Plk4 phosphorylates Ana2 to trigger Sas6 recruitment and 
procentriole formation.’, Curr. Biol., 24(21), pp. 2526–32. 
Eales, K. L., Hollinshead, K. E. R. and Tennant, D. A. (2016) ‘Hypoxia and metabolic 
adaptation of cancer cells.’, Oncogenesis, 5, p. e190. 
Edgar, J. R., Manna, P. T., Nishimura, S., Banting, G. and Robinson, M. S. (2016) 
‘Tetherin is an exosomal tether.’, Elife, 5. 
Eguchi, D., Ikenaga, N., Ohuchida, K., Kozono, S., Cui, L., Fujiwara, K., Fujino, M., et al. 
(2013) ‘Hypoxia enhances the interaction between pancreatic stellate cells and 
cancer cells via increased secretion of connective tissue growth factor’, J. Surg. 
Res., 181(2), pp. 225–233. 
Eichelser, C., Stückrath, I., Müller, V., Milde-Langosch, K., Wikman, H., Pantel, K. and 
Schwarzenbach, H. (2014) ‘Increased serum levels of circulating exosomal 
microRNA-373 in receptor-negative breast cancer patients’, Oncotarget, 5(20), pp. 
9650–63. 
Eldh, M., Ekström, K., Valadi, H., Sjöstrand, M., Olsson, B., Jernås, M. and Lötvall, J. 
(2010) ‘Exosomes Communicate Protective Messages during Oxidative Stress; 
Possible Role of Exosomal Shuttle RNA’, PLoS One, 5(12), pp. 1–8. 
Emmanouilidi, A., Paladin, D., Greening, D. W. and Falasca, M. (2019) ‘Oncogenic and 
Non-Malignant Pancreatic Exosome Cargo Reveal Distinct Expression of 
Oncogenic and Prognostic Factors Involved in Tumor Invasion and Metastasis.’, 
 200 
 
Proteomics, 19(8), p. e1800158. 
Erkan, M., Michalski, C. W., Rieder, S., Reiser-Erkan, C., Abiatari, I., Kolb, A., Giese, N. 
A., et al. (2008) ‘The activated stroma index is a novel and independent 
prognostic marker in pancreatic ductal adenocarcinoma.’, Clin. Gastroenterol. 
Hepatol., 6(10), pp. 1155–61. 
Erkan, M., Adler, G., Apte, M. V, Bachem, M. G., Buchholz, M., Detlefsen, S., Esposito, 
I., et al. (2012) ‘StellaTUM: current consensus and discussion on pancreatic 
stellate cell research’, Gut, 61(2), pp. 172–178. 
Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff, J. and 
Friess, H. (2012) ‘The role of stroma in pancreatic cancer: Diagnostic and 
therapeutic implications’, Nat. Rev. Gastroenterol. Hepatol., pp. 454–467. 
Fava, L. L., Schuler, F., Sladky, V., Haschka, M. D., Soratroi, C., Eiterer, L., Demetz, E., et 
al. (2017) ‘The PIDDosome activates p53 in response to supernumerary 
centrosomes’, Genes Dev. 
Feldmann, G., Karikari, C., Dal Molin, M., Duringer, S., Volkmann, P., Bartsch, D. K., 
Bisht, S., et al. (2011) ‘Inactivation of Brca2 cooperates with Trp53R172H to 
induce invasive pancreatic ductal adenocarcinomas in mice: A mouse model of 
familial pancreatic cancer’, Cancer Biol. Ther., 11(11), pp. 959–968. 
Fendrich, V., Oh, E., Bisht Bang, S., Karikari, C., Ottenhof, N., Bisht Bang, S., Lauth, M., 
et al. (2011) ‘Ectopic overexpression of Sonic Hedgehog (Shh) induces stromal 
expansion and metaplasia in the adult murine pancreas’, Neoplasia, 13(10), pp. 
923–930. 
Ferdek, P. E. and Jakubowska, M. A. (2017) ‘Biology of pancreatic stellate cells—more 
than just pancreatic cancer’, Pflugers Arch. Eur. J. Physiol. Springer Verlag, pp. 
1039–1050. 
Fielding, A. B., Dobreva, I., McDonald, P. C., Foster, L. J. and Dedhar, S. (2008) ‘Integrin-
linked kinase localizes to the centrosome and regulates mitotic spindle 
organization’, J. Cell Biol. 
Fitzner, D., Schnaars, M., Van Rossum, D., Krishnamoorthy, G., Dibaj, P., Bakhti, M., 
 201 
 
Regen, T., et al. (2011) ‘Selective transfer of exosomes from oligodendrocytes to 
microglia by macropinocytosis’, J. Cell Sci., 124(3), pp. 447–458. 
Frampton, A. E., Prado, M. M., López-Jiménez, E., Fajardo-Puerta, A. B., Jawad, Z. A. R., 
Lawton, P., Giovannetti, E., et al. (2018) ‘Glypican-1 is enriched in circulating-
exosomes in pancreatic cancer and correlates with tumor burden’, Oncotarget, 
9(27), pp. 19006–19013. 
Friedman, S. L. (2008) ‘Hepatic stellate cells: protean, multifunctional, and enigmatic 
cells of the liver.’, Physiol. Rev., 88(1), pp. 125–72. 
Froeling, F. E. M., Feig, C., Chelala, C., Dobson, R., Mein, C. E., Tuveson, D. A., Clevers, 
H., et al. (2011) ‘Retinoic acid-induced pancreatic stellate cell quiescence reduces 
paracrine Wnt-β-catenin signaling to slow tumor progression.’, Gastroenterology, 
141(4), pp. 1486–97, 1497.e1–14. 
Frühbeis, C., Fröhlich, D., Kuo, W. P., Amphornrat, J., Thilemann, S., Saab, A. S., 
Kirchhoff, F., et al. (2013) ‘Neurotransmitter-Triggered Transfer of Exosomes 
Mediates Oligodendrocyte-Neuron Communication’, PLoS Biol. Edited by B. A. 
Barres, 11(7), p. e1001604. 
Fu, J. and Glover, D. M. (2012) ‘Structured illumination of the interface between 
centriole and peri-centriolar material’, Open Biol., 2(AUG), p. 120104. 
Fu, J., Hagan, I. M. and Glover, D. M. (2015) ‘The centrosome and its duplication cycle’, 
Cold Spring Harb. Perspect. Med., 5(1), p. a015800. 
Fu, Y., Liu, S., Zeng, S. and Shen, H. (2018) ‘The critical roles of activated stellate cells-
mediated paracrine signaling, metabolism and onco-immunology in pancreatic 
ductal adenocarcinoma’, Mol. Cancer. BioMed Central Ltd. 
Fuentealba, L. C., Eivers, E., Ikeda, A., Hurtado, C., Kuroda, H., Pera, E. M. and De 
Robertis, E. M. (2007) ‘Integrating Patterning Signals: Wnt/GSK3 Regulates the 
Duration of the BMP/Smad1 Signal’, Cell. 
Fujiwara, T., Bandi, M., Nitta, M., Ivanova, E. V., Bronson, R. T. and Pellman, D. (2005) 
‘Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null 
cells’, Nature. 
 202 
 
Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S. and Vande Woude, G. F. (1996) 
‘Abnormal Centrosome Amplification in the Absence of p53’, Science (80-. )., 
271(5256), pp. 1744–1747. 
Galeotti, G. (1893) ‘Beitrag zum Studium des Chromatins in den Epithelzellen der 
Carcinome’, Beitr. Pathol. Anat. Allg. Pathol, 14, pp. 249–271. 
Gallo, A., Tandon, M., Alevizos, I. and Illei, G. G. (2012) ‘The majority of microRNAs 
detectable in serum and saliva is concentrated in exosomes’, PLoS One. Edited by 
K. Afarinkia, 7(3), p. e30679. 
Gandhi, C. R. (2012) ‘Oxidative Stress and Hepatic Stellate Cells: A PARADOXICAL 
RELATIONSHIP.’, Trends cell Mol. Biol., 7(4), pp. 1–10. 
Ganem, N. J., Cornils, H., Chiu, S. Y., O’Rourke, K. P., Arnaud, J., Yimlamai, D., Théry, M., 
et al. (2014) ‘Cytokinesis failure triggers hippo tumor suppressor pathway 
activation’, Cell. 
Ganem, N. J., Godinho, S. A. and Pellman, D. (2009) ‘A mechanism linking extra 
centrosomes to chromosomal instability’, Nature, 460(7252), pp. 278–282. 
Ganier, O., Schnerch, D. and Nigg, E. A. (2018) ‘Structural centrosome aberrations 
sensitize polarized epithelia to basal cell extrusion’, Open Biol., 8(6). 
Gao, R. and Brigstock, D. R. (2005) ‘Connective tissue growth factor (CCN2) in rat 
pancreatic stellate cell function: Integrin α5β1 as a novel CCN2 receptor’, 
Gastroenterology, 129(3), pp. 1019–1030. 
Ge, Q., Zhou, Y., Lu, J., Bai, Y., Xie, X. and Lu, Z. (2014) ‘MiRNA in plasma exosome is 
stable under different storage conditions’, Molecules, 19(2), pp. 1568–1575. 
Ge, R., Tan, E., Sharghi-Namini, S. and Asada, H. H. (2012) ‘Exosomes in cancer 
microenvironment and beyond: Have we overlooked these extracellular 
messengers?’, Cancer Microenviron., 5(3), pp. 323–332. 
Géminard, C., De Gassart, A., Blanc, L. and Vidal, M. (2004) ‘Degradation of AP2 during 
reticulocyte maturation enhances binding of hsc70 and Alix to a common site on 
TFR for sorting into exosomes.’, Traffic, 5(3), pp. 181–93. 
Genkinger, J. M., Kitahara, C. M., Bernstein, L., Berrington de Gonzalez, A., Brotzman, 
 203 
 
M., Elena, J. W., Giles, G. G., et al. (2015) ‘Central adiposity, obesity during early 
adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies’, 
Ann. Oncol. Oxford University Press, pp. 2257–2266. 
Giardiello, F. M., Welsh, S. B., Hamilton, S. R., Offerhaus, G. J., Gittelsohn, A. M., 
Booker, S. V, Krush, A. J., et al. (1987) ‘Increased risk of cancer in the Peutz-
Jeghers syndrome.’, N. Engl. J. Med., 316(24), pp. 1511–4. 
Giehl, M., Fabarius, A., Frank, O., Hochhaus, A., Hafner, M., Hehlmann, R. and Seifarth, 
W. (2005) ‘Centrosome aberrations in chronic myeloid leukemia correlate with 
stage of disease and chromosomal instability’, Leukemia, 19(7), pp. 1192–1197. 
Giet, R., McLean, D., Descamps, S., Lee, M. J., Raff, J. W., Prigent, C. and Glover, D. M. 
(2002) ‘Drosophila Aurora A kinase is required to localize D-TACC to centrosomes 
and to regulate astral microtubules’, J. Cell Biol., 156(3), pp. 437–451. 
Godinho, S. A., Picone, R., Burute, M., Dagher, R., Su, Y., Leung, C. T., Polyak, K., et al. 
(2014) ‘Oncogene-like induction of cellular invasion from centrosome 
amplification’, Nature, 510(7503), pp. 167–171. 
Godinho, S. A. and Pellman, D. (2014) ‘Causes and consequences of centrosome 
abnormalities in cancer.’, Philos. Trans. R. Soc. Lond. B. Biol. Sci., 369(1650). 
Gogendeau, D., Guichard, P. and Tassin, A. M. (2015) ‘Purification of centrosomes from 
mammalian cell lines’, Methods Cell Biol., 129, pp. 171–189. 
Goldstein, D., El-Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., 
Scheithauer, W., et al. (2015) ‘nab-Paclitaxel plus gemcitabine for metastatic 
pancreatic cancer: long-term survival from a phase III trial.’, J. Natl. Cancer Inst., 
107(2). 
Gönczy, P. (2012) ‘Towards a molecular architecture of centriole assembly’, Nat. Rev. 
Mol. Cell Biol. Nature Publishing Group, pp. 425–435. 
Gönczy, P. (2015) ‘Centrosomes and cancer: Revisiting a long-standing relationship’, 
Nat. Rev. Cancer, pp. 639–652. 
Gopalakrishnan, J., Guichard, P., Smith, A. H., Schwarz, H., Agard, D. A., Marco, S. and 
Avidor-Reiss, T. (2010) ‘Self-assembling SAS-6 multimer is a core centriole building 
 204 
 
block.’, J. Biol. Chem., 285(12), pp. 8759–70. 
Goshima, G., Mayer, M., Zhang, N., Stuurman, N. and Vale, R. D. (2008) ‘Augmin: a 
protein complex required for centrosome-independent microtubule generation 
within the spindle.’, J. Cell Biol., 181(3), pp. 421–9. 
Goshima, G. and Kimura, A. (2010) ‘New look inside the spindle: microtubule-
dependent microtubule generation within the spindle’, Curr. Opin. Cell Biol., 
22(1), pp. 44–49. 
Granger, E., McNee, G., Allan, V. and Woodman, P. (2014) ‘The role of the cytoskeleton 
and molecular motors in endosomal dynamics.’, Semin. Cell Dev. Biol., 31, pp. 20–
9. 
Graser, S., Stierhof, Y.-D., Nigg, E. A. and Rattner, J. B. (2007) ‘Cep68 and Cep215 
(Cdk5rap2) are required for centrosome cohesion.’, J. Cell Sci., 120(Pt 24), pp. 
4321–31. 
Grieve, A. G. and Rabouille, C. (2011) ‘Golgi bypass: Skirting around the heart of 
classical secretion’, Cold Spring Harb. Perspect. Biol., 3(4), pp. 1–15. 
Gross, J. C., Chaudhary, V., Bartscherer, K. and Boutros, M. (2012) ‘Active Wnt proteins 
are secreted on exosomes’, Nat. Cell Biol., 14(10), pp. 1036–1045. 
Gruss, O. J. and Vernos, I. (2004) ‘The mechanism of spindle assembly: functions of Ran 
and its target TPX2.’, J. Cell Biol., 166(7), pp. 949–55. 
Guardavaccaro, D., Kudo, Y., Boulaire, J., Barchi, M., Busino, L., Donzelli, M., Margottin-
Goguet, F., et al. (2003) ‘Control of meiotic and mitotic progression by the F box 
protein beta-Trcp1 in vivo.’, Dev. Cell, 4(6), pp. 799–812. 
Guderian, G., Westendorf, J., Uldschmid, A. and Nigg, E. A. (2010) ‘Plk4 trans-
autophosphorylation regulates centriole number by controlling  TrCP-mediated 
degradation’, J. Cell Sci., 123(13), pp. 2163–2169. 
Guichard, P., Desfosses, A., Maheshwari, A., Hachet, V., Dietrich, C., Brune, A., 
Ishikawa, T., et al. (2012) ‘Cartwheel Architecture of Trichonympha Basal Body’, 
Science (80-. )., 337(6094), pp. 553–553. 
Guo, H., Gao, M., Ma, J., Xiao, T., Zhao, L., Gao, Y. and Pan, Q. (2007) ‘Analysis of the 
 205 
 
cellular centrosome in fine-needle aspirations of the breast.’, Breast Cancer Res., 
9(4), p. R48. 
György, B., Szabó, T. G., Pásztói, M., Pál, Z., Misják, P., Aradi, B., László, V., et al. (2011) 
‘Membrane vesicles, current state-of-the-art: Emerging role of extracellular 
vesicles’, Cell. Mol. Life Sci., pp. 2667–2688. 
Habedanck, R., Stierhof, Y. D., Wilkinson, C. J. and Nigg, E. A. (2005) ‘The Polo kinase 
Plk4 functions in centriole duplication’, Nat. Cell Biol., 7(11), pp. 1140–1146. 
Hagan, I. M. and Grallert, A. (2013) ‘Spatial control of mitotic commitment in fission 
yeast.’, Biochem. Soc. Trans., 41(6), pp. 1766–71. 
Hahn, S. A., Schutte, M., Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., 
Weinstein, C. L., et al. (1996) ‘DPC4, a candidate tumor suppressor gene at human 
chromosome 18q21.1’, Science (80-. )., 271(5247), pp. 350–353. 
Hamada, S., Masamune, A., Takikawa, T., Suzuki, N., Kikuta, K., Hirota, M., Hamada, H., 
et al. (2012) ‘Pancreatic stellate cells enhance stem cell-like phenotypes in 
pancreatic cancer cells.’, Biochem. Biophys. Res. Commun., 421(2), pp. 349–54. 
Hansemann, D. (1890) ‘Ueber asymmetrische Zelltheilung in Epithelkrebsen und deren 
biologische Bedeutung’, Arch. für Pathol. Anat. und Physiol. und für Klin. Med., 
119, pp. 299–326. 
Hanson, P. I. and Cashikar, A. (2012) ‘Multivesicular Body Morphogenesis’, Annu. Rev. 
Cell Dev. Biol., 28(1), pp. 337–362. 
Hao, C., Xie, Y., Peng, M., Ma, L., Zhou, Y., Zhang, Y., Kang, W., et al. (2014) ‘Inhibition 
of connective tissue growth factor suppresses hepatic stellate cell activation in 
vitro and prevents liver fibrosis in vivo.’, Clin. Exp. Med., 14(2), pp. 141–50. 
Haqq, J., Howells, L. M., Garcea, G., Metcalfe, M. S., Steward, W. P. and Dennison, A. R. 
(2014) ‘Pancreatic stellate cells and pancreas cancer: Current perspectives and 
future strategies’, Eur. J. Cancer, pp. 2570–2582. 
Harding, Clifford, Heuser, J. and Stahl, P. (1983) ‘Receptor-mediated endocytosis of 
transferrin and recycling of the transferrin receptor in rat reticulocytes.’, J. Cell 
Biol., 97(2), pp. 329–39. 
 206 
 
Harding, C, Heuser, J. and Stahl, P. (1983) ‘Receptor-mediated endocytosis of 
transferrin and recycling of the transferrin receptor in rat reticulocytes.’, J. Cell 
Biol., 97(2), pp. 329–39. 
Hardy, P. and Zacharias, H. (2005) ‘Reappraisal of the Hansemann–Boveri hypothesis 
on the origin of tumors’, Cell Biol. Int., 29(12), pp. 983–992. 
Haren, L., Stearns, T. and Lüders, J. (2009) ‘Plk1-Dependent Recruitment of γ-Tubulin 
Complexes to Mitotic Centrosomes Involves Multiple PCM Components’, PLoS 
One. Edited by N. Hotchin, 4(6), p. e5976. 
He, R., Huang, N., Bao, Y., Zhou, H., Teng, J. and Chen, J. (2013) ‘LRRC45 is a 
centrosome linker component required for centrosome cohesion.’, Cell Rep., 4(6), 
pp. 1100–7. 
Headland, S. E., Jones, H. R., D’Sa, A. S. V., Perretti, M. and Norling, L. V. (2014) 
‘Cutting-edge analysis of extracellular microparticles using imagestreamx imaging 
flow cytometry’, Sci. Rep., 4, pp. 469–486. 
Hemler, M. E., Mannion, B. A. and Berditchevski, F. (1996) ‘Association of TM4SF 
proteins with integrins: Relevance to cancer’, Biochim. Biophys. Acta - Rev. 
Cancer. Elsevier B.V., pp. 67–71. 
Hendrix, A., Maynard, D., Pauwels, P., Braems, G., Denys, H., Van Den Broecke, R., 
Lambert, J., et al. (2010) ‘Effect of the secretory small GTPase Rab27B on breast 
cancer growth, invasion, and metastasis’, J. Natl. Cancer Inst., 102(12), pp. 866–
880. 
Henne, W. M., Stenmark, H. and Emr, S. D. (2013) ‘Molecular mechanisms of the 
membrane sculpting ESCRT pathway’, Cold Spring Harb. Perspect. Med., 3(10), pp. 
a016766–a016766. 
Hervera, A., De Virgiliis, F., Palmisano, I., Zhou, L., Tantardini, E., Kong, G., Hutson, T., et 
al. (2018) ‘Reactive oxygen species regulate axonal regeneration through the 
release of exosomal NADPH oxidase 2 complexes into injured axons’, Nat. Cell 
Biol., 20(3), pp. 307–319. 
Hinchcliffe, E. H., Li, C., Thompson, E. A., Maller, J. L. and Sluder, G. (1999) 
 207 
 
‘Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in 
Xenopus egg extracts.’, Science, 283(5403), pp. 851–4. 
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., 
et al. (2013) ‘Increased survival in pancreatic cancer with nab-paclitaxel plus 
gemcitabine.’, N. Engl. J. Med., 369(18), pp. 1691–703. 
Holland, A. J., Lan, W., Niessen, S., Hoover, H. and Cleveland, D. W. (2010) ‘Polo-like 
kinase 4 kinase activity limits centrosome overduplication by autoregulating its 
own stability.’, J. Cell Biol., 188(2), pp. 191–8. 
Holland, A. J., Fachinetti, D., Zhu, Q., Bauer, M., Verma, I. M., Nigg, E. A. and Cleveland, 
D. W. (2012) ‘The autoregulated instability of Polo-like kinase 4 limits centrosome 
duplication to once per cell cycle’, Genes Dev., 26(24), pp. 2684–2689. 
Holland, A. J. and Cleveland, D. W. (2012) ‘Losing balance: The origin and impact of 
aneuploidy in cancer’, EMBO Rep. European Molecular Biology Organization, pp. 
501–514. 
Horibe, S., Tanahashi, T., Kawauchi, S., Murakami, Y. and Rikitake, Y. (2018) 
‘Mechanism of recipient cell-dependent differences in exosome uptake.’, BMC 
Cancer, 18(1), p. 47. 
Hoshino, A., Costa-Silva, B., Shen, T. L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., 
Molina, H., et al. (2015a) ‘Tumour exosome integrins determine organotropic 
metastasis’, Nature, 527(7578), pp. 329–335. 
Hoshino, A., Costa-Silva, B., Shen, T. L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., 
Molina, H., et al. (2015b) ‘Tumour exosome integrins determine organotropic 
metastasis’, Nature, 527(7578), pp. 329–335. 
Hoshino, D., Kirkbride, K. C., Costello, K., Clark, E. S., Sinha, S., Grega-Larson, N., Tyska, 
M. J., et al. (2013) ‘Exosome secretion is enhanced by invadopodia and drives 
invasive behavior’, Cell Rep., 5(5), pp. 1159–1168. 
Hotz, H. G., Reber, H. A., Hotz, B., Yu, T., Foitzik, T., Buhr, H. J., Cortina, G., et al. (2003) 
‘An orthotopic nude mouse model for evaluating pathophysiology and therapy of 
pancreatic cancer.’, Pancreas, 26(4), pp. e89-98. 
 208 
 
Hruban, R. H., Goggins, M., Parsons, J. and Kern, S. E. (2000) ‘Progression model for 
pancreatic cancer.’, Clin. Cancer Res., 6(8), pp. 2969–72. 
Hruban, R. H., Canto, M. I., Goggins, M., Schulick, R. and Klein, A. P. (2010) ‘Update on 
familial pancreatic cancer.’, Adv. Surg., 44, pp. 293–311. 
Hruban, R. H., Maitra, A. and Goggins, M. (2008) ‘Update on pancreatic intraepithelial 
neoplasia.’, Int. J. Clin. Exp. Pathol., 1(4), pp. 306–16. 
Hsu, C., Morohashi, Y., Yoshimura, S. I., Manrique-Hoyos, N., Jung, S. Y., Lauterbach, M. 
A., Bakhti, M., et al. (2010) ‘Regulation of exosome secretion by Rab35 and its 
GTPase-activating proteins TBC1D10A-C’, J. Cell Biol., 189(2), pp. 223–232. 
Hsu, L. C., Kapali, M., DeLoia, J. A. and Gallion, H. H. (2005) ‘Centrosome abnormalities 
in ovarian cancer’, Int. J. Cancer, 113(5), pp. 746–751. 
Huang, G. and Brigstock, D. R. (2012) ‘Regulation of hepatic stellate cells by connective 
tissue growth factor.’, Front. Biosci. (Landmark Ed., 17, pp. 2495–507. 
Huang, T. and Deng, C. X. (2019) ‘Current progresses of exosomes as cancer diagnostic 
and prognostic biomarkers’, Int. J. Biol. Sci. Ivyspring International Publisher, pp. 
1–11. 
Huber, M. A., Kraut, N. and Beug, H. (2005) ‘Molecular requirements for epithelial-
mesenchymal transition during tumor progression S0955-0674(05)00104-3 [pii] 
10.1016/j.ceb.2005.08.001’, Curr Opin Cell Biol. 2005/08/16, 17(5), pp. 548–558. 
Hui, L. and Chen, Y. (2015) ‘Tumor microenvironment: Sanctuary of the devil.’, Cancer 
Lett., 368(1), pp. 7–13. 
Hurley, J. H. (2015) ‘ESCRTs are everywhere.’, EMBO J., 34(19), pp. 2398–407. 
Hurwitz, S. N., Rider, M. A., Bundy, J. L., Liu, X., Singh, R. K. and Meckes, D. G. (2016) 
‘Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein 
cargo and cancer type-specific biomarkers.’, Oncotarget, 7(52), pp. 86999–87015. 
Hwang, Rosa F, Moore, T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera, A., Ji, 
B., et al. (2008) ‘Cancer-associated stromal fibroblasts promote pancreatic tumor 
progression’, Cancer Res., 68(3), pp. 918–926. 
 209 
 
Hwang, Rosa F., Moore, T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera, A., 
Ji, B., et al. (2008) ‘Cancer-associated stromal fibroblasts promote pancreatic 
tumor progression’, Cancer Res., 68(3), pp. 918–926. 
Hyenne, V., Apaydin, A., Rodriguez, D., Spiegelhalter, C., Hoff-Yoessle, S., Diem, M., 
Tak, S., et al. (2015) ‘RAL-1 controls multivesicular body biogenesis and exosome 
secretion.’, J. Cell Biol., 211(1), pp. 27–37. 
Ilic, M. and Ilic, I. (2016) ‘Epidemiology of pancreatic cancer.’, World J. Gastroenterol., 
22(44), pp. 9694–9705. 
Insolera, R., Bazzi, H., Shao, W., Anderson, K. V and Shi, S.-H. (2014) ‘Cortical 
neurogenesis in the absence of centrioles.’, Nat. Neurosci., 17(11), pp. 1528–35. 
Iodice, S., Gandini, S., Maisonneuve, P. and Lowenfels, A. B. (2008) ‘Tobacco and the 
risk of pancreatic cancer: a review and meta-analysis.’, Langenbeck’s Arch. Surg., 
393(4), pp. 535–45. 
Iqbal, Nida and Iqbal, Naveed (2014) ‘Human Epidermal Growth Factor Receptor 2 
(HER2) in Cancers: Overexpression and Therapeutic Implications.’, Mol. Biol. Int., 
2014, p. 852748. 
Ireland, L., Santos, A., Ahmed, M. S., Rainer, C., Nielsen, S. R., Quaranta, V., Weyer-
Czernilofsky, U., et al. (2016) ‘Chemoresistance in Pancreatic Cancer Is Driven by 
Stroma-Derived Insulin-Like Growth Factors.’, Cancer Res., 76(23), pp. 6851–6863. 
Ito, D. and Bettencourt-Dias, M. (2018) ‘Centrosome Remodelling in Evolution.’, Cells, 
7(7). 
Ito, S., Fujii, H., Matsumoto, T., Abe, M., Ikeda, K. and Hino, O. (2010) ‘Frequent 
expression of Niban in head and neck squamous cell carcinoma and squamous 
dysplasia’, Head Neck, 32(1), pp. 96–103. 
Itoh, K., Jenny, A., Mlodzik, M. and Sokol, S. Y. (2009) ‘Centrosomal localization of 
Diversin and its relevance to Wnt signaling’, J. Cell Sci. 
Jackson, C. E., Scruggs, B. S., Schaffer, J. E. and Hanson, P. I. (2017) ‘Effects of Inhibiting 
VPS4 Support a General Role for ESCRTs in Extracellular Vesicle Biogenesis.’, 
Biophys. J., 113(6), pp. 1342–1352. 
 210 
 
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., et 
al. (2013) ‘Hyaluronan impairs vascular function and drug delivery in a mouse 
model of pancreatic cancer’, Gut, 62(1), pp. 112–120. 
Jakobsen, L., Vanselow, K., Skogs, M., Toyoda, Y., Lundberg, E., Poser, I., Falkenby, L. 
G., et al. (2011) ‘Novel asymmetrically localizing components of human 
centrosomes identified by complementary proteomics methods’, EMBO J. 
Jang, S. C., Crescitelli, R., Cvjetkovic, A., Belgrano, V., Olofsson Bagge, R., Sundfeldt, K., 
Ochiya, T., et al. (2019) ‘Mitochondrial protein enriched extracellular vesicles 
discovered in human melanoma tissues can be detected in patient plasma’, J. 
Extracell. Vesicles, 8(1), p. 1635420. 
Janke, C. and Chloë Bulinski, J. (2011) ‘Post-translational regulation of the microtubule 
cytoskeleton: mechanisms and functions’, Nat. Rev. Mol. Cell Biol., 12(12), pp. 
773–786. 
Janssen, A., Van Der Burg, M., Szuhai, K., Kops, G. J. P. L. and Medema, R. H. (2011) 
‘Chromosome segregation errors as a cause of DNA damage and structural 
chromosome aberrations’, Science (80-. ). 
Janvier, K., Pelchen-Matthews, A., Renaud, J. B., Caillet, M., Marsh, M. and Berlioz-
Torrent, C. (2011) ‘The ESCRT-0 component HRS is required for HIV-1 Vpu-
mediated BST-2/tetherin down-regulation’, PLoS Pathog., 7(2). 
Jiang, F., Zhang, Y. and Dusting, G. J. (2011) ‘NADPH oxidase-mediated redox signaling: 
Roles in cellular stress response, stress tolerance, and tissue repair’, Pharmacol. 
Rev., pp. 218–242. 
Jiang, X., Abiatari, I., Kong, B., Erkan, M., De Oliveira, T., Giese, N. A., Michalski, C. W., 
et al. (2009) ‘Pancreatic islet and stellate cells are the main sources of endocrine 
gland-derived vascular endothelial growth factor/prokineticin-1 in pancreatic 
cancer’, Pancreatology, 9(1–2), pp. 165–172. 
Johansson, A. C., Appelqvist, H., Nilsson, C., Kågedal, K., Roberg, K. and Öllinger, K. 
(2010) ‘Regulation of apoptosis-associated lysosomal membrane 
permeabilization’, Apoptosis, pp. 527–540. 
 211 
 
Johnstone, R. M., Adam, M., Hammond, J. R., Orr, L. and Turbide, C. (1987) ‘Vesicle 
formation during reticulocyte maturation. Association of plasma membrane 
activities with released vesicles (exosomes).’, J. Biol. Chem., 262(19), pp. 9412–
9420. 
Jon Kull, F. and Endow, S. A. (2013) ‘Force generation by kinesin and myosin 
cytoskeletal motor proteins’, J. Cell Sci., pp. 9–19. 
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-
H., et al. (2009) ‘Exomic sequencing identifies PALB2 as a pancreatic cancer 
susceptibility gene.’, Science, 324(5924), p. 217. 
Jung, T., Castellana, D., Klingbeil, P., Cuesta Hernández, I., Vitacolonna, M., Orlicky, D. 
J., Roffler, S. R., et al. (2009) ‘CD44v6 dependence of premetastatic niche 
preparation by exosomes.’, Neoplasia, 11(10), pp. 1093–105. 
Kabeya, Y. (2000) ‘LC3, a mammalian homologue of yeast Apg8p, is localized in 
autophagosome membranes after processing’, EMBO J., 19(21), pp. 5720–5728. 
Kahlert, C., Melo, S. A., Protopopov, A., Tang, J., Seth, S., Koch, O., Zhang, J., et al. 
(2014) ‘Identification of doublestranded genomic dna spanning all chromosomes 
with mutated KRAS and P53 DNA in the serum exosomes of patients with 
pancreatic cancer’, J. Biol. Chem., 289(7), pp. 3869–3875. 
Kalra, H., Simpson, R. J., Ji, H., Aikawa, E., Altevogt, P., Askenase, P., Bond, V. C., et al. 
(2012) ‘Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous 
Community Annotation’, PLoS Biol., 10(12), p. e1001450. 
Kamerkar, S., Lebleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., et 
al. (2017) ‘Exosomes facilitate therapeutic targeting of oncogenic KRAS in 
pancreatic cancer’, Nature, 546(7659), pp. 498–503. 
Kamisawa, T., Isawa, T., Koike, M., Tsuruta, K. and Okamoto, A. (1995) ‘Hematogenous 
metastases of pancreatic ductal carcinoma.’, Pancreas, 11(4), pp. 345–9. 
Kamisawa, T., Wood, L. D., Itoi, T. and Takaori, K. (2016) ‘Pancreatic cancer Seminar’, 
Lancet, 388(10039), pp. 73–85. 
Kanada, M., Bachmann, M. H., Hardy, J. W., Frimannson, D. O., Bronsart, L., Wang, A., 
 212 
 
Sylvester, M. D., et al. (2015) ‘Differential fates of biomolecules delivered to 
target cells via extracellular vesicles.’, Proc. Natl. Acad. Sci. U. S. A., 112(12), pp. 
E1433-42. 
Kanemoto, S., Nitani, R., Murakami, T., Kaneko, M., Asada, R., Matsuhisa, K., Saito, A., 
et al. (2016) ‘Multivesicular body formation enhancement and exosome release 
during endoplasmic reticulum stress.’, Biochem. Biophys. Res. Commun., 480(2), 
pp. 166–172. 
Kannangai, R., Diehl, A. M., Sicklick, J., Rojkind, M., Thomas, D. and Torbenson, M. 
(2005) ‘Hepatic angiomyolipoma and hepatic stellate cells share a similar gene 
expression profile’, Hum. Pathol., 36(4), pp. 341–347. 
van der Kant, R., Fish, A., Janssen, L., Janssen, H., Krom, S., Ho, N., Brummelkamp, T., et 
al. (2013) ‘Late endosomal transport and tethering are coupled processes 
controlled by RILP and the cholesterol sensor ORP1L.’, J. Cell Sci., 126(Pt 15), pp. 
3462–74. 
Kapoor, T. M., Mayer, T. U., Coughlin, M. L. and Mitchison, T. J. (2000) ‘Probing spindle 
assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic 
kinesin, Eg5.’, J. Cell Biol., 150(5), pp. 975–88. 
Karimi, N., Cvjetkovic, A., Jang, S. C., Crescitelli, R., Hosseinpour Feizi, M. A., Nieuwland, 
R., Lötvall, J., et al. (2018) ‘Detailed analysis of the plasma extracellular vesicle 
proteome after separation from lipoproteins.’, Cell. Mol. Life Sci., 75(15), pp. 
2873–2886. 
Karsenti, E. and Vernos, I. (2001) ‘The mitotic spindle: a self-made machine.’, Science, 
294(5542), pp. 543–7. 
Keerthikumar, S., Gangoda, L., Liem, M., Fonseka, P., Atukorala, I., Ozcitti, C., Mechler, 
A., et al. (2015) ‘Proteogenomic analysis reveals exosomes are more oncogenic 
than ectosomes’, Oncotarget, 6(17), pp. 15375–15396. 
Keogh, G. W., Wilson, J. S., Moran, C. S., Crawford, D. H. G., Ramm, G. A., McCaughan, 
G. W., Apte, M. V, et al. (2011) ‘Activation of Pancreatic Stellate Cells in Human 
and Experimental Pancreatic Fibrosis’, Am. J. Pathol., 155(4), pp. 1087–1095. 
 213 
 
Kerr, J. P., Robison, P., Shi, G., Bogush, A. I., Kempema, A. M., Hexum, J. K., Becerra, N., 
et al. (2015) ‘Detyrosinated microtubules modulate mechanotransduction in heart 
and skeletal muscle’, Nat. Commun., 6(1), p. 8526. 
Keustermans, G. C. E., Hoeks, S. B. E., Meerding, J. M., Prakken, B. J. and de Jager, W. 
(2013) ‘Cytokine assays: An assessment of the preparation and treatment of 
blood and tissue samples’, Methods, 61(1), pp. 10–17. 
Kfoury, Y., Nasr, R., Favre-Bonvin, A., El-Sabban, M., Renault, N., Giron, M.-L., 
Setterblad, N., et al. (2008) ‘Ubiquitylated Tax targets and binds the IKK 
signalosome at the centrosome.’, Oncogene, 27(12), pp. 1665–76. 
Kikuta, K., Masamune, A., Watanabe, T., Ariga, H., Itoh, H., Hamada, S., Satoh, K., et al. 
(2010) ‘Pancreatic stellate cells promote epithelial-mesenchymal transition in 
pancreatic cancer cells.’, Biochem. Biophys. Res. Commun., 403(3–4), pp. 380–4. 
Kim, C. B., Ahmed, S. and Hsueh, E. C. (2011) ‘Current surgical management of 
pancreatic cancer’, Society, 2(21), pp. 126–135. 
Kim, J., Gee, Y. and Lee, M. G. (2018) ‘Unconventional protein secretion-new insights 
into the pathogenesis and therapeutic targets of human diseases’. 
Kim, J. H., Lee, C. H. and Lee, S. W. (2019) ‘Exosomal Transmission of MicroRNA from 
HCV Replicating Cells Stimulates Transdifferentiation in Hepatic Stellate Cells’, 
Mol. Ther. - Nucleic Acids, 14, pp. 483–497. 
Kim, J. Y. and Hong, S.-M. (2018) ‘Precursor Lesions of Pancreatic Cancer.’, Oncol. Res. 
Treat., 41(10), pp. 603–610. 
Kim, S. and Dynlacht, B. D. (2013) ‘Assembling a primary cilium.’, Curr. Opin. Cell Biol., 
25(4), pp. 506–11. 
Kim, T.-S., Park, J.-E., Shukla, A., Choi, S., Murugan, R. N., Lee, J. H., Ahn, M., et al. 
(2013) ‘Hierarchical recruitment of Plk4 and regulation of centriole biogenesis by 
two centrosomal scaffolds, Cep192 and Cep152’, Proc. Natl. Acad. Sci., 110(50), 
pp. E4849–E4857. 
Kimura, H., Ohtsuka, T., Matsunaga, T., Watanabe, Y., Tamura, K., Ideno, N., Aso, T., et 
al. (2015) ‘Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal 
 214 
 
Adenocarcinoma: A Retrospective Study.’, Pancreas, 44(7), pp. 1148–54. 
Kinoshita, K., Noetzel, T. L., Pelletier, L., Mechtler, K., Drechsel, D. N., Schwager, A., 
Lee, M., et al. (2005) ‘Aurora A phosphorylation of TACC3/maskin is required for 
centrosome-dependent microtubule assembly in mitosis.’, J. Cell Biol., 170(7), pp. 
1047–55. 
Kitagawa, D., Vakonakis, I., Olieric, N., Hilbert, M., Keller, D., Olieric, V., Bortfeld, M., et 
al. (2011) ‘Structural Basis of the 9-Fold Symmetry of Centrioles’, Cell, 144(3), pp. 
364–375. 
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V, Neale, R. E., et 
al. (2016) ‘Pancreatic cancer.’, Nat. Rev. Dis. Prim., 2, p. 16022. 
Klein, A. P., Brune, K. A., Petersen, G. M., Goggins, M., Tersmette, A. C., Offerhaus, G. J. 
A., Griffin, C., et al. (2004) ‘Prospective Risk of Pancreatic Cancer in Familial 
Pancreatic Cancer Kindreds’, Cancer Res., 64(7), pp. 2634–2638. 
Kleylein-Sohn, J., Westendorf, J., Le Clech, M., Habedanck, R., Stierhof, Y. D. and Nigg, 
E. A. (2007) ‘Plk4-Induced Centriole Biogenesis in Human Cells’, Dev. Cell, 13(2), 
pp. 190–202. 
Kleylein-Sohn, J., Pöllinger, B., Ohmer, M., Hofmann, F., Nigg, E. A., Hemmings, B. A. 
and Wartmann, M. (2012) ‘Acentrosomal spindle organization renders cancer 
cells dependent on the kinesin HSET’, J. Cell Sci., 125(22), pp. 5391–5402. 
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo 
Arozena, A., Adachi, H., et al. (2016) ‘Guidelines for the use and interpretation of 
assays for monitoring autophagy (3rd edition)’, Autophagy, 12(1), pp. 1–222. 
Kobayashi, T., Stang, E., Fang, K. S., De Moerloose, P., Parton, R. G. and Gruenberg, J. 
(1998) ‘A lipid associated with the antiphospholipid syndrome regulates 
endosome structure and function’, Nature, 392(6672), pp. 193–197. 
Kogure, T., Lin, W. L., Yan, I. K., Braconi, C. and Patel, T. (2011) ‘Intercellular 
nanovesicle-mediated microRNA transfer: A mechanism of environmental 
modulation of hepatocellular cancer cell growth’, Hepatology, 54(4), pp. 1237–
1248. 
 215 
 
Kohlmaier, G., Loncarek, J., Meng, X., McEwen, B. F., Mogensen, M. M., Spektor, A., 
Dynlacht, B. D., et al. (2009) ‘Overly long centrioles and defective cell division 
upon excess of the SAS-4-related protein CPAP.’, Curr. Biol., 19(12), pp. 1012–8. 
Koles, K., Nunnari, J., Korkut, C., Barria, R., Brewer, C., Li, Y., Leszyk, J., et al. (2012) 
‘Mechanism of evenness interrupted (Evi)-exosome release at synaptic boutons’, 
J. Biol. Chem., 287(20), pp. 16820–16834. 
Kong, D., Farmer, V., Shukla, A., James, J., Gruskin, R., Kiriyama, S. and Loncarek, J. 
(2014) ‘Centriole maturation requires regulated Plk1 activity during two 
consecutive cell cycles’, J. Cell Biol., 206(7), pp. 855–865. 
Koppers-Lalic, D., Hackenberg, M., Bijnsdorp, I. V, van Eijndhoven, M. A. J., Sadek, P., 
Sie, D., Zini, N., et al. (2014) ‘Nontemplated nucleotide additions distinguish the 
small RNA composition in cells from exosomes.’, Cell Rep., 8(6), pp. 1649–1658. 
Kordes, C., Brookmann, S., Häussinger, D. and Klonowski-Stumpe, H. (2005) 
‘Differential and synergistic effects of platelet-derived growth factor-BB and 
transforming growth factor-beta1 on activated pancreatic stellate cells.’, 
Pancreas, 31(2), pp. 156–67. 
Kore, R. A., Edmondson, J. L., Jenkins, S. V, Jamshidi-Parsian, A., Dings, R. P. M., Reyna, 
N. S. and Griffin, R. J. (2018) ‘Hypoxia-derived exosomes induce putative altered 
pathways in biosynthesis and ion regulatory channels in glioblastoma cells.’, 
Biochem. Biophys. reports, 14, pp. 104–113. 
Korzeniewski, N., Treat, B. and Duensing, S. (2011) ‘The HPV-16 E7 oncoprotein induces 
centriole multiplication through deregulation of Polo-like kinase 4 expression’, 
Mol. Cancer, 10(1), p. 61. 
Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y. and Ochiya, T. (2010) 
‘Secretory mechanisms and intercellular transfer of microRNAs in living cells’, J. 
Biol. Chem., 285(23), pp. 17442–17452. 
Kota, J., Hancock, J., Kwon, J. and Korc, M. (2017) ‘Pancreatic cancer: Stroma and its 
current and emerging targeted therapies’, Cancer Lett. Elsevier Ireland Ltd, pp. 
38–49. 
 216 
 
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, 
F., et al. (2016a) ‘Proteomic comparison defines novel markers to characterize 
heterogeneous populations of extracellular vesicle subtypes’, Proc. Natl. Acad. Sci. 
U. S. A., 113(8), pp. E968–E977. 
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, 
F., et al. (2016b) ‘Proteomic comparison defines novel markers to characterize 
heterogeneous populations of extracellular vesicle subtypes’, Proc. Natl. Acad. 
Sci., 113(8), pp. E968–E977. 
Krämer, A., Neben, K. and Ho, A. D. (2005) ‘Centrosome aberrations in hematological 
malignancies’, Cell Biol. Int., pp. 375–383. 
Kratz, A.-S., Bärenz, F., Richter, K. T. and Hoffmann, I. (2015) ‘Plk4-dependent 
phosphorylation of STIL is required for centriole duplication.’, Biol. Open, 4(3), pp. 
370–7. 
Kreger, B. T., Johansen, E. R., Cerione, R. A. and Antonyak, M. A. (2016) ‘The 
Enrichment of Survivin in Exosomes from Breast Cancer Cells Treated with 
Paclitaxel Promotes Cell Survival and Chemoresistance.’, Cancers (Basel)., 8(12). 
Kruger, S., Elmageed, Z. Y. A., Hawke, D. H., Wörner, P. M., Jansen, D. A., Abdel-
Mageed, A. B., Alt, E. U., et al. (2014) ‘Molecular characterization of exosome-like 
vesicles from breast cancer cells’, BMC Cancer, 14(1), p. 44. 
Kurz, T., Terman, A., Gustafsson, B. and Brunk, Ulf T (2008) ‘Lysosomes and oxidative 
stress in aging and apoptosis’, Biochim. Biophys. Acta - Gen. Subj., pp. 1291–1303. 
Kurz, T., Terman, A., Gustafsson, B. and Brunk, Ulf T. (2008) ‘Lysosomes in iron 
metabolism, ageing and apoptosis’, Histochem. Cell Biol., pp. 389–406. 
Kwon, M., Godinho, S. A., Chandhok, N. S., Ganem, N. J., Azioune, A., Thery, M. and 
Pellman, D. (2008) ‘Mechanisms to suppress multipolar divisions in cancer cells 
with extra centrosomes’, Genes Dev., 22(16), pp. 2189–2203. 
Lacey, K. R., Jackson, P. K. and Stearns, T. (1999) Cyclin-dependent kinase control of 
centrosome duplication, Cell Biol. 
Larsson, S. C. and Wolk, A. (2012) ‘Red and processed meat consumption and risk of 
 217 
 
pancreatic cancer: meta-analysis of prospective studies.’, Br. J. Cancer, 106(3), pp. 
603–7. 
Latifkar, A., Ling, L., Hingorani, A., Johansen, E., Clement, A., Zhang, X., Hartman, J., et 
al. (2019) ‘Loss of Sirtuin 1 Alters the Secretome of Breast Cancer Cells by 
Impairing Lysosomal Integrity’, Dev. Cell, 49(3), pp. 393-408.e7. 
Laulagnier, K., Javalet, C., Hemming, F. J., Chivet, M., Lachenal, G., Blot, B., Chatellard, 
C., et al. (2018) ‘Amyloid precursor protein products concentrate in a subset of 
exosomes specifically endocytosed by neurons’, Cell. Mol. Life Sci., 75(4), pp. 757–
773. 
Lawo, S., Bashkurov, M., Mullin, M., Ferreria, M. G., Kittler, R., Habermann, B., 
Tagliaferro, A., et al. (2009) ‘HAUS, the 8-subunit human Augmin complex, 
regulates centrosome and spindle integrity.’, Curr. Biol., 19(10), pp. 816–26. 
Lawo, S., Hasegan, M., Gupta, G. D. and Pelletier, L. (2012) ‘Subdiffraction imaging of 
centrosomes reveals higher-order organizational features of pericentriolar 
material’, Nat. Cell Biol., 14(11), pp. 1148–1158. 
Lee, K. and Rhee, K. (2011) ‘PLK1 phosphorylation of pericentrin initiates centrosome 
maturation at the onset of mitosis.’, J. Cell Biol., 195(7), pp. 1093–101. 
Lee, K. and Rhee, K. (2012) ‘Separase-dependent cleavage of pericentrin B is necessary 
and sufficient for centriole disengagement during mitosis’, Cell Cycle, 11(13), pp. 
2476–2485. 
Lee, M., Seo, M. Y., Chang, J., Hwang, D. S. and Rhee, K. (2017) ‘PLK4 phosphorylation 
of CP110 is required for efficient centriole assembly.’, Cell Cycle, 16(12), pp. 1225–
1234. 
Lerit, D. A., Jordan, H. A., Poulton, J. S., Fagerstrom, C. J., Galletta, B. J., Peifer, M. and 
Rusan, N. M. (2015) ‘Interphase centrosome organization by the PLP-Cnn scaffold 
is required for centrosome function.’, J. Cell Biol., 210(1), pp. 79–97. 
Lerit, D. A. and Poulton, J. S. (2016) ‘Centrosomes are multifunctional regulators of 
genome stability’, Chromosom. Res., 24(1), pp. 5–17. 
Leung-Toung, R., Li, W., Tam, T. F. and Karimian, K. (2002) ‘Thiol-dependent enzymes 
 218 
 
and their inhibitors: a review.’, Curr. Med. Chem., 9(9), pp. 979–1002. 
Levine, M. S., Bakker, B., Boeckx, B., Moyett, J., Lu, J., Vitre, B., Spierings, D. C., et al. 
(2017) ‘Centrosome Amplification Is Sufficient to Promote Spontaneous 
Tumorigenesis in Mammals’, Dev. Cell, 40(3), pp. 313-322.e5. 
Li, J., Tan, M., Li, L., Pamarthy, D., Lawrence, T. S. and Sun, Y. (2005) ‘SAK, A New Polo-
Like Kinase, Is Transcriptionally Repressed by p53 and Induces Apoptosis upon 
RNAi Silencing’, Neoplasia, 7(4), pp. 312–323. 
Li, J., D’Angiolella, V., Seeley, E. S., Kim, S., Kobayashi, T., Fu, W., Campos, E. I., et al. 
(2013) ‘USP33 regulates centrosome biogenesis via deubiquitination of the 
centriolar protein CP110’, Nature, 495(7440), pp. 255–259. 
Li, Q., Shao, Y., Zhang, X., Zheng, T., Miao, M., Qin, L., Wang, B., et al. (2015) ‘Plasma 
long noncoding RNA protected by exosomes as a potential stable biomarker for 
gastric cancer’, Tumor Biol., 36(3), pp. 2007–2012. 
Li, Z., Ma, Y. Y., Wang, J., Zeng, X. F., Li, R., Kang, W. and Hao, X. K. (2015) ‘Exosomal 
microRNA-141 is upregulated in the serum of prostate cancer patients’, Onco. 
Targets. Ther., 9, pp. 139–148. 
Liang, B., Peng, P., Chen, S., Li, L., Zhang, M., Cao, D., Yang, J., et al. (2013) 
‘Characterization and proteomic analysis of ovarian cancer-derived exosomes’, J. 
Proteomics, 80, pp. 171–182. 
Lin, Y.-C., Chang, C.-W., Hsu, W.-B., Tang, C.-J. C., Lin, Y.-N., Chou, E.-J., Wu, C.-T., et al. 
(2013) ‘Human microcephaly protein CEP135 binds to hSAS-6 and CPAP, and is 
required for centriole assembly.’, EMBO J., 32(8), pp. 1141–54. 
Lineberry, N., Su, L., Soares, L. and Fathman, C. G. (2008) ‘The single subunit 
transmembrane E3 ligase gene related to anergy in lymphocytes (GRAIL) captures 
and then ubiquitinates transmembrane proteins across the cell membrane.’, J. 
Biol. Chem., 283(42), pp. 28497–505. 
Lingle, W. L., Lutz, W. H., Ingle, J. N., Maihle, N. J. and Salisbury, J. L. (1998) 
‘Centrosome hypertrophy in human breast tumors: implications for genomic 
stability and cell polarity.’, Proc. Natl. Acad. Sci. U. S. A., 95(6), pp. 2950–5. 
 219 
 
Lingle, W. L., Barrett, S. L., Negron, V. C., D’Assoro, A. B., Boeneman, K., Liu, W., 
Whitehead, C. M., et al. (2002) ‘Centrosome amplification drives chromosomal 
instability in breast tumor development.’, Proc. Natl. Acad. Sci. U. S. A., 99(4), pp. 
1978–83. 
Lipson, K. E., Wong, C., Teng, Y. and Spong, S. (2012) ‘CTGF is a central mediator of 
tissue remodeling and fibrosis and its inhibition can reverse the process of 
fibrosis’, Fibrogenesis Tissue Repair, 5(S1), p. S24. 
Liszka, Ł., Zielińska-Pajak, E., Pajak, J. and Gołka, D. (2008) ‘Colloid carcinoma of the 
pancreas: Review of selected pathological and clinical aspects’, Pathology, 40(7), 
pp. 655–663. 
Liu, P., Wang, Y. and Li, X. (2019) ‘Targeting the untargetable KRAS in cancer therapy’, 
Acta Pharm. Sin. B. Chinese Academy of Medical Sciences. 
Liu, Y., Gu, Y., Han, Y., Zhang, Q., Jiang, Z., Zhang, X., Huang, B., et al. (2016) ‘Tumor 
Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating 
Alveolar Epithelial TLR3 to Recruit Neutrophils’, Cancer Cell, 30(2), pp. 243–256. 
Locigno, R. and Castronovo, V. (2001) ‘Reduced glutathione system: role in cancer 
development, prevention and treatment (review).’, Int. J. Oncol., 19(2), pp. 221–
36. 
Logozzi, M., De Milito, A., Lugini, L., Borghi, M., Calabrò, L., Spada, M., Perdicchio, M., 
et al. (2009) ‘High levels of exosomes expressing CD63 and caveolin-1 in plasma of 
melanoma patients’, PLoS One. Edited by Y. Cao, 4(4), p. e5219. 
Löhr, M., Schmidt, C., Ringel, J., Kluth, M., Müller, P., Nizze, H. and Jesnowski, R. (2001) 
‘Transforming growth factor-beta1 induces desmoplasia in an experimental model 
of human pancreatic carcinoma.’, Cancer Res., 61(2), pp. 550–5. 
Löhr, M., Klöppel, G., Maisonneuve, P., Lowenfels, A. B. and Lüttges, J. (2005) 
‘Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with 
pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis.’, 
Neoplasia, 7(1), pp. 17–23. 
Lonardo, E., Frias-Aldeguer, J., Hermann, P. C. and Heeschen, C. (2012) ‘Pancreatic 
 220 
 
stellate cells form a niche for cancer stem cells and promote their self-renewal 
and invasiveness.’, Cell Cycle, 11(7), pp. 1282–90. 
Loncarek, J., Hergert, P., Magidson, V. and Khodjakov, A. (2008) ‘Control of daughter 
centriole formation by the pericentriolar material.’, Nat. Cell Biol., 10(3), pp. 322–
8. 
Lončarek, J., Hergert, P. and Khodjakov, A. (2010) ‘Centriole Reduplication during 
Prolonged Interphase Requires Procentriole Maturation Governed by Plk1’, Curr. 
Biol., 20(14), pp. 1277–1282. 
Lopes, C. A. M., Mesquita, M., Cunha, A. I., Cardoso, J., Carapeta, S., Laranjeira, C., 
Pinto, A. E., et al. (2018) ‘Centrosome amplification arises before neoplasia and 
increases upon p53 loss in tumorigenesis’, J. Cell Biol., 217(7), pp. 2353–2363. 
Lowenfels, A. B., Maisonneuve, P., DiMagno, E. P., Elitsur, Y., Gates, L. K., Perrault, J. 
and Whitcomb, D. C. (1997) ‘Hereditary pancreatitis and the risk of pancreatic 
cancer. International Hereditary Pancreatitis Study Group.’, J. Natl. Cancer Inst., 
89(6), pp. 442–6. 
Lozano, E., Betson, M. and Braga, V. M. M. (2003) ‘Tumor progression: Small GTpases 
and loss of cell-cell adhesion’, BioEssays. 
Lucenteforte, E., La Vecchia, C., Silverman, D., Petersen, G. M., Bracci, P. M., Ji, B. T., 
Bosetti, C., et al. (2012) ‘Alcohol consumption and pancreatic cancer: a pooled 
analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4).’, 
Ann. Oncol.  Off. J. Eur. Soc. Med. Oncol., 23(2), pp. 374–82. 
Ma, L., Yang, X., Wei, R., Ye, T., Zhou, J. K., Wen, M., Men, R., et al. (2018) ‘MicroRNA-
214 promotes hepatic stellate cell activation and liver fibrosis by suppressing Sufu 
expression article’, Cell Death Dis., 9(7). 
Macůrek, L., Lindqvist, A., Lim, D., Lampson, M. A., Klompmaker, R., Freire, R., Clouin, 
C., et al. (2008) ‘Polo-like kinase-1 is activated by aurora A to promote checkpoint 
recovery’, Nature, 455(7209), pp. 119–123. 
Maitra, A., Fukushima, N., Takaori, K. and Hruban, R. H. (2005) ‘Precursors to invasive 
pancreatic cancer.’, Adv. Anat. Pathol., 12(2), pp. 81–91. 
 221 
 
Maitra, A. and Hruban, R. H. (2008) ‘Pancreatic Cancer’, Annu. Rev. Pathol. Mech. Dis., 
3(1), pp. 157–188. 
Mantoni, T. S., Lunardi, S., Al-Assar, O., Masamune, A. and Brunner, T. B. (2011) 
‘Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin 
signaling’, Cancer Res., 71(10), pp. 3453–3458. 
Mardin, B. R., Lange, C., Baxter, J. E., Hardy, T., Scholz, S. R., Fry, A. M. and Schiebel, E. 
(2010) ‘Components of the Hippo pathway cooperate with Nek2 kinase to 
regulate centrosome disjunction’, Nat. Cell Biol., 12(12), pp. 1166–1176. 
Mardin, B. R., Agircan, F. G., Lange, C. and Schiebel, E. (2011) ‘Plk1 Controls the Nek2A-
PP1γ Antagonism in Centrosome Disjunction’, Curr. Biol., 21(13), pp. 1145–1151. 
Mardin, B. R. (2014) ‘Separate to operate: control of centrosome positioning and 
separation’, Philos. Trans. R. Soc. Lond. B. Biol. Sci., pp. 20130461–20130461. 
Mardin, B. R. and Schiebel, E. (2012) ‘Breaking the ties that bind: new advances in 
centrosome biology.’, J. Cell Biol., 197(1), pp. 11–8. 
Marteil, G., Guerrero, A., Vieira, A. F., De Almeida, B. P., Machado, P., Mendonça, S., 
Mesquita, M., et al. (2018) ‘Over-elongation of centrioles in cancer promotes 
centriole amplification and chromosome missegregation’, Nat. Commun., 9(1). 
Marteil, G., Dias Louro, M. A. and Bettencourt-Dias, M. (2017) ‘Centrosome Assembly: 
Reconstructing the Core Cartwheel Structure In Vitro’, Curr. Biol. Cell Press, pp. 
R606–R609. 
Marthiens, V., Rujano, M. A., Pennetier, C., Tessier, S., Paul-Gilloteaux, P. and Basto, R. 
(2013) ‘Centrosome amplification causes microcephaly’, Nat. Cell Biol., 15(7), pp. 
731–740. 
Martinez-Useros, J., Li, W., Cabeza-Morales, M. and Garcia-Foncillas, J. (2017) 
‘Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment’, J. 
Clin. Med., 6(3), p. 29. 
Marzec, J., Dayem Ullah, A. Z., Pirrò, S., Gadaleta, E., Crnogorac-Jurcevic, T., Lemoine, 
N. R., Kocher, H. M., et al. (2018) ‘The Pancreatic Expression Database: 2018 
update’, Nucleic Acids Res., 46(D1), pp. D1107–D1110. 
 222 
 
Marzoq, A. J., Mustafa, S. A., Heidrich, L., Hoheisel, J. D. and Alhamdani, M. S. S. (2019) 
‘Impact of the secretome of activated pancreatic stellate cells on growth and 
differentiation of pancreatic tumour cells’, Sci. Rep., 9(1). 
Masamune, A., Sakai, Y., Kikuta, K., Satoh, M., Satoh, A. and Shimosegawa, T. (2002) 
‘Activated rat pancreatic stellate cells express intercellular adhesion molecule-1 
(ICAM-1) in vitro.’, Pancreas, 25(1), pp. 78–85. 
Masamune, A., Yoshida, N., Hamada, S., Takikawa, T., Nabeshima, T. and 
Shimosegawa, T. (2018) ‘Exosomes derived from pancreatic cancer cells induce 
activation and profibrogenic activities in pancreatic stellate cells’, Biochem. 
Biophys. Res. Commun., 495(1), pp. 71–77. 
Masamune, A. and Shimosegawa, T. (2009) ‘Signal transduction in pancreatic stellate 
cells.’, J. Gastroenterol., 44(4), pp. 249–60. 
Masoud, K., Herzog, E., Chabouté, M.-E. and Schmit, A.-C. (2013) ‘Microtubule 
nucleation and establishment of the mitotic spindle in vascular plant cells’, Plant 
J., 75(2), pp. 245–257. 
Mathieu, M., Martin-Jaular, L., Lavieu, G. and Théry, C. (2019) ‘Specificities of secretion 
and uptake of exosomes and other extracellular vesicles for cell-to-cell 
communication’, Nat. Cell Biol., 21(1), pp. 9–17. 
Mathivanan, S., Fahner, C. J., Reid, G. E. and Simpson, R. J. (2012) ‘ExoCarta 2012: 
Database of exosomal proteins, RNA and lipids’, Nucleic Acids Res., 40(D1), pp. 
D1241-4. 
Mathivanan, S., Ji, H. and Simpson, R. J. (2010) ‘Exosomes: Extracellular organelles 
important in intercellular communication’, J. Proteomics, pp. 1907–1920. 
Matsumoto, F., Fujii, H., Abe, M., Kajino, K., Kobayashi, T., Matsumoto, T., Ikeda, K., et 
al. (2006) ‘A novel tumor marker, Niban, is expressed in subsets of thyroid tumors 
and Hashimoto’s thyroiditis’, Hum. Pathol., 37(12), pp. 1592–1600. 
Matsumura, T., Sugimachi, K., Iinuma, H., Takahashi, Y., Kurashige, J., Sawada, G., 
Ueda, M., et al. (2015) ‘Exosomal microRNA in serum is a novel biomarker of 
recurrence in human colorectal cancer’, Br. J. Cancer, 113(2), pp. 275–281. 
 223 
 
Matsuo, K., Ohsumi, K., Iwabuchi, M., Kawamata, T., Ono, Y. and Takahashi, M. (2012) 
‘Kendrin is a novel substrate for separase involved in the licensing of centriole 
duplication.’, Curr. Biol., 22(10), pp. 915–21. 
Mauvezin, C. and Neufeld, T. P. (2015) ‘Bafilomycin A1 disrupts autophagic flux by 
inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent 
autophagosome-lysosome fusion’, Autophagy, 11(8), pp. 1437–1438. 
Mayor, T., Stierhof, Y. D., Tanaka, K., Fry, A. M. and Nigg, E. A. (2000) ‘The centrosomal 
protein C-Nap1 is required for cell cycle-regulated centrosome cohesion.’, J. Cell 
Biol., 151(4), pp. 837–46. 
Meckes, D. G. and Raab-Traub, N. (2011) ‘Microvesicles and Viral Infection’, J. Virol., 
85(24), pp. 12844–12854. 
Megraw, T. L., Li, K., Kao, L. R. and Kaufman, T. C. (1999) ‘The centrosomin protein is 
required for centrosome assembly and function during cleavage in Drosophila.’, 
Development, 126(13), pp. 2829–39. 
Megraw, T. L., Kao, L. R. and Kaufman, T. C. (2001) ‘Zygotic development without 
functional mitotic centrosomes.’, Curr. Biol., 11(2), pp. 116–20. 
Melo, S. A., Sugimoto, H., O’Connell, J. T., Kato, N., Villanueva, A., Vidal, A., Qiu, L., et 
al. (2014) ‘Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and 
Promote Tumorigenesis’, Cancer Cell, 26(5), pp. 707–721. 
Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., Lebleu, 
V. S., et al. (2015) ‘Glypican-1 identifies cancer exosomes and detects early 
pancreatic cancer’, Nature, 523(7559), pp. 177–182. 
Mennella, V., Keszthelyi, B., Mcdonald, K. L., Chhun, B., Kan, F., Rogers, G. C., Huang, 
B., et al. (2012) ‘Subdiffraction-resolution fluorescence microscopy reveals a 
domain of the centrosome critical for pericentriolar material organization’, Nat. 
Cell Biol., 14(11), pp. 1159–1168. 
Mews, P., Phillips, P., Fahmy, R., Korsten, M., Pirola, R., Wilson, J. and Apte, M. (2002) 
‘Pancreatic stellate cells respond to inflammatory cytokines: potential role in 
chronic pancreatitis.’, Gut, 50(4), pp. 535–41. 
 224 
 
Miao, Y., Li, G., Zhang, X., Xu, H. and Abraham, S. N. (2015) ‘A TRP channel senses 
lysosome neutralization by pathogens to trigger their expulsion’, Cell, 161(6), pp. 
1306–1319. 
Mincheva-Nilsson, L. and Baranov, V. (2010) ‘The Role of Placental Exosomes in 
Reproduction’, Am. J. Reprod. Immunol., 63(6), pp. 520–533. 
Mirus, J. E., Zhang, Y., Li, C. I., Lokshin, A. E., Prentice, R. L., Hingorani, S. R. and Lampe, 
P. D. (2015) ‘Cross-species antibody microarray interrogation identifies a 3-
protein panel of plasma biomarkers for early diagnosis of pancreas cancer’, Clin. 
Cancer Res., 21(7), pp. 1764–1771. 
Mittal, K., Ogden, A., Reid, M. D., Rida, P. C. G., Varambally, S. and Aneja, R. (2015) 
‘Amplified centrosomes may underlie aggressive disease course in pancreatic 
ductal adenocarcinoma’, Cell Cycle, 14(17), pp. 2798–2809. 
Mizushima, N. and Yoshimori, T. (2007) ‘How to interpret LC3 immunoblotting’, 
Autophagy, pp. 542–545. 
Montecalvo, A., Larregina, A. T., Shufesky, W. J., Stolz, D. B., Sullivan, M. L. G., Karlsson, 
J. M., Baty, C. J., et al. (2012) ‘Mechanism of transfer of functional microRNAs 
between mouse dendritic cells via exosomes’, Blood, 119(3), pp. 756–766. 
Mooren, O. L., Galletta, B. J. and Cooper, J. A. (2012) ‘Roles for Actin Assembly in 
Endocytosis’, Annu. Rev. Biochem., 81(1), pp. 661–686. 
Morelli, A. E. (2006) ‘The immune regulatory effect of apoptotic cells and exosomes on 
dendritic cells: Its impact on transplantation’, Am. J. Transplant., pp. 254–261. 
Mountain, V., Simerly, C., Howard, L., Ando, A., Schatten, G. and Compton, D. A. (1999) 
‘The kinesin-related protein, HSET, opposes the activity of Eg5 and cross-links 
microtubules in the mammalian mitotic spindle.’, J. Cell Biol., 147(2), pp. 351–66. 
Moutinho-Pereira, S., Debec, A. and Maiato, H. (2009) ‘Microtubule cytoskeleton 
remodeling by acentriolar microtubule-organizing centers at the entry and exit 
from mitosis in Drosophila somatic cells.’, Mol. Biol. Cell, 20(11), pp. 2796–808. 
Moyer, T. C., Clutario, K. M., Lambrus, B. G., Daggubati, V. and Holland, A. J. (2015) 
‘Binding of STIL to Plk4 activates kinase activity to promote centriole assembly.’, J. 
 225 
 
Cell Biol., 209(6), pp. 863–78. 
Mulcahy, L. A., Pink, R. C. and Carter, D. R. F. (2014) ‘Routes and mechanisms of 
extracellular vesicle uptake.’, J. Extracell. vesicles, 3. 
Muller, L., Hong, C. S., Stolz, D. B., Watkins, S. C. and Whiteside, T. L. (2014) ‘Isolation 
of biologically-active exosomes from human plasma’, J. Immunol. Methods, 411, 
pp. 55–65. 
Müller, M., Schmidt, O., Angelova, M., Faserl, K., Weys, S., Kremser, L., Pfaffenwimmer, 
T., et al. (2015) ‘The coordinated action of the MVB pathway and autophagy 
ensures cell survival during starvation’, Elife, 4, p. e07736. 
Munkley, J., Vodak, D., Livermore, K. E., James, K., Wilson, B. T., Knight, B., Mccullagh, 
P., et al. (2016) ‘Glycosylation is an Androgen-Regulated Process Essential for 
Prostate Cancer Cell Viability.’, EBioMedicine, 8, pp. 103–116. 
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. and Luo, L. (2007) ‘A global double-
fluorescent Cre reporter mouse.’, Genesis, 45(9), pp. 593–605. 
Nakazawa, Y., Hiraki, M., Kamiya, R. and Hirono, M. (2007) ‘SAS-6 is a Cartwheel 
Protein that Establishes the 9-Fold Symmetry of the Centriole’, Curr. Biol., 17(24), 
pp. 2169–2174. 
Nazarenko, I., Rana, S., Baumann, A., McAlear, J., Hellwig, A., Trendelenburg, M., 
Lochnit, G., et al. (2010) ‘Cell surface tetraspanin Tspan8 contributes to molecular 
pathways of exosome-induced endothelial cell activation’, Cancer Res., 70(4), pp. 
1668–1678. 
Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., et 
al. (2011) ‘Stromal biology and therapy in pancreatic cancer.’, Gut, 60(6), pp. 861–
8. 
Neesse, A., Algül, H., Tuveson, D. A. and Gress, T. M. (2015) ‘Stromal biology and 
therapy in pancreatic cancer: a changing paradigm.’, Gut, 64(9), pp. 1476–84. 
Nicholl, M. B., Ledgewood, C. L., Chen, X., Bai, Q., Qin, C., Cook, K. M., Herrick, E. J., et 
al. (2014) ‘IL-35 promotes pancreas cancer growth through enhancement of 
proliferation and inhibition of apoptosis: evidence for a role as an autocrine 
 226 
 
growth factor.’, Cytokine, 70(2), pp. 126–33. 
Nielsen, M. F. B., Mortensen, M. B. and Detlefsen, S. (2016) ‘Key players in pancreatic 
cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and 
inflammatory cells.’, World J. Gastroenterol., 22(9), pp. 2678–700. 
Nigg, E. A. (2002) ‘Centrosome aberrations: cause or consequence of cancer 
progression?’, Nat. Rev. Cancer, 2(11), pp. 815–25. 
Nigg, E. A. (2006) ‘Origins and consequences of centrosome aberrations in human 
cancers’, Int. J. Cancer, 119(12), pp. 2717–2723. 
Nigg, E. A. and Holland, A. J. (2018) ‘Once and only once: mechanisms of centriole 
duplication and their deregulation in disease’, Nat. Rev. Mol. Cell Biol., 19(5), pp. 
297–312. 
Nigg, E. A. and Raff, J. W. (2009) ‘Centrioles, Centrosomes, and Cilia in Health and 
Disease’, Cell, 139(4), pp. 663–678. 
Nigg, E. A. and Stearns, T. (2011) ‘The centrosome cycle: Centriole biogenesis, 
duplication and inherent asymmetries’, Nat. Cell Biol., 13(10), pp. 1154–1160. 
Nilsson, E., Ghassemifar, R. and Brunk, U. T. (1997) ‘Lysosomal heterogeneity between 
and within cells with respect to resistance against oxidative stress.’, Histochem. J., 
29(11–12), pp. 857–65. 
Noctor, G. and Foyer, C. H. (2002) ‘ASCORBATE AND GLUTATHIONE: Keeping Active 
Oxygen Under Control’, Annu. Rev. Plant Physiol. Plant Mol. Biol., 49(1), pp. 249–
279. 
Nuha M, M. A. M., Hiba S, E. and Christina Wasunna, M. (2015) ‘In-vitro “Depletion” of 
Mitochondrial Cytochrome C Oxidase Subunit II Affects the Patterns of Gene 
Expression across Multiple Cancer Pathways’, J. Mol. Biomark. Diagn., s2. 
Nussey, S. and Whitehead, S. (2001) ‘Chapter 2 The endocrine pancreas’, in Endocrinol. 
An Integr. Approach. Oxford: BIOS Scientific Publishers. 
O’Connell, C. B. and Khodjakov, A. L. (2007) ‘Cooperative mechanisms of mitotic 
spindle formation’, J. Cell Sci., 120(10), pp. 1717–1722. 
 227 
 
O’Connell, K. F., Caron, C., Kopish, K. R., Hurd, D. D., Kemphues, K. J., Li, Y. and White, J. 
G. (2001) ‘The C. elegans zyg-1 gene encodes a regulator of centrosome 
duplication with distinct maternal and paternal roles in the embryo.’, Cell, 105(4), 
pp. 547–58. 
O’Neill, C., Gilligan, K. and Dwyer, R. (2019) ‘Role of Extracellular Vesicles (EVs) in Cell 
Stress Response and Resistance to Cancer Therapy’, Cancers (Basel)., 11(2), p. 
136. 
Ohnishi, H., Miyata, T., Yasuda, H., Satoh, Y., Hanatsuka, K., Kita, H., Ohashi, A., et al. 
(2004) ‘Distinct Roles of Smad2-, Smad3-, and ERK-dependent Pathways in 
Transforming Growth Factor-β1 Regulation of Pancreatic Stellate Cellular 
Functions’, J. Biol. Chem., 279(10), pp. 8873–8878. 
Ohnishi, N., Miyata, T., Ohnishi, H., Yasuda, H., Tamada, K., Ueda, N., Mashima, H., et 
al. (2003) ‘Activin A is an autocrine activator of rat pancreatic stellate cells: 
potential therapeutic role of follistatin for pancreatic fibrosis.’, Gut, 52(10), pp. 
1487–93. 
Ohta, M., Ashikawa, T., Nozaki, Y., Kozuka-Hata, H., Goto, H., Inagaki, M., Oyama, M., 
et al. (2014) ‘Direct interaction of Plk4 with STIL ensures formation of a single 
procentriole per parental centriole.’, Nat. Commun., 5, p. 5267. 
Omary, M. B., Lugea, A., Lowe, A. W. and Pandol, S. J. (2007) ‘The pancreatic stellate 
cell: a star on the rise in pancreatic diseases.’, J. Clin. Invest., 117(1), pp. 50–9. 
Orozco, C. A., Martinez-Bosch, N., Guerrero, P. E., Vinaixa, J., Dalotto-Moreno, T., 
Iglesias, M., Moreno, M., et al. (2018) ‘Targeting galectin-1 inhibits pancreatic 
cancer progression by modulating tumor-stroma crosstalk.’, Proc. Natl. Acad. Sci. 
U. S. A., 115(16), pp. E3769–E3778. 
Ostrowski, M., Carmo, N. B., Krumeich, S., Fanget, I., Raposo, G., Savina, A., Moita, C. 
F., et al. (2010) ‘Rab27a and Rab27b control different steps of the exosome 
secretion pathway’, Nat. Cell Biol., 12(1), pp. 19–30. 
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C. C., Simpson, T. R., 
Laklai, H., et al. (2014) ‘Depletion of carcinoma-associated fibroblasts and fibrosis 
induces immunosuppression and accelerates pancreas cancer with reduced 
 228 
 
survival’, Cancer Cell, 25(6), pp. 719–734. 
Paintrand, M., Moudjou, M., Delacroix, H. and Bornens, M. (1992) ‘Centrosome 
organization and centriole architecture: their sensitivity to divalent cations.’, J. 
Struct. Biol., 108(2), pp. 107–28. 
Pällmann, N., Livgård, M., Tesikova, M., Zeynep Nenseth, H., Akkus, E., Sikkeland, J., Jin, 
Yixin, et al. (2019) ‘Regulation of the unfolded protein response through ATF4 and 
FAM129A in prostate cancer’, Oncogene. 
Pan, B. T., Teng, K., Wu, C., Adam, M. and Johnstone, R. M. (1985) ‘Electron 
microscopic evidence for externalization of the transferrin receptor in vesicular 
form in sheep reticulocytes.’, J. Cell Biol., 101(3), pp. 942–8. 
Pan, B. T. and Johnstone, R. M. (1983) ‘Fate of the transferrin receptor during 
maturation of sheep reticulocytes in vitro: Selective externalization of the 
receptor’, Cell, 33(3), pp. 967–978. 
Pandharipande, P. V, Heberle, C., Dowling, E. C., Kong, C. Y., Tramontano, A., Perzan, K. 
E., Brugge, W., et al. (2015) ‘Targeted screening of individuals at high risk for 
pancreatic cancer: results of a simulation model.’, Radiology, 275(1), pp. 177–87. 
Pandol, S. J. (2011) ‘Digestive Enzymes and Their Functions’, in The exocrine pancreas. 
Morgan & Claypool Life Sciences. 
Panic, M., Hata, S., Neuner, A. and Schiebel, E. (2015) ‘The centrosomal linker and 
microtubules provide dual levels of spatial coordination of centrosomes.’, PLoS 
Genet., 11(5), p. e1005243. 
Park, S.-Y., Park, J.-E., Kim, T.-S., Kim, J. H., Kwak, M.-J., Ku, B., Tian, L., et al. (2014) 
‘Molecular basis for unidirectional scaffold switching of human Plk4 in centriole 
biogenesis.’, Nat. Struct. Mol. Biol., 21(8), pp. 696–703. 
Parkin, D. M. (2011) ‘Tobacco-attributable cancer burden in the UK in 2010’, Br. J. 
Cancer, 105, pp. S6–S13. 
Parolini, I., Federici, C., Raggi, C., Lugini, L., Palleschi, S., De Milito, A., Coscia, C., et al. 
(2009) ‘Microenvironmental pH is a key factor for exosome traffic in tumor cells’, 
J. Biol. Chem., 284(49), pp. 34211–34222. 
 229 
 
Pellegata, N. S., Sessa, F., Renault, B., Bonato, M., Leone, B. E., Solcia, E. and Ranzani, 
G. N. (1994) ‘K-ras and p53 gene mutations in pancreatic cancer: ductal and 
nonductal tumors progress through different genetic lesions.’, Cancer Res., 54(6), 
pp. 1556–60. 
Pelletier, L., O’Toole, E., Schwager, A., Hyman, A. A. and Müller-Reichert, T. (2006) 
‘Centriole assembly in Caenorhabditis elegans’, Nature, 444(7119), pp. 619–623. 
Peng, T., Zhou, W., Guo, F., Wu, H. S., Wang, C. Y., Wang, L. and Yang, Z. Y. (2017) 
‘Centrosomal protein 55 activates NF-κB signalling and promotes pancreatic 
cancer cells aggressiveness’, Sci. Rep., 7(1). 
Phillips, P. A., Wu, M. J., Kumar, R. K., Doherty, E., McCarroll, J. A., Park, S., Pirola, R. C., 
et al. (2003) ‘Cell migration: a novel aspect of pancreatic stellate cell biology.’, 
Gut, 52(5), pp. 677–82. 
Phillips, P. A., McCarroll, J. A., Park, S., Wu, M.-J., Pirola, R., Korsten, M., Wilson, J. S., et 
al. (2003) ‘Rat pancreatic stellate cells secrete matrix metalloproteinases: 
implications for extracellular matrix turnover.’, Gut, 52(2), pp. 275–82. 
Piel, M., Meyer, P., Khodjakov, A., Rieder, C. L. and Bornens, M. (2000) ‘The respective 
contributions of the mother and daughter centrioles to centrosome activity and 
behavior in vertebrate cells.’, J. Cell Biol., 149(2), pp. 317–30. 
Pihan, G. A., Purohit, A., Wallace, J., Knecht, H., Woda, B., Quesenberry, P. and Doxsey, 
S. J. (1998) ‘Centrosome defects and genetic instability in malignant tumors’, 
Cancer Res., 58(17), pp. 3974–3985. 
Pihan, G. A., Purohit, A., Wallace, J., Malhotra, R., Liotta, L. and Doxsey, S. J. (2001) 
‘Centrosome defects can account for cellular and genetic changes that 
characterize prostate cancer progression.’, Cancer Res., 61(5), pp. 2212–9. 
Pihan, G. A., Wallace, J., Zhou, Y. and Doxsey, S. J. (2003) ‘Centrosome abnormalities 
and chromosome instability occur together in pre-invasive carcinomas.’, Cancer 
Res., 63(6), pp. 1398–404. 
Pinzani, M., Gesualdo, L., Sabbah, G. M. and Abboud, H. E. (1989) ‘Effects of platelet-
derived growth factor and other polypeptide mitogens on DNA synthesis and 
 230 
 
growth of cultured rat liver fat-storing cells’, J. Clin. Invest., 84(6), pp. 1786–1793. 
Piper, R. C. and Katzmann, D. J. (2007) ‘Biogenesis and Function of Multivesicular 
Bodies’, Annu. Rev. Cell Dev. Biol., 23(1), pp. 519–547. 
Poruk, K. E., Gay, D. Z., Brown, K., Mulvihill, J. D., Boucher, K. M., Scaife, C. L., Firpo, M. 
A., et al. (2013) ‘The clinical utility of CA 19-9 in pancreatic adenocarcinoma: 
diagnostic and prognostic updates.’, Curr. Mol. Med., 13(3), pp. 340–51. 
Poulton, J. S., Cuningham, J. C. and Peifer, M. (2014) ‘Acentrosomal Drosophila 
epithelial cells exhibit abnormal cell division, leading to cell death and 
compensatory proliferation.’, Dev. Cell, 30(6), pp. 731–45. 
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D. and Hingorani, S. 
R. (2012) ‘Enzymatic targeting of the stroma ablates physical barriers to treatment 
of pancreatic ductal adenocarcinoma.’, Cancer Cell, 21(3), pp. 418–29. 
Puri, N. and Roche, P. A. (2008) ‘Mast cells possess distinct secretory granule subsets 
whose exocytosis is regulated by different SNARE isoforms.’, Proc. Natl. Acad. Sci. 
U. S. A., 105(7), pp. 2580–5. 
Pylayeva-Gupta, Y., Das, S., Handler, J. S., Hajdu, C. H., Coffre, M., Koralov, S. B. and 
Bar-Sagi, D. (2016) ‘IL35-Producing B Cells Promote the Development of 
Pancreatic Neoplasia.’, Cancer Discov., 6(3), pp. 247–55. 
Qian, D., Lu, Z., Xu, Q., Wu, P., Tian, L., Zhao, L., Cai, B., et al. (2017) ‘Galectin-1-driven 
upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer 
metastasis.’, Cancer Lett., 397, pp. 43–51. 
Qu, J. L., Qu, X. J., Zhao, M. F., Teng, Y. E., Zhang, Y., Hou, K. Z., Jiang, Y. H., et al. (2009) 
‘Gastric cancer exosomes promote tumour cell proliferation through PI3K/Akt and 
MAPK/ERK activation’, Dig. Liver Dis., 41(12), pp. 875–880. 
Quintyne, N. J., Reing, J. E., Hoffelder, D. R., Gollin, S. M. and Saunders, W. S. (2005) 
‘Spindle multipolarity is prevented by centrosomal clustering’, Science (80-. )., 
307(5706), pp. 127–129. 
Raaijmakers, J. A., van Heesbeen, R. G. H. P., Meaders, J. L., Geers, E. F., Fernandez-
Garcia, B., Medema, R. H. and Tanenbaum, M. E. (2012) ‘Nuclear envelope-
 231 
 
associated dynein drives prophase centrosome separation and enables Eg5-
independent bipolar spindle formation.’, EMBO J., 31(21), pp. 4179–90. 
Raaijmakers, J. A. and Medema, R. H. (2014) ‘Function and regulation of dynein in 
mitotic chromosome segregation’, Chromosoma, 123(5), pp. 407–422. 
Rabinowits, G., Gerçel-Taylor, C., Day, J. M., Taylor, D. D. and Kloecker, G. H. (2009) 
‘Exosomal microRNA: A diagnostic marker for lung cancer’, Clin. Lung Cancer, 
10(1), pp. 42–46. 
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M. and Matrisian, 
L. M. (2014) ‘Projecting cancer incidence and deaths to 2030: The unexpected 
burden of thyroid, liver, and pancreas cancers in the united states’, Cancer Res. 
American Association for Cancer Research Inc., pp. 2913–2921. 
Rahier, J., Wallon, J. and Henquin, J. C. (1981) ‘Cell populations in the endocrine 
pancreas of human neonates and infants’, Diabetologia, 20(5), pp. 540–546. 
Raimondi, S., Lowenfels, A. B., Morselli-Labate, A. M., Maisonneuve, P. and Pezzilli, R. 
(2010) ‘Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early 
detection.’, Best Pract. Res. Clin. Gastroenterol., 24(3), pp. 349–58. 
Raimondi, S., Maisonneuve, P. and Lowenfels, A. B. (2009) ‘Epidemiology of pancreatic 
cancer: an overview.’, Nat. Rev. Gastroenterol. Hepatol., 6(12), pp. 699–708. 
Raimondo, F., Morosi, L., Chinello, C., Magni, F. and Pitto, M. (2011) ‘Advances in 
membranous vesicle and exosome proteomics improving biological understanding 
and biomarker discovery’, Proteomics, 11(4), pp. 709–720. 
Rana, S., Yue, S., Stadel, D. and Zöller, M. (2012) ‘Toward tailored exosomes: The 
exosomal tetraspanin web contributes to target cell selection’, Int. J. Biochem. Cell 
Biol., 44(9), pp. 1574–1584. 
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V, Melief, C. J. 
and Geuze, H. J. (1996) ‘B lymphocytes secrete antigen-presenting vesicles.’, J. 
Exp. Med., 183(3), pp. 1161–72. 
Raposo, G. and Stoorvogel, W. (2013) ‘Extracellular vesicles: Exosomes, microvesicles, 
and friends’, J. Cell Biol. Rockefeller University Press, pp. 373–383. 
 232 
 
Rayess, H., Wang, M. B. and Srivatsan, E. S. (2012) ‘Cellular senescence and tumor 
suppressor gene p16.’, Int. J. cancer, 130(8), pp. 1715–25. 
Redmann, M., Benavides, G. A., Berryhill, T. F., Wani, W. Y., Ouyang, X., Johnson, M. S., 
Ravi, S., et al. (2017) ‘Inhibition of autophagy with bafilomycin and chloroquine 
decreases mitochondrial quality and bioenergetic function in primary neurons’, 
Redox Biol., 11, pp. 73–81. 
Reiter, R., Gais, P., Steuer-Vogt, M. K., Boulesteix, A.-L., Deutschle, T., Hampel, R., 
Wagenpfeil, S., et al. (2009) ‘Centrosome abnormalities in head and neck 
squamous cell carcinoma (HNSCC)’, Acta Otolaryngol., 129(2), pp. 205–213. 
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., 
Dekleva, E. N., et al. (2014) ‘Stromal elements act to restrain, rather than support, 
pancreatic ductal adenocarcinoma’, Cancer Cell, 25(6), pp. 735–747. 
Rhys, A. D., Monteiro, P., Smith, C., Vaghela, M., Arnandis, T., Kato, T., Leitinger, B., et 
al. (2018) ‘Loss of E-cadherin provides tolerance to centrosome amplification in 
epithelial cancer cells’, J. Cell Biol., 217(1), pp. 195–209. 
Rhys, A. D. and Godinho, S. A. (2017) ‘Dividing with extra centrosomes: A double edged 
sword for cancer cells’, in Adv. Exp. Med. Biol. Springer, Cham, pp. 47–67. 
Ring, D., Hubble, R. and Kirschner, M. (1982) ‘Mitosis in a cell with multiple centrioles’, 
J. Cell Biol., 94(3), pp. 549–556. 
Ringuette Goulet, C., Bernard, G., Tremblay, S., Chabaud, S., Bolduc, S. and Pouliot, F. 
(2018) ‘Exosomes Induce Fibroblast Differentiation into Cancer-Associated 
Fibroblasts through TGFβ Signaling.’, Mol. Cancer Res., 16(7), pp. 1196–1204. 
Roberts, N. J., Jiao, Y., Yu, J., Kopelovich, L., Petersen, G. M., Bondy, M. L., Gallinger, S., 
et al. (2012) ‘ATM mutations in patients with hereditary pancreatic cancer.’, 
Cancer Discov., 2(1), pp. 41–6. 
Rodrigues-Martins, A., Riparbelli, M., Callaini, G., Glover, D. M. and Bettencourt-Dias, 
M. (2008) ‘From centriole biogenesis to cellular function: Centrioles are essential 
for cell division at critical developmental stages’, Cell Cycle, 7(1), pp. 11–16. 
Rogers, G. C., Rusan, N. M., Roberts, D. M., Peifer, M. and Rogers, S. L. (2009) ‘The 
 233 
 
SCFSlimb ubiquitin ligase regulates Plk4/Sak levels to block centriole 
reduplication’, J. Cell Biol., 184(2), p. 225. 
Rohrmann, S., Linseisen, J., Nöthlings, U., Overvad, K., Egeberg, R., Tjønneland, A., 
Boutron-Ruault, M. C., et al. (2013) ‘Meat and fish consumption and risk of 
pancreatic cancer: Results from the European Prospective Investigation into 
Cancer and Nutrition’, Int. J. Cancer, 132(3), pp. 617–624. 
Roig, J., Mikhailov, A., Belham, C. and Avruch, J. (2002) ‘Nercc1, a mammalian NIMA-
family kinase, binds the Ran GTPase and regulates mitotic progression.’, Genes 
Dev., 16(13), pp. 1640–58. 
Roig, J., Groen, A., Caldwell, J. and Avruch, J. (2005) ‘Active Nercc1 protein kinase 
concentrates at centrosomes early in mitosis and is necessary for proper spindle 
assembly.’, Mol. Biol. Cell, 16(10), pp. 4827–40. 
Romancino, D. P., Paterniti, G., Campos, Y., De Luca, A., Di Felice, V., D’Azzo, A. and 
Bongiovanni, A. (2013) ‘Identification and characterization of the nano-sized 
vesicles released by muscle cells’, FEBS Lett., 587(9), pp. 1379–1384. 
Rosendahl, A. H., Perks, C. M., Zeng, L., Markkula, A., Simonsson, M., Rose, C., Ingvar, 
C., et al. (2015) ‘Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen 
Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast 
Cancer.’, Clin. Cancer Res., 21(8), pp. 1877–87. 
Rozenblum, E., Schutte, M., Goggins, M., Hahn, S. A., Panzer, S., Zahurak, M., 
Goodman, S. N., et al. (1997) ‘Tumor-suppressive pathways in pancreatic 
carcinoma.’, Cancer Res., 57(9), pp. 1731–4. 
Ryan, D. P., Hong, T. S. and Bardeesy, N. (2014) ‘Pancreatic Adenocarcinoma’, N. Engl. 
J. Med., 371(11), pp. 1039–1049. 
Sah, R. P., Nagpal, S. J. S., Mukhopadhyay, D. and Chari, S. T. (2013) ‘New insights into 
pancreatic cancer-induced paraneoplastic diabetes.’, Nat. Rev. Gastroenterol. 
Hepatol., 10(7), pp. 423–33. 
Sahu, R., Kaushik, S., Clement, C. C., Cannizzo, E. S., Scharf, B., Follenzi, A., Potolicchio, 
I., et al. (2011) ‘Microautophagy of cytosolic proteins by late endosomes.’, Dev. 
 234 
 
Cell, 20(1), pp. 131–9. 
Salisbury, J. L., D’Assoro, A. B. and Lingle, W. L. (2004) ‘Centrosome amplification and 
the origin of chromosomal instability in breast cancer.’, J. Mammary Gland Biol. 
Neoplasia, 9(3), pp. 275–83. 
Sánchez-Huertas, C. and Lüders, J. (2015) ‘The augmin connection in the geometry of 
microtubule networks.’, Curr. Biol., 25(7), pp. R294-9. 
Sander, E. E., ten Klooster, J. P., van Delft, S., van der Kammen, R. A. and Collard, J. G. 
(1999) ‘Rac downregulates Rho activity: reciprocal balance between both GTPases 
determines cellular morphology and migratory behavior.’, J. Cell Biol., 147(5), pp. 
1009–22. 
Sato, N., Mizumoto, K., Nakamura, M., Nakamura, K., Kusumoto, M., Niiyama, H., 
Ogawa, T., et al. (1999) ‘Centrosome abnormalities in pancreatic ductal 
carcinoma.’, Clin. Cancer Res., 5(5), pp. 963–70. 
Sato, N., Mizumoto, K., Nakamura, M., Maehara, N., Minamishima, Y. A., Nishio, S., 
Nagai, E., et al. (2001) ‘Correlation between centrosome abnormalities and 
chromosomal instability in human pancreatic cancer cells’, Cancer Genet. 
Cytogenet., 126(1), pp. 13–19. 
Sato, T., Akasu, H., Shimono, W., Matsu, C., Fujiwara, Y., Shibagaki, Y., Heard, J. J., et al. 
(2015) ‘Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate 
transcarbamoylase, and dihydroorotase) protein in a GTP- And effector domain-
dependent manner and influences its cellular localization and 
carbamoylphosphate synthetase (CPSase) activity’, J. Biol. Chem., 290(2), pp. 
1096–1105. 
Sausen, M., Phallen, J., Adleff, V., Jones, S., Leary, R. J., Barrett, M. T., Anagnostou, V., 
et al. (2015) ‘Clinical implications of genomic alterations in the tumour and 
circulation of pancreatic cancer patients.’, Nat. Commun., 6, p. 7686. 
Savina, A., Furlán, M., Vidal, M. and Colombo, M. I. (2003) ‘Exosome release is 
regulated by a calcium-dependent mechanism in K562 cells’, J. Biol. Chem., 
278(22), pp. 20083–20090. 
 235 
 
Savina, A., Fader, C. M., Damiani, M. T. and Colombo, M. I. (2005) ‘Rab11 promotes 
docking and fusion of multivesicular bodies in a calcium-dependent manner’, 
Traffic, 6(2), pp. 131–143. 
Scarpa, A., Capelli, P., Mukai, K., Zamboni, G., Oda, T., Iacono, C. and Hirohashi, S. 
(1993) ‘Pancreatic adenocarcinomas frequently show p53 gene mutations.’, Am. J. 
Pathol., 142(5), pp. 1534–43. 
Schneider, E., Schmid-Kotsas, A., Zhao, J., Weidenbach, H., Schmid, R. M., Menke, A., 
Adler, G., et al. (2001) ‘Identification of mediators stimulating proliferation and 
matrix synthesis of rat pancreatic stellate cells.’, Am. J. Physiol. Cell Physiol., 
281(2), pp. C532-43. 
Schneiderhan, W., Diaz, F., Fundel, M., Zhou, S., Siech, M., Hasel, C., Moller, P., et al. 
(2007) ‘Pancreatic stellate cells are an important source of MMP-2 in human 
pancreatic cancer and accelerate tumor progression in a murine xenograft model 
and CAM assay’, J. Cell Sci., 120(3), pp. 512–519. 
Schnelderhan, W., Diaz, F., Fundel, M., Zhou, S., Siech, M., Hasel, C., Möller, P., et al. 
(2007) ‘Pancreatic stellate cells are an important source of MMP-2 in human 
pancreatic cancer and accelerate tumor progression in a murine xenograft model 
and CAM assay’, J. Cell Sci., 120(3), pp. 512–519. 
Schuh, M. and Ellenberg, J. (2007) ‘Self-organization of MTOCs replaces centrosome 
function during acentrosomal spindle assembly in live mouse oocytes.’, Cell, 
130(3), pp. 484–98. 
Schumacher, J. M., Ashcroft, N., Donovan, P. J. and Golden, A. (1998) ‘A highly 
conserved centrosomal kinase, AIR-1, is required for accurate cell cycle 
progression and segregation of developmental factors in Caenorhabditis elegans 
embryos.’, Development, 125(22), pp. 4391–402. 
Schutte, M., Hruban, R. ., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., 
Moskaluk, C. A., et al. (1997) ‘Abrogation of the Rb/p16 tumor-suppressive 
pathway in virtually all pancreatic carcinomas’, Cancer Res., 57(15), pp. 3126–
3130. 
Sedgwick, A. E. and D’Souza-Schorey, C. (2018) ‘The biology of extracellular 
 236 
 
microvesicles.’, Traffic, 19(5), pp. 319–327. 
Segat, D., Cassaro, M., Dazzo, E., Cavallini, L., Romualdi, C., Salvador, R., Vitale, M. P., et 
al. (2010) ‘Pericentriolar material analyses in normal esophageal mucosa, 
Barrett’s metaplasia and adenocarcinoma.’, Histol. Histopathol., 25(5), pp. 551–
60. 
Serçin, Ö., Larsimont, J.-C., Karambelas, A. E., Marthiens, V., Moers, V., Boeckx, B., Le 
Mercier, M., et al. (2015) ‘Transient PLK4 overexpression accelerates 
tumorigenesis in p53-deficient epidermis.’, Nat. Cell Biol., 18(1), pp. 100–110. 
Shek, F. W.-T., Benyon, R. C., Walker, F. M., McCrudden, P. R., Pender, S. L. F., Williams, 
E. J., Johnson, P. A., et al. (2002) ‘Expression of transforming growth factor-beta 1 
by pancreatic stellate cells and its implications for matrix secretion and turnover 
in chronic pancreatitis.’, Am. J. Pathol., 160(5), pp. 1787–98. 
Shimizu, Y., Yasui, K., Matsueda, K., Yanagisawa, A. and Yamao, K. (2005) ‘Small 
carcinoma of the pancreas is curable: new computed tomography finding, 
pathological study and postoperative results from a single institute.’, J. 
Gastroenterol. Hepatol., 20(10), pp. 1591–4. 
Shono, M., Sato, N., Mizumoto, K., Maehara, N., Nakamura, M., Nagai, E. and Tanaka, 
M. (2001) ‘Stepwise progression of centrosome defects associated with local 
tumor growth and metastatic process of human pancreatic carcinoma cells 
transplanted orthotopically into nude mice’, Lab. Investig., 81(7), pp. 945–952. 
Siegel, R. L., Miller, K. D. and Jemal, A. (2019) ‘Cancer statistics, 2019.’, CA. Cancer J. 
Clin., 69(1), pp. 7–34. 
Sigoillot, F. D., Kotsis, D. H., Serre, V., Sigoillot, S. M., Evans, D. R. and Guy, H. I. (2005) 
‘Nuclear localization and mitogen-activated protein kinase phosphorylation of the 
multifunctional protein CAD.’, J. Biol. Chem., 280(27), pp. 25611–20. 
Silkworth, W. T., Nardi, I. K., Scholl, L. M. and Cimini, D. (2009) ‘Multipolar spindle pole 
coalescence is a major source of kinetochore mis-attachment and chromosome 
mis-segregation in cancer cells’, PLoS One. 
Sillibourne, J. E., Tack, F., Vloemans, N., Boeckx, A., Thambirajah, S., Bonnet, P., 
 237 
 
Ramaekers, F. C. S., et al. (2010) ‘Autophosphorylation of Polo-like Kinase 4 and 
Its Role in Centriole Duplication’, Mol. Biol. Cell, 21(4), p. 547. 
Sincock, P. M., Fitter, S., Parton, R. G., Berndt, M. C., Gamble, J. R. and Ashman, L. K. 
(1999) ‘PETA-3/CD151, a member of the transmembrane 4 superfamily, is 
localised to the plasma membrane and endocytic system of endothelial cells, 
associates with multiple integrins and modulates cell function.’, J. Cell Sci., 112 ( 
Pt 6), pp. 833–44. 
Sir, J.-H., Pütz, M., Daly, O., Morrison, C. G., Dunning, M., Kilmartin, J. V. and Gergely, F. 
(2013) ‘Loss of centrioles causes chromosomal instability in vertebrate somatic 
cells’, J. Cell Biol., 203(5), pp. 747–756. 
Smith, E., Hégarat, N., Vesely, C., Roseboom, I., Larch, C., Streicher, H., Straatman, K., 
et al. (2011) ‘Differential control of Eg5-dependent centrosome separation by Plk1 
and Cdk1.’, EMBO J., 30(11), pp. 2233–45. 
Sonnen, K. F., Schermelleh, L., Leonhardt, H. and Nigg, E. A. (2012) ‘3D-structured 
illumination microscopy provides novel insight into architecture of human 
centrosomes’, Biol. Open, 1(10), pp. 965–976. 
Sonnen, K. F., Gabryjonczyk, A.-M., Anselm, E., Stierhof, Y.-D. and Nigg, E. A. (2013) 
‘Human Cep192 and Cep152 cooperate in Plk4 recruitment and centriole 
duplication’, J. Cell Sci., 126(14), pp. 3223–3233. 
Stankovic-Valentin, N. and Melchior, F. (2018) ‘Control of SUMO and Ubiquitin by ROS: 
Signaling and disease implications.’, Mol. Aspects Med., 63, pp. 3–17. 
Starita, L. M., Machida, Y., Sankaran, S., Elias, J. E., Griffin, K., Schlegel, B. P., Gygi, S. P., 
et al. (2004) ‘BRCA1-Dependent Ubiquitination of  -Tubulin Regulates Centrosome 
Number’, Mol. Cell. Biol., 24(19), pp. 8457–8466. 
Stenmark, H. (2009) ‘Rab GTPases as coordinators of vesicle traffic’, Nat. Rev. Mol. Cell 
Biol., pp. 513–525. 
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, 
E. D., et al. (2011) ‘Massive genomic rearrangement acquired in a single 
catastrophic event during cancer development’, Cell. 
 238 
 
Stevens, N. R., Raposo, A. A. S. F., Basto, R., St Johnston, D. and Raff, J. W. (2007) ‘From 
stem cell to embryo without centrioles.’, Curr. Biol., 17(17), pp. 1498–503. 
Stoka, V., Turk, V. and Turk, B. (2016) ‘Lysosomal cathepsins and their regulation in 
aging and neurodegeneration’, Ageing Res. Rev. Elsevier, pp. 22–37. 
Sumoza-Toledo, A. and Penner, R. (2011) ‘TRPM2: A multifunctional ion channel for 
calcium signalling’, J. Physiol. John Wiley & Sons, Ltd (10.1111), pp. 1515–1525. 
Sun, G. D., Kobayashi, T., Abe, M., Tada, N., Adachi, H., Shiota, A., Totsuka, Y., et al. 
(2007) ‘The endoplasmic reticulum stress-inducible protein Niban regulates eIF2α 
and S6K1/4E-BP1 phosphorylation’, Biochem. Biophys. Res. Commun., 360(1), pp. 
181–187. 
Sun, Y. and Liu, J. (2014) ‘Potential of cancer cell-derived exosomes in clinical 
application: A review of recent research advances’, Clin. Ther., pp. 863–872. 
Sung, B. H., Ketova, T., Hoshino, D., Zijlstra, A. and Weaver, A. M. (2015) ‘Directional 
cell movement through tissues is controlled by exosome secretion’, Nat. 
Commun., 6, p. 7164. 
Svensson, K. J., Christianson, H. C., Wittrup, A., Bourseau-Guilmain, E., Lindqvist, E., 
Svensson, L. M., Mörgelin, M., et al. (2013) ‘Exosome uptake depends on ERK1/2-
heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively 
regulated by caveolin-1.’, J. Biol. Chem., 288(24), pp. 17713–24. 
Szczepanski, M. J., Szajnik, M., Welsh, A., Whiteside, T. L. and Boyiadzis, M. (2011) 
‘Blast-derived microvesicles in sera from patients with acute myeloid leukemia 
suppress natural killer cell function via membrane-associated transforming 
growth factor-β1’, Haematologica, 96(9), pp. 1302–1309. 
Tafani, M., Sansone, L., Limana, F., Arcangeli, T., De Santis, E., Polese, M., Fini, M., et al. 
(2016) ‘The Interplay of Reactive Oxygen Species, Hypoxia, Inflammation, and 
Sirtuins in Cancer Initiation and Progression’, Oxid. Med. Cell. Longev. Hindawi 
Limited. 
Tahara, H., Sato, K., Yamazaki, Y., Ohyama, T., Horiguchi, N., Hashizume, H., Kakizaki, 
S., et al. (2013) ‘Transforming growth factor-α activates pancreatic stellate cells 
 239 
 
and may be involved in matrix metalloproteinase-1 upregulation.’, Lab. Invest., 
93(6), pp. 720–32. 
Tai, Y. L., Chen, K. C., Hsieh, J. T. and Shen, T. L. (2018) ‘Exosomes in cancer 
development and clinical applications’, Cancer Sci. Blackwell Publishing Ltd, pp. 
2364–2374. 
Takahashi, K., Yan, I. K., Kogure, T., Haga, H. and Patel, T. (2014) ‘Extracellular vesicle-
mediated transfer of long non-coding RNA ROR modulates chemosensitivity in 
human hepatocellular cancer’, FEBS Open Bio, 4(1), pp. 458–467. 
Tamai, K., Tanaka, N., Nakano, T., Kakazu, E., Kondo, Y., Inoue, J., Shiina, M., et al. 
(2010) ‘Exosome secretion of dendritic cells is regulated by Hrs, an ESCRT-0 
protein’, Biochem. Biophys. Res. Commun., 399(3), pp. 384–390. 
Tanaka, Y., Kamohara, H., Kinoshita, K., Kurashige, J., Ishimoto, T., Iwatsuki, M., 
Watanabe, M., et al. (2013) ‘Clinical impact of serum exosomal microRNA-21 as a 
clinical biomarker in human esophageal squamous cell carcinoma’, Cancer, 
119(6), pp. 1159–1167. 
Tang, N. and Marshall, W. F. (2012) ‘Centrosome positioning in vertebrate 
development’, J. Cell Sci. 
Tanida, I., Ueno, T. and Kominami, E. (2008) ‘LC3 and autophagy’, Methods Mol. Biol., 
445, pp. 77–88. 
Taylor, D. D. and Gercel-Taylor, C. (2008) ‘MicroRNA signatures of tumor-derived 
exosomes as diagnostic biomarkers of ovarian cancer’, Gynecol. Oncol., 110(1), 
pp. 13–21. 
Telkoparan, P., Erkek, S., Yaman, E., Alotaibi, H., Bayik, D. and Tazebay, U. H. (2013) 
‘Coiled-Coil Domain Containing Protein 124 Is a Novel Centrosome and Midbody 
Protein That Interacts with the Ras-Guanine Nucleotide Exchange Factor 1B and Is 
Involved in Cytokinesis’, PLoS One, 8(7). 
Terino, M., Plotkin, E. and Karagozian, R. (2018) ‘Pancreatoblastoma: an Atypical 
Presentation and a Literature Review’, J. Gastrointest. Cancer, 49(3), pp. 361–364. 
Thakur, B. K., Zhang, H., Becker, A., Matei, I., Huang, Y., Costa-Silva, B., Zheng, Y., et al. 
 240 
 
(2014) ‘Double-stranded DNA in exosomes: a novel biomarker in cancer 
detection’, Cell Res., 24(6), pp. 766–769. 
Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, 
G. Y., Qi, Y. P., et al. (2003) ‘Hedgehog is an early and late mediator of pancreatic 
cancer tumorigenesis.’, Nature, 425(6960), pp. 851–6. 
Théry, C., Amigorena, S., Raposo, G. and Clayton, A. (2006) ‘Isolation and 
characterization of exosomes from cell culture supernatants and biological 
fluids.’, Curr. Protoc. cell Biol., Chapter 3, p. Unit 3.22. 
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, 
R., Antoniou, A., et al. (2018) ‘Minimal information for studies of extracellular 
vesicles 2018 (MISEV2018): a position statement of the International Society for 
Extracellular Vesicles and update of the MISEV2014 guidelines’, J. Extracell. 
Vesicles, 7(1), p. 1535750. 
Théry, C., Ostrowski, M. and Segura, E. (2009) ‘Membrane vesicles as conveyors of 
immune responses’, Nat. Rev. Immunol., pp. 581–593. 
Thomas, D. and Radhakrishnan, P. (2019) ‘Tumor-stromal crosstalk in pancreatic 
cancer and tissue fibrosis’, Mol. Cancer. BioMed Central Ltd. 
Thul, P. J., Akesson, L., Wiking, M., Mahdessian, D., Geladaki, A., Ait Blal, H., Alm, T., et 
al. (2017) ‘A subcellular map of the human proteome’, Science (80-. )., 356(6340). 
Tian, T., Wang, Y., Wang, H., Zhu, Z. and Xiao, Z. (2010) ‘Visualizing of the cellular 
uptake and intracellular trafficking of exosomes by live-cell microscopy’, J. Cell. 
Biochem., 111(2), pp. 488–496. 
Tiwari, N., Wang, C.-C., Brochetta, C., Ke, G., Vita, F., Qi, Z., Rivera, J., et al. (2008) 
‘VAMP-8 segregates mast cell-preformed mediator exocytosis from cytokine 
trafficking pathways.’, Blood, 111(7), pp. 3665–74. 
Tjomsland, V., Pomianowska, E., Aasrum, M., Sandnes, D., Verbeke, C. S. and Gladhaug, 
I. P. (2016) ‘Profile of MMP and TIMP Expression in Human Pancreatic Stellate 
Cells: Regulation by IL-1α and TGFβ and Implications for Migration of Pancreatic 
Cancer Cells.’, Neoplasia, 18(7), pp. 447–56. 
 241 
 
Tkach, M., Kowal, J., Zucchetti, A. E., Enserink, L., Jouve, M., Lankar, D., Saitakis, M., et 
al. (2017) ‘Qualitative differences in T-cell activation by dendritic cell-derived 
extracellular vesicle subtypes.’, EMBO J., 36(20), pp. 3012–3028. 
Townsend, D. M., Tew, K. D. and Tapiero, H. (2003) ‘The importance of glutathione in 
human disease’, Biomed. Pharmacother., pp. 145–155. 
Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L., Wenzel, D., Wieland, F., Schwille, P., et 
al. (2008) ‘Ceramide triggers budding of exosome vesicles into multivesicular 
endosomes.’, Science, 319(5867), pp. 1244–7. 
Tramacere, I., Scotti, L., Jenab, M., Bagnardi, V., Bellocco, R., Rota, M., Corrao, G., et al. 
(2010) ‘Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-
risk relation.’, Int. J. cancer, 126(6), pp. 1474–86. 
Tsang, W. Y., Bossard, C., Khanna, H., Peränen, J., Swaroop, A., Malhotra, V. and 
Dynlacht, B. D. (2008) ‘CP110 suppresses primary cilia formation through its 
interaction with CEP290, a protein deficient in human ciliary disease.’, Dev. Cell, 
15(2), pp. 187–97. 
Tsou, M.-F. B., Wang, W.-J., George, K. A., Uryu, K., Stearns, T. and Jallepalli, P. V (2009) 
‘Polo kinase and separase regulate the mitotic licensing of centriole duplication in 
human cells.’, Dev. Cell, 17(3), pp. 344–54. 
Tsou, M.-F. B. and Stearns, T. (2006) ‘Mechanism limiting centrosome duplication to 
once per cell cycle’, Nature, 442(7105), pp. 947–951. 
Tsuchiya, R., Noda, T., Harada, N., Miyamoto, T., Tomioka, T., Yamamoto, K., 
Yamaguchi, T., et al. (1986) ‘Collective review of small carcinomas of the 
pancreas.’, Ann. Surg., 203(1), pp. 77–81. 
Tung, K., Ernstoff, M., Allen, C. and Shu, S. (2019) ‘A Review of Exosomes and their Role 
in The Tumor Microenvironment and Host-Tumor “Macroenvironment”’, J. 
Immunol. Sci., 3(1), pp. 4–8. 
Turchinovich, A., Weiz, L., Langheinz, A. and Burwinkel, B. (2011) ‘Characterization of 
extracellular circulating microRNA’, Nucleic Acids Res., 39(16), pp. 7223–7233. 
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., et al. 
 242 
 
(2017) ‘A pathology atlas of the human cancer transcriptome’, Science (80-. )., 
357(6352). 
Umezu, T., Ohyashiki, K., Kuroda, M. and Ohyashiki, J. H. (2013) ‘Leukemia cell to 
endothelial cell communication via exosomal miRNAs.’, Oncogene, 32(22), pp. 
2747–55. 
Vaccaro, V., Sperduti, I. and Milella, M. (2011) ‘FOLFIRINOX versus gemcitabine for 
metastatic pancreatic cancer.’, N. Engl. J. Med., 365(8), pp. 768–9; author reply 
769. 
Vaizel-Ohayon, D. and Schejter, E. D. (1999) ‘Mutations in centrosomin reveal 
requirements for centrosomal function during early Drosophila embryogenesis.’, 
Curr. Biol., 9(16), pp. 889–98. 
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J. and Lötvall, J. O. (2007) 
‘Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of 
genetic exchange between cells.’, Nat. Cell Biol., 9(6), pp. 654–9. 
Varmark, H., Llamazares, S., Rebollo, E., Lange, B., Reina, J., Schwarz, H. and Gonzalez, 
C. (2007) ‘Asterless is a centriolar protein required for centrosome function and 
embryo development in Drosophila.’, Curr. Biol., 17(20), pp. 1735–45. 
Verweij, F. J., Bebelman, M. P., Jimenez, C. R., Garcia-Vallejo, J. J., Janssen, H., Neefjes, 
J., Knol, J. C., et al. (2018) ‘Quantifying exosome secretion from single cells reveals 
a modulatory role for GPCR signaling’, J. Cell Biol., 217(3), pp. 1129–1142. 
Villarroya-Beltri, C., Gutiérrez-Vázquez, C., Sánchez-Cabo, F., Pérez-Hernández, D., 
Vázquez, J., Martin-Cofreces, N., Martinez-Herrera, D. J., et al. (2013) ‘Sumoylated 
hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to 
speVillarroya-Beltri, C., Gutiérrez-Vázquez, C., Sánchez-Cabo, F., Pérez-Hernández, 
D., Vázquez, J., Martin-Cofreces, N., … Sánchez-Madrid, F. (2013). Sumoylated 
hnRNPA2B’, Nat. Commun., 4, p. 2980. 
Villarroya-Beltri, C., Baixauli, F., Mittelbrunn, M., Fernández-Delgado, I., Torralba, D., 
Moreno-Gonzalo, O., Baldanta, S., et al. (2016) ‘ISGylation controls exosome 
secretion by promoting lysosomal degradation of MVB proteins’, Nat. Commun., 
7. 
 243 
 
Vitre, B., Holland, A. J., Kulukian, A., Shoshani, O., Hirai, M., Wang, Y., Maldonado, M., 
et al. (2015) ‘Chronic centrosome amplification without tumorigenesis.’, Proc. 
Natl. Acad. Sci. U. S. A., 112(46), pp. E6321–E6330. 
Vlassov, A. V, Magdaleno, S., Setterquist, R. and Conrad, R. (2012) ‘Exosomes: Current 
knowledge of their composition, biological functions, and diagnostic and 
therapeutic potentials’, Biochim. Biophys. Acta - Gen. Subj., pp. 940–948. 
Vlijm, R., Li, X., Panic, M., Rüthnick, D., Hata, S., Herrmannsdörfer, F., Kuner, T., et al. 
(2018) ‘STED nanoscopy of the centrosome linker reveals a CEP68-organized, 
periodic rootletin network anchored to a C-Nap1 ring at centrioles’, Proc. Natl. 
Acad. Sci., 115(10), pp. E2246–E2253. 
Voichitoiu, A.-D., Mihaela Radu, B., Pavelescu, L., Cretoiu, D., Teona Deftu, A., Suciu, N. 
and Maria Cretoiu, S. (2019) ‘Extracellular Vesicles in Cancer’, in Extracell. Vesicles 
[Working Title]. IntechOpen. 
Vonlaufen, A., Joshi, S., Qu, C., Phillips, P. A., Xu, Z., Parker, N. R., Toi, C. S., et al. (2008) 
‘Pancreatic stellate cells: Partners in crime with pancreatic cancer cells’, Cancer 
Res., 68(7), pp. 2085–2093. 
Vonlaufen, A., Phillips, P. A., Yang, L., Xu, Z., Fiala-Beer, E., Zhang, X., Pirola, R. C., et al. 
(2010) ‘Isolation of quiescent human pancreatic stellate cells: A promising in vitro 
tool for studies of human pancreatic stellate cell biology’, Pancreatology, 10(4), 
pp. 434–443. 
Wang, J. D., Jin, K., Chen, X. Y., Lv, J. Q. and Ji, K. W. (2017) ‘Clinicopathological 
significance of SMAD4 loss in pancreatic ductal adenocarcinomas: A systematic 
review and meta-analysis’, Oncotarget, 8(10), pp. 16704–16711. 
Wang, L. M., Silva, M. A., D’Costa, Z., Bockelmann, R., Soonawalla, Z., Liu, S., O’Neill, E., 
et al. (2016) ‘The prognostic role of desmoplastic stroma in pancreatic ductal 
adenocarcinoma’, Oncotarget, 7(4), pp. 4183–4194. 
Wang, X., Xu, C., Hua, Y., Sun, L., Cheng, K., Jia, Z., Han, Y., et al. (2016) ‘Exosomes play 
an important role in the process of psoralen reverse multidrug resistance of 
breast cancer’, J. Exp. Clin. Cancer Res., 35(1), pp. 1–10. 
 244 
 
Wang, Y., Jin, F., Higgins, R. and McKnight, K. (2014) ‘The current view for the silencing 
of the spindle assembly checkpoint’, Cell Cycle. 
Waterman-Storer, C. M., Worthylake, R. A., Liu, B. P., Burridget, K. and Salmon, E. D. 
(1999) ‘Microtubule growth activates Rac1 to promote lamellipodial protrusion in 
fibroblasts’, Nat. Cell Biol. 
Watts, C. A., Richards, F. M., Bender, A., Bond, P. J., Korb, O., Kern, O., Riddick, M., et 
al. (2013) ‘Design, Synthesis, and Biological Evaluation of an Allosteric Inhibitor of 
HSET that Targets Cancer Cells with Supernumerary Centrosomes’, Chem. Biol., 
20(11), pp. 1399–1410. 
Weaver, B. A. A., Silk, A. D., Montagna, C., Verdier-Pinard, P. and Cleveland, D. W. 
(2007) ‘Aneuploidy Acts Both Oncogenically and as a Tumor Suppressor’, Cancer 
Cell. 
Webber, J., Steadman, R., Mason, M. D., Tabi, Z. and Clayton, A. (2010a) ‘Cancer 
exosomes trigger fibroblast to myofibroblast differentiation’, Cancer Res., 70(23), 
pp. 9621–9630. 
Webber, J., Steadman, R., Mason, M. D., Tabi, Z. and Clayton, A. (2010b) ‘Cancer 
exosomes trigger fibroblast to myofibroblast differentiation’, Cancer Res., 70(23), 
pp. 9621–9630. 
Webber, J. and Clayton, A. (2013) ‘How pure are your vesicles?’, J. Extracell. Vesicles, 
2(1), p. 19861. 
Wei, G., Jie, Y., Haibo, L., Chaoneng, W., Dong, H., Jianbing, Z., Junjie, G., et al. (2017) 
‘Dendritic cells derived exosomes migration to spleen and induction of 
inflammation are regulated by CCR7’, Sci. Rep., 7, p. 42996. 
Welton, J. L., Webber, J. P., Botos, L.-A., Jones, M. and Clayton, A. (2015) ‘Ready-made 
chromatography columns for extracellular vesicle isolation from plasma.’, J. 
Extracell. vesicles, 4, p. 27269. 
Weng, S., Wang, Hua, Chen, W., Katz, M. H., Chatterjee, D., Lee, J. E., Pisters, P. W., et 
al. (2012) ‘Overexpression of protein phosphatase 4 correlates with poor 
prognosis in patients with stage II pancreatic ductal adenocarcinoma’, Cancer 
 245 
 
Epidemiol. Biomarkers Prev., 21(8), pp. 1336–1343. 
De Wever, O., Demetter, P., Mareel, M. and Bracke, M. (2008) ‘Stromal myofibroblasts 
are drivers of invasive cancer growth’, Int. J. Cancer. Wiley Subscription Services, 
Inc., A Wiley Company, pp. 2229–2238. 
Whitehead, C. M. and Rattner, J. B. (1998) ‘Expanding the role of HsEg5 within the 
mitotic and post-mitotic phases of the cell cycle.’, J. Cell Sci., 111 ( Pt 17), pp. 
2551–61. 
Whiteman, D. C., Webb, P. M., Green, A. C., Neale, R. E., Fritschi, L., Bain, C. J., Parkin, 
D. M., et al. (2015) ‘Cancers in Australia in 2010 attributable to modifiable factors: 
Introduction and overview’, Aust. N. Z. J. Public Health, 39(5), pp. 403–407. 
Whiteside, T. L. (2013) ‘Immune modulation of T-cell and NK (natural killer) cell 
activities by TEXs (tumour-derived exosomes)’, in Biochem. Soc. Trans., pp. 245–
251. 
Wickman, G., Julian, L. and Olson, M. F. (2012) ‘How apoptotic cells aid in the removal 
of their own cold dead bodies’, Cell Death Differ., 19(5), pp. 735–742. 
Wigley, W. C., Fabunmi, R. P., Lee, M. G., Marino, C. R., Muallem, S., DeMartino, G. N. 
and Thomas, P. J. (1999) ‘Dynamic association of proteasomal machinery with the 
centrosome.’, J. Cell Biol., 145(3), pp. 481–90. 
Wilentz, R. E., Geradts, J., Maynard, R., Offerhaus, G. J., Kang, M., Goggins, M., Yeo, C. 
J., et al. (1998) ‘Inactivation of the p16 (INK4A) tumor-suppressor gene in 
pancreatic duct lesions: loss of intranuclear expression.’, Cancer Res., 58(20), pp. 
4740–4. 
Willms, E., Cabañas, C., Mäger, I., Wood, M. J. A. and Vader, P. (2018) ‘Extracellular 
vesicle heterogeneity: Subpopulations, isolation techniques, and diverse functions 
in cancer progression’, Front. Immunol. Frontiers Media S.A. 
Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., 
Antoniou, A., Arab, T., et al. (2018) ‘Minimal information for studies of 
extracellular vesicles 2018 (MISEV2018): a position statement of the International 
Society for Extracellular Vesicles and update of the MISEV2014 guidelines AU - 
 246 
 
Théry, Clotilde’, J. Extracell. Vesicles, 7, p. 1535750. 
Wojcik, E. J., Glover, D. M. and Hays, T. S. (2000) ‘The SCF ubiquitin ligase protein slimb 
regulates centrosome duplication in Drosophila.’, Curr. Biol., 10(18), pp. 1131–4. 
Wong, Y. L., Anzola, J. V., Davis, R. L., Yoon, M., Motamedi, A., Kroll, A., Seo, C. P., et al. 
(2015) ‘Reversible centriole depletion with an inhibitor of Polo-like kinase 4’, 
Science, 348(6239), p. 1155. 
Wood, L. D. and Hruban, R. H. (2012) ‘Pathology and Molecular Genetics of Pancreatic 
Neoplasms’, Cancer J., 18(6), pp. 492–501. 
Wortzel, I., Dror, S., Kenific, C. M. and Lyden, D. (2019) ‘Exosome-Mediated Metastasis: 
Communication from a Distance’, Dev. Cell, pp. 347–360. 
Wu, J., Mikule, K., Wang, W., Su, N., Petteruti, P., Gharahdaghi, F., Code, E., et al. 
(2013) ‘Discovery and mechanistic study of a small molecule inhibitor for motor 
protein KIFC1’, ACS Chem. Biol., 8(10), pp. 2201–2208. 
Xie, S., Qin, J., Liu, S., Zhang, Y., Wang, J., Shi, X., Li, D., et al. (2016) ‘Cep70 
overexpression stimulates pancreatic cancer by inducing centrosome abnormality 
and microtubule disorganization’, Sci. Rep., 6. 
Xu, R., Rai, A., Chen, M., Suwakulsiri, W., Greening, D. W. and Simpson, R. J. (2018) 
‘Extracellular vesicles in cancer — implications for future improvements in cancer 
care’, Nat. Rev. Clin. Oncol. Nature Publishing Group, pp. 617–638. 
Xu, Z., Vonlaufen, A., Phillips, P. A., Fiala-Beer, E., Zhang, X., Yang, L., Biankin, A. V., et 
al. (2010) ‘Role of pancreatic stellate cells in pancreatic cancer metastasis’, Am. J. 
Pathol., 177(5), pp. 2585–2596. 
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., et al. (2010) 
‘Distant metastasis occurs late during t1. Yachida, S. et al. Distant metastasis 
occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114–7 
(2010).he genetic evolution of pancreatic cancer.’, Nature, 467(7319), pp. 1114–7. 
Yamamoto, Y., Matsuyama, H., Furuya, T., Oga, A., Yoshihiro, S., Okuda, M., Kawauchi, 
S., et al. (2004) ‘Centrosome hyperamplification predicts progression and tumor 
recurrence in bladder cancer’, Clin. Cancer Res., 10(19), pp. 6449–6455. 
 247 
 
Yang, J., Adamian, M. and Li, T. (2006) ‘Rootletin Interacts with C-Nap1 and May 
Function as a Physical Linker between the Pair of Centrioles/Basal Bodies in Cells’, 
Mol. Biol. Cell, 17(2), pp. 1033–1040. 
Ying, X., Wu, Q., Wu, X., Zhu, Q., Wang, Xinjing, Jiang, L., Chen, X., et al. (2016) 
‘Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of 
tumor-associated macrophages.’, Oncotarget, 7(28), pp. 43076–43087. 
Yokode, M., Akita, M., Fujikura, K., Kim, M.-J., Morinaga, Y., Yoshikawa, S., Terada, T., 
et al. (2018) ‘High-grade PanIN presenting with localised stricture of the main 
pancreatic duct: A clinicopathological and molecular study of 10 cases suggests a 
clue for the early detection of pancreatic cancer.’, Histopathology, 73(2), pp. 247–
258. 
Yoshimori, T., Yamamoto, A., Moriyama, Y., Futai, M. and Tashiro, Y. (1991) 
‘Bafilomycin A1, a specific inhibitor of vacuolar-type H+-ATPase, inhibits 
acidification and protein degradation in lysosomes of cultured cells’, J. Biol. 
Chem., 266(26), pp. 17707–17712. 
Yuan-Chen, C., Perihan, N., Jörg, B., Zee-Fen, C. and Gary, M. B. (2008) ‘GEF-H1 Couples 
Nocodazole-induced Microtubule Disassembly to Cell Contractility via RhoA’, Mol. 
Biol. Cell. 
Yue, S., Mu, W., Erb, U. and Zöller, M. (2015) ‘The tetraspanins CD151 and Tspan8 are 
essential exosome components for the crosstalk between cancer initiating cells 
and their surrounding’, Oncotarget, 6(4), pp. 2366–2384. 
Yukawa, M., Yamauchi, T., Kurisawa, N., Ahmed, S., Kimura, K. ichi and Toda, T. (2018) 
‘Fission yeast cells overproducing HSET/KIFC1 provides a useful tool for 
identification and evaluation of human kinesin-14 inhibitors’, Fungal Genet. Biol., 
116, pp. 33–41. 
Yuyama, K., Sun, H., Mitsutake, S. and Igarashi, Y. (2012) ‘Sphingolipid-modulated 
exosome secretion promotes clearance of amyloid-?? by microglia’, J. Biol. Chem., 
287(14), pp. 10977–10989. 
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., 
Lawrence, M. S., et al. (2013) ‘Pan-cancer patterns of somatic copy number 
 248 
 
alteration’, Nat. Genet. 
Zhang, H., Freitas, D., Kim, H. S., Fabijanic, K., Li, Z., Chen, H., Mark, M. T., et al. (2018) 
‘Identification of distinct nanoparticles and subsets of extracellular vesicles by 
asymmetric flow field-flow fractionation.’, Nat. Cell Biol., 20(3), pp. 332–343. 
Zhang, H. G. and Grizzle, W. E. (2014) ‘Exosomes: A novel pathway of local and distant 
intercellular communication that facilitates the growth and metastasis of 
neoplastic lesions’, Am. J. Pathol., pp. 28–41. 
Zhang, L., Zhang, S., Yao, J., Lowery, F. J., Zhang, Q., Huang, W. C., Li, P., et al. (2015) 
‘Microenvironment-induced PTEN loss by exosomal microRNA primes brain 
metastasis outgrowth’, Nature, 527(7576), pp. 100–104. 
Zhang, W., Zhai, L., Wang, Y., Boohaker, R. J., Lu, W., Gupta, V. V, Padmalayam, I., et al. 
(2016) ‘Discovery of a novel inhibitor of kinesin-like protein KIFC1.’, Biochem. J., 
473(8), pp. 1027–35. 
Zhang, X., Chen, Q., Feng, J., Hou, J., Yang, F., Liu, J., Jiang, Q., et al. (2009) ‘Sequential 
phosphorylation of Nedd1 by Cdk1 and Plk1 is required for targeting of the TuRC 
to the centrosome’, J. Cell Sci., 122(13), pp. 2240–2251. 
Zhang, X., Wang, B., Wang, C., Chen, L. and Xiao, Y. (2015) ‘Monitoring Lipid 
Peroxidation within Foam Cells by Lysosome-Targetable and Ratiometric Probe’, 
Anal. Chem., 87(16), pp. 8292–8300. 
Zhang, Y.-F., Zhou, Y.-Z., Zhang, B., Huang, S.-F., Li, P.-P., He, X.-M., Cao, G.-D., et al. 
(2019) ‘Pancreatic cancer-derived exosomes promoted pancreatic stellate cells 
recruitment by pancreatic cancer’, J. Cancer, 10(18), pp. 4397–4407. 
Zhitomirsky, B., Farber, H. and Assaraf, Y. G. (2018) ‘LysoTracker and MitoTracker Red 
are transport substrates of P-glycoprotein: implications for anticancer drug design 
evading multidrug resistance’, J. Cell. Mol. Med., 22(4), pp. 2131–2141. 
Zilfou, J. and Lowe, S. (2009) ‘Tumor suppressive functions of p53.’, Cold Spring Harb 
Perspect Biol., 1(5). 
Zomer, A., Maynard, C., Verweij, F. J., Kamermans, A., Schäfer, R., Beerling, E., 
Schiffelers, R. M., et al. (2015) ‘In Vivo imaging reveals extracellular vesicle-
 249 
 
mediated phenocopying of metastatic behavior.’, Cell, 161(5), pp. 1046–1057. 
Zyss, D. and Gergely, F. (2009) ‘Centrosome function in cancer: guilty or innocent?’, 
Trends Cell Biol., pp. 334–346. 
 
